INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 3 contracts
Samples: Merger Agreement (Cubist Pharmaceuticals Inc), Merger Agreement (Adolor Corp), Merger Agreement (Cubist Pharmaceuticals Inc)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement : “Agreement” Preamble “Alternative Acquisition Agreement 5.2(cAgreement” 5.4(a) Assignee 9.5(a“Company Capitalization Date” 3.8(a) award “Certificate of Merger” 2.2 “Certificates” 2.9(c) “Chosen Courts” 9.10 “Closing” 2.3 “Closing Date” 2.3 “Collective Bargaining Agreement” 3.21(a) “Company” Preamble “Company Board Recommendation” 3.3(a) “Company Board Recommendation Change” 5.4(c)(i) “Company Breach Notice Period” 8.1(e) “Company Disclosure Letter” Article III “Company Related Parties” 8.3(f) “Company Registered Intellectual Property” 3.18(a) “Company SEC Reports” 3.10 “Company Securities” 3.8(c) “Company Stockholder Meeting” 6.4(a) “Confidentiality Agreement” 9.4 “Continuation Period” 6.9(c) “D&O Insurance” 6.8(c) “DGCL” Recitals “DTC” 2.9(d) “Effective Time” 2.2 “Electronic Delivery” 9.14 “Employee Plan” 3.20(a) “ERISA Affiliate” 3.20(a) “ESPP Offering Period” 2.8(c) “Exchange Agent” 2.9(a) “Exchange Fund” 2.9(b) “Exchange Ratio” 2.7(a)(ii) “Excluded Benefits” 6.9(c) “Export Approvals” 3.23(d)(i) “Financial Advisor” 3.3(b) Book-Entry Share 2.1(c“First Extended Termination Date” 8.1(c) business day 9.10(b“Indemnified Persons” 6.8(a) CERCLA 3.18(b“Initial Termination Date” 8.1(c) Certificate of Merger 1.4 Certificate 2.1(c“Integration Committee” 6.6(b) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a“Integration Plan” 6.6(b) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c“Intended Tax Treatment” 6.17 “IT Systems” 3.18(j) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate “Lease” 3.16(b) Exchange Act 1.1(a“Leased Real Property” 3.16(b) Exchange Fund 2.2(a“Material Customers” 3.15 “Material Suppliers” 3.15 “Maximum Annual Premium” 6.8(c) Expiration Date 1.1(a“Merger” Recitals “Merger Consideration” 2.7(a)(ii) FCPA 3.9(c“Merger Sub” Preamble “Midco” Recitals “New Plans” 6.9(d) FDA 3.9(d“Non-U.S. Employee Plan” 3.20(j) Good Clinical Practices 3.9(h“Old Plans” 6.9(d) Good Laboratory Practices 3.9(h“Option Consideration” 2.8(a) Good Manufacturing Practices 3.9(i“Option Consideration Value” 2.8(a) Governmental Entity 9.10(b“Other Required Filing” 6.3(b) Hazardous Materials 3.18(e)(ii“Owned Company Shares” 2.7(a)(iii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (” Preamble “Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the Parent Breach Notice Period” 8.1(g) “Company”), a Delaware corporation.Parent Capitalization Date” 4.15(a) “Parent Disclosure Letter” Article IV “Parent Financial Statements” 4.17(a) “Parent Recent SEC Reports” Article IV “Parent Related Parties” 8.3(g) “Parent SEC Reports” 4.16 “Parent Securities” 4.15(c) “Party” Preamble “Prior Parent SEC Reports” 4.16 “Real Estate Plan” 6.18 “Recent SEC Reports” Article III “Requisite Stockholder Approval” 3.5 “Specified Legal Proceedings” 6.16 “Sublease” 3.16(b) “Surviving Corporation” 2.1 “Takeover Laws” 3.3(c) “Uncertificated Shares” 2.9(c) “Withholding Agent” 2.13 “Voting Agreement” Recitals
Appears in 2 contracts
Samples: Merger Agreement (Ginkgo Bioworks Holdings, Inc.), Agreement and Plan of Merger (Zymergen Inc.)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: 401(k) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dPlans 6.10(f) Agreement Preamble Alternate Financing 6.4(d) Alternative Acquisition Agreement 5.2(c5.3(b) Assignee 9.5(aAnnual Bonus 6.10(e) award 3.3(bAnti-Corruption Laws 3.24 Anti-Money Laundering Laws 3.25 Capitalization Date 3.7(a) Book-Entry Share 2.1(cCash Replacement Company PSU Amounts 2.8(c)(ii) business day 9.10(bCash Replacement Company RSU Amounts 2.8(b)(ii) CERCLA 3.18(bCash Replacement Option Amounts 2.8(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10 Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Commitment Letters 4.12(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.10(e) Company Plans 6.10(c) Company Related Parties 8.3(f)(ii) Company SEC Documents Article III Company Securities 3.7(d) Confidentiality Agreement 9.4 Copyrights 1.1(aaa) DGCL Recitals D&O Insurance 6.9(c) Data Protection Requirements 3.21 Debt Commitment Letter 4.12(a) Debt Financing 4.12(a) Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Equity Commitment Letters 4.12(a) Equity Financing 4.12(a) Export/Import Laws 3.26 FCPA 3.24 Final Exercise Date 2.8(e) Financing 4.12(a) Financing Sources 4.12(a) Guarantee Recitals Guarantor Recitals HMT 1.1(ooo) Indemnified Persons 6.9(a) Information Statement 6.3(b)(i) International Employee Plans 3.18(a) IP Contracts 3.16(d) Kaseya Parent 1.1(d) Lease 3.14 Leased Real Property 3.14 Marks 1.1(aaa) Maximum Annual Premium 6.9(c) Merger Recitals Merger Sub Preamble New Plan 6.10(d) No-Shop Period Start Date 5.3(a) Notice Period 5.3(e)(ii)(3) OFAC 1.1(ooo) Old Plans 6.10(d) Owned Company Shares 2.7(a)(iii) Owned Real Property 3.14 Parent Preamble Parent Breach Notice Period 8.1(g) Parent Disclosure Letter Article IV Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Related Parties 8.3(f)(i) Party Preamble Paying Patents 1.1(aaa) Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(bPer Share Price 2.7(a)(ii) Plans 3.16(aPersonal Information 3.21 Preferred Equity Commitment Letter 4.12(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPreferred Equity Financing 4.12(a) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(iiPreferred Equity Investors 4.12(a) Real Property 3.12(b3.14 Representatives 5.3(a) Regulation M-A 1.1(cRequired Amount 4.12(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Requisite Stockholder Approval 3.4 Sanctioned Persons 3.25 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Parent Termination Fee 8.2(b8.3(c)(i) Time-Third Party Financing 4.12(a) Uncertificated Shares 2.9(c) Unvested Company Option 2.8(a)(ii) Unvested Company PSU 2.8(c)(ii) Unvested Company RSU 2.8(b)(ii) Vested DSU 2.4(cEquity Award Consideration 2.8(c)(i) Top-Up Vested Option 1.10(aConsideration 2.8(a)(i) Top-Up Shares 1.10(aVested PSU Consideration 2.8(c)(i) UK Bribery Act 3.9(cVested RSU Consideration 2.8(b)(i) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Written Consent 3.4
Appears in 2 contracts
Samples: Merger Agreement (Datto Holding Corp.), Merger Agreement (Datto Holding Corp.)
INDEX OF DEFINED TERMS. Capitalized The following terms are defined elsewhere in this Agreement shall have the defined meanings that appear Agreement, as shown in the provisions of the Agreement listed table below. Acceptance Time 5.2(b: “Accounting Firm” Section 3.02(b) Acquisition Proposal 5.2(a“Acquired Competing Business” Section 7.11(c) “Acquired Person” Section 7.11(c) “Acquisition” Section 2.02 “Adverse Recommendation Change 5.2(cChange” Section 7.10(b) Affiliate 3.3(d“Advertising Contract” Section 4.18(a)(xx) Agreement “Agreed Accounting Principles” Schedule 3.02 “Agreement” Preamble Alternative Acquisition Agreement 5.2(c“Arbitration Panel” Section 14.10(a) Assignee 9.5(a“Cash and Cash Equivalents” Section 3.02(h) award 3.3(b“Closing” Section 2.03 “Closing Date” Section 2.03 “Competitor” Section 9.02(a) Book-Entry Share 2.1(c“Competitor List” Section 9.02(a) business day 9.10(b“Direct Claim” Section 12.04(b) CERCLA 3.18(b“Direct Claim Notice” Section 12.04(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals “Estimated Monsoon Closing Date 1.5 Code 2.6 Company Net Cash” Section 3.02(h) “ICDR” Section 13.10(a) “Indemnified Party” Section 12.04(a) “Indemnifying Party” Section 12.04(a) “Independent Directors” Section 8.02(a) “Indigo” Preamble Company “Indigo Balance Sheet 3.6(aSheet” Section 4.07(d) Company Board of Directors Recitals Company “Indigo Closing Date Working Capital” Section 3.02(a) “Indigo Current Assets” Section 3.02(h) “Indigo Current Liabilities” Section 3.02(h) “Indigo Directors” Section 8.02(b) “Indigo Financial Statements” Section 4.07(b) “Indigo Intellectual Property” Section 4.17(a) “Indigo Leased Real Property” Section 4.15 “Indigo Material Contracts” Section 4.18(b) “Indigo Minority Interests” Section 4.02(b) “Indigo Organizational Documents” Section 4.01 “Indigo Parent” Preamble “Indigo Parent Deductible” Section 12.01(b)(i) “Indigo Parent Disclosure Letter SECTION 3 Company Joint Venture 3.4(cLetter” Article IV “Indigo Parent Indemnitees” Section 12.02(a) Company’s knowledge 9.10(b“Indigo Permitted Indebtedness” Section 6.02(j) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) “Indigo Permitted Liens” Section 4.15 “Indigo Real Property 3.12(bLease” Section 4.15 “Indigo Securities” Section 4.03(a) Regulation M-A 1.1(c“Indigo Shares” Preamble “Indigo Working Capital” Section 3.02(h) Release 3.18(e)(iii“Interim Indigo Financial Statements” Section 4.07(b) Representatives 5.2(a“Labor Union” Section 4.11(h) Reporting Tail Endorsement 6.8(b“Liabilities” Section 4.07(d) Restraints 8.1(b)(i“Losses” Section 12.01(a) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a“Monsoon” Preamble “Monsoon Balance Sheet” Section 5.06(f) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Monsoon Cash” Section 3.02(h), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 2 contracts
Samples: Transaction Agreement (Naspers LTD), Transaction Agreement (MakeMyTrip LTD)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: 2018 and 2020 Performance Unit Consideration 6.9(e)(i)
(a) Acquisition Proposal 5.2(a1.1(b) Adverse Recommendation Change 5.2(cAdjusted Performance Unit Award 6.9(a)(ii) Adjusted RSU 2.8(b)(i) Affiliate 3.3(d1.1(c) Agreement Preamble Alternative Acquisition Antitrust Law 1.1(d) Approval Time 5.5(b) Australia Credit Agreement 5.2(c1.1(e) Assignee 9.5(aBonus Termination Percentage 6.9(f) award 3.3(bBusiness Day 1.1(f) Book-Entry Share 2.1(cBylaws 3.1(c) business day 9.10(bCanada Credit Agreement 1.1(g) CERCLA 3.18(bCancelled Shares 2.7(a)(iii) Capitalization Date 3.7(a) Cash Consideration 2.7(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c0 Certificates 2.9(d) Charter 1.1(h) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 Code 2.6 1.1(i) Company Preamble Company Balance Sheet 3.6(a2020 Bonus Pool 6.9(f) Company Board of Directors Recitals 1.1(j) Company Board Recommendation 3.3(a) Company Board Recommendation Change 5.5(a)(iii) Company Common Stock 1.1(k) Company Credit Agreement 1.1(l) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cDirector RSU 2.8(b)(ii) Company’s knowledge 9.10(bCompany Employee RSU 2.8(b)(i) Company ESPP 1.1(m) Company Indebtedness 1.1(n) Company Indenture 1.1(o) Company Intellectual Property 1.1(p) Company Material Adverse Effect 3.1(a1.1(q) Company Option 2.4(aOptions 1.1(r) Company Performance Unit Award 1.1(t) Company Preferred Stock 3.3(a1.1(u) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs 1.1(s) Company Restricted Stock 2.4(bRegistered Intellectual Property 3.15(a) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSUs 1.1(v) Company SEC Reports 3.5 3.9 Company Stockholder Approval 6.1 Securities 3.7(c) Company Stock Plans 2.4(a1.1(w) Company Subsidiary 3.4(aStockholder Meeting 6.4(a) Company Stockholders 1.1(x) Company Termination Fee 1.1(y) Confidentiality Agreement 1.2(c9.4 Continuation Period 6.9(c) Continuing Employee 6.11(bEmployees 1.1(z) CPR Recitals CPR Agreement Recitals Current Contract 1.1(aa) Converted Shares 2.7(a)(iii) Copyrights 1.1(rr) COVID-19 1.1(bb) COVID-19 Measures 1.1(cc) D&O Insurance 6.8(b) Delisting Period 6.3 Data Privacy Laws 1.1(dd) DGCL Recitals Director RSU Consideration 2.8(b)(ii) Dissenting Company Shares 2.3(a2.7(d)(i) DSU 2.4(cDividend Consideration 2.7(a)(ii) DOJ 1.1(ee) DTC 2.9(e) Effective Time 1.4 0 Effects 1.1(q) Electronic Delivery 9.13 Employee Release 6.11(dPlan 1.1(ff) Enforceability Exceptions 3.2 Environmental Laws 3.18(e)(i1.1(gg) ERISA 3.16(a) ERISA Affiliate 3.16(b1.1(hh) Exchange Act 1.1(a1.1(ii) Exchange Agent 2.9(a) Exchange Fund 2.2(a2.9(b) Expiration Date 1.1(aExchange Ratio Reduction Number 2.9(c) FCPA 3.9(c3.24 Foreign Plan 3.17(a) FDA 3.9(dFractional Entitlements 2.7(c) Good Clinical Practices 3.9(hFractional Share Consideration 2.7(c) Good Laboratory Practices 3.9(hFTC 1.1(jj) Good Manufacturing Practices 3.9(iGAAP 1.1(kk) Governmental Entity 9.10(bAuthority 1.1(ll) Governmental Authorization 1.1(mm) Group 1.1(nn) Hazardous Materials 3.18(e)(ii1.1(oo) HSR Act 3.19 IC Plans 6.11(a1.1(pp) Incentive Compensation Plan 6.11(aIndebtedness 1.1(qq) Indemnified Parties Persons 6.8(a) Independent Directors 6.9(aIntellectual Property 1.1(rr) IRS 3.16(aIntercompany Australia Facility Agreement 1.1(ss) Laws 3.9(bIntervening Event 1.1(tt) Layoff Laws 3.17(bXxxxxxxx 1.1(uu) Knowledge of Parent 1.1(vv) Knowledge of the Company 1.1(ww) LAOD Credit Agreement 1.1(xx) Law 1.1(yy) Lease 3.14(b) Leased Real Property 3.14(b) Legal Proceeding 1.1(zz) Lien 1.1(aaa) Loan 1.1(bbb) Loan Agreement 3.20 Marks 1.1(rr) Material Contract 1.1(ccc) Maximum Premium 6.8(b) Merger 1.3(aRecitals Merger Sub Preamble Multiemployer Plan 3.17(b) Merger New Plan 6.9(d) Non-Recourse Subsidiary 1.1(eee) NYSE 1.1(fff) ODAF Credit Agreement Annex I Merger 1.1(ggg) ODART Credit Agreement 1.1(hhh) Old Plans 6.9(d) Option Consideration 2.1(c2.8(d) Minimum Condition Annex I Notice Period 5.2(dOrder 3.22(b) OECD Convention 3.9(cOrganizational Documents 1.1(jjj) Offer Recitals Offer Condition 1.1(aOther Required Filing 6.3(b) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOwned Company Shares 2.7(a)(iii) Parent Preamble Paying Agent 2.2(aParent Board 1.1(kkk) Performance-Based DSU 2.4(cParent Common Stock 1.1(lll) Parent Disclosure Letter Article IV Parent Material Adverse Effect 7.3(a) Parent Options 1.1(nnn) Parent RSUs 1.1(ooo) Parent SEC Reports 4.8 Parent Securities 4.6(c) Parent Stock Plans 1.1(ppp) Parent Trading Price 1.1(qqq) Party Preamble Patents 1.1(rr) Permits 3.9 person 9.10(b3.19(b) Plans 3.16(aPermitted Liens 1.1(rrr) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPerson 1.1(sss) Program 3.9(kPersonal Data 1.1(ttt) Prohibited Payment 3.9(cPORT Credit Agreement 1.1(uuu) Proprietary Rights 3.12(aProcessing 1.1(vvv) Products 1.1(www) Proxy Statement 1.8(a)(ii) Real Property 3.12(b6.3(a)(i) Regulation MS-A 1.1(c) K 3.11 Release 3.18(e)(iii1.1(xxx) Representatives 5.2(a5.5(a) Reporting Tail Endorsement 6.8(bRequisite Filings 6.3(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bRequisite Stockholder Approval 3.4 Sanctions 3.24 SBAF Credit Agreement 1.1(zzz) SEC 1.1(a1.1(aaaa) Securities Act 3.11(c1.1(bbbb) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Security Breach 1.1(eeee), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 2 contracts
Samples: Merger Agreement (Enova International, Inc.), Merger Agreement (Enova International, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this 2021 First Lien Notes 8.6 2021 First Lien Notes Indenture 8.6 2021 First Lien Notes Trustee 8.6 2023 Company RSU 2.4(e) Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) 8.6 affiliate 8.6 agent 8.6 Agreement Preamble Alternate Debt Financing 5.13(d) Alternative Acquisition Agreement 5.2(cArrangement Contract 3.4(c) Assignee 9.5(aAnti-Corruption Laws 3.9(i) award 3.3(bAnti-Money Laundering Laws 8.6 Approval 8.6 BofA Securities 3.20 Book Entry Shares 2.6(c) Book-Entry Share 2.1(cBurdensome Condition 5.5(d) business day 9.10(bBusiness Day 8.6 Cancelled Shares 2.1(a) CERCLA 3.18(bCapital Expenditure Budget 5.1(a)(xi) CARES Act 8.6 Certificate of Merger 1.4 Certificate 2.1(c1.3 Certificates 2.6(b) Change of Recommendation 5.4(b) Change of Recommendation Notice 5.4(f) Claims 8.6 Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 3.11(e) Collective Bargaining Agreement 8.6 Commitment Letters 4.9(a) Common Stock 2.1 Company Preamble Company Balance Sheet 3.6(a) Acquisition Proposal 8.6 Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Schedule Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployees 3.12(a) Company Material Adverse Effect 3.1(aIP 3.14(a) Company LTI Awards 2.4(f) Company Option Award 2.4(a) Company Preferred Stock 3.3(aRecommendation 3.3(b) Company Quarterly Balance Sheet 3.7 Related Party 8.6 Company Restricted Share 2.4(bReports 3.5(a) Company Restricted Stock 2.4(bSeverance Plan 5.6(b) Company Rights 3.3(aStock Plan 2.4(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 3.19 Company Stock Plans 2.4(aStockholders Meeting 5.3(b) Company Subsidiary 3.4(a) Superior Proposal 8.6 Company Termination Fee 8.6 Company Warrant 2.2 Compliance Requirements 8.6 Confidentiality Agreement 1.2(c8.6 Continuing Employees 5.6(a) Continuing Employee 6.11(bContract 8.6 control 8.6 Converted Award 2.4(e) CPR Recitals CPR Copyrights 8.6, 8.6 COVID-19 8.6 COVID-19 Actions 8.6 COVID-19 Measures 8.6 Credit Agreement Recitals Current 8.6 Credit Agreement Payoff Amount 5.17(a) D&O Insurance 6.8(b5.7(b) Delisting Period 6.3 Data Protection Obligations 3.14(i) Debt Commitment Letter 4.9(a) Debt Financing 4.9(a) DGCL Recitals 1.1 Dissenting Shares 2.3(a2.5(a) DSU 2.4(c) DPA 4.11 Effect 8.6 Effective Time 1.4 Employee Release 6.11(d1.3 End Date 7.1(c) Environmental Laws 3.18(e)(i3.15(b)(i) Equity Commitment Letter 4.9(a) Equity Financing 4.9(a) Equity Syndication 5.18 ERISA 3.12(a) ERISA 3.16(a) ERISA Affiliate 3.16(bAffiliates 3.12(c) Exchange Act 1.1(a3.5(a) Exchange Fund 2.2(aExempted Person 8.6 Expense and Interest Payments 7.2(e) Expiration Extended End Date 1.1(a7.1(c) FCPA 3.9(cFamilies First Act 8.6 Fee Letter 4.9(a) FDA 3.9(dFinancing 4.9(a) Good Clinical Practices 3.9(hForeign Benefit Plan 3.12(g) Good Laboratory Practices 3.9(hForeign Regulatory Filings 5.5(a) Good Manufacturing Practices Foreign Regulatory Laws 3.4(a) Government Official 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) 8.6 Guarantor 8.6 HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.4(a) Indemnified Parties 6.8(a5.7(a) Independent Directors 6.9(aIndenture Redemption Amount 5.17(b) IRS 3.16(aInfringing 8.6 Initial End Date 7.1(c) Insurance Amount 5.7(b) Insurance Policies 3.17 Intellectual Property 8.6 International Trade Laws 3.9(b8.6 Intervening Event 8.6 IT Assets 3.14(m)(i) Layoff Laws 3.17(bknowledge 8.6 Law 8.6 Leases 3.16(b) Maximum Premium 6.8(bLegal Requirement 8.6 Lender Related Party 8.6 Lenders 8.6 Liens 8.6 Limited Guarantee Recitals LTI Award Consideration 2.4(f) Marketing Period 8.6 Marks 8.6, 8.6 Material Adverse Effect 8.6 Material Contract 3.10(a) Materials of Environmental Concern 8.6 Merger Recitals Merger Consideration 2.1(b) Merger 1.3(aSub Preamble Misconduct 3.13(e) Merger Agreement Annex I Merger Consideration 2.1(cMoney Transfer Agent 8.6 Money Transfer Change of Control Filings 5.5(a) Minimum Condition Annex I Money Transmitter License 8.6 Money Transmitter Requirements 8.6 NASDAQ 8.6 New Approval 5.18 New Debt Commitment Letters 5.13(d) Notice Period 5.2(d5.4(e)(iii) OECD Convention 3.9(cOFAC 8.6 Open Source License 8.6 Open Source Software 3.14(g) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOrder 8.6 Parent Preamble Parent Disclosure Schedule Article IV Parent Liability Limitation 7.2(e) Parent Preamble Material Adverse Effect 8.6 Parent Plans 5.6(c) Parent Related Party 8.6 Parent Termination Fee 8.6 Patents 8.6, 8.6 Paying Agent 2.2(a2.6(a) PBGC 3.12(e) Permitted Co-Investor 8.6 Permitted Lien 8.6 Permitted LP 8.6 Permitted Preferred Purchaser 8.6 person 8.6 Personal Data 3.14(m)(ii) Plan 3.12(a) Pre-2023 Company Performance Cash Award 2.4(d) Pre-2023 Company Performance-Based DSU RSU Award 2.4(c) Permits 3.9 person 9.10(bPre-2023 Company Time-Based RSU Award 2.4(b) Plans 3.16(aPrior Bidder 5.4(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPrivacy Laws 3.14(m)(iii) Program 3.9(kPrivacy Policy 3.14(m)(iv) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aLP 8.6 Protection Period 5.6(a) Proxy Statement 1.8(a)(ii3.4(a) Real Property 3.12(bRegistered IP 3.14(a) Regulation M-A 1.1(c) Release 3.18(e)(iii) Related Software 8.6 Representatives 5.2(a) Reporting Tail Endorsement 6.8(bRequired Financial Information 8.6 Required Financing Amount 4.9(d) Restraints 8.1(b)(iRequired Money Transfer Approval 6.2(c) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aSanctions 3.9(g) Sanctions Authority 3.9(g) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b3.5(a) SEC 1.1(a) 8.6 Securities Act 3.11(c3.5(a) Severance 6.11(dSecurity Incident 3.14(l) Securityholder 8.6 Shares Recitals Special Meeting 1.8(a)(i2.1 Software 8.6 Solicitation Period End Date 5.4(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Standstill Agreement 8.6 Subsidiary 8.6 Superior Proposal 5.2(bNotice 5.4(e)(ii) Surviving Corporation 1.3(a) Company 1.1 Tax 3.15(a) Taxable 3.15(a3.11(q)(i) Tax Return 3.15(a3.11(q)(ii) Tender Completion Time 6.2 Tender Transaction Documents 8.6 U.S. GAAP 8.6 WARN Act 3.13(c) Warrant Consideration 2.2 Willful and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS Material Breach 8.6 This AGREEMENT AND PLAN OF MERGER MERGER, dated as of February 14, 2022 (as amended, supplemented or otherwise modified from time to time, this “Agreement”) dated as of October 24), 2011 is entered into by and among CUBIST PHARMACEUTICALSMobius Parent Corp., INC. a Delaware Corporation (“Parent”), Mobius Merger Sub, Inc., a Delaware corporation, FRD ACQUISITION CORPORATION corporation and a Subsidiary of Parent (“Merger Sub”), and MoneyGram International, Inc., a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 2 contracts
Samples: Merger Agreement (Moneygram International Inc), Merger Agreement (Moneygram International Inc)
INDEX OF DEFINED TERMS. Capitalized The following terms in this Agreement shall have the defined meanings that appear in the provisions of the ascribed to them, as indicated below: 2010 Health Care Law 4.12(d) Acceptable Confidentiality Agreement listed below. 10.01(a) Acceptance Time 5.2(b1.03(a) Acquisition Proposal 5.2(aAgreement 6.02(e) Adverse Recommendation Change 5.2(c6.02(e) Affiliate 3.3(d10.01(b) Agreement Preamble Alternative Acquisition Agreement 5.2(cArticles of Merger 2.03 Authorizations 4.10(a) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(cBoard Actions 4.04(b) business day 9.10(b) CERCLA 3.18(b10.03(e) Certificate of Merger 1.4 Certificate 2.1(c3.01(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 10.01(d) Company Preamble Company Balance Sheet 3.6(aBenefit Agreement 4.12(o) Company Board of Directors Benefit Plan 4.12(o) Company Bylaws 4.01 Company Charter 4.01 Company Common Stock Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b10.01(e) Company Material Adverse Effect 3.1(aEmployee 7.04(a) Company Option 2.4(aExecutive Team 10.01(f) Company Incentive Plan 4.03(a) Company Intellectual Property 4.15(a) Company Noncompete Restrictions 4.09(a)(v) Company Owned Intellectual Property 4.15(b) Company Preferred Stock 3.3(a4.03(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bProduct 10.01(g) Company Restricted Stock 2.4(bRegistered Intellectual Property 4.15(a) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aCompensation Committee 4.12(g) Confidentiality Agreement 1.2(c10.01(h) Continuing Employee 6.11(bContract 4.05 Current Premium 7.05(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Department 2.03 Effective Time 1.4 Employee Release 6.11(d2.03 Environmental Claims 4.16(b) Environmental Laws 3.18(e)(iLaw 4.16(b) ERISA 3.16(a4.12(a) ERISA Affiliate 3.16(b4.12(e) Exchange Act 1.1(a1.01(a) Exchange Fund 2.2(a3.03(a) Expiration Date 1.1(aExclusive Rights 4.09(a)(v) FCPA 3.9(cFairness Opinion 4.25 FDA 4.18(a) FDA 3.9(dFiled SEC Documents IV Fully Diluted Shares 10.01(i) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP 4.06(b) Governmental Entity 9.10(bAuthority 4.05 Guaranteed Obligations 11.12(a) Hazardous Materials 3.18(e)(ii4.16(b) Health Care Laws 10.01(k) HIPAA 10.01(l) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”4.05 Indebtedness 6.01(a)(viii), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 2 contracts
Samples: Merger Agreement (Smith & Nephew PLC), Merger Agreement (Osiris Therapeutics, Inc.)
INDEX OF DEFINED TERMS. Capitalized The following terms in this Agreement shall have the defined meanings that appear in the provisions of the ascribed to them, as indicated below: 2010 Health Care Law 4.12(d) Acceptable Confidentiality Agreement listed below. 10.01(a) Acceptance Time 5.2(b1.04(a) accredited investor 1.03(c) Acquisition Proposal 5.2(aAgreement 6.02(e) Adverse Recommendation Change 5.2(c6.02(e) Affiliate 3.3(d10.01(b) Agreement Preamble Alternative Acquisition Agreement 5.2(cArticles of Merger 2.03 Authorizations 4.10(a) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(cBoard Actions 4.04(c) business day 9.10(b) CERCLA 3.18(b10.01(c) Certificate 3.01(c) Code 1.01(i) Committee of Merger 1.4 Certificate 2.1(cDisinterested Directors 4.04(b) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a401(k) Plan 4.03(a) Company Articles of Incorporation 4.01 Company Benefit Agreement 4.12(p) Company Benefit Plan 4.12(p) Company Board of Directors Recitals Company By-Laws 4.01 Company Common Stock Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b10.01(d) Company Material Adverse Effect 3.1(aDSUs 4.03(a) Company Option 2.4(aEmployee 7.05(a) Company Equity Awards 4.03(a) Company Executive Team 10.01(e) Company Incentive Plans 4.03(a) Company Intellectual Property 10.01(f) Company Noncompete Restrictions 4.09(a)(v) Company Preferred Stock 3.3(a4.03(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs 4.03(a) Company Restricted Stock 2.4(bAwards 4.03(a) Company Rights 3.3(aRSUs 4.03(a) Company Rights Agreement 3.3(aStock Options 4.03(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aSwaps 4.22 Compensation Committee 4.12(g) Confidentiality Agreement 1.2(c10.01(g) Continuing Employee 6.11(bContract 4.05 Current Premium 7.06(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bDissenters’ Rights 3.01(d) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c3.01(d) Effective Time 1.4 Employee Release 6.11(d2.03 Environmental Claims 4.16(b) Environmental Laws 3.18(e)(iLaw 4.16(b) Equity Award Amounts 3.04(f) ERISA 3.16(a4.12(a) ERISA Affiliate 3.16(b4.12(e) Exchange Act 1.1(a1.01(a)
(a) Exchange Fund 2.2(aExclusive Rights 4.09(a)(v) Expiration Date 1.1(aExisting Credit Agreement 10.01(h) FCPA 3.9(cFairness Opinion 4.27 FDD 4.18(g) FDA 3.9(dFiled SEC Documents IV Foreign Company Plan 4.12(n) Good Clinical Practices 3.9(hFranchise 4.18(a) Good Laboratory Practices 3.9(hFranchise Laws 4.10(b) Good Manufacturing Practices 3.9(iFranchised Restaurant 4.18(a) Franchisee 4.18(g) FTC Rule 4.10(b) Fully Diluted Shares 1.03(a) GAAP 4.06(b) Governmental Entity 9.10(bAuthority 4.05 group 6.02(b)(ii) Hazardous Materials 3.18(e)(ii4.16(b) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a4.05 Indebtedness 6.01(a)(viii) Indemnified Parties 6.8(aParty 7.06(b) Independent Directors 6.9(a1.04(a) IRS 3.16(aInitial Offer Expiration Date 1.01(d) Laws 3.9(bIntellectual Property 4.15(f) Layoff Laws 3.17(bIntermediate Parent Preamble Intervening Event 6.02(b)(iv) Maximum Premium 6.8(bJudgment 4.05 Key Intellectual Property 4.15(a) Knowledge 10.01(i) Law 4.05 Leased Real Property 4.14(b) Liens 4.02 Litigation 4.08 Master Franchise Rights 4.09(a)(v) Match Right Notice 6.02(h) Material Adverse Effect 10.01(j) MBCA Recitals Measurement Time 4.03(a) Merger 1.3(a) Recitals Merger Agreement Annex I Closing 2.02 Merger Closing Date 2.02 Merger Consideration 2.1(c3.01(c) Minimum Tender Condition Annex I Notice Period 5.2(d11.13 NASDAQ 1.04(a) OECD Convention 3.9(cNew Specified Contracts 6.01(a)(xv) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) PerformanceNon-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.U.S. Merger Control Laws 4.05
Appears in 2 contracts
Samples: Merger Agreement (Restaurant Brands International Inc.), Merger Agreement (Popeyes Louisiana Kitchen, Inc.)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the capitalized terms below: Acceptable Confidentiality Agreement listed below. Acceptance Time 5.2(bSection 1.1(a) Acquisition Proposal 5.2(aSection 1.1(c) Adverse Recommendation Change 5.2(cAcquisition Transaction Section 1.1(d) Affiliate 3.3(dSection 1.1(e) Agreement Preamble Alternative Acquisition Agreement 5.2(cSection 5.3(a) Assignee 9.5(aAntitrust Laws Section 1.1(f) award 3.3(bAudited Company Balance Sheet Section 1.1(g) Book-Entry Share 2.1(cBusiness Day Section 1.1(h) business day 9.10(bCash Consideration Section 2.7(a)(iii)(1) CERCLA 3.18(bCash Election Section 2.7(b)(ii) Cash Election Stock Section 2.7(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cSection 2.2 Certificates Section 2.9(d) Chosen Courts Section 9.10 Closing 1.5 Closing Amount Recitals Section 2.3 Closing Date 1.5 Section 2.3 Code 2.6 Section 1.1(q) Collective Bargaining Agreement Section 3.19(a) Company Preamble Company Balance Sheet 3.6(a401(k) Plan Section 6.9(c) Company Board of Directors Recitals Section 1.1(r) Company Disclosure Letter SECTION 3 Board Recommendation Change Section 5.3(c)(i) Company Joint Venture 3.4(cCapital Stock Section 1.1(s) Company’s knowledge 9.10(bCompany Common Stock Section 1.1(t) Company Director RSU Section 2.8(c) Company Equity Plans Section 1.1(u) Company ESPP Section 1.1(v) Company Intellectual Property Section 1.1(w) Company Loan Agreement Section 1.1(x) Company Material Adverse Effect 3.1(aSection 1.1(y) Company Option 2.4(aPersonal Information Section 3.16(l) Company Preferred Stock 3.3(aSection 1.1(z) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs Section 1.1(aa) Company Restricted Stock 2.4(bRegistered Intellectual Property Section 1.1(bb) Company Rights 3.3(aRelated Parties Section 8.3(f)(i) Company Rights Agreement 3.3(aRSUs Section 1.1(cc) Company SEC Reports 3.5 Software Section 3.16(e) Company Stockholder Approval 6.1 Company Stock Plans 2.4(aMeeting Section 6.4(a) Company Subsidiary 3.4(aStockholders Section 1.1(dd) Company Termination Fee Section 1.1(ee) Confidentiality Agreement 1.2(cSection 9.4 Continuing Employees Section 1.1(ff) Continuing Employee 6.11(bContract Section 1.1(gg) CPR Recitals CPR Agreement Recitals Current Controlled Group Liability Section 1.1(ii) Copyrights Section 1.1(mmm) COVID-19 Section 1.1(kk) Customs & Trade Laws Section 1.1(ll) D&O Insurance 6.8(bSection 6.8(c) Delisting Period 6.3 DGCL Recitals Dissenting Company Shares 2.3(aSection 2.7(f) DSU 2.4(cDTC Section 2.9(e) DTC Payment Section 2.9(e) Effect Section 1.1(y) Effective Time 1.4 Section 2.2 Elected Share Consideration Section 2.7(c) Election Section 2.7(b)(ii) Election Deadline Section 2.7(b)(i) Election Form Section 2.7(b)(i) Electronic Delivery Section 9.13 Employee Release 6.11(dPlan Section 1.1(uu) Environmental Laws 3.18(e)(iLaw Section 1.1(vv) Environmental Permits Section 1.1(ww) ERISA 3.16(aSection 1.1(xx) ERISA Affiliate 3.16(bSection 1.1(yy) Excess Amount Section 2.7(c) Exchange Act 1.1(aSection 1.1(zz) Exchange Agent Section 2.9(a) Exchange Fund 2.2(aSection 2.9(b) Expiration Date 1.1(aFinal Purchase Period Section 2.8(d) FCPA 3.9(cForeign Investment Laws Section 1.1(ccc) FDA 3.9(dForeign Plan Section 3.18(j) Good Clinical Practices 3.9(hForm F-4 Section 6.3(b) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP Section 1.1(ddd) Governmental Entity 9.10(bAuthority Section 1.1(eee) Governmental Authorization Section 1.1(hhh) Group Section 1.1(iii) Hazardous Materials 3.18(e)(iiSubstance Section 1.1(jjj) HSR Act 3.19 IC Plans 6.11(aSection 1.1(kkk) Incentive Compensation Plan 6.11(aImprovements Section 3.14(c) Indebtedness Section 1.1(mmm) Indemnified Parties Person Section 6.8(a) Independent Directors 6.9(aIndemnified Persons Section 6.8(a) Intellectual Property Section 1.1(mmm) Intervening Event Section 1.1(ooo) IRS 3.16(aSection 1.1(ppp) Laws 3.9(bKnowledge Section 1.1(qqq) Layoff Laws 3.17(bLaw Section 1.1(rrr) Legal Proceeding Section 1.1(sss) Mailing Date Section 2.7(b)(i) Marks Section 1.1(mmm) Material Contract Section 1.1(ttt) Maximum Annual Premium 6.8(bSection 6.8(c) Maximum Stock Amount Section 1.1(uuu) Merger 1.3(aRecitals Merger Sub Preamble Mixed Consideration Section 2.7(a)(iii)(3) Merger Agreement Annex I Merger Mixed Consideration 2.1(cExchange Ratio Section 1.1(uuu) Minimum Condition Annex I Mixed Election Section 2.7(b)(ii) Mixed Election Stock Section 2.7(b)(ii) Multiemployer Plan Section 3.18(b) NASDAQ Section 1.1(vvv) Notice Period 5.2(dSection 5.3(d)(ii)(3) OECD Convention 3.9(cOpen Source Definition Section 1.1(aaaa) Offer Recitals Offer Condition 1.1(aOpen Source License Section 1.1(aaaa) Offer Order Section 1.1(bbbb) Organizational Documents 1.1(cSection 1.1(cccc) Offer Price Recitals Offer to Purchase 1.1(aOther Required Filing Section 6.3(c) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOwned Real Property Section 3.14(a) Parent ADSs Section 2.7(a)(iii)(3) Parent Material Adverse Effect Section 1.1(dddd) Parent Related Parties Section 8.3(f)(ii) Parent RSU Section 2.8(a) Parent Termination Fee Section 1.1(ffff) Party Preamble Paying Agent 2.2(aPatents Section 1.1(mmm) Performance-Based DSU 2.4(cPayoff Letters Section 6.16 Permitted Liens Section 1.1(gggg) Permits 3.9 person 9.10(bPerson Section 1.1(hhhh) Plans 3.16(aPersonal Information Section 1.1(iiii) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPrivacy Laws Section 1.1(hhhh) Proxy Statement 1.8(a)(iiSection 6.3(a) Real Property 3.12(bLeases Section 3.14(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiRegistered Intellectual Property Section 1.1(kkkk) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aSection 1.1(mmmm) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bSection 1.1(rrrr) SEC 1.1(aSection 1.1(ssss) Securities Act 3.11(cSection 1.1(tttt) Severance 6.11(dShare Consideration Section 2.7(a)(iii)(2) Shares Recitals Special Meeting 1.8(a)(iShare Consideration Exchange Ratio Section 1.1(ssss) Sub Preamble Sub Common Share Election Section 2.7(b)(ii) Share Election Stock 2.1 Successor Plan 6.11(cSection 2.7(b)(ii) Software Section 1.1(tttt) Subsidiary Section 1.1(yyyy) Superior Proposal 5.2(bSection 1.1(zzzz) Surviving Corporation 1.3(aSection 2.1 Surviving Corporation 401(k) Plan Section 6.9(c) Tax 3.15(a) Taxable 3.15(aSection 1.1(aaaaa) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dSection 1.1(ccccc) Termination Fee 8.2(bDate Section 8.1(c) Time-Vested DSU 2.4(cTransaction Section 1.1(ddddd) Top-Up Option 1.10(aTransaction Litigation Section 1.1(eeeee) Top-Up Treasury Regulations Section 1.1(fffff) Uncertificated Shares 1.10(aSection 2.9(d) UK Bribery Act 3.9(cUnited States Section 1.1(ggggg) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”VDR Section 1.3(q) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”WARN Section 1.1(hhhhh), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 2 contracts
Samples: Merger Agreement (Infinera Corp), Merger Agreement (Nokia Corp)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAnnual Bonus 6.10(d) award 3.3(bAnti-Corruption Laws 3.14 Assumed Restricted Stock Award 2.8(b) BookAssumed RSU Award 2.8(c)(iii) Capitalization Date 3.5(a) Care Professional 3.12(e) Cash-Entry Share 2.1(cOut Equity Award Consideration 2.8(c)(i) business day 9.10(bCash-Out Equity Award Holders 2.8(f) CERCLA 3.18(bCash-Out Option Consideration 2.8(a)(i) Cash-Out RSU Consideration 2.8(c)(i) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.11 Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.2(b) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.10(d) Company Information Systems 3.26(a) Company Related Parties 8.3(e)(i) Company SEC Documents Article III Company Securities 3.5(e) Company Stockholder Meeting 6.4(a) Converted Option Cash Award 2.8(a)(ii) Converted RSU Cash Award 2.8(c)(ii) Counterparties 1.1(l) D&O Insurance 6.9(c) De-Identified Data 3.26(g) DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.15 Enforceability Exceptions 3.2(a) Extended Termination Date 8.1(c) Indemnified Persons 6.9(a) Initial Termination Date 8.1(c) Leased Real Property 3.15(c) Material Contract 3.22(b) Material Real Property Lease 3.15(c) Maximum Annual Premium 6.9(c) Merger Recitals Merger Sub Preamble New Plan 6.10(e) Notice Period 5.3(c)(ii)(A) OIG 3.12(f) Old Plan 6.10(e) Other Indemnified Persons 6.9(e) Other Required Company Filing 6.3(b) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent 401(k) Plan 6.10(f) Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Related Parties 8.3(e)(ii) Parent Termination Fee 8.3(c) Party Preamble Paying Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPayoff Debt 6.5 Per Share Price 2.7(a)(ii) Proxy Statement 1.8(a)(ii6.3(a) Real Qualifying Termination 6.10(d) Registered Owned Intellectual Property 3.12(b3.16(e) Regulation M-A 1.1(cRemedial Actions 6.2(b) Release 3.18(e)(iiiRequisite Stockholder Approval 3.2(a) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Security Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b3.26(c) Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aUltimate Parent Preamble Uncertificated Shares 2.9(c) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Withholding Agent 2.12
Appears in 2 contracts
Samples: Merger Agreement (CVS HEALTH Corp), Merger Agreement (Oak Street Health, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the Agreement listed section or place indicated below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c: AAA Section 9.4(b) Affiliate 3.3(dSection 1.3(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cArbitration Section 9.4(b) Assignee 9.5(aAuthorizations Section 2.17 Base Closing Payment Section 1.3(a) award 3.3(bBase Purchase Price Section 1.3(a) Book-Entry Share 2.1(cBenefit Plans Section 2.21(a) business day 9.10(bBuyer Preamble Buyer Indemnified Parties Section 7.2 CERCLA Section 2.22(c) CERCLA 3.18(bCanadian Affiliate Property Section 2.11(a) Certificate of Merger 1.4 Certificate 2.1(cCanadian Subsidiary Section 1.3(a) Closing 1.5 Section 1.2 Closing Amount Recitals Cash Section 1.3(a) Closing Date 1.5 Section 1.2 Closing Indebtedness Section 1.3(a) Closing Payment Certificate Section 1.3(b) Closing Prepaid Taxes Section 1.3(a) Closing 338(h)(10) Tax Amount Section 1.3(a) Closing Working Capital Section 1.3(a) Closing Working Capital Adjustment Section 1.3(a) Closing Working Capital Closing Payment Section 1.3(a) Code 2.6 Section 1.3(a) Commitment Letter Section 5.21 Company Preamble Company Balance Sheet 3.6(a) Charter Documents Section 2.1 Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIntellectual Property Section 2.13(a) Company Material Adverse Effect 3.1(aSection 1.3(a) Company Option 2.4(aTechnology Section 2.13(a) Company Preferred Stock 3.3(aContest Section 5.7(d) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bCut-Off Date Section 7.1 Debt Financing Section 5.21 Deferred Working Capital Amount Section 1.3(a) Company Restricted Stock 2.4(bDesignated Liabilities Section 1.3(a) Company Rights 3.3(aDisclosure Supplement Section 5.6(a) Company Rights Agreement 3.3(aDetermination Date Section 1.6(c) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aDisabling Device Section 2.13(d) Company Subsidiary 3.4(aDisputed Items Section 1.6(b) Confidentiality Agreement 1.2(cDisputed Items Notice Section 1.6(b) Continuing Employee 6.11(bElection Date Section 2.18(d) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bEnvironment Section 2.22(c) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(dEnvironmental Claim Section 2.22(c) Environmental Laws 3.18(e)(iSection 2.22(c) Environmental Liabilities Section 2.22(c) ERISA 3.16(aSection 2.21(a) ERISA Affiliate 3.16(bEscrow Agent Section 1.3(a) Exchange Act 1.1(aEscrow Agreement Section 1.3(a) Exchange Escrow Fund 2.2(aSection 1.3(a) Expiration Date 1.1(aEstimated Closing Cash Section 1.3(a) FCPA 3.9(cEstimated Closing Indebtedness Section 1.3(a) FDA 3.9(dEstimated Closing Prepaid Taxes Section 1.3(a) Good Clinical Practices 3.9(hEstimated Closing 338(h)(10) Good Laboratory Practices 3.9(hTax Amount Section 1.3(a) Good Manufacturing Practices 3.9(iEstimated Closing Working Capital Adjustment Section 1.3(a) Estimated Closing Working Capital Closing Payment Section 1.3(a) Estimated Sellers’ Expenses Section 1.3(a) Existing Edmonton Facility Lease Section 1.3(a) Existing Houston Facility Lease Section 1.3(a) Financial Statements Section 2.8 Financing Sources Section 1.3(a) GAAP Section 1.3(a) Governmental Entity 9.10(bAuthority Section 1.3(a) Hazardous Materials 3.18(e)(iiSubstances Section 2.22(c) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(aSection 5.4(b) Independent Directors 6.9(aAccounting Firm Section 1.6(c) IRS 3.16(aInsurance Policies Section 2.23 Intellectual Property Section 2.13(a) Laws 3.9(bIP Licenses Section 2.13(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger Knowledge Section 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions Each of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) following terms is defined on the page set forth below opposite such term: Term: Section: Agreement Preamble Alternative Acquisition Agreement 5.2(cBalance Sheet Date 4.9 Breaching Company Stockholder 9.4(g) Assignee Business Recitals Buyer Preamble Buyer Indemnified Parties 9.2 Claim Notice 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClaim Response 9.5(c) Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Closing Payment 3.1(a) Company Preamble Company Balance Sheet 3.6(aIntellectual Property 4.21(c) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aStockholders Preamble Confidential Information 7.5(a) Confidentiality Agreement 1.2(c10.1 Deductible Amount 9.4(a) Continuing Employee 6.11(bEarnout End Date 3.1(c)(iii) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bEarnout Payments 3.1(c)(i) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aEarnout Share Value 3.1(c)(ii) DSU 2.4(cEmployment Agreements 2.3(a)(xi) Effective Time 1.4 Employee Release 6.11(dEquipment 4.11 Financial Statements 4.9 Fractional Interest 2.3(a)(xviii) Environmental Laws 3.18(e)(iFundamental Representations 9.1(a) ERISA 3.16(aFunds Flow Certificate 2.3(a)(xvii) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aIndemnification Claim 9.5(a) Indemnified Party 9.5(a) Indemnifying Party 9.5(a) LBH 4.31 Leased Real Property 4.14 Leases 4.14 Licenses and Permits 4.24 Material Contracts 4.6(a) Term: Section: Members ARTICLE IV Membership Interests 4.4(b) Non-Breaching Company Stockholder 9.4(g) Overall Cap 9.4(b) Owned Intellectual Property 4.21(a) Partners ARTICLE IV Partnership Interests 4.4(c) Party or Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cTax Period 7.1(a) Program 3.9(kPromissory Note 3.1(b) Prohibited Proposed Earnout Payment 3.9(c3.1(c)(iv) Proprietary Rights 3.12(aPurchase Price 3.1 RBA New Jersey Preamble Response Period 9.5(c) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(aRule 144 5.8(f) Securities Act 3.11(c3.2(c) Severance 6.11(d) Seller Indemnified Parties 9.3 Shares Recitals Special Meeting 1.8(a)(iStockholder Representative Preamble Stockholders ARTICLE IV Straddle Period 7.1(b) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(aStraddle Period Returns 7.1(b) Tax 3.15(aContest 7.1(d) Taxable 3.15(aThird Party Claim 9.5(e) Tax Return 3.15(a2016 Additional Shares 3.1(c)(i)(A) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up 2017 Additional Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.1(c)(i)(B), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location Acceptable Contango Confidentiality Agreement shall have the defined meanings that appear in the provisions of the 5.3(a) Acceptable Mid-Con Confidentiality Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Action 3.10 Affiliate 3.3(d8.3(a) Agreement Preamble Alternative Acquisition Asset Purchase Agreement 5.2(c) Assignee 9.5(a) award 3.3(bRecitals Available Negotiation Expenses Pool 8.3(b) Book-Entry Share 2.1(cUnits 2.3(b) business day 9.10(bBusiness Day 8.3(c) CERCLA 3.18(bcapital stock 8.3(d) Certificate of Merger 1.4 Certificate 2.1(c1.1(b) Certificates 2.3(b) CG&A 3.20(a) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 Code 2.6 Company 1.2 Xxxx 4.20(a) COBRA 3.12(c)(vi) Commodity Derivative Instrument 3.16(a)(xviii) Confidentiality Agreement 5.5 Consent Statement/Proxy Statement/Prospectus 3.8 Contango Preamble Company Balance Sheet 3.6(aContango Acquisition Proposal 5.3(f)(i) Company Definition Location Contango Adverse Recommendation Change 5.3(b)(i) Contango Alternative Acquisition Agreement 5.3(b)(ii) Contango Base Amount 7.3(c)(ii) Contango Board of Directors Recitals Company Contango Bylaws 4.4 Contango Common Stock 2.1(a)(i) Contango Designated Proposal 5.3(f)(ii) Contango Designated Proposal Negotiation Period 5.3(b) Contango Disclosure Letter SECTION 3 Company Joint Venture 3.4(cArticle IV Contango Expenses 7.3(b)(i) Company’s knowledge 9.10(bContango Group Entities 8.3(e) Company Contango Intellectual Property 4.21 Contango Intervening Event 5.3(f)(iii) Contango Intervening Event Negotiation Period 5.3(b) Contango Leased Real Property 4.18 Contango Material Adverse Effect 3.1(a8.3(f) Company Option 2.4(aContango Material Contract 4.16(a) Company Contango Owned Real Property 4.18 Contango Parties Preamble Contango Plan 8.3(g) Contango Preferred Stock 3.3(a4.2(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Contango Real Property Lease 4.18 Contango Reimbursement Amount 7.3(b)(i) Contango Related Party 4.24 Contango Reserve Report 4.20(a) Contango SEC Documents 4.6(a) Contango Shareholder Approval 4.4 Contango Special Shareholders Meeting 5.4(a) Contango Stock Issuance Recitals Contango Subsidiaries 8.3(h) Contango Termination Amount 7.3(c)(i) Contango Termination Fee 7.3(c)(ii) Contango Written Consent 8.3(i) Contract 3.5(a) control 8.3(j) Controlled Group 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO Delaware Secretary of State 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Section 5.3(i)(i) Acceptance Time 5.2(bSection 1.1(a) Acquisition Proposal 5.2(aSection 5.3(i)(ii); Section 7.3(c)(i) Adjusted Exchange Ratio Section 2.1(c) Adverse Recommendation Change 5.2(cSection 5.3(d) Aggregate Consideration Section 2.1(d) Affiliate 3.3(d) Section 8.12 Agreement Preamble Alternative Acquisition Agreement 5.2(cAppraisal Cash Amount Section 8.12 Appraisal Rights Section 2.2(i) Assignee 9.5(aAssets Section 3.15 Assumed Options Section 2.1(f)(i) award 3.3(bAssumed RSUs Section 2.1(f)(ii) Beneficial Owner Section 8.12 Book-Entry Share Shares Section 2.1(c) business day 9.10(b) CERCLA 3.18(b) Business Day Section 8.12 Cash Consideration Recitals Certificate of Merger 1.4 Certificate Section 2.1(c) Class A Common Stock Recitals Class B Common Stock Recitals Closing Section 1.5 Closing Amount Recitals Closing Date Section 1.5 Code 2.6 Recitals Company Preamble Company Balance Sheet 3.6(aBenefit Plan Section 8.12 Company Board Recitals Company Business Personnel Section 3.12(a) Company Board of Directors Capital Stock Section 3.2(a) Company Common Stock Recitals Company Credit Agreement Section 5.16(a) Company Determination Section 3.3(b) Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Article III Company Material Adverse Effect 3.1(a) Section 8.12 Company Option 2.4(a) Material Contract Section 8.12 Company Material Intellectual Property Section 8.12 Company NDA Section 8.12 Company Preferred Stock 3.3(aSection 3.2(a) Company Quarterly Balance Sheet 3.7 Recommendation Recitals Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSU Section 2.1(f)(ii) Company SEC Reports 3.5 Documents Section 3.5(a) Company Stockholder Approval 6.1 SEC Financial Statements Section 3.5(c) Company Stock Option Section 2.1(f)(i) Company Stock Plans 2.4(aSection 2.1(f)(i) Company Subsidiary 3.4(aSection 3.1(c) Confidentiality Agreement 1.2(cSection 8.12 Consent Section 3.4(a) Constituent Documents Section 8.12 Continuing Employee 6.11(bEmployees Section 5.11(a) CPR Recitals CPR Contract Section 8.12 Conversion Ratio Section 2.1(f)(i) Credit Agreement Recitals Current Consents and Amendments Section 5.16(a) Cut-Off Date Section 8.12 D&O Insurance 6.8(bSection 5.9(c) Delisting Period 6.3 DGCL Recitals DLLCA Recitals Dissenting Shares 2.3(aSection 2.2(i) DSU 2.4(cDOJ Section 5.8(c) Effective Time 1.4 Employee Release 6.11(d) Employment Arrangements Recitals Environmental Claim Section 8.12 Environmental Laws 3.18(e)(iSection 8.12 Environmental Permits Section 3.13(a) ERISA 3.16(a) Section 8.12 ERISA Affiliate 3.16(bSection 8.12 Exchange Act Section 3.1(c) Exchange Act 1.1(aAgent Section 2.2(a) Exchange Agent Agreement Section 2.2(a) Exchange Fund Section 2.2(a) Excluded Shares Section 2.1(b) Expiration Date 1.1(aSection 1.1(d) FCPA 3.9(cFiling Section 3.4(a) FDA 3.9(dFirst Certificate of Merger Section 1.3(b) Good Clinical Practices 3.9(hFirst Effective Time Section 1.3(b) Good Laboratory Practices 3.9(hFirst Merger Recitals First Surviving Corporation Section 1.3(a) Good Manufacturing Practices 3.9(iForm S-4 Section 1.1(e)(ii) Fraud and Bribery Laws Section 3.9(b) FTC Section 5.8(c) GAAP Section 8.12 Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(iiSection 3.4(a) HSR Act 3.19 IC Plans 6.11(aSection 3.4(a) Incentive Compensation Plan 6.11(a) Indebtedness Section 8.12 Indemnified Parties 6.8(aSection 5.9(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration Initial Exchange Ratio Section 2.1(c) Intellectual Property Section 8.12 Intervening Event Section 8.12 IT Systems Section 3.19(a) Knowledge Section 8.12 Laws Section 8.12 L/C Agreement Section 5.16(b) L/C Consent Section 5.16(b) L/C Issuer Section 5.16(b) Leased Real Property Section 3.14 Lien Section 8.12 Materials of Environmental Concern Section 8.12 Mergers Recitals Merger Sub 2 Preamble Merger Subs Preamble Minimum Tender Condition Annex I Section 1.1(b)(i) Nasdaq Section 8.12 Non-US Plans Section 8.12 Notice of Superior Proposal Section 5.3(f)(ii) Notice Period 5.2(d) OECD Convention 3.9(cSection 5.3(f)(ii) Offer Recitals Offer Condition Commencement Date Section 1.1(a) Offer Documents 1.1(cConditions Section 1.1(b)(ii) Offer Price Recitals Documents Section 1.1(e)(i)(A) Offer to Purchase Section 1.1(a) on a fully diluted basis 9.10(b) Order Section 8.12 Outside Date 8.1(b)(iiSection 7.1(b)(iii) Parent Preamble Paying Agent 2.2(aParent Board Section 8.12 Parent Capital Stock Section 4.3(a) Performance-Based DSU 2.4(cParent Common Stock Section 4.3(a) Parent Disclosure Letter Article IV Parent Material Adverse Effect Section 8.12 Parent Preferred Stock Section 4.3(a) Parent Share Signing Price Section 2.1(d) Parent QVC Common Stock Section 4.3(a) Parent QVC Series A Stock Section 4.3(a) Parent QVC Series B Stock Section 4.3(a) Parent QVC Series C Stock Section 4.3(a) Parent SEC Documents Section 4.6(a) Parent SEC Financial Statements Section 4.6(c) Parent Subsidiary Section 4.1(c) Parent Ventures Series A Stock Section 4.3(a) Parent Ventures Series B Stock Section 4.3(a) Parent Ventures Series C Stock Section 4.3(a) Party or Parties Preamble Permits 3.9 person 9.10(bSection 3.10 Permitted Lien Section 8.12 Person Section 8.12 Personal Information Section 8.12 Policies Section 3.21 PPACA Section 3.11(e) Plans 3.16(aPremium Cap Section 5.9(c) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Privacy Laws Section 8.12 Proceeding Section 8.12 Purchaser Preamble Purchaser Shares Section 2.1(a) Qualified Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(iiSection 3.11(b) Real Property 3.12(b) Regulation M-A 1.1(c) Leases Section 3.14 Release 3.18(e)(iiiSection 8.12 Reporting Subsidiary Section 4.6(a) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Section 8.12 Xxxxxxxx-Xxxxx Act 3.6(bSection 3.5(b) Schedule 14D-9 1.2(bSection 1.2(a) Schedule TO 1.1(bSection 1.1(e)(i)(A) SEC 1.1(aSection 3.4(a) SEC Transaction Documents Section 3.7 Second Certificate of Merger Section 1.3(b) Second Effective Time Section 1.3(b) Second Merger Recitals Securities Act 3.11(cSection 3.4(a) Severance 6.11(dSecurity Section 8.12 Specified Definitive Acquisition Agreement Section 7.1(d)(iii) Shares Recitals Special Meeting 1.8(a)(iStock Consideration Section 2.1(c) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSubsidiary Section 8.12 Subsidiary SEC Documents Section 4.6(a) Subsidiary SEC Financial Statements Section 4.6(c) Superior Proposal 5.2(bSection 5.3(i)(iii) Surviving Corporation Company Section 1.3(a) Tax 3.15(aTakeover Laws Section 3.3(d) Taxable 3.15(a) Taxes Section 8.12 Tax Return 3.15(a) Tender Completion Time 6.2 Section 8.12 Tax Sharing Agreement Section 8.12 Taxing Authority Section 8.12 Tender and Voting Agreements Support Agreement Recitals Terminated Employee 6.11(d) Termination Fee 8.2(bSection 7.3(c)(ii) Time-Vested DSU 2.4(cTotal Cash Consideration Section 2.1(d) Top-Up Option 1.10(aTotal Consideration Section 8.12 Total Stock Consideration Section 2.1(d) Top-Up Shares 1.10(aTrade Secrets Section 8.12 Transaction Consideration Recitals Transactions Recitals Treasury Regulations Section 8.12 WARN Act Section 3.12(d) UK Bribery Act 3.9(c) THIS Willful Breach Section 8.12 This AGREEMENT AND PLAN OF MERGER REORGANIZATION, dated as of August 16, 2015 (this “Agreement”) dated as of October 24), 2011 is made and entered into by and among CUBIST PHARMACEUTICALSLiberty Interactive Corporation, INC. a Delaware corporation (“Parent”), zulily, inc., a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), Mocha Merger Sub, Inc., a Delaware corporationcorporation and a direct, wholly owned Subsidiary of Merger Sub 2 (“Purchaser”), and Ziggy Merger Sub, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Parent (“Merger Sub 2” and together with the Purchaser, the “Merger Subs”). Parent, each of the Merger Subs and the Company are referred to individually as a “Party” and collectively as the “Parties.”
Appears in 1 contract
Samples: Agreement and Plan of Reorganization (Zulily, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d1.1(e) Agreement Preamble AST 3.2(a) Bankruptcy and Equity Exception 4.4(c) Bylaws 2.5 Certificate 3.1(a)(ii) Certificate of Incorporation 2.4 Certificate of Merger 2.3 Closing 2.2 Closing Date 2.2 Closing Vested Company Option Consideration 3.4(a) Company Preamble Company 13E-3 1.3 Company Acquisition Proposal 6.2(d) Company Alternative Acquisition Agreement 5.2(c6.2(e) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a4.6(c) Company Board of Directors Recitals Company Board Recommendation Recitals Company Bylaws 4.1 Company Capital Stock 4.3(a) Company Change in Recommendation 6.2(e) Company Charter 4.1 Company Disclosure Letter SECTION 3 Article IV Company Joint Venture 3.4(cFinancial Advisor 4.21 Company In-bound License of IP 4.16(d) Company’s knowledge 9.10(bCompany Intervening Event 6.2(d) Company Leases 4.19(c) Company Licensed Registered IP 4.16(a) Company Material Adverse Effect 3.1(aContract 4.13(b) Company Option 2.4(aOwned Registered IP 4.16(a) Company Permits 4.18(a) Company Preferred Stock 3.3(a4.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRegistered IP 4.16(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aDocuments 4.6(a) Company Subsidiary 3.4(aSubsidiaries 4.1 Company Superior Proposal 6.2(d) Confidentiality Agreement 1.2(cContemplated Transactions Recitals CVR 1.1(a) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) DPA 4.26 Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) 2.3 ERISA Affiliate 3.16(b4.10(e) Exchange Act 1.1(aAgent 3.2(a) Exchange Fund 2.2(a3.2(a) Excluded Share 3.1(a)(i) Excluded Shares 3.1(a)(i) Expiration Date 1.1(aTime 1.1(d)(i) FCPA 3.9(cExport Approvals 4.25 FDA Fraud Policy 4.18(d) FDA 3.9(dFiled Company Contract 4.13(a) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Filed Company SEC Documents Article IV Fraud 8.6 Indemnified Parties Persons 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b4.10(d) Merger 1.3(a) Merger Agreement Annex I Recitals Merger Consideration 2.1(c3.1(a)(i) Purchaser Preamble Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c1.1(a)(i) Offer Recitals Offer Condition Consideration 1.1(a) Offer Documents 1.1(c1.1(f)(i)(A) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(aParent 13E-3 1.3 Parent Board Recitals Parent Disclosure Letter Article V Parent Owned Shares 5.10(a) Performance-Based DSU 2.4(cParties Preamble Party Preamble Permits 4.18(a) Permits 3.9 person 9.10(b) Plans 3.16(a) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiPeriod 6.1(a) Representatives 5.2(a6.2(a) Reporting Tail Endorsement 6.8(bRequired Consents 6.3(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Rule 13e-3 1.3 Schedule 13E-3 1.3 Schedule 14D-9 1.2(b1.2(a) Schedule TO 1.1(b1.1(f)(i)(A) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(dShare Recitals Share Adjustment 1.1(c) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Support Agreements Recitals Terminated Employee 6.11(dSurviving Company 2.1 Termination Date 8.2(a) Termination Fee 8.2(bTrade Laws 4.25 Uncertificated Shares 3.1(a)(ii) Time-Unvested Company Option 3.4(b) Vested DSU 2.4(cCompany Option 3.4(a) Top-Up Vested Company Option 1.10(aConsideration 3.4(a) Top-Up Shares 1.10(aWARN Act 4.11(f) UK Bribery Act 3.9(cWillful Breach 8.6 Withholding Agent 3.2(f) THIS This AGREEMENT AND PLAN OF MERGER (hereinafter referred to as this “Agreement”) ), dated as of October 24April 16, 2011 2023, is entered into by and among CUBIST PHARMACEUTICALSSatsuma Pharmaceuticals, INC. (“Parent”)Inc., a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation (“Parent”), and SNBL23 Merger Sub, Inc., a Delaware corporationcorporation and a direct wholly owned Subsidiary of Parent (“Purchaser”). Parent, Purchaser and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties”.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Section number where such definition is contained: Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d9.5(a)(i) Agreement Preamble Alternative Acquisition Agreement 5.2(cFirst Paragraph Approved Legal Representative 5.1(c) Assignee 9.5(aApproved Representative 5.1(c) award 3.3(bAudit 3.12(l)(i) Book-Entry Share 2.1(cBanking Regulatory Approvals 9.5(a)(ii) business day 9.10(bBenefit Plans 3.11(a) CERCLA 3.18(bCertificate 2.1(b) Certificate of Merger 1.4 Certificate 2.1(c1.2 Change of Recommendation 5.2(d) Change of Recommendation Notice 5.2(d)(iii) Closing 1.5 1.3 Closing Amount Recitals Balance Sheet 9.5(a)(iii) Closing Date 1.5 1.3 Code 2.6 3.12(l)(ii) Comerica Loan 3.1(b) Common Stock Recitals Company Preamble Company Balance Sheet 3.6(a) First Paragraph Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Schedule 3.1(a) Company Joint Venture 3.4(cEmployees 6.10(a) Company’s knowledge 9.10(bCompany IP 3.16(l)(i) Company Material Adverse Effect 3.1(a9.5(a)(iv) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aPermits 3.18(b) Company SEC Reports 3.5 Documents 3.7(a) Company Software 3.16(l)(ii) Company Stockholder Approval 6.1 3.3 Company Stock Plans 2.4(aStockholders’ Meeting 6.2(a) Company Subsidiary 3.4(a3.1(a) Computer Software 3.16(l)(iii) Confidentiality Agreement 1.2(c6.4(a) Continuing Employee 6.11(bContract 3.6(d) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bCopyrights 3.16(l)(iv) Delisting Period 6.3 Customer Contracts 3.13(b) Data Room 9.5(a)(v) Delaware Courts 9.10 Director 9.5(a)(vi) Dissenting Shares 2.6 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 1.2 Employee Release 6.11(d6.4(b) employees at the director level 9.5(a)(vii) Encumbrances 3.1(b) Environmental Claim 3.20(e)(i) Environmental Laws 3.18(e)(i3.20(e)(ii) ERISA 3.16(a3.11(a) ERISA Affiliate 3.16(b3.11(a) ESPP 2.5(b) Exchange Act 1.1(a3.6(c) Exchange Fund 2.2(aFinancial Statements 3.7(b) Expiration Date 1.1(aForeign Benefit Plan 3.11(q) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP 3.7(b) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii3.6(b) HSR Act 3.19 IC Plans 6.11(a3.6(c) Incentive Compensation Plan 6.11(aInactive Employee 6.4(b) Inbound License Agreements 3.16(l)(v) Indemnified Parties 6.8(a6.6(a) Independent Directors 6.9(aIntellectual Property 3.16(l)(vi) IRS 3.16(aKnowledge 9.5(a)(viii) Laws 3.9(bLeased Real Property 3.14(a) Layoff Laws 3.17(bLTD Policy 6.10(c) Maximum Premium 6.8(bMaterial Acquisition Agreement 3.27(b)(ii) Material Acquisitions 3.27(b)(i) Material Contracts 3.13(b) Materials of Environmental Concerns 3.20(e)(iii) Merger 1.3(aRecitals Merger Consideration 2.1(b) Merger Sub First Paragraph Net Tangible Asset Value 9.5(a)(ix) New Plans 6.10(c) Old Plans 6.10(c) Open Source Materials 3.16(l)(vii) Option 2.5(d)(i) Option Plans 2.5(d)(ii) Outbound License Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii3.16(l)(viii) Parent Preamble First Paragraph Patents 3.16(l)(ix) Paying Agent 2.2(a) Performance-Based DSU 2.4(cPermitted Encumbrances 3.14(e) Permits 3.9 person 9.10(bPerson 9.5(a)(x) Plans 3.16(aPreferred Stock 3.2(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aActs Coverage 6.6(b) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii3.21 Registered Company IP 3.16(l)(x) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a3.6(c) Securities Act 3.11(c3.7(a) Severance 6.11(dSenior Management Personnel 9.5(a)(xi) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSubsidiary 9.5(a)(xii) Superior Proposal 5.2(b5.2(c) Surviving Corporation 1.3(a1.1 Tax 3.12(l)(iii) Tax 3.15(a) Taxable 3.15(aAuthority 3.12(l)(iv) Tax Return 3.15(aReturns 3.12(l)(v) Tender Completion Time 6.2 Tender and Termination Fee 8.2(b)(i) Xxxxxx Xxxxxx Partners 3.22 Trade Secrets 3.16(l)(xii) Trademarks 3.16(l)(xi) Transactions 3.3 Updata 3.24 Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Voting Debt 3.2(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following terms in this Agreement shall have the defined meanings that appear in the provisions of the ascribed to them, as indicated below: 2003 Plan 3.03(a) 2003 Plan Options 3.03(a) 2010 Health Care Law 3.12(d) 2012 Plan 3.03(a) 2012 Plan Options 3.03(a) 2012 Plan PSUs 3.03(a) 2012 Plan RSUs 3.03(a) 2017 Plan 3.03(a) Acceptable Confidentiality Agreement listed below. Acceptance Time 5.2(b9.01(a) Acquisition Proposal 5.2(aAgreement 5.02(e) Adverse Recommendation Change 5.2(c5.02(e) Advertising Funds 3.18(e) Affiliate 3.3(d9.01(b) Agreement Preamble Alcohol Laws 3.10(c) Alternative Acquisition Agreement 5.2(cFinancing 6.08(c) Assignee 9.5(aArticles of Merger 1.03 Authorizations 3.10(a) award 3.3(bAvailable Financing 6.09(a) Book-Entry Share 2.1(cBoard Actions 3.04(b) beneficial ownership 9.01(c) business day 9.10(b) CERCLA 3.18(b9.01(d) Certificate of Merger 1.4 Certificate 2.1(c2.01(c) Closing 1.5 Closing Amount Recitals 1.02 Closing Date 1.5 1.02 Code 2.6 2.03(h) Company Preamble Company Balance Sheet 3.6(aArticles of Incorporation 3.01 Company Benefit Plan 3.12(o) Company Board of Directors 2.04 Company Bylaws 3.01 Company Common Stock Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b9.01(e) Company Material Adverse Effect 3.1(aEmployee 6.05(a) Company Option 2.4(aEquity Awards 3.03(a) Company Preferred Stock 3.3(aESPP Shares 3.03(a) Company Quarterly Balance Sheet 3.7 Executive Team 9.01(f) Company Restricted Share 2.4(bIncentive Plan 3.03(a) Company Intellectual Property 9.01(g) Company Noncompete Restrictions 3.09(a)(v) Company PSUs 3.03(a) Company Related Parties 8.03(e) Company Restricted Stock 2.4(bAwards 3.03(a) Company Rights 3.3(aRSUs 3.03(a) Company Rights Agreement 3.3(aStock Options 3.03(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a2.04(e) Company Subsidiary 3.4(aSwaps 3.22 Company Termination Fee 9.01(h) Compliant 9.01(i) Confidentiality Agreement 1.2(c9.01(j) Continuing Employee 6.11(bConsent Requirements 6.08(a) CPR Recitals CPR Agreement Recitals Contract 9.01(k) Current D&O Insurance 6.8(bPremium 6.06(a) Delisting Period 6.3 DGCL Recitals Debt Commitment Letter 4.04 Debt Financing 4.04 Debt Financing Agreements 6.08(a) Debt Financing Sources 9.01(l) Dissenters’ Rights 2.01(d) Dissenting Shares 2.3(a) DSU 2.4(c2.01(d) Effective Time 1.4 Employee Release 6.11(d1.03 Environmental Claims 3.16(b) Environmental Laws 3.18(e)(iLaw 3.16(b) Equity Award Amounts 2.04(e) Equity Commitment Letter 4.04 Equity Financing 4.04 Equity Financing Agreements 6.08(b) Equity Financing Source 9.01(m) Equity Investor 4.04 ERISA 3.16(a3.12(a) ERISA Affiliate 3.16(b3.12(f) ESPP 2.05 ESPP Cut-Off Date 2.05 Exchange Act 1.1(a) 3.05 Exchange Fund 2.2(a2.03(a) Expiration Date 1.1(aExclusive Rights 3.09(a)(v) FCPA 3.9(cExisting Credit Agreement 9.01(n) FDA 3.9(dFairness Opinion 3.28 FDD 3.18(g) Good Clinical Practices 3.9(hFee Letters 4.04 Filed SEC Documents Article III Financing 4.04 Financing Agreements 6.08(a) Good Laboratory Practices 3.9(hFinancing Letters 4.04 Financing Sources 9.01(o) Good Manufacturing Practices 3.9(iForeign Company Plan 3.12(m) Franchise Agreements 3.18(a) Franchise Laws 3.10(c) Franchised Restaurant 3.18(a) Franchisee 3.18(g) FTC Rule 3.10(c) GAAP 3.06(b) Governmental Entity 9.10(bAuthority 3.05 group 5.02(b)(ii) Hazardous Materials 3.18(e)(ii3.16(b) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.05 Indebtedness 5.01(b)(viii) Indemnified Parties 6.8(aParty 6.06(b) Independent Directors 6.9(aIntellectual Property 3.15(g) IRS 3.16(aIntervening Event 5.02(b)(iv) Laws 3.9(bJudgment 3.05 Key Intellectual Property 3.15(a) Layoff Laws 3.17(bKnowledge 9.01(p) Maximum Premium 6.8(bLaw 3.05 Leased Real Property 3.14(b) Liens 3.02 Liquor License 3.10(c) Litigation 3.08 Marketing Period 9.01(q) Master Franchise Rights 3.09(a)(v) Match Right Notice 5.02(h)(i) Match Right Period 5.02(h)(i) Material Adverse Effect 9.01(r) MBCA Preamble Measurement Time 3.03(a) Merger 1.3(aRecitals Merger Consideration 2.01(c) Merger Agreement Annex I Sub Preamble NASDAQ 3.05 Nevada Gaming Laws 3.10(c) New Specified Contracts 5.01(b)(xv) Non-U.S. Merger Consideration 2.1(cControl Laws 6.03(a) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOrdinary Course of Business 9.01(s) Outside Date 8.1(b)(ii8.01(b)(i) Owned Intellectual Property 9.01(g) Owned Real Property 3.14(a) Parent Preamble Parent Disclosure Letter 9.01(t) Parent Material Adverse Effect 9.01(u) Parent Related Parties 8.03(e) Parent Termination Fee 9.01(v) Party Preamble Parties Preamble Paying Agent 2.2(a2.03(a) Performance-Based DSU 2.4(cPayoff Letter 6.09(e) Permits 3.9 Permitted Liens 9.01(w) person 9.10(b9.01(x) Plans 3.16(aPersonal Information 3.15(e) Post-Closing SEC Reports 6.3 Plan of Merger Preamble Principal Stockholders Recitals Prior Plan 6.11(cSupplier 3.24(a) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aProposed Changed Terms 5.02(h)(iii) Proxy Statement 1.8(a)(ii3.05 PSU Shares 2.04(c) Real Property 3.12(bLeases 3.14(b) Regulation M-A 1.1(cReal Property Subleases 3.14(c) Recommendation 3.04(b) Relationship Laws 3.10(c) Release 3.18(e)(iii3.16(b) Representatives 5.2(aRepresentative 9.01(y) Reporting Tail Endorsement 6.8(bRequired Information 9.01(z) Restraints 8.1(b)(i7.01(c) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aSanctioned Country 9.01(aa) Xxxxxxxx-Xxxxx Act 3.6(bSanctioned Person 9.01(bb) Schedule 14D-9 1.2(b) Schedule TO 1.1(bSanctions Laws 9.01(cc) SEC 1.1(aArticle III SEC Documents 3.06(a) Securities Act 3.11(c3.06(a) Severance 6.11(dShareholder Approval 3.04(a) Shares Recitals Special Shareholders’ Meeting 1.8(a)(i6.01(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSpecified Contract 3.09(a) Specified Franchisee 3.18(a) Subsidiary 9.01(dd) Superior Proposal 5.2(b5.02(b)(iii) Surviving Corporation 1.3(a1.01 Takeover Proposal 5.02(b)(i) Tax 3.15(a) Taxable 3.15(aTakeover Statute 9.01(ee) Tax Return 3.15(a3.13(j) Tender Completion Time 6.2 Tender and Tax Sharing Agreements 3.13(j) Taxes 3.13(j) Terminated Plan 6.05(d) Third Party 9.01(ff) Transaction Litigation 6.03(e) Voting Agreements Agreement Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Voting Company Debt 3.03(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms Each defined term in this Agreement shall have has the defined meanings that appear corresponding meaning, as applicable, set forth in Annex I or in the provisions section of the this Agreement listed set forth below. : Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Annex I Agreement Preamble AKS 3.22(h) Alternative Acquisition Agreement 5.2(c) Anti-Corruption Laws 3.20(a) Antitrust Laws 3.4(b) Assignee 9.5(a) award 3.3(bBDO 3.12(l) Benefit Plan 3.10(a) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bAnnex I Bylaws 3.1 Capitalization Date 3.2 Certificate 2.1(c) Certificate of Merger 1.4 Certificate 2.1(c) of Incorporation 3.1 Closing 1.5 Closing Amount Recitals Closing Date 1.5 COBRA 3.10(g) Code 2.6 2.7 Company Preamble Company Balance Sheet 3.6(a) Acquisition Proposal Annex I Company Adverse Recommendation Change Annex I Company Board of Directors Recitals Company Common Stock Recitals Company Disclosure Letter SECTION 3 Annex I Company Joint Venture 3.4(cIntellectual Property Annex I Company Intervening Event Annex I Company Leased Real Property 3.16(b) Company’s knowledge 9.10(b) Company Licensed IP Annex I Company Material Adverse Effect 3.1(aAnnex I Company Material Contract 3.13(a) Company Options 2.4(a) Company Option 2.4(aGrant Date 3.2(b) Company Owned IP Annex I Company Owned Real Property 3.16(a) Company Permits 3.9(a)(i) Company Preferred Stock 3.3(a3.2(a) Company Quarterly Balance Sheet 3.7 Real Property 3.16(b) Company Restricted Share Recommendation Annex I Company Registered IP Company RSUs 2.4(b) Company Restricted Stock 2.4(bSEC Documents 3.5(a) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aStock Plan Awards 2.4(c) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(bConsent 3.4(b) CPR Recitals CPR Agreement Recitals Contract Annex I Control Annex I Controlled Group Liability 3.10(a) Copyrights Annex I Current D&O Insurance 6.8(b6.6(b) Customs & International Trade Authorizations Annex I Customs & International Trade Laws Annex I Delisting Period 6.3 6.1 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) XXXXX 3 Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) Annex I ERISA 3.16(a3.10(a) ERISA Affiliate 3.16(b3.10(a) Exchange Act 1.1(a) Exchange Fund 2.2(a) Existing Credit Agreements Annex I Expiration Date 1.1(a1.1(c) FCPA 3.9(cAnnex I FDA Laws Annex I FDCA Annex I Federal Health Care Program 3.23(b) FDA 3.9(dFederal Health Care Program Laws 3.23(c) Good Clinical Practices 3.9(hFederal Privacy and Security Regulations 3.23(e) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP 3.5(a) Governmental Entity 9.10(b) Authority Annex I Hazardous Materials 3.18(e)(iiAnnex I HIPAA 3.23(c) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aAnnex I Indebtedness Annex I Indemnified Party 6.6(a) Indemnified Parties 6.8(a6.6(a) Independent Directors 6.9(aIntellectual Property Annex I Intervening Event 5.2(e) IRS 3.16(aKnowledge of the Company Annex I Labor Agreement 3.11(a)(ii) Laws 3.9(bLaw Annex I Lease 3.16(b) Layoff Laws 3.17(bLien Annex I Lookback Date 3.5(a) Maximum Premium 6.8(b6.6(b) Moelis 3.26 Merger 1.3(a) Merger Agreement Annex I Recitals Merger Consideration 2.1(c) Minimum Condition Annex I Merger Sub Preamble Merger Sub Common Stock 2.1 Multiemployer Pension Plans 3.10(a) Notice Period 5.2(d) OECD Convention 3.9(c) NYSE 1.1 Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c1.1(b) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Annex I Order Annex I Outside Date 8.1(b)(ii) Parent Preamble Parent Material Adverse Effect 4.1 Parent Organizational Documents Annex I Patents Annex I Payoff Letter 5.6 Paying Agent 2.2(a) Performance-Based DSU 2.4(cPension Plans 3.10(a) Permits 3.9 person 9.10(b) Plans 3.16(a) Permitted Lien Annex I Person Annex I Post-Closing SEC Reports 6.3 6.1 Pre-Closing Period 5.1 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Proceedings Annex I Registrations Annex I Regulatory Authority Annex I Reporting Tail Endorsement 6.8(b6.6(b) Representative Annex I Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Sanctioned Country Annex I Sanctioned Person Annex I Sanctions Annex I Xxxxxxxx-Xxxxx Act 3.6(b3.5(a) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d3.5(a) Shares Recitals Special Meeting 1.8(a)(iSoftware Annex I SSA 3.23(b) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cStockholder List Date 1.2(c) Subsidiary Annex I Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Annex I Tax Return 3.15(a) Returns Annex I Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(cTrade Secrets Annex I Trademarks Annex I Union 3.11(a) Top-Up Option 1.10(aWARN Act 3.11(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Warrants 2.5
Appears in 1 contract
Samples: Merger Agreement (Invuity, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the Agreement listed section or place indicated below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c: Term Section or Place Where Defined AAA 9.4(a) Affiliate 3.3(d) 1.1 Agreement Preamble Alternative Acquisition Agreement 5.2(cAlternate Transaction 5.3 Anti-Bribery Laws 1.1 Authorizations 2.17 Balancing Preferred Interests 1.8(e) Assignee 9.5(aBenefit Plan 1.1 Business Day 9.12(e) award 3.3(bBusiness Employees 1.1 Business Service Provider 2.21(b) Book-Entry Share 2.1(cBuyer Preamble Buyer 401(k) business day 9.10(bPlan 5.11(e) CERCLA 3.18(bBuyer Disclosure Schedule 1.1 Buyer FSA 5.11(h) Certificate of Merger 1.4 Certificate 2.1(cBuyer Fundamental Representations 1.1 Buyer Indemnified Parties 7.2 Buyer Related Party 8.2(c) Calculation Principles 1.1 Cap 7.2(a)(ii) CDIB 4.6 CDIB Commitment Letter 4.6 CDIB Financing 4.6 CDIB Note 1.1 Claim 9.4(b) Claim Notice 9.4(b) Closing 1.5 Closing Amount Recitals 1.4 Closing Date 1.5 1.4 Closing Indebtedness 1.1 Closing Net Working Capital 1.1 Code 2.6 1.1 Combined Tax 1.1 Commitment Letters 4.6 Company Preamble Company Balance Sheet 3.6(a) Cash 1.1 Company Board of Directors Recitals Database 1.1 Company Disclosure Letter SECTION 3 Schedule 1.1 Company Joint Venture 3.4(cEntities 1.1 Company Fundamental Representations 1.1 Company Intellectual Property 2.12(a) Company’s knowledge 9.10(b80 Term Section or Place Where Defined Company IT Systems 2.12(g) Company Material Adverse Effect 3.1(a) 1.1 Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(bPlansCompany Shares 1.11.1 Confidential Information 5.1(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b9.4(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aCut-Off Date 7.1 Data Breach 2.13(b) DSU 2.4(cDebt Commitment Letter 4.6 Debt Financing 4.6 Debt Financing Sources 4.6 Deductible 7.2(a)(ii) Effective Time 1.4 Employee Release 6.11(dDesignated Firm 9.15 Dispute 9.15 Disputed Items 1.8(c) Disputed Items Notice 1.8(c) Distributed Subsidiaries 1.1 Environment 1.1 Environmental Claim 1.1 Environmental Laws 3.18(e)(i) 1.1 Equity Commitment Letters 4.6 Equity Financing 4.6 ERISA 3.16(a) 1.1 ERISA Affiliate 3.16(b1.1 ERISA Affiliate Liability 1.1 Estimated Indebtedness 1.1 Estimated Purchase Price 1.8(a)(i) Exchange Act 1.1(aEstimated Purchase Price Certificate 1.8(a)(i) Exchange Fund 2.2(aETA 1.1 Excluded Assets 1.1 Existing Credit Facilities 1.1 Final Commitments Certificate 1.8(a)(i) Expiration Date 1.1(aFinal Purchase Price 1.1 Financial Statements 2.7 Financing 4.6 Financing Sources 1.1 Foreign Plan 2.22(f) FCPA 3.9(cFSA Participation Period 5.11(h) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) GAAP 1.1 Government Official 1.1 Governmental Authority 1.1 Term Section or Place Where Defined Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) 1.1 GST/HST 1.1 Guarantee Recitals Guarantor Recitals Helfrich Dispute 7.2 HQ Lease and License Agreements 1.1 HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a2.5 Immaterial Leases 1.1 Xxxxxxedness 1.1 Indemnified Party 7.4(a) Indemnified Parties 6.8(aPersons 5.8(a) Indemnifying Party 7.4(a) Independent Directors 6.9(aAccounting Firm 1.8(d) IRS 3.16(aInsurance Policies 2.24 Intellectual Property 2.12(a) IP Licenses 2.12(d) Later Discovered Asset 5.6 Laws 3.9(b1.1 Lease Disputes 7.2 Leases 2.10 Liabilities 1.1 Lien 1.1 Limited Guarantee Limited Partnership Agreement 1.11.1 Losses 1.1 Managed Services Agreement 1.1 Master Sourcing Agreement 1.1 Material Contracts 2.9 Material Leases 1.1 Material Vendors 2.15(a) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Measurement Date 1.1 Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Employees 1.1 Ohio Lease Dispute 7.2 OpCapita Funds 1.1 Outside Date 8.1(b)(ii8.1(e) Parent Preamble Paying Agent 2.2(aPaid Indebtedness 1.5(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostPatent Dispute 7.2 Permitted Liens 1.1 Person 1.1 Personal Data 1.1 Term Section or Place Where Defined Pre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cTax Periods 5.7(b)(i) Program 3.9(kPrevailing Party Reimbursement Amount 8.2(d) Prohibited Payment 3.9(cPrivacy Claims 2.13(c) Proprietary Rights 3.12(aPrivacy Incident 2.13(c) Proxy Statement 1.8(a)(iiProceeding 5.8(a) Protected Seller Communications 9.15 Purchase Price 1.5(a) Purchase Price Certificate 1.8(b) Purchased Securities 1.3 R&W Insurer 1.1 R&W Policy 1.1 Real Property 3.12(b1.1 Reference Date 2.7 Related Party 2.26 Remedies Exception 2.4 Reorganization 1.2 Response Period 7.4(a) Regulation M-A 1.1(cRevitalization Partners Dispute 7.2 Rollover Interests 1.1 Rollover Purchased Securities 1.1 Rollover Value 1.1 Seasonal Bonus Plan 5.11(d) Release 3.18(e)(iiiSeller Preamble Seller 401(k) Representatives 5.2(aPlan 5.11(e) Reporting Tail Endorsement 6.8(bSeller Benefit Plan 1.1 Seller Disclosure Schedule 1.1 Seller FSA 5.11(h) Restraints 8.1(b)(iSeller Fundamental Representations 1.1 Seller Indemnified Parties 7.3 Seller’s Expenses 1.1 Seller Termination Claim Parties 8.2(c) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Senior Loan 1.1 Services Agreements 1.1 Shares Recitals Special Meeting 1.8(a)(iSolvent 4.8 Sourcing Services Agreement 1.1 Straddle Periods 5.7(b)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSubsidiary(ies) Superior Proposal 5.2(b) 1.1 Surviving Corporation 1.3(aObligation 1.1 Target Working Capital 1.1 Tax Act 1.1 Term Section or Place Where Defined Tax Benefit 7.5 Tax Contest 5.7(b)(vi) Tax 3.15(a) Taxable 3.15(aLoss 5.7(g) Tax Return 3.15(aReturns 1.1
1.1 Tax(es) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) 1.1 Termination Fee 8.2(b) Time-Vested DSU 2.4(cThird Party Claim 7.4(b) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Transaction Documents 1.1 Transactions 1.3 Transition Services Agreement 1.1 Unconditional Date 1.4 Utah Lease Dispute 7.2 WARN Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (1.1 [The remainder of this “Agreement”) dated as of October 24, 2011 page is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporationintentionally left blank.]
Appears in 1 contract
Samples: Stock Purchase Agreement (Ascena Retail Group, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms The following capitalized terms, which may be used in more than one Section or other location of this Agreement shall have the Agreement, are defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bfollowing Sections or other locations: 510(k) Acquisition Proposal 5.2(aClearance 3.15(b) Adverse Recommendation Change 5.2(cAdjusted Initial Cash Payment 1.6(b) ADR Depositary Annex I ADSs 1.5(a) Affiliate 3.3(dAnnex I Agreement 11.8(a) Agreement Another Transaction 5.6(b) Assigned Contracts 1.1(b)(i) Assumed Liabilities 1.3 Bill of Sale 1.7 Business Preamble Alternative Acquisition Agreement 5.2(cBusiness Assets Annex I Business Day Annex I Buyer Caption Buyer Indemnified Persons Xxxxx X Buyer Indemnifying Persons Xxxxx X Buyer Losses Annex I Cap 7.5(a)(ii) Assignee 9.5(aCash Consideration 1.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CE Xxxx Xxxxx I CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Annex I CERCLIS Annex I Claim Notice 7.2 Closing 1.5 Closing Amount Recitals Article II Closing Date 1.5 Article II Code 2.6 Annex I Commercial Partners Schedule 1.5(c) Companies Caption Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Employee Plans 2.4(a) Company Subsidiary 3.4(a3.18(a) Confidentiality Agreement 1.2(c8.3 Consideration Shares 1.5(a) Continuing Contingent Consideration .1.5(c) Contract Annex I Control Annex I Copyright Assignment 1.7 Employees 3.17(a) Employee 6.11(bBenefit Plan 3.18(d) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Encumbrances Annex I Environmental, Health and Safety Laws 3.18(e)(iAnnex I Equipment 1.1(a)(iii) ERISA 3.16(a) Annex I ERISA Affiliate 3.16(b3.18(d) Escrow Agreement 1.6(b) Escrow Agent 1.6(b) Escrow Amount 1.6(a)(ii) Escrow Fund 1.6(b) Escrow Income 10.1(a) Estoppel Certificate 6.1(i)(iv) Exchange Act Annex I Exchange Proceeds 5.10 Excluded Assets 1.2 Excluded Liabilities 1.4 Facilities 3.10(a) FDA Annex I Federal Health Care Program Annex 1 Financial Statements 3.5(a) Flow of Funds Memorandum 1.6(f) Fraud Xxxxx X Fundamental Documents Annex I Fundamental Representations 7.4 GAAP Annex I Governmental Entity Annex I Hazardous Materials Annex I Health Care Laws Annex 1 HIPAA Annex 1 Hired Employees 5.11(a) IP Assets 1.1(c) IP Contracts 3.11(a)(ii) Indemnification Claim 10.1(b)(i) Indemnified Persons Xxxxx X Indemnifying Persons Annex I Initial Cash Consideration 1.5(a) Intellectual Property Rights Xxxxx X Interests Annex I Interim Financial Statements 3.5(a) Inventory Annex I ISO Annex I ISO 13485 3.15(c)(v) Knowledge 11.8(a) Latest Balance Sheet 3.5(a) Latest Balance Sheet Date 3.5(b) Law Annex I Lease Assets 1.1(d) Leased Facility 3.10(a) Liability Annex I Licensed Requisite Rights 3.11(a)(i) Litigation Expenses Annex I Long Stop Date 8.1(b)(iii) Losses Annex I Material Adverse Change Annex I MDR 3.15(c)(vi) Medical Waste Annex I Non-Competition Agreement 6.1(i)(i) OFAC 3.24(a) Orders Annex I Operational Assets 1.1(b) Ordinary Shares 1.6(c) Other Assets 1.1(g) Owned Facility 3.10(a) Owned Requisite Rights 3.11(a)(i) Parent Caption Partner Agreements Schedule 1.5(c) Partner Agreement Measuring Period Schedule 1.5(c) Partner Agreement Proceeds Schedule 1.5(c) Partner Agreement Trigger Schedule 1.5(c) Patent Assignment 1.7 PDF Annex I Payment Direction Letter Section 6.1(i)(viii) Perceptive Preamble Perceptive Indebtedness Xxxxx X Permits Annex I Permit Assignment 1.7 Permitted Encumbrances Annex I Person Annex I PMA 3.15(b) Pre-Closing Period 5.2 Proceedings Annex I Products Preamble Product Liability Tail 5.13 Purchased Assets 1.1(a) Exchange Fund 2.2(aPurchase Price 1.5(d) Expiration Date 1.1(aPurchase Price Allocation 1.5(d) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement QSRs Annex I Merger Consideration 2.1(cRelease Date 10.1(b)(iii) Minimum Condition Related Document 6.1(i) Representatives Xxxxx X Requisite Rights 3.11(a)(i) Sale Preamble SEC Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(cAnnex I Seller Expenses 1.6(f) Severance 6.11(d) Shares Recitals Sellers Caption Seller Indemnified Persons Xxxxx X Seller Indemnifying Persons Annex I Seller Losses Annex I Special Meeting 1.8(a)(iTax Losses Annex I Straddle Period Annex I Straddle Returns 9.2(c) Sub Preamble Caption Sub Common Stock 2.1 Successor Plan 6.11(cShares 1.1(f) Superior Proposal 5.2(bSubscription Price 1.6(c) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(aSurvival Date 7.4 Taxes 3.8(e) Tax Return 3.15(a3.8(g) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTaxing Authority 3.8(f) Termination Fee 8.2(bTerm Sheet 5.6(a) TimeThird Person Claim 7.3 Third Person Claim Notice 7.3(a) Threshold 7.5(a)(i) Trademark Assignment 1.7 Trading Trigger Schedule 1.5(c) Trading Trigger Measuring Period Schedule 1.5(c) Transaction Taxes 1.9 Transferee 3.8(e) Triggering Event Schedule 1.5(c) Trinity Preamble Waveform Caption Waveform Side Letter Section 6.1(i)(ix) Wilsonville Facility 1.1(b)(i) Wilsonville Landlord 1.1(b)(i) Wilsonville Lease 1.1(b)(i) Year-Vested DSU 2.4(cEnd Financial Statements 3.5(a) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT ASSET AND PLAN OF MERGER (this “Agreement”) SHARE PURCHASE AGREEMENT, dated as of October 24January 30, 2011 is 2024, among CUBIST PHARMACEUTICALSTRIB Biosensors Inc., INC. a Delaware corporation (“Buyer”), WaveForm Technologies, Inc., a Delaware corporation (“Waveform”), WaveForm Holdings, LLC, a Delaware limited liability company (“Parent,” and, together with Waveform, the “Sellers”), and Waveform EU d.o.o., a Delaware corporationSlovenian company with the registration number: 8868450000, FRD ACQUISITION CORPORATION with its business address at Xxxxxx xxxxx 00, 0000 Xxxxxxxxxx, Xxxxxxxx (“Sub,” and, together with the Sellers, the “Companies”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Asset and Share Purchase Agreement (Trinity Biotech PLC)
INDEX OF DEFINED TERMS. Capitalized terms in this Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Section 8.03 Acquisition Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(aSection 4.02(a) Adverse Recommendation Change 5.2(cSection 4.02(d) Affiliate 3.3(dSection 8.03 Aggregate Exchange Ratio Section 2.01(c) Agreement Preamble Alternative Acquisition Agreement 5.2(cAnnual Amount Section 5.05(c) Assignee 9.5(aAnnual Meeting Section 5.01(c) award 3.3(bAntitrust Laws Section 5.03(a) Book-Entry Share 2.1(cAppraisal Shares Section 2.01(d) business day 9.10(bAssumed Company Restricted Stock Unit Section 5.13(b) CERCLA 3.18(bAssumed Option Section 5.13(a) Authorizations Section 3.01(j)(iii) Business Day Section 8.03 Cash Consideration Section 2.01(c) Cash Percentage Section 8.03 Certificate of Merger 1.4 Certificate 2.1(cSection 1.03 Claim Section 5.05(b) Closing 1.5 Closing Amount Recitals Section 1.02 Closing Date 1.5 Section 1.02 Closing Parent Stock Price Section 8.03 Code 2.6 Section 1.06 Commonly Controlled Entity Section 8.03 Company Preamble Company Balance Sheet 3.6(aBenefit Plan Section 8.03 Company Board Recommendations Section 3.01(d)(i) Company Board Bylaws Section 3.01(a) Company Certificate of Directors Incorporation Section 3.01(a) Company Common Stock Recitals Company Convertible Notes Section 8.03 Company Disclosure Letter SECTION 3 Section 8.03 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployees Section 5.04(a) Company Material Adverse Effect 3.1(a) Filed SEC Documents Section 3.01 Company Option 2.4(aIntellectual Property Section 8.03 Company NYSE Stockholder Approval Section 3.01(q) Company Preferred Stock 3.3(aSection 3.01(c)(i) Company Quarterly Balance Sheet 3.7 Products Section 8.03 Company Restricted Share 2.4(b) Registered IP Section 8.03 Company Restricted Stock 2.4(bUnits Section 3.01(c)(i) Company Rights 3.3(aStock Options Section 3.01(c)(i) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Stock Plans Section 8.03 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aSection 3.01(q) Company Subsidiary 3.4(aTermination Fee Section 8.03 Company Warrants Section 3.01(c)(i) Confidentiality Agreement 1.2(cSection 8.03 Consents Section 8.03 Contract Section 8.03 Convertible Notes Section 3.01(c)(i) Continuing Employee 6.11(bAnnual Meeting Section 5.01(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bTail Premium Cap Section 5.05(c) Delisting Period 6.3 Determination Date Section 3.01(c)(i) Designated Specified Contracts Section 4.01(a)(xvi) DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Section 1.01 Effective Time 1.4 Employee Release 6.11(d) Section 1.03 Environmental Laws 3.18(e)(i) Law Section 8.03 ERISA 3.16(a) ERISA Affiliate 3.16(bSection 8.03 Exchange Act Section 3.01(d)(iii) Exchange Act 1.1(aAgent Section 2.02(a) Exchange Fund 2.2(aSection 2.02(a) Expiration Date 1.1(aExpense Reimbursement Section 5.06(c) FCPA 3.9(cSection 3.01(j)(ii) FDA 3.9(dFinancial Statements Section 3.01(e)(ii) Good Clinical Practices 3.9(hForm S-4 Section 5.01(a) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP Section 3.01(e)(ii) Governmental Entity 9.10(bSection 3.01(d)(iii) Government Official Section 8.03 Hazardous Materials 3.18(e)(ii) Section 8.03 HSR Act 3.19 IC Plans 6.11(aSection 3.01(d)(iii) Incentive Compensation Plan 6.11(aIndebtedness Section 4.01(a)(ix) Indemnified Parties 6.8(aParty Section 5.05(b) Independent Directors 6.9(aIndenture Section 8.03 Intellectual Property Section 8.03 Intervening Event Section 8.03 IPO Litigation Section 4.01(a)(xi) IT Assets Section 8.03 IRS 3.16(aSection 3.01(l)(i) Laws 3.9(bKnowledge Section 8.03 Law Section 3.01(d)(ii) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Leased Real Property 3.12(bSection 3.01(v)(ii) Regulation M-A 1.1(cLicensed Intellectual Property Section 8.03 Liens Section 3.01(b) Release 3.18(e)(iiiMajor Customers Section 3.01(i)(xv) Representatives 5.2(aMajor Suppliers Section 3.01(i)(xvi) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Material Adverse Effect Section 8.03
Appears in 1 contract
Samples: Merger Agreement (Ciena Corp)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of certain terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection numbers where such definitions are contained: 2011 Earnout Amount 3.2(a)(i) Acquisition Proposal 5.2(a0000 Xxxxxxx Xxxxxx Xxxxx 3.2(a)(i) Adverse Recommendation Change 5.2(c2012 Earnout Amount 3.2(a)(ii) Affiliate 3.3(d2013 Earnout Amount 3.2(a)(iii) Agreement 30-Day Period 3.4(b) AAG 2.2(a)(xiv) Accounting Arbitrator 3.2(d) Acquired Assets 2.1 Actual Excluded Pipeline Loan Commissions 3.3(a)(ii) Actual Seller-Owed Commissions 3.3(b)(ii) Assumed Contracts 2.1(b) Assumed Liabilities 2.3 Basket Amount 11.2(b)(i) Business Recital A Buyer Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cBuyer Indemnified Persons 11.2(a) Closing 1.5 Closing Amount Recitals 4.1 Closing Date 1.5 Code 2.6 Company Preamble Company 4.1 Collateral Source 11.6(e) Competing Business 8.3(a) Covered Liabilities 6.7 Earnout Amount 3.2(a) Earnout Worksheet 3.2(b) Eligible Pipeline Floor 3.4(d) Eligible Pipeline Period 3.4(b) Estimated Excluded Pipeline Loan Commissions 3.3(a)(i) Estimated Seller-Owed Commissions 3.3(b)(i) Excluded Assets 2.1(a) Excluded Liabilities 2.4 Excluded Pipeline Loans 2.2(a)(i) FCRA 8.8(c) Financial Statements 6.5(a) Franchise Premium 3.1(a) General Cap Amount 11.2(b)(ii) Hired Employee 8.5(b) Indemnified Person 11.4(a) Indemnifying Person 11.4(a) Interim Balance Sheet 3.6(a6.5(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Interim Balance Sheet 3.7 Company Date 6.5(a) X. Xxxx Preamble X. Xxxx Trust Preamble JAMS 12.8 JAMS Rules 12.8 Leased Employee 8.6(e) Neutral Accounting Firm 3.2(d) New Event 7.6 Nonassignable Assets 8.9 Parties Preamble Party Preamble plan assets 2.2(a)(x) Property Taxes 8.4(b) Purchase Price 3.1 Purchase Price Ceiling 3.1 Restricted Share 2.4(bGeographic Area 8.3(a) Company Restricted Stock 2.4(bRETS 2.1(g) Company Rights 3.3(aX. Xxxx Preamble X. Xxxx Trust Preamble Seller 6.17, 6.19, Preamble Seller Indemnified Persons 11.3(a) Company Rights Seller IP License 6.16(d) Settlement Agreement 3.3(a4.2(a)(viii) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aShareholders Preamble Specified Representations 11.1(a) Company Subsidiary 3.4(aStraddle Period 8.4(b) Confidentiality Agreement 1.2(cSurvival Period 11.1(a) Continuing Employee 6.11(bTransition Costs 3.2(e)(xiii) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Updated Schedules 7.6 Wind Down 8.7(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Definition Location 409A Authorities 4.11(g) Acceptance Time 5.2(b1.1(e) Acquisition Proposal 5.2(a6.4(f)(i) Action 4.9(a) Adverse Recommendation Change 5.2(c6.4(c) Affiliate 3.3(d9.3(a) Affordable Care Act 4.11(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cAJCA 4.11(g) Assignee 9.5(aAntitrust Condition Exhibit A ¶(b) award 3.3(bAntitrust Law 6.6(g) Book-Entry Share 2.1(cShares 3.3(b) business day 9.10(b) CERCLA 3.18(bBusiness Day 9.3(b) Certificate of Merger 1.4 Certificate 2.1(c2.3 Certificates 3.3(b) Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 2.2 Code 2.6 3.5 Company Preamble Company Balance Sheet 3.6(aAcquisition Agreement 6.4(a) Company Board of Directors Recitals Company Bylaws 4.1(b) Company Charter 4.1(b) Company Disclosure Letter SECTION 3 Article IV Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployee 6.10(a) Company Material Adverse Effect 3.1(aIP 4.18(a) Company Option 2.4(aParty 8.3(d) Company Preferred Stock 3.3(aPlans 4.11(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRegistered IP 4.18(a) Company SEC Reports 3.5 Documents 4.5(a) Company Stockholder Approval 6.1 Stock Awards 4.2(a) Company Stock Option 3.2(a) Company Stock Plans 2.4(a3.2(a) Company Subsidiary 3.4(aStock Right 3.2(b) Company Unregistered IP 4.18(a) Confidentiality Agreement 1.2(c6.5(b) Continuing Employee 6.11(bContract 4.4(a) CPR Recitals CPR control 9.3(c) Costs 6.9(a) Credit Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 6.17 Delaware Secretary of State 2.3 DGCL Recitals Definition Location Dissenting Shares 2.3(a) DSU 2.4(c) 3.4 Effective Time 1.4 Employee Release 6.11(d2.3 Environmental Laws 4.13(c)(i) Environmental Laws 3.18(e)(iPermits 4.13(c)(ii) ERISA 3.16(a4.11(a) ERISA Affiliate 3.16(b) ESPP Purchased Rights 6.20 Exchange Act 1.1(a) Exchange Fund 2.2(aExcluded Shares 3.1(b) Expiration Date 1.1(a1.1(b) FCPA 3.9(c4.23(a) FDA 3.9(dFIRPTA Certificate 3.5 Foreign Antitrust Laws 4.4(b)(ii) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP 4.5(b) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii4.4(b) HSR Act 3.19 IC Plans 6.11(a4.4(b)(ii) Incentive Compensation Plan 6.11(aIndebtedness 9.3(e) Indemnified Parties 6.8(a) Independent Directors 6.9(a) Initial Expiration Date 1.1(b) Intellectual Property 4.18(c) IRS 3.16(a4.11(a)(ii) Laws 3.9(bknowledge 9.3(d) Layoff Laws 3.17(bLaw 4.4(a) Maximum Premium 6.8(bLiens 4.2(b) Material Adverse Effect 4.1(a) Material Contract 4.15(a) Materials of Environmental Concern 4.13(c)(iii) Merger 1.3(aRecitals Merger Agreement Exhibit A Merger Consideration 3.1(a) Merger Agreement Annex I Merger Consideration 2.1(c) Sub Preamble Minimum Condition Annex I Notice Period 5.2(dExhibit A ¶(a) OECD Convention 3.9(cNASDAQ 1.1(c)(ii) Nonqualified Deferred Compensation Plan 4.11(g) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Recitals
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBIS 3.21(b) award 3.3(bBylaws 3.1 Capitalization Date 3.7(a) Book-Entry Share 2.1(cCFIUS 4.5 Charter 3.1 Charter Agreements 7.2(k) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cChosen Courts 10.10(a) Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Collective Bargaining Agreement 3.19(a) Comcast Agreement(s) 7.2(l) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(c) Company Breach Notice Period 9.1(e) Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Article III Company Preferred Stock 3.3(a3.7(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRelated Parties 9.3(e)(i) Company SEC Reports 3.5 3.9 Company Securities 3.7(c) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aMeeting 6.4(a) Confidentiality Agreement 1.2(c10.4 Contracting Party 10.12 Copyrights 1.1(vv) Continuing Employee 6.11(bData 1.1(vv) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.1 Electronic Delivery 10.14 Expense Reimbursement 9.3(b)(iii) Indemnified Parties 6.8(aParty 8.4(d) Independent Directors 6.9(aIndemnity Cap 8.4(a) IRS 3.16(aIndemnifying Party 8.4(d) Laws 3.9(bLease 3.14(b) Layoff Laws 3.17(bLeased Real Property 3.14(b) Maximum Premium 6.8(bLosses 8.2 Marks 1.1(vv) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Nonparty Affiliate 10.12 Notice Period 5.2(d5.3(d)(ii)(3) OECD Convention 3.9(cOFAC 3.21(a) Offer Recitals Offer Condition 1.1(aOwned Real Property 3.14(a) Offer Documents 1.1(cParty Preamble Patents 1.1(vv) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Payoff Letters 6.6 Proxy Statement 1.8(a)(ii6.3(a) Purchaser Preamble Purchaser Breach Notice Period 9.1(g) Purchaser Related Parties 9.3(e)(ii) Real Property 3.12(b3.14(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiRecovery Costs 9.3(d) Representatives 5.2(a5.3(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dRequisite Stockholder Approvals 3.4 Stockholders Agreement 7.2(j) Termination Fee 8.2(bDate 9.1(c) TimeThird-Vested DSU 2.4(cParty Claim 8.5 Trade Laws 3.21(a) Top-Up Option 1.10(aTrade Secrets 1.1(vv) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Transaction Recitals
Appears in 1 contract
Samples: Series B Convertible Preferred Stock Purchase Agreement (Comscore, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Term Section Reference Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d1.1(f) Agreement Preamble Alternative Acquisition Agreement 5.2(cAppointment Time 1.3(a) Assignee 9.5(a) award 3.3(b) Assets 3.20 Book-Entry Share 2.1(cShares 2.8(c) business day 9.10(bCanceled Company Shares 2.7(b) CERCLA 3.18(bCapitalization Representation 1.1(b) Certificate of Merger 1.4 Certificate 2.1(c2.1(b) Certificates 2.8(c) Closing 1.5 Closing Amount Recitals 2.3(a) Closing Date 1.5 Code 2.6 2.3(a) Collective Bargaining Agreements 3.18(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.2(c) Company Board of Directors Recitals Recommendation Change 6.2(b) Company Disclosure Letter SECTION 3 Schedule Article III Preamble Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIndemnified Parties 6.10(a) Company Material Adverse Effect 3.1(aPlans 6.9(b) Company Option 2.4(aRegistered Intellectual Property 3.21(b) Company Preferred Stock 3.3(aRepresentatives 6.1(b) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bSecurities 3.5(d) Company Restricted Stock 2.4(bStockholders’ Meeting 2.2(a) Company Rights 3.3(aComparable Plans 6.9(b) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aCompensation Committee 3.2(e) Confidentiality Agreement 1.2(c8.8 Consent 3.3 Continuing Directors 1.3(b) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b6.10(b) Delisting Period 6.3 DGCL Recitals Delaware Secretary of State 2.1(b) Dissenting Company Shares 2.3(a2.7(b) DSU 2.4(cXxxx-Xxxxx Act 3.7 EAR 3.23(a) Effective Time 1.4 2.1(b) Term Section Reference Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(aPlans 3.17(a) Exchange Fund 2.2(a2.8(b) Expiration Date 1.1(aExport Controls 3.23(a) FCPA 3.9(cImport Restrictions 3.23(a) FDA 3.9(dIn-Licenses 3.21(i) Good Clinical Practices 3.9(hInternational Employee Plans 3.17(a) Good Laboratory Practices 3.9(hIP Contracts 3.21(j) Good Manufacturing Practices 3.9(iITAR 3.23(a) Governmental Entity 9.10(bLeased Real Property 3.19(b) Hazardous Materials 3.18(e)(iiLeases 3.19(b) HSR Act 3.19 IC Plans 6.11(aMaterial Contract 3.12(a) Incentive Compensation Plan 6.11(aMaterial Customer 3.26(a) Indemnified Parties 6.8(aMaterial Jurisdiction 1.1(b) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(bMaterial Supplier 3.26(b) Maximum Annual Premium 6.8(b6.10(b) Merger 1.3(a2.1(a) Merger Agreement Annex I Consideration 2.7(b) Merger Consideration 2.1(c) Sub Preamble Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”New Plans 6.9(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternate Debt Financing 6.4(d) Alternative Acquisition Agreement 5.2(c5.3(b) Assignee 9.5(aCapex Budget 5.2(x) award 3.3(bCapitalization Date 3.7(a) Book-Entry Share 2.1(cCash Replacement Company PSU Amounts 2.8(b)(ii) business day 9.10(b) CERCLA 3.18(bCash Replacement Company RSU Amounts 2.8(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Commitment Letters 4.12(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(e)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIT Systems 3.21(b) Company Related Parties 8.3(f)(i) Company SEC Documents Article III Company Securities 3.7(c) Company Termination Fee 8.3(b)(iii) Copyrights 1.1(bbb) D&O Indemnification Agreement 6.9(a) D&O Insurance 6.9(c) Debt Commitment Letters 4.12(a) Debt Financing 4.12(a) DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Equity Award Holders 2.8(c) Equity Commitment Letter 4.12(a) Equity Financing 4.12(a) Fee Letter 4.12(a) Final Exercise Date 2.8(d) Financing 4.12(a) Foreign Employee Plans 3.18(h) Go-Shop Period 5.3(a) Guarantee Recitals Guarantor Recitals Indemnified Person 6.9(a) Indemnified Persons 6.9(a) Information Statement 6.3(b)(i) KKR 6.2(b) Lease 3.14 Leased Real Property 3.14 Marks 1.1(bbb) Maximum Annual Premium 6.9(c) Merger Recitals Merger Sub Preamble New Debt Commitment Letters 6.4(d) New Plan 6.10(d) Notice Period 5.3(d)(ii)(1) Old Plans 6.10(d) Order 3.22(b) Other Indemnified Persons 6.9(e) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Disclosure Letter Article IV Parent Material Adverse Effect 3.1(a7.3(a) Company Option 2.4(aParent Related Parties 8.3(f)(i) Company Preferred Stock 3.3(aParty Preamble Patents 1.1(bbb) Company Quarterly Balance Sheet 3.7 Company Restricted Payment Agent 2.9(a) Payment Fund 2.9(b) Per Share 2.4(bPrice 2.7(a)(ii) Company Restricted Stock 2.4(bReimbursement Obligations 6.5(g) Company Rights 3.3(aRequired Amount 4.12(c) Company Rights Agreement 3.3(aRequired Financing Information 6.5(a)(iv) Company SEC Reports 3.5 Company Requisite Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) 3.4 Solvent 4.14 Sublease 3.14 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aUncertificated Shares 2.9(c) Taxable 3.15(aUnvested Company PSU 2.8(b)(ii) Tax Return 3.15(aUnvested Company RSU 2.8(a)(ii) Tender Completion Time UPE 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dVested Equity Award Consideration 2.8(b)(i) Termination Fee 8.2(bVested PSU Consideration 2.8(b)(i) Time-Vested DSU 2.4(cRSU Consideration 2.8(a)(i) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Written Consent 3.4
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bAccounting Arbitrator Section 2.2(b)(iii) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Membership Interests Recitals Additional Guarantee Section 11.5(d) Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(b) Affiliate Contract Section 1.2(fff)(xv) Affiliate Transactions Section 5.10 Agreed Rate Section 1.2(c) Agreement Preamble Alternative Acquisition Allocated Value Section 2.2(a) Allocation Objection Notice Section 2.2(b)(ii) Antitrust Laws Section 1.2(d) Asset Taxes Section 1.2(e) Assignment of Interests Section 8.2(a) Benefit Plan Section 1.2(f) BOEM Section 1.2(g) BSEE Section 1.2(h) Burdens Section 1.2(i) Business Day Section 1.2(j) Cash Purchase Price Section 2.1(a) Castex Section 5.1 Casualty Loss Section 5.13 Claim Section 11.3(b) Claim Notice Section 11.3(b) Closing Section 8.1 Closing Cash Payment Section 2.4(a) Closing Date Section 8.1 Closing Settlement Statement Section 2.4(a) Code Section 1.2(k) Company Section 1.2(l) Company Assets Section 1.2(m) Company Business Section 1.2(n) Company Contract Section 1.2(o) Company Derivatives Section 1.2(p) Company Leases Section 1.2(m)(i) Company Personal Property Section 1.2(m)(vii) Company Properties Section 1.2(m)(iii) Company Records Section 1.2(q) Company Rights-of-Way Section 1.2(m)(vi) Company Units Section 1.2(m)(iii) Company Xxxxx Section 1.2(m)(ii) Confidentiality Agreement 5.2(cSection 1.2(r) Assignee 9.5(aConsent Section 3.11(b) award 3.3(bConsolidated Group Section 1.2(s) BookControlled Group Liabilities Section 1.2(t) Credit Agreement Section 1.2(u) Cure Period Section 1.2(v) Current Assets Section 1.2(w) Current Liabilities Section 1.2(x) Customary Post-Entry Share Closing Consents Section 1.2(y) Damages Section 11.2(d) Decommission or Decommissioning Section 1.2(z) Defect Arbitrator Exhibit D Defect and Indemnity Escrow Account Section 1.2(aa) Defensible Title Section 1.2(bb) Deposit Section 2.1(c) business day 9.10(bDerivatives Section 5.7 Determination Date Section 2.4(b)(ii) CERCLA 3.18(bDispute Auditor Section 2.4(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cDisputed Amount Section 6.7 Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 DOJ Section 5.5 Effective Time Section 1.2(cc) Closing 1.5 Closing Effective Time Net Working Capital Section 1.2(dd) Environmental Arbitrator Exhibit D Environmental Defect Section 1.2(ee) Environmental Defect Amount Recitals Closing Section 1.2(ff) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Deductible Section 6.6(d) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 1.2(gg) Environmental Liabilities Section 1.2(hh) Environmental Notice Section 1.2(ii) Environmental Threshold Section 6.5(c) ERISA Section 1.2(jj) ERISA Affiliate Section 1.2(kk) Escrow Account Section 1.2(ll) Escrow Agent Section 1.2(kk) Escrow Agreement Section 1.2(nn) Escrow Percentage Section 11.5(a) Exchange Act Section 4.5 Excluded Assets Section 1.2(oo) Excluded Assets Assignment Section 1.2(pp) Excluded Company Records Section 1.2(q)(v) Execution Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aFinancial Statements Section 1.2(qq) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cFinal Allocation Section 2.2(b)(iv) Company’s knowledge 9.10(bFinancing Section 4.7 FTC Section 5.5 Fundamental Representations Section 11.4(a) Company Governmental Authority Section 1.2(rr) Guarantee Section 8.2(l) Hard Consent Section 5.11(b)(i) Hazardous Materials Section 1.2(ss) HSR Act Section 1.2(tt) Hydrocarbons Section 1.2(uu) Idle Iron Report Section 3.21(e) Imbalance Section 1.2(vv) INC Section 1.2(ww) Included Title Defect Properties Section 6.4(b)(ii) Income Taxes Section 1.2(xx) Indemnified Person Section 11.3(a) Indemnifying Person Section 11.3(a) Indemnity Escrow Amount Section 1.2(yy) Information Statement Section 5.17 Intellectual Property Section 1.2(zz) Intended Tax Treatment Section 2.2(b)(i) Interim Breach Section 11.2(b)(ii) Interim Breach Provision Section 11.2(b)(ii) Laws Section 1.2(aaa) Lease Annex Section 1.2(bbb) Liens Section 1.2(ccc) Loan Section 1.2(ddd) Lowest Cost Response Section 1.2(eee) Material Adverse Effect 3.1(aSection 3.31(e) Company Option 2.4(aMaterial Contract Section 1.2(fff) Company Preferred Stock 3.3(aNet Revenue Interest Section 1.2(ggg) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNORM Section 3.8 Organizational Documents Section 1.2(hhh) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOther PSA Section 1.2(iii) Outside Date 8.1(b)(iiSection 10.1(c) Parent Party or Parties Preamble Paying Agent 2.2(aPermits Section 1.2(jjj) Performance-Based DSU 2.4(cPermitted Encumbrance Section 1.2(kkk) Permits 3.9 person 9.10(bPermitted Interest Encumbrance Section 1.2(lll) Plans 3.16(aPerson Section 1.2(mmm) Phase I Activities Section 1.2(nnn) Post-Closing Statement Section 2.4(b) Pre-Effective Date Period Section 1.2(ooo) Preferential Purchase Right Section 3.11(a) Proceedings Section 3.6 Proposed Allocation Section 2.2(b)(ii) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Indemnified Parties Section 11.2(b) Purchaser Parent Preamble Purchaser Parent SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cSection 4.13 Purchaser Parent Shares Section 2.1(a) Program 3.9(kPurchaser Tax Returns Section 9.2(b) Prohibited Payment 3.9(cPurchaser’s Environmental Review Section 6.2(a) Proprietary Purchaser’s Representatives Section 6.1(a) R&W Conditional Binder Section 5.19(a) R&W Policy Section 5.19(a) Registration Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cAgreement Section 8.2(g) Release 3.18(e)(iiiSection 1.2(ppp) Representatives 5.2(aReleased Parties Section 5.12 Releasing Parties Section 5.12 Remediate, Remediation or Remedial Section 1.2(qqq) Reporting Tail Endorsement 6.8(bRequired Purchaser Filings Section 5.16(a) Restraints 8.1(b)(iRetained Employee-Related Liabilities Section 1.2(rrr) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 Riverstone Section 1.2(b) Schedule TO 1.1(bRiverstone Portfolio Company or Riverstone Portfolio Companies Section 1.2(b) SEC 1.1(a) Scheduled Closing Date Section 8.1 Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeismic Data Section 1.2(sss) Shares Recitals Special Meeting 1.8(a)(iSeller Preamble Seller Indemnified Parties Section 11.2(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Tax Section 1.2(ttt) Superior Proposal 5.2(bSeller Tax Returns Section 9.2(a) Surviving Corporation 1.3(aSeller’s Knowledge Section 1.2(uuu) Sinking Funds Section 1.2(oo)(xii) Specified Matters Section 3.33 Straddle Period Section 1.2(vvv) Suspended Funds Section 1.2(www) Tax 3.15(a) Taxable 3.15(aSection 1.2(xxx) Tax Effective Date Section 1.2(yyy) Tax Partnership Section 1.2(zzz) Tax Partnership Interest Section 1.2(aaaa) Tax Proceeding Section 9.4 Tax Return 3.15(aSection 1.2(bbbb) Tender Completion Time 6.2 Tender Third-Party Loans Section 1.2(cccc) Title Arbitrator Exhibit D Title Benefit Section 1.2(dddd) Title Benefit Amount Section 6.5(b) Title Deductible Section 6.5(c) Title Defect Section 1.2(eeee) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Dispute Election Section 6.4(b) Title Notice Section 1.2(ffff) Title Threshold Section 6.5(c) Transaction Costs Section 1.2(gggg) Transaction Documents Section 5.2 Transfer Taxes Section 9.5 Treasury Regulations Section 1.2(hhhh) Unadjusted Purchase Price Section 2.1(a) Well Annex Section 1.2(iiii) Willful Breach Section 1.2(jjjj) Working Interest Section 1.2(kkkk) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 10, 2011 is 2019 (the “Execution Date”), by and among CUBIST PHARMACEUTICALSCastex Energy 2014, INC. LLC, a Delaware limited liability company (“Seller”), Talos Production Inc., a Delaware corporation (“Purchaser”), and solely with respect to its obligations related to the Purchaser Parent Shares (as defined herein), Talos Energy Inc., a Delaware corporation (“Purchaser Parent”). Seller, a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation Purchaser and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (Purchaser Parent are referred to collectively as the “CompanyParties” and individually as a “Party.”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Term Section Reference 401(k) Termination Date 6.10(a) Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d1.1(f) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Assets 3.20 Book-Entry Share 2.1(cShares 2.7(c) business day 9.10(bCanceled Company Shares 2.6(b)(ii) CERCLA 3.18(bCapitalization Representation 1.1(b)(iii) Certificate of Merger 1.4 Certificate 2.1(c2.1(a) Certificates 2.7(c) Closing 1.5 Closing Amount Recitals 2.2(a) Closing Date 1.5 Code 2.6 2.2(a) Collective Bargaining Agreement 3.18(b) Commercially Available Licenses 3.21(h) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.2(d) Company Board of Directors Recitals Recommendation Change 6.2(b) Company Disclosure Letter SECTION 3 Schedule Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIndemnified Parties 6.11(a) Company Material Adverse Effect 3.1(aRegistered Intellectual Property 3.21(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bRepresentatives 6.1(b) Company Restricted Stock 2.4(bShares 3.5(a) Company Rights 3.3(aSecurities 3.5(d) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aCompensation Committee 3.2(f) Confidentiality Agreement 1.2(c8.8 Consent 3.3 Continuing Employees 6.10(a) Continuing Employee D&O Insurance 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bDelaware Secretary of State 2.1(a) Delisting Period 6.3 DGCL Recitals Dissenting Company Shares 2.3(a2.6(b)(iii)(A) DSU 2.4(c) Xxxx-Xxxxx Act 3.7 Effective Time 1.4 2.1(a) Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(aPlans 3.17(a) Exchange Fund 2.2(a2.7(b) Expiration Date 1.1(aExcluded Leases 3.19(b) FCPA 3.9(cExport Controls 3.23(a) FDA 3.9(dFundamental Representations 1.1(b)(iii) Good Clinical Practices 3.9(hImport Restrictions 3.23(a) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans Indemnification Agreements 6.11(a) Incentive Compensation Plan 6.11(aIndependent Contractor 3.18(a) Indemnified Parties 6.8(aInternational Employee Plans 3.17(a) Independent Directors 6.9(aIntervening Event Notice 6.2(d) IRS 3.16(aIP Contracts 3.21(i) Laws 3.9(bLeased Real Property 3.19(b) Layoff Laws 3.17(bLeases 3.19(b) Material Contract 3.12(a) Material Customer 3.25(a) Material Supplier 3.25(b) Maximum Annual Premium 6.8(b6.11(b) Merger 1.3(aRecitals Merger Consideration 2.6(b)(i) Merger Agreement Annex I Merger Consideration 2.1(c) Sub Preamble Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c1.1(b)(i) Offer Recitals Offer Condition 1.1(aClosing 1.1(f) Offer Conditions 1.1(b)(ix) Offer Documents 1.1(c1.1(g)(i) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOut-Licenses 3.21(i) Parent Preamble Paying Parent Employee Plans 6.10(b) Payment Agent 2.2(a) Performance-Based DSU 2.4(c2.7(a) Permits 3.9 person 9.10(b3.13 Privacy Policies 3.21(s) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bRegulatory Condition 1.1(b)(ii) Schedule 14D-9 1.2(b) Schedule TO 1.1(b1.1(g)(i) SEC 1.1(aReports 3.7 Section 409A 3.15(j) Specified Representations 1.1(b)(iii) Subsequent Determination Notice 6.2(c) Subsidiary Securities Act 3.11(c3.6(d) Severance 6.11(d) Shares Support Agreement Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Support Agreements Recitals Surviving Corporation 1.3(a2.1(a) Tax 3.15(aTail Policy 6.11(b) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTermination Date 7.1(c) Termination Fee 8.2(bAmount 7.4(a) Time-Transfer Regulations 6.10(d) Unvested Company Option 6.9(a) Vested DSU 2.4(cCompany Option 6.9(b) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery WARN Act 3.9(c3.18(f) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated is made and entered into as of October 24June 16, 2011 is 2014 by and among CUBIST PHARMACEUTICALSSanDisk Corporation, INC. a Delaware corporation (“Parent”), Flight Merger Sub, Inc., a Delaware corporation, FRD ACQUISITION CORPORATION corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Fusion-io, Inc., a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.. All capitalized terms that are used in this Agreement but not defined herein shall have the respective meanings ascribed thereto in Annex A.
Appears in 1 contract
Samples: Merger Agreement (Fusion-Io, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Definition Location Acquisition Proposal 5.2(a5.4(g)(i) Action 3.9 Adverse Recommendation Change 5.2(c5.4(c) Affiliate 3.3(d8.3(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cSection 5.4(g)(ii) Assignee 9.5(aAntitrust Law 8.3(b) award 3.3(bArticles of Merger 1.3 Bass Pro 5.20 BBCV Receivables-Q 2010 LLC Purchase Facility 8.3(c) Book-Entry Share 2.1(cShares 2.1(a) business day 9.10(bBRFC-Q 2010 LLC Purchase Facility 8.3(d) CERCLA 3.18(bBusiness Day 8.3(e) Business Intellectual Property 3.20(a) Certificate of Merger 1.4 Certificate 2.1(c2.1(a) Choice 5.20 Class A Shares 3.2(a) Class B Shares 3.2(a) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 8.3(f) Company Preamble Company Balance Sheet 3.6(aBoard Recitals Company Bylaws 3.1(b) Company Board of Directors Recitals Charter 3.1(b) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployee 8.3(g) Company Material Adverse Effect 3.1(aEntity 8.3(h) Company Option 2.4(aERISA Affiliate Section 3.11(b)(iii) Company Preferred Stock 3.3(aIncentive Plan 3.2(a) Company Quarterly Balance Sheet 3.7 Indemnitees 5.21(b) Company Restricted Share 2.4(bIntellectual Property 8.3(i) Company Management Agreement Section 3.18(a)(viii) Company Manager Section 3.18(a)(viii) Company Offering Documents 8.3(j) Company Organizational Documents 3.1(b) Company Plans 3.11(a) Company Proprietary Software 8.3(k) Company Real Property 3.17(b) Company Real Property Lease 3.17(d) Company Receivables Financings 8.3(p) Company Receivables-Backed Facilities 8.3(l) Company Receivables-Backed Facilities Commitment Letters 8.3(m) Company Receivables-Backed Facility 8.3(n) Company Receivables-Backed Facility Instrument 8.3(o) Company Recommendation 3.3(b) Company Registered IP 3.20(a) Company Restricted Stock 2.4(bAward 2.2 Company SEC Documents 3.5(a) Definition Location Company Securitization Transaction 8.3(q) Company Rights Special Purpose Subsidiary Section 8.3(r) Company Stockholder Approval 3.3(a) Company Rights Agreement 3.3(aStockholders’ Meeting 5.6(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aThird-Party Leases 3.17(c) Company Subsidiary 3.4(aTimeshare Lender 3.18(e)(i) Company Timeshare Receivables 3.18(e) Compliant Section 8.3(s) Confidentiality Agreement 1.2(c5.7(b) Continuing Employee 6.11(b5.9(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContract 3.4(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(acontrol Section 8.3(t) DSU 2.4(cCredit Suisse 3.25 Debt Financing Section 8.3(u) Debt Financing Parties Section 8.3(v) Debt Financing Sources Section 8.3(w) Debt Instruments 3.18(e) XXXXX Section 8.3(x) Effective Time 1.4 Employee Release 6.11(d1.3 Employment Matters Section 8.3(y) Environmental Laws 3.18(e)(iSection 8.3(z) Environmental Permits 8.3(aa) Equitable Principles Section 8.3(bb) ERISA 3.16(a) ERISA Affiliate 3.16(b3.11(a) Exchange Act 1.1(a3.4(b) Exchange Fund 2.2(aProgram Section 8.3(cc) Expiration Date 1.1(aExcluded Information Section 8.3(dd) FCPA 3.9(cExcluded Shares 2.1(b) FDA 3.9(dFBCA Recitals FFS Arrangements 8.3(ee) Good Clinical Practices 3.9(hFFS Developers 8.3(ff) Good Laboratory Practices 3.9(hFFS Documents 8.3(gg) Good Manufacturing Practices 3.9(iFifth Third Credit Facility 8.3(hh) Fundamental Action Section 5.4(d) Funded Indebtedness 8.3(ii) GAAP 8.3(jj) Governmental Antitrust Authority 5.8(f) Governmental Entity 9.10(b8.3(kk) Hazardous Materials 3.18(e)(iiGovernmental Filings 8.3(ll) HGV Warehouse Facility 8.3(mm) Hilton Recitals Hilton Consent Recitals Hilton License Agreement Recitals HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.4(b) Indemnified Parties 6.8(a5.12(a) Independent Directors 6.9(aIntellectual Property 8.3(nn) IRS 3.16(a3.11(a) Laws 3.9(bIT Systems Section 8.3(oo) Layoff Laws Key Stockholders Section 8.3(pp) knowledge Section 8.3(qq) Law 3.4(a) Definition Location Leakage Section 8.3(rr) Leased Real Property 3.17(b) Maximum Premium 6.8(bLiberty Bank Facility Section 8.3(ss) Liens 3.2(a) Marketing Period Section 8.3(tt) Material Adverse Effect Section 8.3(uu) Material Contracts 3.15(a) Materials of Environmental Concern Section 8.3(vv) Merger 1.3(aRecitals Merger Consideration 2.1(a) Merger Agreement Annex I Sub Preamble Merger Consideration 2.1(cSub Board Recitals NBA Receivables Facility Section 8.3(ww) Minimum Condition Annex I Non-Profit VCA Section 8.3(xx) Non-Profit VOA Section 8.3(yy) Notice 5.4(d) Notice Period 5.2(d5.4(d) OECD Convention 3.9(cNYSE 3.4(b) Offer Recitals Offer Condition 1.1(aOff-the-Shelf Software Section 8.3(zz) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOpen Source Software Section 8.3(aaa) Outside Date 8.1(b)(ii7.1(b)(i) Owned Real Property 3.17(b) Pacific Western Facility Section 8.3(bbb) Parent Preamble Parent Board Recitals Parent Common Stock Section 8.3(ccc) Parent Disclosure Letter Article IV Parent Employee Benefit Plan 5.9(c) Parent Indemnity and Reimbursement Obligations 5.21(b) Parent Material Adverse Effect Section 8.3(ddd) Parent Plan Section 8.3(eee) Parent SEC Documents 4.5(a) Patents 8.3(nn) Paying Agent 2.2(a2.3(a) Performance-Based DSU 2.4(cPayment Fund 2.3(a) PCB Loan Section 8.3(fff) Permits 3.9 person 9.10(b3.10 Permitted Company Receivables-Back Facilities Activity Section 8.3(ggg) Plans 3.16(aPermitted Confidentiality Agreement 5.4(b) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPermitted Liens Section 8.3(hhh) Program 3.9(kPerson Section 8.3(iii) Prohibited Payment 3.9(cPersonal Data Section 8.3(jjj) Proprietary Rights 3.12(aPreferred Stock 3.2(a) Prepayment Amendment Section 5.22(a) Privacy and Security Requirements Section 8.3(kkk) Processing Section 8.3(lll) Proxy Statement 1.8(a)(ii3.7 R&W Policy 5.18 Representatives 5.4(a) Real Property 3.12(bRequired Information Section 8.3(mmm) Regulation M-A 1.1(cRule 144A 8.3(s) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Definition Location Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b3.5(a) SEC 1.1(a3.5(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.4(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Bluegreen Vacations Holding Corp)
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the section or place indicated below: 2008 Purchase Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cSection 2.8(c) Affiliate 3.3(dSection 1.3(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cApplicable Food Laws Section 2.16 Audited Financial Statements Section 2.8(a) Assignee 9.5(aAuthorizations Section 2.17 Base Cash Purchase Price Section 1.3(a) award 3.3(bBenefit Plans Section 2.21(a) Book-Entry Share 2.1(cBuyer Preamble Buyer Indemnified Parties Section 7.2 Buyer Prepared Tax Returns Section 5.7(b) business day 9.10(bCash Purchase Price Section 1.3(a) CERCLA 3.18(b) Cash Purchase Price Certificate of Merger 1.4 Certificate 2.1(cSection 1.5(a) Closing 1.5 Section 1.2 Closing Amount Recitals Cash Section 1.3(a) Closing Date 1.5 Section 1.2 Closing Indebtedness Section 1.3(a) Closing Working Capital Schedule 1.3 Closing Working Capital Lower Target Section 1.3(a) Closing Working Capital Upper Target Section 1.3(a) Code 2.6 Section 1.7 Company Preamble Company Balance Sheet 3.6(a) Charter Documents Section 2.1 Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIntellectual Property Section 2.13(a) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aSection 1.3(a) Confidentiality Agreement 1.2(cSection 5.1(b) Continuing Employee 6.11(bConsent Section 1.3(a) CPR Recitals CPR Consideration Section 1.3(a) Contest Section 5.7(e) Cut-Off Date Section 7.1 Defense Notice Section 7.4(b) Designated Firms Section 9.13 Dispute Section 9.13 Disputed Items Section 1.5(b) Disputed Items Notice Section 1.5(b) Earnout Agreement Recitals Current D&O Insurance 6.8(bSection 1.3(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Earnout Payment Section 1.6 Environment Section 2.22 Environmental Claim Section 2.22 Environmental Laws 3.18(e)(iSection 2.22 Environmental Permits Section 2.22 ERISA Section 2.21(a) ERISA 3.16(aEscrow Agent Section 1.3(a) ERISA Affiliate 3.16(bEscrow Agreement Section 1.3(a) Exchange Act 1.1(aEscrow Fund Section 1.3(a) Exchange Fund 2.2(aEstimated Cash Purchase Price Section 1.3(a) Expiration Date 1.1(aEstimated Cash Purchase Price Certificate Section 1.3(b) FCPA 3.9(cFinancial Statements Section 2.8(a) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iGAAP Section 1.3(a) Governmental Entity 9.10(bAuthority Section 1.3(a) Hazardous Materials 3.18(e)(ii) Substances Section 2.22 Holdings Preamble HSR Act 3.19 IC Plans 6.11(aSection 5.4(c) Incentive Compensation Plan 6.11(aIncome Tax(es) Section 2.18(q) Indemnification Parties Section 7.3 Indemnified Persons Section 5.8(a) Independent Accounting Firm Section 1.5(c) Intellectual Property Section 2.13(a) Interim Financial Statements Section 2.8(a) IP Licenses Section 2.13(c) Knowledge Section 1.3(a) Leases Section 2.11(b) Leased Real Property Section 2.11(b) Legal Requirement(s) Section 2.16 Lien Section 1.3(a) Losses Section 7.5(a) Material Contracts Section 2.10 Opco Preamble Owned Real Property Section 2.11(a) Permitted Liens Section 2.12 Person Section 1.3(a) Personal Information Section 5.1(a) Pre-Closing Taxable Periods Section 5.7(b) Proceeding Section 5.8(a) Protected Seller Communications Section 9.13 Purchased Securities Section 1.1 Real Property Section 2.11(b) Reference Date Section 2.13(e) Release Section 2.22 Response Period Section 7.4(a) Sale Bonuses Section 1.3(a) Section 1.5 Notice Section 1.5(f) Section 280G Waived Payments Section 5.13 Seller Preamble Seller Indemnified Parties 6.8(aSection 7.3 Seller Prepared Tax Returns Section 5.7(b) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger Seller’s Expenses Section 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(cSurvey Section 5.4(b)(iii) Minimum Condition Annex I Notice Period 5.2(dTax(es) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(aSection 2.18(q) Tax 3.15(aReturns Section 2.18(q) Taxable 3.15(aTechnology Section 2.13(a) Tax Return 3.15(aTitle Company Section 5.4(a)(ii) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (Transactions Section 1.1 [ The remainder of this “Agreement”) dated as of October 24, 2011 page is among CUBIST PHARMACEUTICALS, INCintentionally left blank. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.]
Appears in 1 contract
Samples: Securities Purchase Agreement (TreeHouse Foods, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the Agreement listed section or place indicated below. Acceptance Time 5.2(b: Term: Section or Place Where Defined: Action Section 2.19 Affiliate Section 1.3(a) Acquisition Proposal 5.2(aAgent Section 9.13(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dAgent Fund Section 1.4(d) Agreement Preamble Alternative Acquisition Agreement 5.2(cAuthorizations Section 2.17 Bain Section 1.3(a) Assignee 9.5(aBain Blocker Section 1.3(a) award 3.3(bBain Blocker Contest Section 5.7(a) Book-Entry Share 2.1(cBalance Sheet Date Section 2.8(a)2.8(a) business day 9.10(bBase Purchase Price Section 1.3(a) CERCLA 3.18(bBenefit Plans Section 2.21(a) Certificate of Merger 1.4 Certificate 2.1(cBusiness Section 2.12(b) Buyer Preamble Buyer Indemnified Parties Section 7.2 Buyer’s Plans Section 5.10 Closing Section 1.2 1.2 Closing Cash Section 1.3(a) Closing 1.5 Date Section 1.2 Closing Amount Recitals Indebtedness Section 1.3(a) Closing Date 1.5 Items Section 1.7(a) Closing Tax Benefit Section 1.3(a) Closing Working Capital Section 1.3(a) Closing Working Capital Target Section 1.3(a) Code 2.6 Section 2.21(b) Company Preamble Company Balance Sheet 3.6(a) Charter Documents Section 2.1 Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIntellectual Property Section 2.13(a) Company Material Adverse Effect 3.1(aSection 1.3(a) Company Option 2.4(aPlans Section 5.10 Contest Section 5.7(c) Company Preferred Stock 3.3(aCovered Liabilities Section 3.5 Cut-Off Date Section 7.1 Designated Firms Section 9.14 Disclosure Supplement Section 5.6(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bDispute Section 9.14 Disputed Items Section 1.7(b) Company Restricted Stock 2.4(bDisputed Items Notice Section 1.7(b) Company Rights 3.3(aEnvironment Section 2.22(a)(i) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(dEnvironmental Claim Section 2.22(a)(ii) Environmental Laws 3.18(e)(iSection 2.22(a)(iii) ERISA 3.16(aSection 2.21(a) ERISA Affiliate 3.16(bEscrow Agent Section 1.4(c) Exchange Act 1.1(aEscrow Agreement Section 6.1(g) Exchange Escrow Fund 2.2(aSection 1.4(c) Expiration Date 1.1(aEstimated Purchase Price Section 1.3(a) FCPA 3.9(cEstimated Purchase Price Certificate Section 1.3(b) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iFinancing Section 5.11 GAAP Section 1.3(a) Governmental Entity 9.10(bAuthority Section 1.3(a) Guidance Section 2.21(c) Hazardous Materials 3.18(e)(iiSubstances Section 2.22(a)(iv) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aSection 5.4(b) Indemnified Parties 6.8(aPersons Section 5.8(a) Independent Directors 6.9(aAccounting Firm Section 1.7(c) IRS 3.16(aIntellectual Property Section 2.13(a) Laws 3.9(bIP Licenses Section 2.13(d) Layoff Laws 3.17(bLease Section 2.11(b) Maximum Premium 6.8(b) Merger Legal Requirements Section 2.16 Lien Section 1.3(a) Merger LLC Agreement Annex I Merger Consideration 2.1(cSection 1.6(a) Minimum Condition Annex I Notice Period 5.2(dLosses Section 7.6 Market Reaction New Matter Section 5.6 Material Contracts Section 2.10 Member Section 1.3(a) OECD Convention 3.9(cMost Recent Balance Sheet Section 2.8(a) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) New Matter Section 5.6 Owned Real Property 3.12(bSection 2.11(a) Regulation M-A 1.1(cPayment Schedule Section 1.6(c) Release 3.18(e)(iiiPermitted Liens Section 2.12 Person Section 1.3(a) Representatives 5.2(aPersonal Information Section 5.1(a) Reporting Tail Endorsement 6.8(bPrior Service Section 5.10 Proceeding Section 5.8(a) Restraints 8.1(b)(iPro Rata Share Section 7.2 Protected Seller Communications Section 9.14 Purchase Price Section 1.3(a) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aPurchase Price Certificate Section 1.7(a) Xxxxxxxx-Xxxxx Act 3.6(bPurchased Securities Section 1.1 Response Period Section 7.5(a) Schedule 14D-9 1.2(bSale Bonuses Section 1.3(a) Schedule TO 1.1(bSeller Indemnified Parties Section 7.4 Sellers Preamble Sellers’ Expenses Section 1.3(a) SEC 1.1(aSpecified Representations Section 7.2 Straddle Period Section 5.7(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation Subsidiary Section 1.3(a) Tax 3.15(a) Taxable 3.15(aTaxes Section 2.18(a) Tax Return 3.15(aReturns Section 2.18(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Technology Section 2.13(a) Terminated Employee 6.11(dContracts Section 2.10 Units Section 1.3(a) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Upward Closing Working Capital Adjustment Section 1.3(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Securities Purchase Agreement (Henry Jack & Associates Inc)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b2015 Closing Section 1.1 2015 Signing Section 1.1 2015 SPA Recitals Accountant Section 3.7(c) Accounting Principles Section 1.1 Acquired Intellectual Property Section 4.16(a) Acquisition Proposal 5.2(aFinancing Section 5.5(b) Adverse Recommendation Change 5.2(c) Adjustment Amount Section 1.1 Affiliate 3.3(d) Section 1.1 Agreement Preamble Alternative Acquisition Alternate Financing Section 6.5(c) Applicable Accounting Standards Section 1.1 Assets Section 4.20(a) Assignment Agreement 5.2(cSection 1.1 Audited Financial Statements Section 4.9(a) Assignee 9.5(aBusiness Section 1.1 Business Day Section 1.1 Business Employee Section 1.1 Business Financial Information Section 4.9(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Business Material Adverse Effect 3.1(aSection 1.1 Cash and Cash Equivalents Section 1.1 CBAs Section 4.10(a) Change of Control Payment Section 1.1 Closing Section 3.1 Closing Cash Section 1.1 Closing Consideration Section 1.1 Closing Date Section 3.1 Closing Indebtedness Section 1.1 Closing Purchase Price Section 1.1 Closing Working Capital Section 1.1 CMA Recitals CMA Orders Recitals Code Section 1.1 Commitment Letter Section 5.5(b) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Benefit Plan Section 1.1 Continuing Employee 6.11(bSection 6.9(a) CPR Recitals CPR Agreement Recitals Current Contract Section 1.1 Controlling Party Section 8.4(c) D&O Insurance 6.8(bIndemnified Persons Section 6.10(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aDamages Section 1.1 Disclosure Letters Section 1.1 Dispute Notice Section 3.7(c) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Enforceability Exceptions Section 4.4 Environmental Laws 3.18(e)(i) Section 1.1 ERISA 3.16(a) Section 1.1 ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iSection 1.1 Estimated Adjustment Amount Section 3.2 Estimated Closing Cash Section 3.2 Estimated Closing Indebtedness Section 3.2 Estimated Closing Statement Section 3.2 Estimated Trayport Transaction Expenses Section 3.2 Excluded Taxes Section 1.1 Federal Funds Rate Section 1.1 Final CMA Order Recitals Foreign Company Benefit Plan Section 4.10(h) Governmental Entity 9.10(b) Authority Section 1.1 Guarantor Preamble Hazardous Materials 3.18(e)(iiSection 1.1 Indebtedness Section 1.1 Information Technology Section 1.1 Initial Enforcement Order Recitals Intellectual Property Section 1.1 IRS Section 1.1 Knowledge Section 1.1 Law Section 1.1 Leased Real Property Section 1.1 Leases Section 1.1 Leave of Absence Section 1.1 Lenders Section 5.5(b) HSR Act 3.19 IC Liability Section 1.1 Lien Section 1.1 London Lease Agreements Section 6.11 Marks Section 1.1 Material Contracts Section 4.15(a) New Benefit Plans 6.11(aSection 6.9(b) Incentive Compensation Plan 6.11(aNew Commitment Letter Section 6.5(c) Indemnified Parties 6.8(aNGX Agreement Section 1.1 NGX Base Value Section 1.1 NGX Long Stop Date Section 1.1 NGX Sale Section 1.1 NGX/Shorcan Equity Interests Section 1.1 Non-controlling Party Section 8.4(c) Independent Directors 6.9(aNon-Disclosure Agreement Section 6.3(c)(i) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOFAC Section 4.21 Open Source Software Section 1.1 Order Section 1.1 Ordinary Course Section 4.14(a) Outside Date 8.1(b)(iiSection 9.1(c) Parent Owned Intellectual Property Section 4.16(a) Owned Software Section 4.17(c) Parties Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Party Preamble Patents Section 1.1 Permits 3.9 person 9.10(b) Plans 3.16(a) Section 1.1 Permitted Lien Section 1.1 Person Section 1.1 Post-Closing SEC Reports 6.3 Principal Stockholders Period Section 1.1 Pre-Closing Period Section 1.1 Pre-Closing Representation Section 6.12 Proceeding Section 1.1 Purchaser Preamble Purchaser Material Adverse Effect Section 1.1 Purchasers Preamble Purchasers Disclosure Letter Section 1.1 Regulatory Proceeding Section 4.7(c) Related Agreements Section 1.1 Release Section 1.1 Restricted Person Section 6.6 Revised Adjustment Amount Section 3.7(a) Revised Closing Cash Section 3.7(a) Revised Closing Indebtedness Section 3.7(a) Revised Statement Section 3.7(a) Revised Trayport Transaction Expenses Section 3.7(a) Sale Section 2.1 Second CMA Order Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Section 1.1 Securities Act 3.11(cSection 1.1 Self-Regulatory Organization Section 1.1 Seller Preamble Seller Disclosure Letter Section 1.1 Seller Group Section 1.1 Seller’s Bank Account Section 10.1 SFRS Section 1.1 Shearman Section 6.12 Software Section 1.1 Straddle Period Section 1.1 Subsequent Loss Section 8.3(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Subsidiary Section 1.1 Tax 3.15(a) Taxable 3.15(aSection 1.1 Tax Claim Section 1.1 Tax Item Section 1.1 Tax Proceeding Section 8.4(b) Tax Return 3.15(aSection 1.1 Taxes Section 1.1 Taxing Authority Section 1.1 TMX Group Limited Preamble TMX Group US Preamble Transfer Taxes Section 8.10 Transition Services Agreement Section 1.1 Trayport Companies Section 4.2(a) Tender Completion Time 6.2 Tender and Voting Agreements Trayport Company Section 4.2(a) Trayport Entities Recitals Terminated Employee 6.11(dTrayport Equity Interests Section 2.1 Trayport Improvements Section 4.13(b) Termination Fee 8.2(bTrayport Leased Real Property Section 4.13(a) Time-Vested DSU 2.4(cTrayport Permits Section 4.7(a) Top-Up Option 1.10(aTrayport Subsidiaries Section 4.2(a) Top-Up Shares 1.10(aTrayport Subsidiary Section 4.2(a) UK Bribery Act 3.9(cTrayport Subsidiary Interests Section 4.3(b) THIS Trayport Transaction Expenses Section 1.1 U.K. Equity Interests Section 2.1 U.K. GAAP Section 1.1 U.S. Equity Interests Section 2.1 U.S. GAAP Section 1.1 Unaudited Financial Statements Section 4.9(a) Working Capital Section 1.1 Working Capital Target Section 1.1 This STOCK PURCHASE AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated is entered into as of October 2427, 2011 is 2017 by and among CUBIST PHARMACEUTICALSIntercontinentalExchange International, INC. Inc., a Delaware corporation (“ParentSeller”), TMX Group Limited, a Delaware corporation, FRD ACQUISITION CORPORATION corporation organized under the Business Corporations Act (Ontario) (“SubTMX Group Limited”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”)TMX Group US Inc., a Delaware corporationcorporation (“TMX Group US”, and together with TMX Group Limited, “Purchasers” and each, a “Purchaser”) and, solely for the purposes set forth in Article X, Intercontinental Exchange, Inc., a Delaware corporation (“Guarantor”) (Seller, together with Purchasers, and, solely for the purposes set forth in this preamble, Guarantor collectively, the “Parties,” and each, individually, a “Party”).
Appears in 1 contract
Samples: Stock Purchase Agreement (Intercontinental Exchange, Inc.)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Section number where such definition is contained: TERM SECTION: 409A Liability Section 3.16.9 1998 Plan Section 2.3.1 2000 Plan Section 2.3.1 Accountants Section 2.5.5 Affiliate Section 9.2.1 Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) First Paragraph Business Day Section 9.2.2 Certificate of Merger 1.4 Certificate 2.1(c) Section 1.3 Certificates Section 2.4.2 Certifications Section 3.4.1 Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Code 2.6 Company Preamble Company Section 1.2 Closing Date Balance Sheet 3.6(aSection 2.5.5 Code Section 2.4.6 Company First Paragraph Company Acquisition Agreement Section 6.2.3 Company Board Approval Section 3.1.2 Company Business First Recital Company Common Stock Section 2.2.1 Company Financial Statements Section 3.4.2 Company Intellectual Property Section 3.13.1 Company-owned Intellectual Property Section 3.13.9(d) Company Board of Directors Recitals Listed Contracts Section 3.8.1 Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bMaterial Breach Section 8.1(c) Company Options Section 2.3.1 Company Option Plans Section 2.3.1 Company Plan or Company Plans Section 3.16.1 Company Products Section 3.13.9(f) Company Registered Intellectual Property Section 3.13.1 Company SEC Documents Section 3.4.1 Company SEC Financial Statements Section 3.4.2 Company Source Code Section 3.13.9(g) Company Stockholders Section 2.2.1 Company Stockholder Approval Section 3.1.2 Company Stockholders’ Meeting Section 6.2.1 Company Transaction Costs Section 3.26 Company Triggering Event Section 8.1(d) Confidentiality Agreement Section 6.3 Contract Section 9.2.3 Copyrights Section 3.13.9(a) Credit Agreement Amendment Section 4.6 DGCL Second Recital Delaware Secretary of State Section 1.3 Dissenting Shares Section 2.4.7 Dissenting Stockholder Section 2.4.7 Domestication Section 3.1.4 Effective Time Section 1.3 End Date Section 8.1(b)(i) Environmental Claims Section 3.14.3(d)(i) Environmental Laws Section 3.14.3(d)(ii) Environmental Permits Section 3.14.3(d)(iii) ERISA Section 3.16.1 ERISA Affiliate Section 3.16.3 Escrow Account Section 2.5.4(a) Escrow Agent Section 2.5.4(a) Escrow Agreement Section 2.5.4(a) Escrow Amount Section 2.5.4(a) Estimated Working Capital Section 2.5.3 Estimated Working Capital Adjustment Section 2.5.3 Estimated Working Capital Statement Section 2.5.2 Exchange Act Section 3.2.4 Exchange Agent Section 2.4.1 Execution Date First Paragraph file Section 3.4.1 Final Distribution Date Section 2.5.4(d) Final Working Capital Section 2.5.5 Final Working Capital Adjustment Section 2.5.5 GAAP Section 2.5.1 Governmental or Regulatory Authority Section 3.9.1 Hazardous Materials Section 3.14.3(d)(iv) Holdback Section 2.5.4(a) Indebtedness Section 9.2.4 Independent Auditors Section 2.5.5 Intellectual Property Section 3.13.9(a) IRS Section 3.11(c) Knowledge Section 9.2.5 Law Section 3.9.1 Legal Requirement Section 9.2.6 Legal Restraints Section 7.1.3 Licensed Intellectual Property Section 3.13.1 Liens Section 3.3 Losses Section 2.5.4(c) Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Section 9.2.7 Merger 1.3(a) Merger Agreement Annex I Second Recital Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiSection 2.2.1 Merger Sub First Paragraph Nextwave Section 9.2.10 Non-affiliated Nextwave Directors Section 3.4.5 Option Conversion Section 2.3.1 Orders Section 3.9.1 Ordinary Course of Business Section 9.2.8 OTCBB Section 3.4.1 Parent First Paragraph Parent Escrow Distribution Section 2.5.4(c) Parent Preamble Paying Agent 2.2(aMaterial Breach Section 8.1(e) Performance-Based DSU 2.4(cParty and Parties First Paragraph Patent Application Section 3.13.9(b) Patents Section 3.13.9(a) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Section 3.14.2 Per Share Merger Consideration Section 2.2.1 Person Section 9.2.9 Permitted Liens Section 3.6.2 Proxy Statement 1.8(a)(ii) Section 6.1.1 Public Software Section 3.13.7 Real Property 3.12(bLease Section 3.7.2 Release Section 3.14.3(d)(v) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) Representative Section 9.12.1 SEC 1.1(a) Section 3.4.1 Securities Act 3.11(cSection 3.2.5 Shrinkwrap Software Section 3.13.9(e) Severance 6.11(dSoftware Section 3.13.9(c) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Determination Section 2.5.5 Subsequent Determination Section 6.2.3 Subsidiary Section 9.2.10 Superior Proposal 5.2(bSection 5.2.1(b)(ii) Surviving Corporation 1.3(aSection 1.1 Takeover Proposal Section 5.2.1(b)(ii) Target Working Capital Section 2.5.1 Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dor Taxes Section 3.11(a) Termination Fee 8.2(bSection 6.6.2 Third Party Section 5.2.1(b)(ii) TimeTrade Secrets Section 3.13.9(a) Trademarks Section 3.13.9(a) WC Escrow Section 2.5.4(a) Wholly-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Owned Subsidiary Section 2.5.1 Working Capital Section 2.5.1
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of certain terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection numbers where such definitions are contained: AAA 12.9 AAA Rules 12.9 Acquired Assets 2.1 Acquired Subsidiary Employees 8.5(b) Acquisition Proposal 5.2(aAssumed Contracts 2.1(b) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share Assumed Liabilities 2.3 Assumed Office Leases 2.1(c) business day 9.10(bBalance Sheet 6.4(b) CERCLA 3.18(bBalance Sheet Date 6.4(b) Certificate of Merger 1.4 Certificate 2.1(cBasket Amount 11.2(b)(i) Business Recitals B Business Event 3.1 Buyer Preamble Buyer Indemnified Persons 11.2(a) Buyer Closing Condition Failure 10.4 Buyer’s Plans 8.5(i) Closing 1.5 Closing Amount Recitals 4.1 Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 4.1 Closing Payment 3.1(a) Company Option 2.4(aIntellectual Property 6.15(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(aCompeting Business 8.3(a) ERISA Affiliate 3.16(b6.18(a)) Exchange Act 1.1(aExcluded Assets 2.2 Excluded Liabilities 2.4 FCRA 8.7(b) Exchange Fund 2.2(aFinal Stub Period 3.1 Financial Statements 6.4(a) Expiration Date 1.1(aFirst Measurement Period 3.1 General Cap Amount 11.2(b)(ii) FCPA 3.9(cHired Employees 8.5(b) FDA 3.9(dHLC Escrow Preamble HLC Inc. Preamble Indemnified Person 11.4(a) Good Clinical Practices 3.9(hIndemnifying Person 11.4(a) Good Laboratory Practices 3.9(hLead Sale Agreement 4.2(a)(x) Good Manufacturing Practices 3.9(iLendingTree Preamble Material Contracts 6.13(a) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Measurement Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiRevenue 3.1 Nonassignable Assets 8.8 Owned Software 6.15(g) Parent Preamble Paying Agent 2.2(aPart(ies) Performance-Based DSU 2.4(cPreamble Permitted Section 8.3 Acquirer 8.3(a) Permits 3.9 person 9.10(bPermitted Section 8.3 Transaction 8.3(a) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aProperty Taxes 8.4(b) Proxy Statement 1.8(a)(ii7.5(a) Real Property 3.12(bPurchase Price 3.1 Reference Month 7.13 RETS 401(k) Regulation M-A 1.1(cPlan 8.5(h) Release 3.18(e)(iiiSection 338(h)(10) Representatives 5.2(aElection 8.4(e) Reporting Tail Endorsement 6.8(bSeller Benefit Plan 6.18(a) Restraints 8.1(b)(iSeller Indemnified Persons 11.3(a) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aSeller Part(ies) Xxxxxxxx-Xxxxx Act 3.6(bPreamble Seller(s) Schedule 14D-9 1.2(bPreamble Specified Representations 11.1(a) Schedule TO 1.1(bStockholders’ Meeting 7.5(a) SEC 1.1(aSubsequent Measuring Period 3.1 Survival Period 11.1(a) Securities Act 3.11(cTransition Services Agreement 7.10(b) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Wind Down 8.6(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of certain terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection numbers where such definitions are contained: TERM SECTION: 401(k) Acquisition Proposal 5.2(aPlan Accounting Arbitrator 6.18(g) Adverse Recommendation Change 5.2(c3.2(c) Affiliate 3.3(dAcquired Assets 2.1 Actual Accruals Amount 3.6(b) Actual Book Value Amount 3.2(c) Actual Seller-Owed Commissions 3.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(cTransaction 7.6 Arbitrator 12.9(c) Assignee 9.5(aAssumed Contracts 2.1(b) award 3.3(bAssumed Liabilities 2.3 Assumed Pre-Closing Benefit Plan Liabilities 2.3 Basket Amount 11.2(b)(i) Book-Entry Share 2.1(cBloxom Preamble Book Value Statement 3.2(b) business day 9.10(bBusiness Recital A Buyer Preamble Buyer Financial Statements 5.5(a)
(a) CERCLA 3.18(bBuyer Interim Balance Sheet 5.5
(a) Certificate of Merger 1.4 Certificate 2.1(cBuyer Interim Balance Sheet Date 5.5(a) Cap 11.2(b)(ii) Closing 1.5 Closing Amount Recitals 4.1 Closing Date 1.5 Code 2.6 Company Preamble Company 4.1 Consent Delay 10.1(b)
(a) Covered Claims 12.9(e) Dollar 1 Matters 11.2(a)(vii) Estimated Accruals Amount 3.6(a) Estimated Book Value Amount 3.2(a) Estimated Seller-Owed Commissions 3.3(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Extension Period 10.1(b) FCRA 8.8(d) Financial Statements 6.5(a) Global Settlement Funds 9.2(f) Indemnified Person 11.4(a) Indemnifying Person 11.4(a) Initial Termination Date 10.1(b) Interim Balance Sheet 3.6(a6.5(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Interim Balance Sheet 3.7 Company Date 6.5(a) JAMS 12.9(a) Xxxxxxx Preamble Leased Property 6.20(a)(i) Licensing Approval Delay 10.1(b) TERM SECTION: Neutral Accounting Firm 3.2(c) Non-Signatory Action 12.9(e) Nonassignable Assets 8.9 Party (ies) Preamble Property Taxes 8.4(b) Purchase Price 3.1 PTO 8.5(b) Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bGeographic Area 8.3(a) Schedule 14D-9 1.2(bSupplement 7.7 Seller Preamble Seller IP License 6.15(d) Schedule TO 1.1(bServicing Condition Notice 9.2(g)(ii) SEC 1.1(aStockholders Preamble Stockholder Representative 12.15 Specified Representations 11.1(a) Securities Act 3.11(cStraddle Period 8.4(b) Severance 6.11(dSurvival Period 11.1(a) Shares Recitals Special Meeting 1.8(a)(iTransferred Personal Property 2.1(d) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Wind Down 8.7(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Asset Purchase Agreement
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: “Agreement” Preamble “Alternate Debt Financing” 6.5(d) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble “Alternative Acquisition Agreement 5.2(cAgreement” 5.3(a) Assignee 9.5(a“Capitalization Date” 3.8(a) award 3.3(b“Certificates” 2.9(c) Book-Entry Share 2.1(c“Chosen Courts” 9.10(a) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) “CICL” Recitals “Closing” 2.3 “Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Date” 2.3 “Collective Bargaining Agreement” 3.20 “Company” Preamble Company Balance Sheet 3.6(a) “Company Board of Directors Recitals Recommendation” 3.3(a) “Company Board Recommendation Change” 5.3(d)(i) “Company Disclosure Letter SECTION 3 Letter” Article III “Company Joint Venture 3.4(cRelated Parties” 8.3(f)(ii) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) “Company SEC Reports 3.5 Reports” 3.10 “Company Stockholder Approval 6.1 Securities” 3.8(c) “Company Stock Plans 2.4(aShareholder Meeting” 6.4(a) “Company Subsidiary 3.4(aSource Code” 3.17(j) “Company Termination Fee” 8.3(b)(i) “Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan Agreement” 9.4 “Continuation Period” 6.11(c) Program 3.9(k“D&O Insurance” 6.10(c) Prohibited Payment 3.9(c“Debt Commitment Letters” 4.11(a) Proprietary Rights 3.12(a“Debt Financing” 4.11(a) Proxy Statement 1.8(a)(ii“DTC” 2.9(d) Real Property 3.12(b“Effective Time” 2.2 “Electronic Delivery” 9.14 “Employee Plans” 3.19(a) Regulation M-A 1.1(c“Equity Commitment Letter” 4.11(a) Release 3.18(e)(iii“Equity Financing” 4.11(a) Representatives 5.2(a“ERISA Affiliate” 3.19(a) Reporting Tail Endorsement 6.8(b“Fee Letter” 4.11(a) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Financing” 4.11(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Cision Ltd.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Term Section Reference 401(k) Termination Date 6.9(g) Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d1.1(f) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Assets 3.20 Board Actions Recitals Book-Entry Share 2.1(cShares 2.7(c) business day 9.10(bCanceled Company Shares 2.6(b)(ii) CERCLA 3.18(bCapitalization Representation 1.1(b)(iii) Certificate of Merger 1.4 Certificate 2.1(c2.1(b) Certificates 2.7(c) Closing 1.5 Closing Amount Recitals 2.2(a) Closing Date 1.5 Code 2.6 2.2(a) Collective Bargaining Agreements 3.18(b) Commitment Letter 4.7 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation Recitals Company Board Recommendation Change 6.2(b) Company Board of Directors Recitals Disclosure Schedule Article III Preamble Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIndemnified Parties 6.10(a) Company Material Adverse Effect 3.1(aRegistered Intellectual Property 3.21(b) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bRepresentatives 6.1(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports Shares 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aSecurities 3.5(d) Company Subsidiary 3.4(aCompensation Committee 3.2(d) Confidentiality Agreement 1.2(c8.8 Consent 3.3 Contaminants 3.21(o) Continuing Employee 6.11(bEmployees 6.9(g) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b6.10(b) Delisting Period 6.3 DGCL Recitals Delaware Secretary of State 2.1(b) Dissenting Company Shares 2.3(a2.6(b)(iii)(A) DSU 2.4(c) Xxxx-Xxxxx Act 3.7 Effective Time 1.4 2.1(b) Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(aPlans 3.17(a) Exchange Fund 2.2(a2.7(b) Expiration Date 1.1(aExport Controls 3.23(a) FCPA 3.9(cFinancing 4.7 Import Restrictions 3.23(a) FDA 3.9(dIndemnification Agreements 6.10(a) Good Clinical Practices 3.9(hIn-Licenses 3.12(a)(viii) Good Laboratory Practices 3.9(hLeased Real Property 3.19(b) Good Manufacturing Practices 3.9(iLeases 3.19(b) Governmental Entity 9.10(bMaterial Contract 3.12(a) Hazardous Materials 3.18(e)(iiMaterial Customer 3.25(a) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(bMaterial Supplier 3.25(b) Maximum Annual Premium 6.8(b6.10(b) Merger 1.3(a) Merger Agreement Annex I Recitals Merger Consideration 2.1(c2.6(b)(i) Term Section Reference Merger Sub Preamble Minimum Condition Annex I Notice Period 5.2(d1.1(b)(i) OECD Convention 3.9(cNew Plan 6.9(l) Offer Recitals Offer Condition 1.1(aClosing 1.1(f) Offer Conditions 1.1(b)(x) Offer Documents 1.1(c1.1(g)(i) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Payment Agent 2.2(a) Performance-Based DSU 2.4(c2.7(a) Permits 3.9 person 9.10(b3.13 Privacy Policies 3.21(r) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bRegulatory Condition 1.1(b)(ii) Schedule 14D-9 1.2(b) Schedule TO 1.1(b1.1(g)(i) SEC 1.1(aReports 3.7 Section 409A 3.17(o) Specified Representations 1.1(b)(iii) Subsidiary Securities Act 3.11(c3.6(d) Severance 6.11(dSubstitute Financing 6.15(a) Shares Support Agreement Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Support Agreements Recitals Surviving Corporation 1.3(a2.1(a) Tail Policy 6.10(b) Tax 3.15(aIncentive 3.15(h) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTermination Date 7.1(c) Termination Fee 8.2(bAmount 7.4(a) Time-Transfer Regulations 6.9(i) Unvested Company Option 6.9(a) Vested DSU 2.4(cCompany Option 6.9(a) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery WARN Act 3.9(c3.18(f) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated is made and entered into as of October 24January 26, 2011 is 2015 by and among CUBIST PHARMACEUTICALSLattice Semiconductor Corporation, INC. a Delaware corporation (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”)Xxxxxxxx Merger Company, a newly-formed Delaware corporation and a direct or indirect wholly-wholly owned subsidiary of ParentParent (“Merger Sub”), and ADOLOR CORPORATION Silicon Image, Inc., a Delaware corporation (the “Company”), a Delaware corporation.. All capitalized terms that are used in this Agreement but not defined herein shall have the respective meanings ascribed thereto in Annex A.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Definition Location Acquisition Proposal 5.2(a5.4(g)(i) Action 3.9 Adverse Recommendation Change 5.2(c5.4(c) Affiliate 3.3(d8.3(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cSection 5.4(g)(ii) Assignee 9.5(aAntitrust Law 8.3(b) award 3.3(bArticles of Merger 1.3 Bass Pro 5.20 BBCV Receivables-Q 2010 LLC Purchase Facility 8.3(c) Book-Entry Share 2.1(cShares 2.1(a) business day 9.10(bBRFC-Q 2010 LLC Purchase Facility 8.3(d) CERCLA 3.18(bBusiness Day 8.3(e) Business Intellectual Property 3.20(a) Certificate of Merger 1.4 Certificate 2.1(c2.1(a) Choice 5.20 Class A Shares 3.2(a) Class B Shares 3.2(a) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 8.3(f) Company Preamble Company Balance Sheet 3.6(aBoard Recitals Company Bylaws 3.1(b) Company Board of Directors Recitals Charter 3.1(b) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployee 8.3(g) Company Material Adverse Effect 3.1(aEntity 8.3(h) Company Option 2.4(aERISA Affiliate Section 3.11(b)(iii) Company Preferred Stock 3.3(aIncentive Plan 3.2(a) Company Quarterly Balance Sheet 3.7 Indemnitees 5.21(b) Company Restricted Share 2.4(bIntellectual Property 8.3(i) Company Management Agreement Section 3.18(a)(viii) Company Manager Section 3.18(a)(viii) Company Offering Documents 8.3(j) Company Organizational Documents 3.1(b) Company Plans 3.11(a) Company Proprietary Software 8.3(k) Company Real Property 3.17(b) Company Real Property Lease 3.17(d) Company Receivables Financings 8.3(p) Company Receivables-Backed Facilities 8.3(l) Company Receivables-Backed Facilities Commitment Letters 8.3(m) Company Receivables-Backed Facility 8.3(n) Company Receivables-Backed Facility Instrument 8.3(o) Company Recommendation 3.3(b) Company Registered IP 3.20(a) Company Restricted Stock 2.4(bAward 2.2 Company SEC Documents 3.5(a) Company Rights Securitization Transaction 8.3(q) Company Special Purpose Subsidiary Section 8.3(r) Company Stockholder Approval 3.3(a) Company Rights Agreement 3.3(aStockholders’ Meeting 5.6(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aThird-Party Leases 3.17(c) Company Subsidiary 3.4(aTimeshare Lender 3.18(e)(i) Company Timeshare Receivables 3.18(e) Compliant Section 8.3(s) Confidentiality Agreement 1.2(c5.7(b) Continuing Employee 6.11(b5.9(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContract 3.4(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(acontrol Section 8.3(t) DSU 2.4(cCredit Suisse 3.25 Debt Financing Section 8.3(u) Debt Financing Parties Section 8.3(v) Debt Financing Sources Section 8.3(w) Debt Instruments 3.18(e) XXXXX Section 8.3(x) Effective Time 1.4 Employee Release 6.11(d1.3 Employment Matters Section 8.3(y) Environmental Laws 3.18(e)(iSection 8.3(z) Environmental Permits 8.3(aa) Equitable Principles Section 8.3(bb) ERISA 3.16(a) ERISA Affiliate 3.16(b3.11(a) Exchange Act 1.1(a3.4(b) Exchange Fund 2.2(aProgram Section 8.3(cc) Expiration Date 1.1(aExcluded Information Section 8.3(dd) FCPA 3.9(cExcluded Shares 2.1(b) FDA 3.9(dFBCA Recitals FFS Arrangements 8.3(ee) Good Clinical Practices 3.9(hFFS Developers 8.3(ff) Good Laboratory Practices 3.9(hFFS Documents 8.3(gg) Good Manufacturing Practices 3.9(iFifth Third Credit Facility 8.3(hh) Fundamental Action Section 5.4(d) Funded Indebtedness 8.3(ii) GAAP 8.3(jj) Governmental Antitrust Authority 5.8(f) Governmental Entity 9.10(b8.3(kk) Hazardous Materials 3.18(e)(iiGovernmental Filings 8.3(ll) HGV Warehouse Facility 8.3(mm) Hilton Recitals Hilton Consent Recitals Hilton License Agreement Recitals HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.4(b) Indemnified Parties 6.8(a5.12(a) Independent Directors 6.9(aIntellectual Property 8.3(nn) IRS 3.16(a3.11(a) Laws 3.9(bIT Systems Section 8.3(oo) Layoff Laws Key Stockholders Section 8.3(pp) knowledge Section 8.3(qq) Law 3.4(a) Leakage Section 8.3(rr) Leased Real Property 3.17(b) Maximum Premium 6.8(bLiberty Bank Facility Section 8.3(ss) Liens 3.2(a) Marketing Period Section 8.3(tt) Material Adverse Effect Section 8.3(uu) Material Contracts 3.15(a) Materials of Environmental Concern Section 8.3(vv) Merger 1.3(aRecitals Merger Consideration 2.1(a) Merger Agreement Annex I Sub Preamble Merger Consideration 2.1(cSub Board Recitals NBA Receivables Facility Section 8.3(ww) Minimum Condition Annex I Non-Profit VCA Section 8.3(xx) Non-Profit VOA Section 8.3(yy) Notice 5.4(d) Notice Period 5.2(d5.4(d) OECD Convention 3.9(cNYSE 3.4(b) Offer Recitals Offer Condition 1.1(aOff-the-Shelf Software Section 8.3(zz) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOpen Source Software Section 8.3(aaa) Outside Date 8.1(b)(ii7.1(b)(i) Owned Real Property 3.17(b) Pacific Western Facility Section 8.3(bbb) Parent Preamble Parent Board Recitals Parent Common Stock Section 8.3(ccc) Parent Disclosure Letter Article IV Parent Employee Benefit Plan 5.9(c) Parent Indemnity and Reimbursement Obligations 5.21(b) Parent Material Adverse Effect Section 8.3(ddd) Parent Plan Section 8.3(eee) Parent SEC Documents 4.5(a) Patents 8.3(nn) Paying Agent 2.2(a2.3(a) Performance-Based DSU 2.4(cPayment Fund 2.3(a) PCB Loan Section 8.3(fff) Permits 3.9 person 9.10(b3.10 Permitted Company Receivables-Back Facilities Activity Section 8.3(ggg) Plans 3.16(aPermitted Confidentiality Agreement 5.4(b) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPermitted Liens Section 8.3(hhh) Program 3.9(kPerson Section 8.3(iii) Prohibited Payment 3.9(cPersonal Data Section 8.3(jjj) Proprietary Rights 3.12(aPreferred Stock 3.2(a) Prepayment Amendment Section 5.22(a) Privacy and Security Requirements Section 8.3(kkk) Processing Section 8.3(lll) Proxy Statement 1.8(a)(ii3.7 R&W Policy 5.18 Representatives 5.4(a) Real Property 3.12(bRequired Information Section 8.3(mmm) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRule 144A 8.3(s) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b3.5(a) SEC 1.1(a3.5(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.4(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) : Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cNotice Period 5.3(c)(ii)(2) Affiliate 3.3(d) Arrangements 6.20 Agreement Preamble Alternate Debt Financing 6.5(d) Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBring Forward Awards 2.8(e)(i) award 3.3(bBurdensome Condition 6.2(c) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCapitalization Date 3.7(a) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) CFIUS 6.2(c) CFIUS Approval 6.2(c) CFIUS Notice 6.2(c) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bPhantom Stock Award Consideration 2.8(a) Company PSU Consideration 2.8(d) Company Related Parties 8.3(e) Company Restricted Share Consideration 2.8(d) Company RSU Consideration 2.8(b) Company SEC Documents Article III Company Securities 3.7(c) Company Stockholder Meeting 6.4(a) Copyrights 1.1(hhh) D&O Insurance 6.10(c) Data Protection Laws 3.21(c) Debt Commitment Letter 4.11(a) Debt Financing 4.11(a) DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Equity Award Consideration 2.8(d) Equity Award Holders 2.8(e) Equity Commitment Letters 4.11(a) Equity Financing 4.11(a) Fee Letter 4.11(a) Financing 4.11(a) Financing Letters 4.11(a) Finance Source Related Parties 8.3(e) Financing Sources 8.4 Financing Sources Protection Provisions 8.4 Foreign Employee Plans 3.18(h) Guarantees Recitals Guarantors Recitals Indemnified Persons 6.10(a) Intervening Event Notice Period 5.3(c)(i)(1) Lease 3.14(a) Leased Real Property 3.14(a) Marks 1.1(hhh) Maximum Premium 6.10(c) Merger Recitals Merger Sub Preamble Multiemployer Plan 3.18(b) New Plan 6.11(d) Old Plans 6.11(d) Other Indemnified Persons 6.10(e) Other Required Company Filing 6.3(b) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Preamble Paying Agent 2.2(aRelated Parties 8.3(e) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Parent Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”8.3(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Perficient Inc)
INDEX OF DEFINED TERMS. Capitalized The following terms are defined elsewhere in this Agreement shall have the defined meanings that appear Agreement, as shown in the provisions of the Agreement listed table below. Acceptance Time 5.2(b: Term Location “Accounting Firm” Section 3.02(b) Acquisition Proposal 5.2(a“Acquired Competing Business” Section 7.11(c) “Acquired Person” Section 7.11(c) “Acquisition” Section 2.02 “Adverse Recommendation Change 5.2(cChange” Section 7.10(b) Affiliate 3.3(d“Advertising Contract” Section 4.18(a)(xx) Agreement “Agreed Accounting Principles” Schedule 3.02 “Agreement” Preamble Alternative Acquisition Agreement 5.2(c“Arbitration Panel” Section 14.10(a) Assignee 9.5(a“Cash and Cash Equivalents” Section 3.02(h) award 3.3(b“Closing” Section 2.03 “Closing Date” Section 2.03 “Competitor” Section 9.02(a) Book-Entry Share 2.1(c“Competitor List” Section 9.02(a) business day 9.10(b“Direct Claim” Section 12.04(b) CERCLA 3.18(b“Direct Claim Notice” Section 12.04(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals “Estimated Monsoon Closing Date 1.5 Code 2.6 Company Net Cash” Section 3.02(h) “ICDR” Section 13.10(a) “Indemnified Party” Section 12.04(a) “Indemnifying Party” Section 12.04(a) “Independent Directors” Section 8.02(a) “Indigo” Preamble Company “Indigo Balance Sheet 3.6(aSheet” Section 4.07(d) Company Board of Directors Recitals Company “Indigo Closing Date Working Capital” Section 3.02(a) “Indigo Current Assets” Section 3.02(h) “Indigo Current Liabilities” Section 3.02(h) “Indigo Directors” Section 8.02(b) “Indigo Financial Statements” Section 4.07(b) “Indigo Intellectual Property” Section 4.17(a) “Indigo Leased Real Property” Section 4.15 “Indigo Material Contracts” Section 4.18(b) “Indigo Minority Interests” Section 4.02(b) “Indigo Organizational Documents” Section 4.01 “Indigo Parent” Preamble “Indigo Parent Deductible” Section 12.01(b)(i) “Indigo Parent Disclosure Letter SECTION 3 Company Joint Venture 3.4(cLetter” Article IV “Indigo Parent Indemnitees” Section 12.02(a) Company’s knowledge 9.10(b“Indigo Permitted Indebtedness” Section 6.02(j) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) “Indigo Permitted Liens” Section 4.15 “Indigo Real Property 3.12(bLease” Section 4.15 “Indigo Securities” Section 4.03(a) Regulation M-A 1.1(c“Indigo Shares” Preamble “Indigo Working Capital” Section 3.02(h) Release 3.18(e)(iiiTerm Location “Interim Indigo Financial Statements” Section 4.07(b) Representatives 5.2(a“Labor Union” Section 4.11(h) Reporting Tail Endorsement 6.8(b“Liabilities” Section 4.07(d) Restraints 8.1(b)(i“Losses” Section 12.01(a) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a“Monsoon” Preamble “Monsoon Balance Sheet” Section 5.06(f) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Monsoon Cash” Section 3.02(h), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Transaction Agreement
INDEX OF DEFINED TERMS. Capitalized terms As used in this Agreement Agreement, the following terms shall have the defined meanings that appear assigned to them in the provisions of the Agreement listed respective locations set forth below. Acceptance Time 5.2(b: Term Location Accounts Receivable Securitization Facility Section 7.1(d) Acquisition Proposal 5.2(aTransaction Section 7.15 Actuarial Mediator Section 2.11(c) Adverse Recommendation Change 5.2(cAdjusted Purchase Price Section 2.8(d) Affiliate 3.3(dAggregate Cap Section 9.6(d) Agreement Alternate Financing Section 7.6(c) ASC Transferred Employee Section 7.5(c) Ashland Preamble Alternative Acquisition Agreement 5.2(cAshland Indemnitees Section 9.2 Asset Allocations Section 2.9 Assumed Contracts Section 2.2(e) Assignee 9.5(aAssumed Employee Liabilities Section 2.5(i) award 3.3(bAssumed Liabilities Section 2.5 Assumed Tax Liabilities Section 2.5(k) Book-Entry Share 2.1(cBasket Section 9.6(a) business day 9.10(bBlended Chemicals Section 7.7(g) CERCLA 3.18(bBuyer Preamble Buyer Fee Section 8.2(b) Certificate of Merger 1.4 Certificate 2.1(cBuyer Indemnitees Section 9.1 Buyer’s 401(k) Plan Section 7.5(l) Ceiling Section 9.6(a) Chemicals Section 7.7(g) Closing 1.5 Account Section 2.8(a) Closing Amount Recitals Account Principles Section 2.8(a) Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect Section 3.1(a) Company Option Term Location Closing Date Amount Section 2.7 Commitment Letters Section 6.4(a) Competitive Activity Section 7.7(b) Continuing Credit Support Obligations Section 7.11(d) Conveyed Assets Section 2.2 Conveyed Real Property Section 2.2(a) CVG Section 7.1(d) Debt Commitment Letter Section 6.4(a) Debt Financing Section 6.4(a) Deferred Business Section 3.1(b) Deferred Jurisdiction Section 3.1(b) Deferred Transfer Section 3.1(b)(ii) Definitive Agreements Section 7.6(a) Delivery Notice Section 7.6(d) Disputed Item Section 2.8(b) End Date Section 8.1(e) Environmental Loss Section 10.1 Environmental Permits Section 7.1(b) Environmental Tests Section 10.2 Equity Commitment Letter Section 6.4(a) Equity Financing Section 6.4(a) Estimated Unfunded Liability Section 2.7 EU Section 7.5(b)(ii) European Employee Section 7.5(b)(ii) European Transferred Employee Section 7.5(b)(ii) Excluded Assets Section 2.4(a) Company Preferred Stock 3.3(aFCPA Section 5.20(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bFee Letter Section 6.4(b) Company Restricted Stock 2.4(bFinancial Statements Section 5.5 Financing Section 6.4(a) Company Rights 3.3(aFIRPTA Affidavits Section 7.4(d) Company Rights Agreement 3.3(aFleet Vehicle Leases Section 2.2(d) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aFleet Vehicles Section 2.2(b) Company Subsidiary 3.4(aFormer Employees Section 7.5(g) Confidentiality Agreement 1.2(cFee Letter Section 6.4(b) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iForeign Jurisdictions Section 7.16 Fundamental Representations Section 9.5(c) Governmental Entity 9.10(bCompetition Authority Section 7.2(a) Hazardous Materials 3.18(e)(iiGuarantee Termination Date Section 6.8 Indemnified Party Section 9.3(a) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(aIndemnifying Party Section 9.3(a) Independent Directors 6.9(aAccountant Section 2.8(c) IRS 3.16(aISRA Section 7.1(a) Laws 3.9(bLeased Real Property Section 5.8(b) Layoff Laws 3.17(bLenders Section 6.4(a) Maximum Premium 6.8(bTerm Location Loss or Losses Section 9.1 Material Contracts Section 5.9(a) Merger 1.3(aNJDEP Section 7.1(a) Merger Agreement Annex I Merger Consideration 2.1(cNon-Transferred Employees Section 7.7(f) Minimum Condition Annex I Notice Period 5.2(dNorth America Section 7.7(g) OECD Convention 3.9(cOperating Income Section 7.7(g) Offer Recitals Offer Condition 1.1(aOwned Real Property Section 5.8(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(aParty Section 2.8(e) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cAshland Employees Section 7.7(f) Program 3.9(kPost-Closing Hires Section 7.7(f) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(iiPurchase Price Section 2.7 Purchase Price Cap Section 9.6(e) Real Property 3.12(bLeases Section 5.8(b) Regulation MReceiving Party Section 2.8(e) Resolution Period Section 2.8(c) Retained Employee Liabilities Section 7.5(g)(iii) Retained Indebtedness Section 2.6(i) Retained Liabilities Section 2.6 Retained Names Section 7.14(a) Retained Tax Liabilities Section 2.6(c) Retention Period Section 7.4(a)(ii) Required Information Section 7.6(d) Sale Agreement Section 7.1(d) Sale Notice Section 3.1(viii) Self-A 1.1(cManufactured Chemicals Section 7.7(g) Release 3.18(e)(iiiSeller’s 401(k) Representatives 5.2(aPlan Section 7.5(l) Reporting Tail Endorsement 6.8(bSeller Entity Allocation Section 2.9 Separation Benefits Section 7.5(f) Restraints 8.1(b)(iShared Contract Section 2.3(c) Rights Agent Recitals Sales Incentive Compensation Sponsor Fund Section 6.4(a) Sponsor Guarantee Section 6.8 TAA Section 7.1(d) Tangible Personal Property Section 2.2(c) Tangible Personal Property Leases Section 2.2(d) Thermoplastics Section 7.7(g) Thermoplastics Territory Section 7.7(g) Third Party Chemicals Section 7.7(g) Third Party Claim Section 9.4(a) Third Party Non-Chemicals Section 7.7(g) Third Party Thermoplastics Section 7.7(g) Title and Survey Information Section 7.6(d) Transfer Taxes Section 7.4(c) Transferred Employees Section 7.5(c) Transferred Plan 6.11(aAssets Section 2.2(l) Xxxxxxxx-Xxxxx Act 3.6(bUnderlying Data Section 2.11(a) Schedule 14D-9 1.2(bTerm Location Unfunded Liability Disputed Item Section 2.11(b) Schedule TO 1.1(bUnfunded Liability Paying Party Section 2.11(e) SEC 1.1(aUnfunded Liability Receiving Party Section 2.11(e) Securities Act 3.11(cUnfunded Liability Resolution Period Section 2.11(c) Severance 6.11(dUnfunded Liability Statement Section 2.11(a) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Union Contracts Section 5.18(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Purchase and Sale Agreement (Nexeo Solutions Finance Corp)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bAccounting Arbitrator Section 2.2(b)(iii) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Membership Interests Recitals Additional Escrow Amount Section 1.2(b) Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(c) Affiliate Contract Section 1.2(fff)(xv) Affiliate Transactions Section 5.10 Agreed Rate Section 1.2(d) Agreement Preamble Alternative Acquisition Allocated Value Section 2.2(a) Allocation Objection Notice Section 2.2(b)(ii) Antitrust Laws Section 1.2(e) Asset Taxes Section 1.2(f) Assignment of Interests Section 8.2(a) Benefit Plan Section 1.2(g) BOEM Section 1.2(h) BSEE Section 1.2(i) Burdens Section 1.2(j) Business Day Section 1.2(k) Cash Purchase Price Section 2.1(a) Castex Section 5.1 Casualty Loss Section 5.13 Claim Section 11.3(b) Claim Notice Section 11.3(b) Closing Section 8.1 Closing Cash Payment Section 2.4(a) Closing Date Section 8.1 Closing Settlement Statement Section 2.4(a) Code Section 1.2(l) Company Section 1.2(m) Company Assets Section 1.2(n) Company Business Section 1.2(o) Company Contract Section 1.2(p) Company Derivatives Section 1.2(q) Company Leases Section 1.2(n)(i) Company Personal Property Section 1.2(n)(vii) Company Properties Section 1.2(n)(iii) Company Records Section 1.2(r) Company Rights-of-Way Section 1.2(n)(vi) Company Units Section 1.2(n)(iii) Company Xxxxx Section 1.2(n)(ii) Confidentiality Agreement 5.2(cSection 1.2(s) Assignee 9.5(aConsent Section 3.11(b) award 3.3(bConsolidated Group Section 1.2(t) BookControlled Group Liabilities Section 1.2(u) Cure Period Section 1.2(v) Current Assets Section 1.2(w) Current Liabilities Section 1.2(x) Customary Post-Entry Share Closing Consents Section 1.2(y) Damages Section 11.2(d) Decommission or Decommissioning Section 1.2(z) Defect Arbitrator Exhibit D Defect and Indemnity Escrow Account Section 1.2(aa) Defensible Title Section 1.2(bb) Deposit Section 2.1(c) business day 9.10(bDerivatives Section 5.7 Determination Date Section 2.4(b)(ii) CERCLA 3.18(bDispute Auditor Section 2.4(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cDisputed Amount Section 6.7 Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 DOJ Section 5.5 Effective Time Section 1.2(cc) Closing 1.5 Closing Effective Time Net Working Capital Section 1.2(dd) Environmental Arbitrator Exhibit D Environmental Defect Section 1.2(ee) Environmental Defect Amount Recitals Closing Section 1.2(ff) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Deductible Section 6.6(d) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 1.2(gg) Environmental Liabilities Section 1.2(hh) Environmental Notice Section 1.2(ii) Environmental Threshold Section 6.5(c) ERISA Section 1.2(jj) ERISA Affiliate Section 1.2(kk) Escrow Account Section 1.2(ll) Escrow Agent Section 1.2(kk) Escrow Agreement Section 1.2(nn) Exchange Act Section 4.5 Excluded Assets Section 1.2(oo) Excluded Assets Assignment Section 1.2(pp) Excluded Company Records Section 1.2(q)(v) Execution Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aFinancial Statements Section 1.2(qq) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cFinal Allocation Section 2.2(b)(iv) Company’s knowledge 9.10(bFinancing Section 4.7 FTC Section 5.5 Fundamental Representations Section 11.4(a) Company Governmental Authority Section 1.2(rr) Hard Consent Section 5.11(b)(i) Hazardous Materials Section 1.2(ss) HSR Act Section 1.2(tt) Hydrocarbons Section 1.2(uu) Idle Iron Report Section 3.21(e) Imbalance Section 1.2(vv) INC Section 1.2(ww) Included Title Defect Properties Section 6.4(b)(ii) Income Taxes Section 1.2(xx) Indemnified Person Section 11.3(a) Indemnifying Person Section 11.3(a) Indemnity Escrow Amount Section 1.2(yy) Information Statement Section 5.17 Intellectual Property Section 1.2(zz) Intended Tax Treatment Section 2.2(b)(i) Interim Breach Section 11.2(b)(ii) Interim Breach Provision Section 11.2(b)(ii) Laws Section 1.2(aaa) Lease Annex Section 1.2(bbb) Liens Section 1.2(ccc) Loan Section 1.2(ddd) Lowest Cost Response Section 1.2(eee) Material Adverse Effect 3.1(aSection 3.31(e) Company Option 2.4(aMaterial Contract Section 1.2(fff) Company Preferred Stock 3.3(aNet Revenue Interest Section 1.2(ggg) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNORM Section 3.8 Organizational Documents Section 1.2(hhh) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOther PSA Section 1.2(iii) Outside Date 8.1(b)(iiSection 10.1(c) Parent Party or Parties Preamble Paying Agent 2.2(aPermits Section 1.2(jjj) Performance-Based DSU 2.4(cPermitted Encumbrance Section 1.2(kkk) Permits 3.9 person 9.10(bPermitted Interest Encumbrance Section 1.2(lll) Plans 3.16(aPerson Section 1.2(mmm) Phase I Activities Section 1.2(nnn) Post-Closing Statement Section 2.4(b) Pre-Effective Date Period Section 1.2(ooo) Preferential Purchase Right Section 3.11(a) Proceedings Section 3.6 Proposed Allocation Section 2.2(b)(ii) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Indemnified Parties Section 11.2(b) Purchaser Parent Preamble Purchaser Parent SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cSection 4.13 Purchaser Parent Shares Section 2.1(a) Program 3.9(kPurchaser Tax Returns Section 9.2(b) Prohibited Payment 3.9(cPurchaser’s Environmental Review Section 6.2(a) Proprietary Rights 3.12(aPurchaser’s Representatives Section 6.1(a) Proxy Statement 1.8(a)(iiR&W Conditional Binder Section 5.19(a) Real Property 3.12(b) Regulation M-A 1.1(cR&W Policy Section 5.19(a) Release 3.18(e)(iiiSection 1.2(ppp) Representatives 5.2(aReleased Parties Section 5.12 Releasing Parties Section 5.12 Remediate, Remediation or Remedial Section 1.2(qqq) Reporting Tail Endorsement 6.8(bRequired Purchaser Filings Section 5.16(a) Restraints 8.1(b)(iRetained Employee-Related Liabilities Section 1.2(rrr) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Scheduled Closing Date Section 8.1 Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeismic Data Section 1.2(sss) Shares Recitals Special Meeting 1.8(a)(iSeller Preamble Seller Indemnified Parties Section 11.2(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Tax Section 1.2(ttt) Superior Proposal 5.2(bSeller Tax Returns Section 9.2(a) Surviving Corporation 1.3(aSeller’s Knowledge Section 1.2(uuu) Sinking Funds Section 1.2(oo)(xii) Specified Matters Section 3.33 Straddle Period Section 1.2(vvv) Suspended Funds Section 1.2(www) Tax 3.15(a) Taxable 3.15(aSection 1.2(xxx) Tax Effective Date Section 1.2(yyy) Tax Partnership Section 1.2(zzz) Tax Partnership Interest Section 1.2(aaaa) Tax Proceeding Section 9.4 Tax Return 3.15(aSection 1.2(bbbb) Tender Completion Time 6.2 Tender Third-Party Loans Section 1.2(cccc) Title Arbitrator Exhibit D Title Benefit Section 1.2(dddd) Title Benefit Amount Section 6.5(b) Title Deductible Section 6.5(c) Title Defect Section 1.2(eeee) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Dispute Election Section 6.4(b) Title Notice Section 1.2(ffff) Title Threshold Section 6.5(c) Transaction Costs Section 1.2(gggg) Transaction Documents Section 5.2 Transfer Taxes Section 9.5 Treasury Regulations Section 1.2(hhhh) Unadjusted Purchase Price Section 2.1(a) Well Annex Section 1.2(iiii) Willful Breach Section 1.2(jjjj) Working Interest Section 1.2(kkkk) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 10, 2011 is 2019 (the “Execution Date”), by and among CUBIST PHARMACEUTICALSCastex Energy 2016, INC. LP, a Delaware limited partnership (“Seller”), Talos Production Inc., a Delaware corporation (“Purchaser”), and solely with respect to its obligations related to the Purchaser Parent Shares (as defined herein), Talos Energy Inc., a Delaware corporation (“Purchaser Parent”). Seller, a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation Purchaser and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (Purchaser Parent are referred to collectively as the “CompanyParties” and individually as a “Party.”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bDefinition Location 2023 Company Warrants 8.4(a) Accounting Firm 2.4(f) Acquisition Proposal 5.2(a5.4(f)(i) Action 3.8(a) Adverse Recommendation Change 5.2(c5.4(c) Affiliate 3.3(d8.4(b) Affordable Care Act 3.10(a) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(bAuthorized Share Increase 5.7(e) Book-Entry Share 2.1(cShares 2.6(b) business day 9.10(bBusiness Day 8.4(c) CERCLA 3.18(bBusiness System(s) 8.4(d) Cash and Cash Equivalents 8.4(e) Certificate of Merger 1.4 Certificate 2.1(c1.3 Certificates 2.6(b) Closing 1.5 1.2 Closing Amount Recitals Adjusted Cash Consideration 8.4(f) Closing Cash and Cash Equivalents 8.4(g) Closing Date 1.5 1.2 Closing Date Schedule 2.4(b) Closing Liabilities and Debt 8.4(h) Closing Net Working Capital Amount 8.4(i) Code 2.6 8.4(j) Company Preamble Company Balance Sheet 3.6(aAcquisition Agreement 5.4(a) Company Board of Directors Recitals Company Bylaws 3.1(b) Company Capitalization Representations 8.4(k) Company Charter 3.1(b) Company Data 8.4(l) Company Delayed Share Consideration 8.4(m) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bFully Diluted Common Stock 8.4(n) Company Material Adverse Effect 3.1(aFundamental Representations 8.4(o) Company Initial Share Consideration 8.4(p) Company IP 3.18(a) Company Party 7.3(e) Company Plan 8.4(q) Company Products 3.25(c) Company Registered IP 3.18(a) Company SEC Documents 3.5(a) Definition Location Company Stock Option 3.2(a) Company Stock Plans 3.2(a) Company Stockholder Approval 3.3(b)(iii) Company Stockholders Meeting 5.7(d) Company Support Agreements Recitals Company Unaudited Financial Statements 2.4(a) Company Preferred Stock 3.3(aUnregistered IP 3.18 (a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bWarrants 3.2(a) Company Restricted Stock 2.4(bConcurrent Investment 8.4(s) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary Contract 3.4(a) Confidentiality Agreement 1.2(ccontrol 8.4(r) Continuing Employee 6.11(bCosts 5.10(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bDeficit Cash Consideration 8.4(t) Delisting Period 6.3 Delaware Secretary of State 1.3 Delayed Net Working Capital Amount 8.4(u) Delayed Per Share Stock Consideration 8.4(v) Determination 2.4(f) DGCL Recitals Disposed Asset Payment Right 2.3 Dispute Notice 2.4(d) Dissenting Shares 2.3(a) DSU 2.4(c) 2.7 DLLCA Recitals Effective Time 1.4 1.3 Employee Release 6.11(dCensus 3.12(a)(xi) End Date 7.1(b)(i) Environmental Claim 3.13(b)(i) Environmental Laws 3.18(e)(i3.13(b)(ii) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Environmental Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.13(b)(iii), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions Each of the Agreement listed below. Acceptance Time 5.2(bfollowing terms is defined on the page set forth below opposite such term: Term: Section: Accredited Company Stockholder Adjustment Statement 5.8(a) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d3.2(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cBalance Sheet Date 4.9 Business Recitals Buyer Preamble Buyer Indemnified Parties 10.2 Claim Notice 10.5(a) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClaim Response 10.5(c) Closing 1.5 2.2 Closing Amount Recitals Cash Payment 3.1(a) Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a2.2 Closing Payment 3.1(b) Closing Shares 3.1(b) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bCovered Persons Preamble 4.20(c) Company Material Adverse Effect 3.1(aIntellectual Property 4.21(c) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aStockholders Preamble Confidential Information 7.5(a) Confidentiality Agreement 1.2(c11.1 Covered Persons 8.1(a) Continuing Employee 6.11(bDeductible Amount Disqualification Event 10.4(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b4.20(c) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aEmployment Agreements Energenz Energenz HK 2.3(a)(vii) DSU 2.4(c4.1(b) Effective Time 1.4 Employee Release 6.11(d4.1(b) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Equipment Exchange Act 1.1(a4.11 5.8(e) Exchange Fund 2.2(aFinancial Statements Form 8-K 4.9 7.8(d) Expiration Date 1.1(aFundamental Representations 10.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aIndemnification Claim 10.5(a) Indemnified Party 10.5(a) Indemnifying Party 10.5(a) Leased Real Property 4.14 Leases 4.14 Licenses and Permits 4.24 Lock-Up Agreement 3.3(b) Xxxx 10.2(l) Material Contracts Non-Accredited Investor 4.6(a) 7.2(a) Owned Intellectual Property 4.21(a) Owned Real Property 4.13 Party or Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cTax Period 7.1(a) Program 3.9(kPromissory Note 3.1(c) Prohibited Payment 3.9(cPurchase Price 3.1 Reserve Fund 9.1 Response Period 10.5(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(aRule 144 5.8(f) Securities Act 3.11(c3.1(c) Severance 6.11(dSeller Indemnified Parties 10.3 Share Value 3.1(b) Shares Recitals Special Meeting 1.8(a)(iStockholder Representative Preamble Straddle Period 7.1(b) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(aStraddle Period Returns 7.1(b) Tax 3.15(aContest 7.1(d) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Third Party Claim 10.5(e), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Term Section Affiliate 3.3(d8.1(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cBalance Sheet Date 3.12(a) Assignee 9.5(a) award 3.3(b) Bankruptcy and Equity Exception 3.3 Book-Entry Share 2.1(cShares 2.1(c)(ii) business day 9.10(b) CERCLA 3.18(bBusiness Day 8.1(b) Certificate of Merger 1.4 Certificate 2.1(c) 1.3 Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 2.2(f) Communications Act 3.16(a) Communications Laws 3.16(a) Company Preamble Company Balance Sheet 3.6(aAssets 3.7(b) Company Benefit Plans 3.17(a) Company Board of Directors Recitals Company Common Stock 2.1(b) Company Confidential Information 3.21(d) Company Disclosure Letter SECTION 3 III Company Joint Venture 3.4(cExcluded Shares 2.1(b) Company’s knowledge 9.10(bCompany Financial Advisors 3.28 Company Group 3.19(a) Company Intellectual Property 3.21(a) Company IP Licenses 3.21(b) Company Material Adverse Effect 3.1(a8.1(c) Company Material Contracts 3.15(a) Company Option 2.4(a2.3(a) Company Organizational Documents 3.4 Company Owned Intellectual Property 3.21(a) Company Permits 3.23(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a3.8(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 3.10 Company Stock Plans 2.4(aAward 2.3(b) Company Subsidiary 3.4(aTermination Fee 7.6(b) Confidentiality Agreement 1.2(c5.3(b) Continuing Employee 6.11(bContinuation Period 5.6(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContract 8.1(f) Delisting Period 6.3 Conversion Ratio 2.3(d) Converted Stock Award 2.3(d) Damages 5.7(b) DGCL Recitals Term Section Dissenting Shares 2.3(a) DSU 2.4(c2.4(a) Effective Time 1.4 Employee Release 6.11(d1.3 End Date 7.2(a) Environmental Laws 3.18(e)(iLaw 3.20(a) ERISA 3.16(a) ERISA Affiliate 3.16(b3.17(a) Exchange Act 1.1(a3.6(b) Exchange Fund 2.2(aExercise Price 2.3(a) Expiration Date 1.1(aExpenses 5.12 Fiber Route 3.31(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iFinancing 5.14 GAAP 3.11(a)(ii) Governmental Entity 9.10(bAuthority 8.1(j) Governmental Authorizations 3.6 Hazardous Materials 3.18(e)(iiSubstances 8.1(k) HSR Act 3.19 IC Plans 6.11(a3.6(c) Incentive Compensation Plan 6.11(aILEC Agreements 3.15(a)(ix) Indemnified Parties 6.8(a5.7(a) Independent Directors 6.9(aInformation Statement 5.5(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Intellectual Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”8.1(l), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Itc Deltacom Inc)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cBankruptcy and Equity Exceptions 3.2 Buyer Preamble Buyer Disclosure Letter Article VI Buyer Indemnified Party 7.9(b) Closing 1.5 Closing Amount Recitals 2.1 Closing Date 1.5 Code 2.6 2.1 Company Preamble Company Audited Financial Statements 3.6(a) Company Confidential Material 3.11(h) Company Contract 3.17(a) Company Disclosure Letter Article Company Financial Statements 3.6(a) Company Health Plan 3.13(m) Company Interim Financial Statements 3.6(a) Company Leased Real Property 3.12(b) Company Measures 3.23(b) Company Products 3.11(g) Company Real Property Leases 3.12(b) Company Security Measures 3.11(h) Company Suppliers 3.11(j) Company Unaudited Balance Sheet 3.6(a) Confidentiality Agreement 12.10 Continuing Employee 7.7(a) Debt Financing 7.11(a) DocuSign 12.12 Engagement 12.19(c) Equity Commitment Letter Recitals Equity Financing 6.6 Equity Financing Source Recitals ERISA Affiliate 3.13(f) Estimated Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cClosing Statement 1.8 Excluded Benefits 7.7(a) Company’s knowledge 9.10(bExisting Policy 7.8(b) Company Material Adverse Effect 3.1(aForeign Plan 3.13(t) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Governmental Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(cHakkasan USA Preamble Healthcare Reform Laws 3.13(m) Continuing Employee 6.11(bIndebtedness for Borrowed Money 2.3(e) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bIRS 2.3(d) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aMultiemployer Plan 3.13(e) DSU New Plans 7.7(b) Non-Recourse Party 12.2 Notice of Disagreement 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bNYS Regulatory Actions 2.3(f) Outside Date 8.1(b)(ii9.1(e) Payment Spreadsheet 1.8 Payoff Letters 2.3(e) Pre-Closing Indemnitees 7.8(a) Pre-Closing Tax Returns 10.3(b)(i) Preliminary Closing Statement 2.4(b) Prior Counsel 12.19(a) Pro Rata Portion 1.7(b) Proposal 7.12 Purchase Price Allocation 10.3(a)(i) Regulatory Approvals 7.3(e) Representative Losses 7.10(c) RWI Policy 7.9(a) Sample Closing Statement 1.8 Seller Protected Parties 12.1 Sellers Preamble Sellers’ Representative Preamble Sellers’ Representative Expenses 7.10(d) Shortfall Amount 2.4(f)(ii) Shortfall Guaranty 10.3(k) Straddle Period Tax Returns 10.3(b)(ii) Subsidiary Equity Interests 3.3(a) TAO Holdings Preamble TAO Intermediate 3.6(a) TAO Parent Preamble Paying Agent 2.2(aTax Claims 10.3(e) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC Transferred Securities 1.1(a) Securities Act 3.11(cVATA 1994 3.15(p) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”WARN 3.14(d), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Transaction Agreement (Madison Square Garden Entertainment Corp.)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the capitalized terms below: Term Section Reference Acceptable Confidentiality Agreement listed below. Acceptance Time 5.2(b1.1(a) Acquisition Proposal 5.2(a1.1(b) Adverse Recommendation Change 5.2(cAcquisition Transaction 1.1(c) Affiliate 3.3(d1.1(d) Agreement Preamble Alternate Debt Financing 6.5(d) Alternative Acquisition Agreement 5.2(c5.3(b) Assignee 9.5(aAntitrust Authorities 6.2(a) award 3.3(bAntitrust Law 1.1(e) Book-Entry Share 2.1(cAudited Company Balance Sheet 1.1(f) business day 9.10(bBusiness Day 1.1(g) CERCLA 3.18(bBylaws 3.1(b) Capitalization Date 3.7(a) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Charter 3.1(b) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 Code 2.6 1.1(h) Collective Bargaining Agreement 3.20(a) Company Preamble Company Balance Sheet 3.6(aBoard 1.1(i) Company Board of Directors Recitals Recommendation 3.3(a) Company Board Recommendation Change 5.3(d)(i) Company Common Stock 1.1(k) Company Credit Agreement 1.1(j) Company Disclosure Letter SECTION 3 III Company Joint Venture 3.4(cIndebtedness 1.1(l) Company’s knowledge 9.10(bCompany Intellectual Property 1.1(m) Company Material Adverse Effect 3.1(a1.1(n) Company Option 2.4(aNon-Voting Common Stock 1.1(o) Company Options 1.1(p) Company Preferred Stock 3.3(a1.1(q) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs 1.1(r) Company Restricted Stock 2.4(bRelated Parties 8.3(f)(ii) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSUs 1.1(s) Company SEC Reports 3.5 3.9 Company Stockholder Approval 6.1 Securities 3.7(c) Company Stock Plans 2.4(a1.1(t) Company Subsidiary 3.4(aStockholder Meeting 6.4(a) Company Stockholders 1.1(u) Company Voting Common Stock 1.1(w) Confidentiality Agreement 1.2(c9.4 Continuing Employees 1.1(x) Continuing Employee 6.11(bContract 1.1(y) CPR Recitals CPR Agreement Recitals Current Copyrights 1.1(qq) Cut-Off Date 5.3(b) D&O Insurance 6.8(b6.10(c) Delisting Period 6.3 Debt Commitment Letter 4.11(a) Debt Financing 4.11(a) DGCL Recitals Dissenting Company Shares 2.3(a2.7(c) DSU 2.4(cDOJ 1.1(z) DTC 2.9(d) Effective Time 1.4 2.2 Electronic Delivery 9.14 Employee Release 6.11(dPlan 1.1(aa) Environmental Laws 3.18(e)(iLaw 1.1(bb) Environmental Permits 1.1(cc) Equitable Exceptions 3.2 Equity Award Consideration 2.8(c) Equity Award Holders 2.8(d) Equity Commitment Letter 4.11(a) Equity Financing 4.11(a) ERISA 3.16(a) ERISA Affiliate 3.16(b1.1(dd) Exchange Act 1.1(a1.1(ee) Exchange Fund 2.2(aExcluded Party 1.1(ff) Expiration Date 1.1(aFee Funding Arrangement Recitals Fee Letter 4.11(a) FCPA 3.9(cFinancing 4.11(a) FDA 3.9(dFinancing Letters 4.11(a) Good Clinical Practices 3.9(hFinancing Sources 1.1(gg) Good Laboratory Practices 3.9(hFTC 1.1(ii) Good Manufacturing Practices 3.9(iGAAP 1.1(jj) GDPR 3.17 Governmental Authority 1.1(kk) Governmental Entity 9.10(bAuthorization 1.1(ll) Group 1.1(mm) Hazardous Materials 3.18(e)(iiSubstance 1.1(nn) HSR Act 3.19 IC Plans 6.11(a1.1(oo) Incentive Compensation Plan 6.11(aIndebtedness 1.1(pp) Indemnified Parties 6.8(aPerson 6.10(a) Independent Directors 6.9(aIndemnified Persons 6.10(a) IRS 3.16(aIntellectual Property 1.1(qq) Laws 3.9(bIntervening Event 1.1(rr) Layoff Laws 3.17(bKnowledge 1.1(ss) Labor Organization 3.20(a) Law 1.1(tt) Lease 3.14 Leased Real Property 3.14 Legal Proceeding 1.1(uu) Marks 1.1(qq) Material Contract 1.1(vv) Maximum Annual Premium 6.8(b6.10(c) Merger 1.3(aRecitals Merger Sub Preamble Multiemployer Plan 3.19(b) Merger Agreement Annex I Merger Consideration 2.1(cNew Debt Commitment Letters 6.5(d) Minimum Condition Annex I New Plan 6.11(d) No-Shop Period Start Date 5.3(a) Notice Period 5.2(d5.3(e)(ii)(3) OECD Convention 3.9(cNYSE 1.1(ww) Offer Recitals Offer Condition 1.1(aOld Plans 6.11(d) Offer Option Consideration 2.8(a) Organizational Documents 1.1(c1.1(xx) Offer Price Recitals Offer to Purchase 1.1(aOther Indemnified Persons 6.10(e) on a fully diluted basis 9.10(bOther Required Company Filing 6.3(b) Outside Date 8.1(b)(iiOwned Company Shares 2.7(a)(iii) Owned Real Property 3.14 Parent Preamble Parent Material Adverse Effect 7.3(a) Parent Related Parties 8.3(f)(i) Parent Termination Fee 8.3(c) Party Preamble Paying Patents 1.1(qq) Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(bPer Share Price 2.7(a)(ii) Plans 3.16(aPermitted Communications 6.13 Permitted Liens 1.1(yy) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPerson 1.1(zz) Proxy Statement 1.8(a)(ii6.3(a) PSU Consideration 2.8(c) Real Property 3.12(b3.14 Registered Intellectual Property 1.1(aaa) Regulation M-A 1.1(cRegulatory Authority 1.1(bbb) Release 3.18(e)(iiiReimbursement Obligations 1.1(ccc) Representatives 5.2(a5.3(a) Reporting Tail Endorsement 6.8(bRequired Approvals 7.1(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRequisite Stockholder Approval 3.4 RSU Consideration 2.8(b) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b1.1(ddd) SEC 1.1(a1.1(eee) Securities Act 3.11(c1.1(fff) Severance 6.11(dService Provider 1.1(ggg) Shares Software 1.1(qq) Sponsors Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSubsidiary 1.1(hhh) Superior Proposal 5.2(b1.1(iii) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) 2.1 Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d1.1(kkk) Termination Fee 8.2(bDate 8.1(c) Time-Vested DSU 2.4(cTransaction 1.1(lll) Top-Up Option 1.10(aTransaction Litigation 1.1(mmm) Top-Up Uncertificated Shares 1.10(a2.9(c) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”WARN 1.1(nnn), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Cambrex Corp)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bAccounting Arbitrator Section 2.2(b)(iii) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Membership Interests Recitals Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(b) Affiliate Contract Section 1.2(ccc)(xv) Affiliate Transactions Section 5.10 Agreed Rate Section 1.2(c) Agreement Preamble Alternative Acquisition Allocated Value Section 2.2(a) Allocation Objection Notice Section 2.2(b)(ii) Antitrust Laws Section 1.2(d) Asset Taxes Section 1.2(e) Assignment of Interests Section 8.2(a) Benefit Plan Section 1.2(f) BOEM Section 1.2(g) BSEE Section 1.2(h) Burdens Section 1.2(i) Business Day Section 1.2(j) Cash Purchase Price Section 2.1(a) Casualty Loss Section 5.13 Claim Section 11.3(b) Claim Notice Section 11.3(b) Closing Section 8.1 Closing Cash Payment Section 2.4(a) Closing Date Section 8.1 Closing Settlement Statement Section 2.4(a) Code Section 1.2(k) Company or Companies Section 1.2(l) Company Assets Section 1.2(m) Company Business or Company Businesses Section 1.2(n) Company Contract Section 1.2(o) Company Derivatives Section 1.2(p) Company Leases Section 1.2(m)(i) Company Operating Expenses Section 1.2(q) Company Personal Property Section 1.2(m)(vii) Company Properties Section 1.2(m)(iii) Company Records Section 1.2(r) Company Rights-of-Way Section 1.2(m)(vi) Company Units Section 1.2(m)(iii) Company Xxxxx Section 1.2(m)(ii) Confidentiality Agreement 5.2(cSection 1.2(s) Assignee 9.5(aConsent Section 3.11(b) award 3.3(bConsolidated Group Section 1.2(t) BookControlled Group Liabilities Section 1.2(u) Cure Period Section 1.2(w) Customary Post-Entry Share Closing Consents Section 1.2(x) Cut-Off Date Section 1.4(c) Damages Section 11.2(d) Decommission or Decommissioning Section 1.2(y) Defect Arbitrator Exhibit D Defect Escrow Account Section 1.2(z) Defensible Title Section 1.2(aa) Deposit Section 2.1(c) business day 9.10(bDerivatives Section 5.7 Determination Date Section 2.4(b)(ii) CERCLA 3.18(bDispute Auditor Section 2.4(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cDisputed Amount Section 6.7 Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 DOJ Section 5.5 Effective Time Section 1.2(bb) Closing 1.5 Closing Environmental Arbitrator Exhibit D Environmental Defect Section 1.2(cc) Environmental Defect Amount Recitals Closing Section 1.2(dd) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Deductible Section 6.6(d) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 1.2(ee) Environmental Liabilities Section 1.2(ff) Environmental Notice Section 1.2(gg) Environmental Threshold Section 6.5(c) ERISA Section 1.2(hh) ERISA Affiliate Section 1.2(ii) Escrow Account Section 1.2(jj) Escrow Agent Section 1.2(kk) Escrow Agreement Section 1.2(ll) Exchange Act Section 4.5 Excluded Assets Section 1.2(mm) Excluded Assets Assignment Section 1.2(nn) Excluded Company Records Section 1.2(r)(v) Execution Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aFinancial Statements Section 1.2(oo) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cFinal Allocation Section 2.2(b)(iv) Company’s knowledge 9.10(bFinancing Section 4.7 FTC Section 5.5 Fundamental Representations Section 11.4(a) Company Governmental Authority Section 1.2(pp) Hard Consent Section 5.11(b)(i) Hazardous Materials Section 1.2(qq) HSR Act Section 1.2(rr) Hydrocarbons Section 1.2(ss) Imbalance Section 1.2(tt) INC Section 1.2(uu) Included Title Defect Properties Section 6.4(b)(ii) Income Taxes Section 1.2(vv) Indemnified Liabilities Section 11.2(b)(iii) Indemnified Person Section 11.3(a) Indemnifying Person Section 11.3(a) Information Statement Section 5.16 Intellectual Property Section 1.2(ww) Intended Tax Treatment Section 2.2(b)(i) Interim Breach Section 11.2(b)(ii) Interim Breach Provision Section 11.2(b)(ii) Laws Section 1.2(xx) Lease Annex Section 1.2(yy) Liens Section 1.2(zz) Loan Section 1.2(aaa) Lowest Cost Response Section 1.2(bbb) Material Adverse Effect 3.1(aSection 3.31(e) Company Option 2.4(aMaterial Contract Section 1.2(ccc) Company Preferred Stock 3.3(aNet Revenue Interest Section 1.2(ddd) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNORM Section 3.8 Organizational Documents Section 1.2(eee) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOther PSA Section 1.2(fff) Outside Date 8.1(b)(iiSection 10.1(c) Parent Party or Parties Preamble Paying Agent 2.2(aPermits Section 1.2(ggg) Performance-Based DSU 2.4(cPermitted Encumbrance Section 1.2(hhh) Permits 3.9 person 9.10(bPermitted Interest Encumbrance Section 1.2(iii) Plans 3.16(aPerson Section 1.2(jjj) Phase I Activities Section 1.2(kkk) Post-Closing Statement Section 2.4(b) Pre-Effective Date Period Section 1.2(lll) Preferential Purchase Right Section 3.11(a) Proceedings Section 3.6 Proposed Allocation Section 2.2(b)(ii) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Indemnified Parties Section 11.2(b) Purchaser Parent Preamble Purchaser Parent SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cSection 4.13 Purchaser Parent Shares Section 2.1(a) Program 3.9(kPurchaser Tax Returns Section 9.2(b) Prohibited Payment 3.9(cPurchaser’s Phase I Environmental Review Section 6.2(a) Proprietary Purchaser’s Representatives Section 6.1(a) R&W Conditional Binder Section 5.18(a) R&W Policy Section 5.18(a) Registration Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cAgreement Section 8.2(g) Release 3.18(e)(iiiSection 1.2(mmm) Representatives 5.2(aReleased Parties Section 5.12 Releasing Parties Section 5.12 Remediate, Remediation or Remedial Section 1.2(nnn) Reporting Tail Endorsement 6.8(bRequired Purchaser Filings Section 5.15(a) Restraints 8.1(b)(iRetained Employee-Related Liabilities Section 1.2(ooo) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRidgewood Section 5.1 Ridgewood MSA Section 1.2(ppp) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 Riverstone Section 1.2(b) Schedule TO 1.1(bRiverstone Portfolio Company or Riverstone Portfolio Companies Section 1.2(b) SEC 1.1(a) Scheduled Closing Date Section 8.1 Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeismic Data Section 1.2(qqq) Shares Recitals Special Meeting 1.8(a)(iSeller Preamble Seller Indemnified Parties Section 11.2(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Tax Section 1.2(rrr) Superior Proposal 5.2(bSeller Tax Returns Section 9.2(a) Surviving Corporation 1.3(aSeller’s Knowledge Section 1.2(sss) Sinking Funds Section 1.2(mm)(xiii) Specified Matters Section 3.33 Straddle Period Section 1.2(ttt) Subsidiary or Subsidiaries Section 3.3(a) Subsidiary Interests Section 3.3(d) Suspended Funds Section 1.2(uuu) Tax 3.15(a) Taxable 3.15(aSection 1.2(vvv) Tax Effective Date Section 1.2(www) Tax Proceeding Section 9.4 Tax Return 3.15(aSection 1.2(xxx) Tender Completion Time 6.2 Tender Third-Party Loans Section 1.2(yyy) Title Arbitrator Exhibit D Title Benefit Section 1.2(zzz) Title Benefit Amount Section 6.5(b) Title Deductible Section 6.5(c) Title Defect Section 1.2(aaaa) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Dispute Election Section 6.4(b) Title Notice Section 1.2(bbbb) Title Threshold Section 6.5(c) Transaction Costs Section 1.2(cccc) Transaction Documents Section 5.2 Transfer Taxes Section 9.5 Treasury Regulations Section 1.2(dddd) Unadjusted Purchase Price Section 2.1(a) Well Annex Section 1.2(eeee) Willful Breach Section 1.2(ffff) Working Interest Section 1.2(gggg) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 10, 2011 is 2019 (the “Execution Date”), by and among CUBIST PHARMACEUTICALSILX Holdings, INC. LLC, a Delaware limited liability company (“Seller”), Talos Production Inc., a Delaware corporation (“Purchaser”), and solely with respect to its obligations related to the Purchaser Parent Shares (as defined herein), Talos Energy Inc., a Delaware corporation (“Purchaser Parent”). Seller, a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation Purchaser and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (Purchaser Parent are referred to collectively as the “CompanyParties” and individually as a “Party.”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAlternative Debt Commitment Letters 6.16(b) award 3.3(bAlternative Debt Financing 6.16(b) BookAML and Anti-Entry Share 2.1(ccorruption Laws 3.24 Bylaws 3.1(b) business day 9.10(bCapitalization Date 3.6(a) CERCLA 3.18(bCard Association Registrations 3.26(a) Card Associations 3.26(a) Cash Out RSU Award 2.7(b) Certificate of Merger 1.4 Certificate 2.1(c2.3(a) Certificates 2.8(b) Charter 3.1(b) Chosen Courts 9.9 Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(c)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.7(d) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRelated Parties 8.3(e) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a3.8(a), 3.9(b) Company Subsidiary 3.4(aSecurities 3.6(d) Compensation Committee 6.5(b) Confidentiality Agreement 1.2(c9.4 Continuation Period 6.7(b) Continuing Employee 6.11(bCopyrights 1.1(zz) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b6.6(c) Delisting Period 6.3 Data Protection Laws 3.16(b) Debt Commitment Letter 4.11(a) Debt Financing Cooperation Expenses 6.16(d) Debt Financing 4.11(a) Delaware Secretary 2.3(a) Depository Agent 2.8(a) Determination Notice 5.3(d)(ii) DGCL Recitals Dissenting Company Shares 2.3(a2.6(c) DSU 2.4(cDTC 2.8(c) Effect 1.1(q) Effective Time 1.4 Employee Release 6.11(d2.3(b) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(aElectronic Delivery 9.13 Enforceability Exceptions 3.2 Existing Credit Agreement 4.11(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.24 Fee Letter 4.11(a) Indemnified Parties 6.8(aPerson 6.6(a) Independent Directors 6.9(aIndemnified Persons 6.6(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(bMarks 1.1(zz) Maximum Premium 6.8(b6.6(c) Member Bank 3.26(a) Merger 1.3(aRecitals Merger Consideration 2.6(a)(ii) Merger Agreement Annex I Merger Consideration 2.1(c) Sub Preamble Minimum Condition Annex I Multiemployer Plan 3.18(b) Multiple Employer Plan 3.18(b) Network Rules 3.26(b) New Plans 6.7(c) Notice Period 5.2(d) OECD Convention 3.9(c5.3(d)(ii) Offer Recitals Offer Condition 1.1(aAcceptance Time 2.1(d) Offer Commencement Date 2.1(b) Offer Conditions 2.1(b) Offer Documents 1.1(c2.1(f) Offer Price Recitals Expiration Time 2.1(c) Offer to Purchase 1.1(a2.1(b) on a fully diluted basis 9.10(bOld Plans 6.7(c) Outside Date 8.1(b)(iiOption Consideration 2.7(a) Owned Company Shares 2.6(a)(iii) Parent Preamble Paying Parent Material Adverse Effect 4.3 Party Preamble Patents 1.1(zz) Payment Agent 2.2(a2.8(a) Performance-Based DSU 2.4(cPayment Fund 2.8(a) Permits 3.9 person 9.10(bPayoff Amount 6.12(a) Plans 3.16(aPayoff and Release 6.12(a) PostPayoff Documents 6.12(a)
(a) Per Share Price Recitals Pre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Period 5.1 Real Property 3.12(bLeases 3.13(b) Regulation M-A 1.1(cRelated Party Contracts 3.26 RSU Consideration 2.7(b) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bSanctioned Country 3.25(b) Schedule 14D-9 1.2(b2.1(j)(ii) Schedule TO 1.1(bStockholder List Date 2.1(j)(iii) SEC 1.1(a) Subsidiary Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b3.7(c) Surviving Corporation 1.3(a2.3(c) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(aTail Policy 6.6(c) Tender Completion Time 6.2 Tender and Voting Agreements Support Agreement Recitals Terminated Employee 6.11(dTermination Agreement Recitals Termination Condition Annex I Termination Date 8.1(c) Termination Fee 8.2(bTrade Secrets 1.1(zz) Time-Vested DSU 2.4(cTransactions Recitals Uncertificated Shares 2.8(b) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”USRPHC 3.17(e), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: “Agreement” Preamble “Alternate Debt Financing” 6.5(d) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble “Alternative Acquisition Agreement 5.2(cAgreement” 5.3(a) Assignee 9.5(a“Capitalization Date” 3.8(a) award “Cash Replacement Option Amounts” 2.8(a) “Cash Replacement PSU Amounts” 2.8(b) “Cash Rollover Company RSU” 2.8(d) “Cashout Company Equity Awards” 2.8(d) “Cashout Company Options” 2.8(d) “Cashout Company RSU” 2.8(d) “Certificate of Merger” 2.2 “Certificates” 2.9(c) “Chosen Courts” 9.10(a) “Closing” 2.3 “Closing Date” 2.3 “Collection Costs” 8.3(e) “Collective Bargaining Agreement” 3.20(a) “Company” Preamble “Company Board Recommendation” 3.3(a) “Company Board Recommendation Change” 5.3(c)(i) “Company Disclosure Letter” Article III “Company Related Parties” 8.3(f)(ii) “Company SEC Reports” 3.10 “Company Securities” 3.8(c) “Company Stockholder Meeting” 6.4(a) “Confidentiality Agreement” 9.4 “Continuation Period” 6.11(c) “Current Premium” 6.10(c) “Customer Data” 3.17(i) “D&O Insurance” 6.10(c) “Debt Commitment Letter” 4.11(a) “Debt Financing” 4.11(a) “Debt Financing Sources” 4.11(a) “DGCL” Recitals “Dissenting Company Shares” 2.7(c)(i) “DTC” 2.9(d) “Effective Time” 2.2 “Electronic Delivery” 9.14 “Employee Plans” 3.19(a) “Equity Commitment Letter” 4.11(a) “Equity Financing” 4.11(a) “ERISA Affiliate” 3.19(a) “Fee Letter” 4.11(a) “Financial Advisor” 3.3(b) Book-Entry Share 2.1(c“Financing” 4.11(a) business day 9.10(b“Financing Letters” 4.11(a) CERCLA 3.18(b“Financing Uses” 4.11(c) Certificate of “Guarantee” Recitals “Guarantor” Recitals “Indemnified Persons” 6.10(a) “Lease” 3.15(a) “Leased Real Property” 3.15(a) “Merger” Recitals “Merger 1.4 Certificate 2.1(cSub” Preamble “New Debt Commitment Letters” 6.5(d) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release “New Plans” 6.11(d) Environmental Laws 3.18(e)(i“Notice Period” 5.3(d)(ii)(3) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance “Old Plans” 6.11(d) Shares Recitals Special Meeting 1.8(a)(i“Option Consideration” 2.8(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c“Other Required Company Filing” 6.3(b) Superior Proposal 5.2(b“Owned Company Shares” 2.7(a)(iii) Surviving Corporation 1.3(a) Tax “Owned Real Property” 3.15(a) Taxable “Parent” Preamble “Parent Liability Cap” 8.3(f)(i) “Parent Related Parties” 8.3(f)(i) “Party” Preamble “Payment Agent” 2.9(a) “Payment Fund” 2.9(b) “Per Share Price” 2.7(a)(ii) “Pre 2018 RSU Cash Amount” 2.8(b) “Proxy Statement” 6.3(a) “PSU Consideration” 2.8(c) “Reimbursement Obligations” 6.6(f) “Representatives” 5.3(a) “Required Financing Information” 6.6(a)(iv) “Requisite Stockholder Approval” 3.5 “RSU Consideration” 2.8(b) “Sublease” 3.15(a) “Surviving Corporation” 2.1 “Tax Return 3.15(aReturns” 3.18(a) Tender Completion Time 6.2 Tender and “Termination Date” 8.1(c) “Uncertificated Shares” 2.9(c) “Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.” Recitals
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Each of the following capitalized terms has the meaning ascribed to it in the Section of this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bset forth opposite such term: Accountant 1.4(a) Acquisition Proposal 5.2(aAction 3.14 Additional Documents 7.1(a) Adverse Recommendation Change 5.2(cAdjusted Benchmark 8.1 Affiliate 8.1 Aggregate Consideration 1.2(a) Affiliate 3.3(dAgreement, this Preamble Applicable Laws 3.10(a) Agreement April Working Capital 8.1 Audited Financial Statements 3.7 Autobraze Preamble Alternative Acquisition Agreement 5.2(cAutobraze Shareholders Preamble Autobraze Shares 3.4(b) Assignee 9.5(aBenchmark 8.1 Business Personnel 3.20 Cap 7.3(a) award 3.3(bClaim Notice 7.4(a) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cand 7.5(a) Closing 1.5 1.3 Closing Amount Recitals Balance Sheet 1.4(a) Closing Date 1.5 1.3 Closing Date Working Capital 8.1 Closing Statement 1.4(a) Code 2.6 8.1 Company Preamble Company Permits 3.10(e) Company Transaction Expenses 8.1 Conticast Property 5.3(m)(i)
(a) Controlled Group Liability 3.16(a)(i) Damages 7.2(a) Debt Adjustment Amount 1.2(a) December Balance Sheet 3.6(a3.7 December Statements 3.7 Disclosure Schedule 3.1(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture Employment Agreements 5.3(p) Environmental Laws 3.13(a) Environmental Permits 3.13(e) ERISA 3.16(a)(i) ERISA Affiliate 3.16(a)(i) Escrow Agreement 1.2(b)(i) Escrow Amount 8.1 Estimated Working Capital Amount 1.2(c)(i) Financial Statements 3.7 GAAP 1.2(a) General Escrow Amount 8.1 Governmental Authority 8.1 Hxxxxx-Euro Preamble Hxxxxx-Euro Shareholders Preamble Hxxxxx-Euro Shares 3.4(c) Company’s knowledge 9.10(bHxxxxx-Euro Subsidiaries 3.2(c) Company Hxxxxx Spain Preamble Hazardous Materials 3.13(a) HSR Act 2.3(d) Indemnifiable Claim(s) 7.2(a), (b) and (c) Indemnified Party 7.3(d) Indemnifying Party 7.3(d) J.X. Xxxxxx Preamble J.X. Xxxxxx International 3.9(m) J.X. Xxxxxx Shares 3.4(a) J.X. Xxxxxx Shareholders Preamble J.X. Xxxxxx Subsidiaries 3.2(a) Knowledge of the Shareholders 8.1 Lien 8.1 Lincoln Working Capital Payment 1.4(b)(i) Lincoln Electric Preamble Lincoln Electric Indemnified Party 7.2(a) Majority Holders 7.6 Mxxxx Property 5.3(m)(i) Material Adverse Effect 3.1(a8.1 Mexican Labor Regulations 3.16(b)(i) Company Option 2.4(aMultiemployer Plan 3.16(a)(vi) Company Preferred Stock 3.3(aMultiple Employer Plan 3.16(a)(vi) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNet Consideration 8.1 Noncompetition Agreements 5.3(h) Company Restricted Stock 2.4(bOrdinary Course of Business 8.1 Parties 8.1 Permitted Liens 8.1 Person 8.1 Plans 3.16(a)(i) Company Rights 3.3(aPrincipal Shareholders Preamble to Article III Product Liability 3.22 Projected Closing Statement 1.2(c)(i)
(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Qualified Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii3.16(a)(iii) Real Property 3.12(b3.12(c) Regulation M-A 1.1(cReal Property Transfers 5.3(m)(iii) Release 3.18(e)(iiiResolution Period 1.4(a) Representatives 5.2(aSection 338(h)(10) Reporting Tail Endorsement 6.8(bElections 4.2(e) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(aSection 338 Forms 4.2(e) Securities Act 3.11(c3.2(a) Severance 6.11(dShareholder Indemnified Party 7.2(b) Shareholders’ Representative 7.6 Shareholders Preamble Shareholders Working Capital Payment 1.4(b)(ii) Shares Recitals Special Meeting 1.8(a)(i8.1 Software 3.11(e) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Subsidiaries 8.1 Subsidiary 8.1 Tax 3.15(a) Taxable 3.15(a) 8.1 Tax Return 3.15(a8.1 Threshold 7.3(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTitle Policy 5.3(m)(iv)(1) Termination Fee 8.2(bTransactions 8.1 Transfer Documents 5.3(m)(iv) Time-Vested DSU 2.4(cTransferred Properties 5.3(m)(i) Top-Up Option 1.10(aTrust 3A.1(b) Top-Up Shares 1.10(aTrust Instrument 3A.1(b) UK Bribery Act 3.9(cUnlimited Representations 7.3(b)(i) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”Welding Fumes Litigation 8.1 Withdrawal Liability 3.16(a)(i) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Working Capital Escrow Amount 8.1
Appears in 1 contract
Samples: Share Purchase Agreement (Lincoln Electric Holdings Inc)
INDEX OF DEFINED TERMS. Capitalized terms As used in this Agreement Agreement, the following terms shall have the defined meanings that appear assigned to them in the provisions respective locations set forth below: Accounting Firm Section 2.3(c) Actuary Adjustment Statement Section 2.3(j) Actuary Firm Section 2.3(j) Actuary Notice of the Agreement listed below. Acceptance Time 5.2(bDisagreement Section 2.3(j) Acquisition Proposal 5.2(aAgreed Section 338(h)(10) Adverse Recommendation Change 5.2(cElections Section 10.10(c) Affiliate 3.3(dAllocation Statement Section 2.4(a) Agreement Alternative Debt Financing Commitments Section 7.12(b) Alternative Financing Section 7.12(b) Annexes Section 1.3(b) Aon Section 2.3(j) Applicable Tax Contest Section 10.9(a) Articles Section 1.3(b) Attorney-Client Communications Section 13.19(b) Australian MEC Group Section 10.11(a) Available Financing Section 6.8(a) Business IP Section 5.11(b) Business IP Registrations and Applications Section 5.11(a) Business Real Property Section 5.8(b) Business Transfer Documents Section 2.1(e) Buyer Preamble Alternative Acquisition Agreement 5.2(cBuyer Disclosure Schedules Section 1.3(b) Assignee 9.5(aBuyer Financial Statements Section 6.9(a) award 3.3(bBuyer Guarantor Preamble Buyer Indemnitees Section 11.2(a) BookBuyer-Entry Share 2.1(cSigned Tax Returns Section 10.8(a) business day 9.10(bCFIUS Notice Section 7.7 Chancery Court Section 13.10(B) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClaim Section 11.8 Closing Accounting Principles Section 2.6 Closing Date Section 3.1(a) Closing 1.5 Net Indebtedness Section 2.3(a) Closing Amount Recitals Net Working Capital Section 2.3(a) communication Section 1.3(j) Competitive Activity Section 8.3(a) Confidential Information Section 7.1(b) Copyrights Section 5.11(e)(iii) Debt Financing Section 7.12(a) Debt Financing Unavailability Notice Section 7.12(b) Deferred Employee Section 3.1(b)(vi) Deferred Transfer Section 3.1(b)(i) Deferred Transfer Holdback Section 3.1(b)(i) Deposit Section 2.2(a) Disclosing Party Section 7.1(b) Domain Names Section 5.11(e)(v) End Date Section 12.1(b)(i) Environmental Loss Section 11.10(b) Environmental Permits Section 7.3(b) Equity Interest Certificates Section 2.1(a) Estimated Net Indebtedness Section 2.2(d) Estimated Net Working Capital Section 2.2(d) Estimated Statement Section 2.2(d) Exhibits Section 1.3(b) Export Approvals Section 5.24(a)(ii) Export Control Laws Section 5.24(a) Financial Statements Section 5.5(a) FIRPTA Affidavits Section 10.5(a) General Assignment and Assumption Agreement Section 2.1(a) Governmental Competition Authority Section 7.4(a) Huntsman Returns Section 5.19(a) Import Control Laws Section 5.24(b) Indemnified Party Section 11.8 Indemnified Tax Party Section 10.1(c) Indemnified Taxes Section 10.1(a) Indemnifying Party Section 11.8 Independent Accountant Section 2.4(b) India Deferred Closing Date 1.5 Code 2.6 Company Preamble Company Section 3.1(b)(i) India Transfer Agreement Section 2.1(e) Insurance Policies Section 5.27 Interim Period Section 3.1(b)(iii) IP Matters Agreement Section 2.1(a) IP Registration and Application Section 5.11(a) IP Rights Section 5.11(e) Latest Balance Sheet 3.6(aSection 5.5(a)(iii) Company Board Law Firm Section 13.19(a) Leased Real Property Section 5.8(b) Legal Advisors Section 13.19(a) Xxxx Section 1.1 Material Contracts Section 5.9(a) Material Parties Section 5.9(b) Notice of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cDisagreement Section 2.3(c) Company’s knowledge 9.10(bOFAC Section 5.24(a) Company Material Adverse Effect 3.1(aOpen Field Section 8.6(a) Company Option 2.4(aOperating Income Section 8.3(k) Company Preferred Stock 3.3(aOwned IP Section 5.11(d) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bOwned Real Property Section 5.8(a) Company Restricted Stock 2.4(bParties, and each, a 'Party' Preamble Patents Section 5.11(e)(i) Company Rights 3.3(aPresident Section 1.1 Price Adjustment Due Date Section 2.3(k) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares Price Adjustment Statement Section 2.3(a) DSU 2.4(cPrivileged Information Section 13.19(c) Effective Time 1.4 Employee Release 6.11(dPrivileges Section 13.19(c) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Purchase Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(iiSection 2.2(c) Real Property 3.12(bLeases Section 5.8(b) Regulation M-A 1.1(cReceiving Party Section 7.1(b) Release 3.18(e)(iiiRefund Recipient Section 10.10(a) Representatives 5.2(aRemedy Actions Section 7.4(c) Reporting Tail Endorsement 6.8(bRequired Consents Section 5.4 Retained Business Field Section 8.6(a) Restraints 8.1(b)(iRetention Escrow Account Section 3.2(b)(ii) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRetention Escrow Amount Section 3.2(b)(ii) Xxxxxxxx-Xxxxx Act 3.6(bSanctioned Person Section 5.24(a)(i) Schedule 14D-9 1.2(bSection 1.3(b) Schedule TO 1.1(bSections Section 1.3(b) SEC 1.1(aSeller Preamble Seller Disclosure Schedules Section 1.3(b) Securities Act 3.11(cSeller Indemnitees Section 11.3(a) Severance 6.11(dSeller-Signed Tax Returns Section 10.8(a) Shares Recitals Special Meeting 1.8(a)(iStraddle Period Tax Returns Section 10.8(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Supply Provider Section 10.3 Supply Recipient Section 10.3 Tax Return 3.15(aFiler Section 10.8(f) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dThird Party Claim Section 11.8 Title Policies Section 5.8(a) Termination Fee 8.2(bTop Customers Section 5.9(b) Time-Vested DSU 2.4(cTop Suppliers Section 5.9(b) Top-Up Option 1.10(aTrademarks Section 5.11(e)(ii) Top-Up Shares 1.10(aTransfer Tax Returns Section 10.8(a) UK Bribery Act 3.9(cTransferred IP Assignments Section 2.1(g) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”Transition Plan Issue Section 7.13(a) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”TSA Issue Section 7.13(a) Union Contract Section 5.20(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Equity and Asset Purchase Agreement (Huntsman International LLC)
INDEX OF DEFINED TERMS. Capitalized terms in this pdf 8.3 2015 Notes 5.13(e) 2021 Notes 5.13(a) 4-Year Credit Agreement shall have the defined meanings that appear in the provisions of the 5.13(g) 5-Year Credit Agreement listed below. Acceptance Time 5.2(b5.13(g) Acquisition Proposal 5.2(aAcceptable Confidentiality Agreement 8.15(b)(ii) Adverse Recommendation Change 5.2(cAdjusted Option 2.3(a) Affiliate 3.3(dAdjusted RSU Award 2.3(c) Affiliates 8.15(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cFinancing 5.12(c) Assignee 9.5(aAlternative Financing Documents 5.12(c) award 3.3(bAppraisal Provisions 2.1(b) Award Exchange Ratio 2.3(a) Book-Entry Share 2.1(cShares 2.1(a) business day 9.10(bBusiness Day 8.15(b)(ii) CERCLA 3.18(bCancelled Shares 2.1(a)(ii) Cash Consideration 2.1(a)(iii) Certificate 2.1(a) Certificate of Merger 1.4 Certificate 2.1(c1.3 Change of Control Offer 5.13(a) Change of Control Offer Documents 5.13(a) Clean Team Confidentiality Agreement 5.2(a) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 Code 2.6 1.2 Collective Bargaining Agreement 3.14 Commitment Letter 4.10(a) Company Preamble Company Balance Sheet 3.6(aAcquisition Agreement 5.3(e) Company Adverse Recommendation Change 5.3(e) Company Approvals 3.3(b) Company Benefit Plan 8.15(b)(iii) Company Board of Directors Recitals Company Common Stock 3.2(a) Company Directors and Officers 5.9(a) Company Disclosure Letter SECTION 3 Schedule Article III Company Joint Venture 3.4(cEmployees 5.5(a) Company’s knowledge 9.10(bCompany Financial Statements 3.4(b) Company Indemnified Parties 5.9(b) Company Leased Real Property 3.16(b) Company Material Adverse Effect 3.1(aContracts 3.19(a) Company Option 2.4(a2.3(a) Company Organizational Documents 3.1(b) Company Owned Real Property 3.16(c) Company Permits 3.7(b) Company Preferred Stock 3.2(a) Company PSR Award 2.3(b) Company Real Property Leases 3.16(b) Company Recommendation 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bRegistered Intellectual Property 3.15(a) Company Restricted Stock 2.4(bRSU Award 2.3(c) Company Rights SEC Documents 3.4(a) Company Stock Awards 2.3(e) Company Stock Plan 8.15(b)(iv) Company Stockholder Approval 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aStockholders’ Meeting 5.4(b) Company Subsidiary 3.4(aOrganizational Documents 3.1(b) Company Superior Proposal 8.15(b)(v) Company Takeover Proposal 8.15(b)(vi) Company Takeover Transaction 7.3(a) Confidentiality Agreement 1.2(c5.2(e) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Contract 8.15(b)(vii), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Dollar Tree Inc)
INDEX OF DEFINED TERMS. Capitalized The following defined terms have the meanings ascribed to such terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed Sections set forth below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d: Acquired Entities Recitals Acquired Interests Recitals Actual Cash 2.4 Actual Company Expenses 2.4 Actual Indebtedness 2.4 Actual Net Working Capital 2.4 Agreed Claims 7.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cAllocation 2.8 Balance Sheet Date 3.13 Class B Sellers Preamble Closing 2.6 Closing Balance Sheet 2.3(a) Closing 1.5 Date 2.6 Closing Amount Payment Certificate 2.2(b) Company Recitals Continuing Employees 6.3 Dispute Notice 2.3(b) DOL 3.17(b) Enforceability Exceptions 4.1 ERISA Affiliate 3.17(a) Estimated Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a2.2(c) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cEstimated Net Working Capital Deficiency 2.2(d) Company’s knowledge 9.10(bEstimated Net Working Capital Excess 2.2(d) Company Final Disputed Items 2.3(c) Financial Statements 3.13 FLSA 3.23(a) Indemnified Party 7.3(a) Indemnifying Party 7.3(a) IP Licenses 3.10(a) Purchaser Preamble Leased Premises 3.20(b) Leases 3.20(b) Manifest Error 2.3(c) Material Adverse Effect 3.1(aContracts 3.11(a) Company Option 2.4(aMaterial Customer 3.28 Material Vendor 3.29 Non-Recourse Party 8.3 Notices 8.7 Objection Notice 7.3(b) Company Preferred Stock 3.3(aPre-Closing Period Tax Return 6.2(b)(ii) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPurchase Price 2.2(a) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares Purchaser Preamble Purchaser Closing Certificate 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Purchaser Financial Statements 5.7 Purchaser Indemnified Parties 6.8(a7.2(a) Independent Directors 6.9(aPurchaser Preamble Relevant Courts 8.12 Resolution Period 2.3(b) IRS 3.16(aSeller Representative Preamble Seller Representative Matters 8.15(a) Laws 3.9(bSellers Preamble Straddle Periods 6.2(b)(ii) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Survival Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a7.1(a) Tax 3.15(a) Taxable 3.15(aContest 6.2(e) Tax Return 3.15(aIndemnification Obligations 6.2(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dThird-Party Claim 7.3(d) Termination Fee 8.2(bThird-Party Claim Notice 7.3(d) Time-Vested DSU 2.4(cThreshold 7.4(a) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Transfer Taxes 6.2(f), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Equity Purchase Agreement (Innovex Downhole Solutions, Inc.)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection number where such definition is contained: 1993 Plan 3.3(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c1997 Plan 3.3(b) Affiliate 3.3(d9.3(a) Affiliate Agreement Preamble Alternative Acquisition 6.12 Agreement 5.2(cFirst Paragraph Benefit Plans 3.12(a) Assignee 9.5(aBenefit Plan Termination Date 5.3(b) award 3.3(bBusiness Day 9.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCertificates 2.2(b) Certificate of Merger 1.4 Certificate 2.1(c) 1.3 Certifications 3.5 Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 Company Preamble Company Balance Sheet 3.6(a2.2(f) Company First Paragraph Company Board of Directors Recitals Approval 3.4(c) Company Common Stock 2.1(a) Company Disclosure Letter SECTION Schedule Article 3 Company Joint Venture 3.4(cFinancial Statements 3.5(b) Company’s knowledge 9.10(bCompany Intellectual Property 3.15(a) Company Listed Contracts 3.9(a) Company Material Adverse Effect 3.1(aBreach 8.1(c) Company-owned Intellectual Property 3.15(i)(iv) Company Option 2.4(a) Permits 3.8 Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bProducts 3.15(i)(vi) Company Restricted Stock 2.4(bRegistered Intellectual Property 3.15(a) Company Rights 3.3(aSEC Documents 3.5(a) Company SEC Financial Statements 3.5(a) Company Source Code 3.15(i)(vii) Company Stockholder Approval 3.4(b) Company Stockholders’ Meeting 6.2(a) Company Triggering Event 8.1(d) Company Warrant 2.1(e) Confidentiality Agreement 6.3 Contract 9.3(c) Controlled Group Member 3.10(a)(ii) Copyrights 3.15(i)(i) D&O Policy 6.8(b) Debt Obligations 3.9(a)(vii) Delaware Secretary of State 1.3 Dissenting Shares 2.2(f) Dissenting Stockholders 2.2(f) DGCL Recitals Effective Time 1.3 Employment Agreement 5.3(b) End Date 8.1(b)(i) Environmental Claims 3.17(d)(i) Environmental Laws 3.17(d)(ii) Environmental Permits 3.17(d)(iii) Equity Benefit Plans 3.10(a)(i) ERISA 3.10(a)(ii) ERISA Benefit Plans 3.10(a)(ii) Exchange Act 3.3(d) Exchange Agent 2.2(a) GAAP 3.5 Governmental Entity 3.4(e) Hazardous Materials 3.17(d)(iv) HSR Act 3.4(e) Intellectual Property 3.15(i)(i) JDA Recitals JDA Agreement Recitals Knowledge 9.3(d) Legal Requirements 9.3(e) Legal Restraints 7.1(f) Licensed Intellectual Property 3.15(a) Liens 3.2 Material Adverse Effect 9.3(f) Merger Recitals Merger Consideration 2.1(c) Merger Sub First Paragraph Non-ERISA Benefit Plans 3.10(a)(iii) Option 3.3(b) Ordinary Course of Business 9.3(g) Parent First Paragraph Party(ies) 9.3(h) Patent Applications 3.15(i)(ii) Patents 3.15(i)(i) Person 9.3(i) Proxy Statement 6.1(a) Public Software 3.15(h) Release 3.17(d)(v) Registration Statement 6.1(a) Rights 3.3(g) Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a3.4(e) Securities Act 3.11(c4.5(a) Severance 6.11(dShare Right Award 2.1(d)(iv) Shares Recitals Special Meeting 1.8(a)(iShrinkwrap Software 3.15(i)(v) Sub Preamble Sub Common Software 3.15(i)(i) Stock 2.1 Successor Plan 6.11(cPlans 3.3(b) Subsidiary(ies) 9.3(j) Superior Proposal 5.2(b5.2(a) Surviving Corporation 1.3(a1.1 Takeover Proposal 5.2(a) Tax 3.15(aTaxes 3.13 Trade Secrets 3.15(i)(i) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTrademarks 3.15(i)(i) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”6.6(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (QRS Corp)
INDEX OF DEFINED TERMS. Capitalized terms in this Term Section Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dSection 5.5(b) Agreement Preamble Alternative Acquisition Agreement 5.2(cAppraisal Provisions Section 2.1(b) Assignee 9.5(aBankruptcy and Equity Exception Section 3.3(e) award 3.3(bBenefits Continuation Period Section 5.6(a) Book-Entry Share 2.1(cShares Section 2.1(a)(iii) business day 9.10(bCancelled Shares Section 2.1(a)(ii) CERCLA 3.18(bCapitalization Date Section 3.2(a) Certificate Section 2.1(a)(iii) Certificate of Merger 1.4 Certificate 2.1(c) Section 1.3 Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Code 2.6 Section 1.2 Company Preamble Company Balance Sheet 3.6(aAcquisition Agreement Section 5.5(d) Company Adverse Recommendation Change Section 5.5(d) Company Benefit Plans Section 3.13(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Bylaws Section 3.1(d) Company Certificate Section 3.1(d) Company Common Stock Recitals Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIndemnified Parties Section 5.10(a) Company Material Adverse Effect 3.1(aContract Section 3.14(a) Company MSU Award Section 2.3(c) Company Option 2.4(aSection 2.3(a) Company Organizational Documents Section 3.1(d) Company Parties Section 7.3(c) Company Preferred Stock 3.3(aSection 3.2(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSU Award Section 2.3(b) Company Restricted Stock 2.4(bRegistered Intellectual Property Section 3.15(c) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSU Award Section 2.3(d) Company SEC Reports 3.5 Documents Article III Company SEC Financial Statements Section 3.6(d) Company Stock Awards Section 2.3(d) Company Stockholder Approval 6.1 Meeting Section 5.4 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aTermination Fee Section 7.3(b) Confidentiality Agreement 1.2(cSection 5.2(d) Continuing Employee 6.11(bEmployees Section 5.6(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bSection 5.10(c) Delisting Period 6.3 Damages Cap Section 7.2(a) Delaware Secretary Section 1.3 DGCL Recitals Term Section Dissenting Shares 2.3(aSection 2.1(b) DSU 2.4(cDissenting Stockholder Section 2.1(b) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(iSection 1.3 End Date Section 7.1(c) ERISA 3.16(aSection 3.13(a) ERISA Affiliate 3.16(bSection 3.13(c) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) Article III Guarantors Recitals Xxxxxxxx Xxxxx Section 3.24 HSR Act 3.19 IC Plans 6.11(aSection 3.5 Insurance Permits Section 3.22(e) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(aInsurance Subsidiaries Section 3.1(c) IRS 3.16(aSection 3.13(a) Laws 3.9(bLetter of Transmittal Section 2.2(c)(i) Layoff Laws 3.17(b) Maximum Premium 6.8(bLimited Guarantee Recitals Merger Recitals Merger Sub Preamble Merger Sub Bylaws Section 4.1(b) Merger 1.3(aSub Certificate Section 4.1(b) Merger Agreement Annex I Merger Consideration 2.1(cSub Common Stock Section 2.1(a)(iii) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiNasdaq Section 3.5 Parent Preamble Parent Bylaws Section 4.1(b) Parent Certificate Section 4.1(b) Parent Disclosure Letter Article IV Parties Preamble Party Preamble Paying Agent Section 2.2(a) Performance-Based DSU 2.4(cPayment Fund Section 2.2(b) Permits Section 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPremium Cap Section 5.10(c) Proxy Statement 1.8(a)(iiSection 3.5 Regulatory Filings Section 3.22(c) Real Property 3.12(bRemedial Action Section 5.7(c) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Required Funding Amount Section 4.11 Schedule 14D-9 1.2(b) Schedule TO 1.1(b) 13E-3 Section 3.5 SEC 1.1(a) Article III Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Article III Solvent Section 4.12
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBIS 3.21(b) award 3.3(bBylaws 3.1 Capitalization Date 3.7(a) Book-Entry Share 2.1(cCFIUS 4.5 Charter 3.1 Charter Agreements 7.2(k) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cChosen Courts 10.10(a) Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Collective Bargaining Agreement 3.19(a) Comcast Agreement(s) 7.2(l) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(c) Company Breach Notice Period 9.1(e) Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Article III Company Preferred Stock 3.3(a3.7(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRelated Parties 9.3(e)(i) Company SEC Reports 3.5 3.9 Company Securities 3.7(c) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aMeeting 6.4(a) Confidentiality Agreement 1.2(c10.4 Contracting Party 10.12 Copyrights 1.1(tt) Continuing Employee 6.11(bData 1.1(tt) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bDGCL 3.1 Electronic Delivery 10.14 Expense Reimbursement 9.3(b)(iii) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aEquity Commitment Letter 4.11(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aEquity Financing 4.11(a) Indemnified Parties 6.8(aParty 8.4(d) Independent Directors 6.9(aIndemnity Cap 8.4(a) IRS 3.16(aIndemnifying Party 8.4(d) Laws 3.9(bLease 3.14(b) Layoff Laws 3.17(bLeased Real Property 3.14(b) Maximum Premium 6.8(bLosses 8.2 Marks 1.1(tt) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Nonparty Affiliate 10.12 Notice Period 5.2(d5.3(d)(ii)(3) OECD Convention 3.9(cOFAC 3.21(a) Offer Recitals Offer Condition 1.1(aOwned Real Property 3.14(a) Offer Documents 1.1(cParty Preamble Patents 1.1(tt) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Payoff Letters 6.7 Proxy Statement 1.8(a)(ii6.3(a) Purchaser Preamble Purchaser Breach Notice Period 9.1(g) Purchaser Related Parties 9.3(e)(ii) Real Property 3.12(b3.14(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiRecovery Costs 9.3(d) Representatives 5.2(a5.3(a) Reporting Tail Endorsement 6.8(bRequisite Stockholder Approvals 3.4 Sponsor 6.2(d) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dStockholders Agreement 7.2(j) Termination Fee 8.2(bDate 9.1(c) TimeThird-Vested DSU 2.4(cParty Claim 8.5 Trade Laws 3.21(a) Top-Up Option 1.10(aTrade Secrets 1.1(tt) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Transaction Recitals
Appears in 1 contract
Samples: Series B Convertible Preferred Stock Purchase Agreement (Comscore, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms that are used in this Agreement shall have the Agreement, but not defined meanings that appear in Section 1.01, are defined in the provisions following sections of the Agreement listed below. Acceptance Time 5.2(bthis Agreement: 401(k) Plan 5.08(b) MIC Preamble Acquisition Proposal 5.2(a5.03(h)(i) Adverse Recommendation Change 5.2(cMM Preamble Action 3.07 Net Book Value Target 5.25 Additional Payment 5.25 Net Recovery 8.05(c) Affiliate 3.3(dAgreed Tax Treatment 5.16(f) Agreement Preamble No-Shop Period Start Date 5.03(b)(i) Alternative Acquisition Agreement 5.2(cArrangement 5.03(c)(ii) Assignee 9.5(aNotice Period 5.03(c)(ii) award 3.3(bBurdensome Condition 5.05 Original Date 5.21(a) Book-Entry Share 2.1(cCC Preamble Outside Date 7.01(b)(i) business day 9.10(bChange of Recommendation 5.03(c)(i)(E) CERCLA 3.18(b) Parent Preamble Chosen Courts 9.07 Parent Closing Certificate of Merger 1.4 Certificate 2.1(c6.02(d) Closing 1.5 Closing Amount Recitals 2.02 Parent Disclosure Letter III Closing Date 1.5 Code 2.6 2.02 Parent Indemnitee 8.02(b) Closing Date Net Book Value 5.25 Parent Plans 3.09(a) Closing Date Surplus Amount 5.25 Parent Supplement 5.23 Closing Surplus 5.19 Patents 1.01(t) Closing Surplus Target 5.25 Permits 3.08(c) Company and Companies Preamble Proxy Statement 5.20(a) Company Equity Recitals Purchase Price 2.01(b) Company Indemnified Persons 5.24(a) Purchaser Preamble Company Balance Sheet 3.6(aIP 3.16(a) Purchaser Common Stock 4.02(a) Company Board of Directors Recitals Company Plans 3.09(a) Purchaser Disclosure Letter SECTION 3 IV Company Joint Venture 3.4(cRecommendation 3.05(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aPurchaser Indemnitee 8.02(a) Confidentiality Agreement 1.2(c5.04(b) Continuing Employee 6.11(bPurchaser Preferred Stock 4.02(a) CPR Recitals CPR Consolidated Net Book Value 6.02(e) Purchaser Regulatory Agreement Recitals Current D&O Insurance 6.8(b4.08(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aCopyrights 1.01(t) DSU 2.4(cPurchaser Supplement 5.23 Deductible 8.05(a) Regulatory Agreement 3.08(d) Effective Time 1.4 Date Preamble Reinsurance Arrangements 3.28 Employee Release 6.11(dPlans 3.09(a) Requisite Company Vote 3.04(b) Environmental Laws 3.18(e)(iLaw 3.11(b) ERISA 3.16(aRequisite Regulatory Approvals 5.05 Equity Plan Stock 4.02(a) ERISA Affiliate 3.16(bRestricted Business 5.12(a) Exchange Act 1.1(aEquity Sale 2.01(a) Exchange Restricted Period 5.12(a) Estimated Closing Date Balance Sheet 6.02(i) Section 338(h)(10) Election 2.04(a) Financial Statements 3.06(a) STAT Financial Statements 3.06(b) Fund 2.2(aand Funds 5.17(b) Expiration Date 1.1(aStatutory Capital Requirements 3.08(b) FCPA 3.9(cFundamental Representations 8.01(a) FDA 3.9(dStockholders Meeting 5.21(a) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cGAAP 3.06(a) Superior Proposal 5.2(b5.03(h)(ii) Surviving Corporation 1.3(aGo-Shop Period 5.03(a) Tax 3.15(aSupplement 5.23 Hazardous Substance 3.11(c) Taxable 3.15(aSurplus Note Payment 2.01(b) Tax Return 3.15(aIndemnifying Party 8.03(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTampa Office Lease 5.17(a) Termination Fee 8.2(bIndemnitees 8.02(b) TimeTarget Closing Date 2.02 Loans 3.19(a) Third-Vested DSU 2.4(cParty Claim 8.03(a) Top-Up Option 1.10(aMarks 1.01(t) Top-Up Shares 1.10(aTransfer Taxes 5.16(h) UK Bribery Act 3.9(cMaterial Contract 3.13(a) THIS EQUITY PURCHASE AGREEMENT AND PLAN OF MERGER (this “Agreement”) is dated as of October 24February 25, 2011 2019 (the “Effective Date”), and is among CUBIST PHARMACEUTICALSby and between FEDNAT HOLDING COMPANY, a Florida corporation (“Purchaser”), 1347 PROPERTY INSURANCE HOLDINGS, INC. ., a Delaware corporation (“Parent”), MAISON MANAGERS, INC., a Delaware corporation, FRD ACQUISITION CORPORATION corporation (“SubMM”), MAISON INSURANCE COMPANY, a newly-formed Delaware Louisiana corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “CompanyMIC”), and CLAIMCOR, LLC, a Delaware corporationFlorida limited liability company (“CC” and, together with MM and MIC, each, a “Company” and, together, the “Companies”).
Appears in 1 contract
Samples: Equity Purchase Agreement (1347 Property Insurance Holdings, Inc.)
INDEX OF DEFINED TERMS. Capitalized Each of the following defined terms is defined in the corresponding Section of this Agreement shall have the defined meanings that appear listed in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) following index: Adverse Recommendation Change 5.2(cSection 5.02(b) Affiliate 3.3(d) Section 1.01 Agreement Preamble Alternative Acquisition Agreement 5.2(cAnnual Amount Section 6.05(c) Assignee 9.5(aAppraisal Shares Section 3.01(d) award 3.3(bBridge Financing Section 4.02(d) Book-Entry Share 2.1(cBridge Marketing Period Section 6.09(b) business day 9.10(b) CERCLA 3.18(bSection 1.01 Certificate Section 3.01(c) Certificate of Merger 1.4 Certificate 2.1(cSection 2.03 Claim Section 6.05(b) Closing 1.5 Closing Amount Recitals Section 2.02 Closing Date 1.5 Section 2.02 Code 2.6 Section 3.02(h) Commonly Controlled Entity Section 4.01(l)(i) Company Preamble Company Balance Sheet 3.6(aBenefit Agreement Section 4.01(l)(i) Company Board Benefit Plan Section 4.01(l)(i) Company Bylaws Section 2.05(b) Company Certificate of Directors Incorporation Section 2.05(a) Company Common Stock Recitals Company Disclosure Letter SECTION 3 Section 1.01 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(aEmployees Section 6.04(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bSection 4.01(c)(i) Company Restricted Stock 2.4(bSection 4.01(c)(i) Company Rights 3.3(aRSU Section 4.01(c) Company Rights Agreement 3.3(aSARs Section 4.01(c)(i) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Stock Options Section 4.01(c)(i) Company Stock Plans 2.4(a) Company Subsidiary 3.4(aSection 4.01(c)(i) Confidentiality Agreement 1.2(cSection 6.02 Contract Section 4.01(d) Continuing Employee 6.11(bCopyrights Section 1.01 Corporation Section 2.05(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bIFOC Section 4.01(s)(xvi) Delisting Current Offering Period 6.3 Section 3.03(c) Current UFOC Section 4.01(s)(xvi) DGCL Recitals Dissenting Shares 2.3(aSection 2.01 Debt Financing Section 4.02(d) DSU 2.4(cEarnings Claims Section 4.01(s)(vi) Effective Time 1.4 Employee Release 6.11(dSection 2.03 Environmental Claims Section 4.01(j)(ii)(B) Environmental Laws 3.18(e)(iLaw Section 4.01(j)(ii)(B) Equity Financing Section 4.02(d) ERISA 3.16(aSection 1.01 ESPP Termination Date Section 3.03(c) ERISA Affiliate 3.16(bESPPs Section 4.01(c)(i) Exchange Act 1.1(aSection 4.01(d) Exchange Fund 2.2(aSection 3.02(a) Expiration Date 1.1(aFiled Exhibits Section 4.01(i) FCPA 3.9(cFiled SEC Documents Section 4.01 Financing Section 4.02(d) FDA 3.9(dFinancing Commitments Section 4.02(d) Good Clinical Practices 3.9(hForeign Franchises Section 4.01(s)(iv) Good Laboratory Practices 3.9(hFranchise Section 4.01(s)(i) Good Manufacturing Practices 3.9(iFranchise Agreements Section 4.01(s)(i) Franchised Restaurant Section 4.01(s)(i) Franchisee Section 4.01(s)(xvi) FTC Rule Section 4.01(s)(xvi) GAAP Section 4.01(e) Governmental Entity 9.10(bSection 4.01(d) Hazardous Materials 3.18(e)(iiSection 4.01(j)(ii)(B) HSR Act 3.19 IC Plans 6.11(aSection 4.01(d) Incentive Compensation Plan 6.11(aIndebtedness Section 4.01(c)(iv) Indemnified Parties 6.8(aParty Section 6.05(a) Independent Directors 6.9(aIntellectual Property Rights Section 1.01 Judgment Section 4.01(d) IRS 3.16(aKnowledge Section 1.01 Law Section 4.01(d) Laws 3.9(bLeased Real Property Section 4.01(n)(ii) Layoff Laws 3.17(bLiens Section 4.01(b) Maximum Premium 6.8(b) Material Adverse Effect Section 1.01 Merger 1.3(a) Merger Agreement Annex I Recitals Merger Consideration 2.1(cSection 3.01(c) Minimum Condition Annex I Multiemployer Plan Section 4.01(l)(vi) Notice of Superior Proposal Section 5.02(b) Offering Period 5.2(dLast Day Section 3.03(c) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOption/SAR Amount Section 3.03(a) Outside Date 8.1(b)(iiSection 8.01(b)(i) Owned Real Property Section 4.01(n)(i) Parent Preamble Parent Material Adverse Effect Section 1.01 Paying Agent 2.2(aSection 3.02(a) Performance-Based DSU 2.4(cPatents Section 1.01 Permits Section 4.01(j)(i) Permits 3.9 Permitted Liens Section 4.01(n)(iii) person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Section 1.01 Proxy Statement 1.8(a)(iiSection 4.01(d) Real Property 3.12(bLeases Section 4.01(n)(ii) Regulation M-A 1.1(cReal Property Subleases Section 4.01(n)(v) Rebates Section 4.01(s)(xvi) Recommendation Section 4.01(d) Registered Intellectual Property Rights Section 4.01(o) Registration Laws Section 4.01(s)(xvi) Relationship Laws Section 4.01(s)(xiv) Release 3.18(e)(iiiSection 4.01(j)(ii)(B) Representatives 5.2(a) Reporting Tail Endorsement 6.8(bSection 5.02(a) Restraints 8.1(b)(iSection 7.01(c) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bRSU Amount Section 3.03(b) SEC 1.1(aSection 4.01 SEC Documents Section 4.01(e) Section 262 Section 3.01(d) Securities Act 3.11(cSection 4.01(e) Severance 6.11(dSecuritization Section 4.02(d) Shares Recitals Special Software Section 1.01 SPD Section 4.01(l)(i) Specified Contract Section 4.01(i) Stockholder Approval Section 4.01(q) Stockholders’ Meeting 1.8(a)(iSection 6.01(b) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Subsidiary Section 1.01 Superior Proposal 5.2(bSection 5.02(a) Surviving Corporation 1.3(aSection 2.01 Takeover Proposal Section 5.02(a) Tax 3.15(atax return Section 4.01(m)(viii) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dtaxes Section 4.01(m)(viii) Termination Fee 8.2(bSection 6.06(b) Time-Vested DSU 2.4(cTrademarks Section 1.01 Trade Secrets Section 1.01 UFOC Section 4.01(s)(xvi) Top-Up Option 1.10(aUFOC Guidelines Section 4.01(s)(xvi) Top-Up Shares 1.10(aUnited States Jurisdictions Section 4.01(s)(xvi) UK Bribery Voting Company Debt Section 4.01(c)(i) WARN Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Section 1.01
Appears in 1 contract
Samples: Merger Agreement (Ihop Corp)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) : Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dTermination Fee 8.3(b)(iv) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBIS 3.21(b) award 3.3(bBylaws 3.1 Capitalization Date 3.7(a)(i) Book-Entry Share 2.1(cCasdin PGEF II Preamble Casdin PMF Preamble Casdin Transaction Recitals Change of Recommendation Termination Fee 8.3(b)(iii) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Charter 3.1 Chosen Courts 9.10 Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Collective Bargaining Agreement 3.19(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(b) Company Breach Notice Period 8.1(e) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIntellectual Property 3.16(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(aOwned IP 3.16(b) Company Preferred Stock 3.3(a3.7(a)(i) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aProduct 3.22(a) Company SEC Reports 3.5 3.9 Company Securities 3.7(c) Company Stockholder Approval 6.1 Company Stock Plans 2.4(aMeeting 6.4(a) Company Subsidiary 3.4(aContracting Parties 9.12 DGCL 3.1 Electronic Delivery 9.14 Expense Reimbursement 8.3(b)(i) Confidentiality Agreement 1.2(cFDA 3.22(a) Continuing Employee 6.11(bForeign Benefit Plan 3.18(i) CPR Recitals CPR Fully Participating Parties 6.16(a) Healthcare Authorities 3.22(a) Lease 3.14(b) Leased Real Property 3.14(b) Loan Agreement Recitals Current D&O Insurance 6.8(bLock-Up Shares 6.15(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aNew Securities 6.16(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(cNonparty Affiliates 9.12 OFAC 3.21(b) Offer Recitals Offer Condition 1.1(aNotice 6.16(b)
(a) Offer Documents 1.1(cParticipating Parties 6.16(a) Offer Price Recitals Offer to Purchase 1.1(aParties Preamble Party Preamble Permitted Transferees 6.15(b)(ii) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPreemptive Percentage 6.16(a) Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(bPurchaser Preamble Purchaser Breach Notice Period 8.1(g) Regulation M-A 1.1(cRecall 3.22(b) Release 3.18(e)(iiiRegistration Rights Agreement Recitals Representatives 5.3(a) Representatives 5.2(aRequisite Stockholder Approval 3.4(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dSeries B-1 Conversion 6.2(a) Termination Fee 8.2(bDate 8.1(c) Time-Vested DSU 2.4(cTrade Laws 3.21(b) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Transfer 6.15(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Series B 1 Convertible Preferred Stock Purchase Agreement (Fluidigm Corp)
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location Company Transaction Litigation 6.11(a) Encina Loan Agreement shall have the defined meanings that appear in the provisions of the 9.3(u) Innovus CVRs 9.3(w) Non-Assumed Company Option 9.3(z) Termination Fees 8.3(b)(i) Acceptable Confidentiality Agreement listed below. Acceptance Time 5.2(b9.3(a) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Action 4.10 Affiliate 3.3(d9.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(c6.2(b)(ii) Assignee 9.5(aAnnual Premium Amount 4.18 Applicable Date 4.6(a) award 3.3(bAssumed Company Option 9.3(c) Book-Entry Share 2.1(cShares 3.3(b) business day 9.10(bBridge Adjustment 3.1(d) CERCLA 3.18(bBridge Note Recitals Business Day 9.3(d) Certificate of Merger 1.4 Certificate 2.1(c2.4 Certificates 3.3(b) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 COBRA 4.13(c)(vi) Code 2.6 Recitals Company Preamble Company Balance Sheet 3.6(aAcquisition Proposal 6.2(h)(i) Company Adverse Recommendation Change 9.3(e) Company Board of Directors Recitals Company Board Recommendation 4.4(b) Company Bylaws 4.1(b) Company Charter 4.1(b) Company Common Stock Recitals Company Designees 1.1(a)(ii) Company Disclosure Letter SECTION 3 Article IV Company Joint Venture 3.4(cEquity Plan 9.3(f) Company’s knowledge 9.10(bCompany Intervening Event 6.2(h)(iii) Company IP Agreement 9.3(g) Company Loan Agreement 9.3(h) Company Loan Facilities 9.3(i) Company Manufactured Products 4.12(e) Company Manufacturing Facility 4.12(e) Company Material Adverse Effect 3.1(a4.1(a) Company Notice Period 6.2(b)(ii)(I)(A) Definition Location Company Option 2.4(a9.3(j) Company Owned IP 9.3(k) Company Plan 4.13(a) Company Preferred Stock 3.3(a4.2(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bRegistered IP 4.20(a) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSU 9.3(l) Company SEC Reports 3.5 Documents 4.6(a) Company Stock Awards 4.2(b) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a4.4(a) Company Subsidiary 3.4(aStockholders Meeting 6.4(a) Confidentiality Company Superior Proposal 6.2(h)(ii) Company Termination Fee 8.3(b)(i) Confidential Disclosure Agreement 1.2(c6.5(d) Continuation Period 6.14(a) Continuing Employee 6.11(b6.14(a) CPR Recitals CPR Agreement Recitals Current Contract 9.3(m) control 9.3(n) Controlled Group 4.13(b) Conversion of the Deerfield Notes 6.1(a)(vii) Cowen 5.23 D&O Insurance 6.8(b6.9(a) Delisting Period 6.3 Damages 9.3(o) Debt Facility Letters 9.3(q) Debt Financing Sources 9.3(p) Deerfield Debt Facility Letter 9.3(r) Deerfield Loan Facility 9.3(s) Delaware Secretary of State 2.4 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d2.4 Encina Debt Facility Letter 9.3(t) Environmental Laws 3.18(e)(iLaw 4.15(b) Environmental Permits 4.15(a) ERISA 3.16(a) ERISA Affiliate 3.16(b4.13(a) Exchange Act 1.1(a4.5(b) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.3(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b1.1(a) Accounting Firm 3.7(e) Acquisition Inquiry 1.1(b) Acquisition Proposal 5.2(a1.1(c) Adverse Recommendation Change 5.2(cAcquisition Transaction 1.1(d) Action 4.9 Additional Permitted Bridge Financing 1.1(e) Additional Permitted Bridge Financing Agreement 1.1(f) Affiliate 3.3(d1.1(g) Agreement Preamble Alternative Acquisition Agreement 5.2(cAllocation Certificate 7.13 Anticipated Meeting Date 3.7(a) Assignee 9.5(a) award 3.3(b) Assumed Option 3.3 Book-Entry Share 2.1(cShares 3.4(b) business day 9.10(bBusiness Day 1.1(h) CERCLA 3.18(bCash Determination Date 3.7(a) Certificate of Merger 1.4 Certificate 2.1(c2.4 Certificates 3.4(b) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 COBRA 4.12(d)(iv) Code 2.6 Recitals Company Preamble Company Audited Financial Statements 7.1(g) Company Balance Sheet 3.6(a4.6(b) Company Board of Directors Recitals Company Board Adverse Recommendation Change 7.2(c) Company Board Recommendation 7.2(c) Company Bylaws 4.1(b) Company Charter 4.1(b) Company Common Stock Recitals Company Disclosure Letter SECTION 3 Article IV Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEquity Plan 1.1(i) Company Material Adverse Effect 3.1(aFinancial Statements 4.6(b) Company Option 2.4(aInterim Financial Statements 4.6(b) Company Intervening Event 7.2(d) Company Notice Period 7.2(d) Company Options 1.1(j) Company Outstanding Shares 3.1(a)(i)(A) Company Owned IP 1.1(k) Company Plan 1.1(l) Company Preferred Stock 3.3(a1.1(n) Company Quarterly Balance Sheet 3.7 Preferred Stock Conversion 3.1(b) Company Restricted Share 2.4(bProducts 4.11(c) Company Registered IP 4.19(a) Company Restricted Shares 3.2 Company Stock 2.4(bAwards 4.2(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Recitals Company Stock Plans 2.4(aSupport Agreements Recitals Company Termination Fee 9.3(b) Company Subsidiary 3.4(aTriggering Event 1.1(m) Company Unaudited Financial Statements 4.6(a) Company Unaudited Interim Financial Statements 4.6(a) Company Valuation 3.1(a)(i)(B) Company Value Per Share 3.1(a)(i)(C) Confidentiality Agreement 1.2(c1.1(o) Continuing Employee 6.11(bContract 4.5(a) CPR Recitals CPR Agreement Recitals control 1.1(p) Controlled Group 4.12(c) Current Offering Period 6.9 D&O Insurance 6.8(bIndemnified Parties 7.5(a) Delisting Period 6.3 Delaware Secretary of State 2.4 Delivery Date 3.7(a) DGCL Recitals Dispute Notice 3.7(b) Dissenting Shares 2.3(a) DSU 2.4(c) 3.6 Effective Time 1.4 2.4 Employee Release 6.11(dPlan 1.1(q) End Date 9.1(b) Environmental Laws 3.18(e)(iLaw 4.14(b) ERISA 3.16(a) ERISA Affiliate 3.16(b1.1(r) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”4.5(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Allovir, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bAccounting Arbitrator Section 2.2(b)(iii) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Membership Interests Recitals Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(b) Affiliate Contract Section 1.2(ccc)(xv) Affiliate Transactions Section 5.10 Agreed Rate Section 1.2(c) Agreement Preamble Alternative Acquisition Allocated Value Section 2.2(a) Allocation Objection Notice Section 2.2(b)(ii) Antitrust Laws Section 1.2(d) Asset Taxes Section 1.2(e) Assignment of Interests Section 8.2(a) Benefit Plan Section 1.2(f) BOEM Section 1.2(g) BSEE Section 1.2(h) Burdens Section 1.2(i) Business Day Section 1.2(j) Cash Purchase Price Section 2.1(a) Casualty Loss Section 5.13 Claim Section 11.3(b) Claim Notice Section 11.3(b) Closing Section 8.1 Closing Cash Payment Section 2.4(a) Closing Date Section 8.1 Closing Settlement Statement Section 2.4(a) Code Section 1.2(k) Company or Companies Section 1.2(l) Company Assets Section 1.2(m) Company Business or Company Businesses Section 1.2(n) Company Contract Section 1.2(o) Company Derivatives Section 1.2(p) Company Leases Section 1.2(m)(i) Company Operating Expenses Section 1.2(q) Company Personal Property Section 1.2(m)(vii) Company Properties Section 1.2(m)(iii) Company Records Section 1.2(r) Company Rights-of-Way Section 1.2(m)(vi) Company Units Section 1.2(m)(iii) Company Xxxxx Section 1.2(m)(ii) Confidentiality Agreement 5.2(cSection 1.2(s) Assignee 9.5(aConsent Section 3.11(b) award 3.3(bConsolidated Group Section 1.2(t) BookControlled Group Liabilities Section 1.2(u) Cure Period Section 1.2(w) Customary Post-Entry Share Closing Consents Section 1.2(x) Cut-Off Date Section 1.4(c) Damages Section 11.2(d) Decommission or Decommissioning Section 1.2(y) Defect Arbitrator Exhibit D Defect Escrow Account Section 1.2(z) Defensible Title Section 1.2(aa) Deposit Section 2.1(c) business day 9.10(bDerivatives Section 5.7 Determination Date Section 2.4(b)(ii) CERCLA 3.18(bDispute Auditor Section 2.4(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cDisputed Amount Section 6.7 Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 DOJ Section 5.5 Effective Time Section 1.2(bb) Closing 1.5 Closing Environmental Arbitrator Exhibit D Environmental Defect Section 1.2(cc) Environmental Defect Amount Recitals Closing Section 1.2(dd) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Deductible Section 6.6(d) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 1.2(ee) Environmental Liabilities Section 1.2(ff) Environmental Notice Section 1.2(gg) Environmental Threshold Section 6.5(c) ERISA Section 1.2(hh) ERISA Affiliate Section 1.2(ii) Escrow Account Section 1.2(jj) Escrow Agent Section 1.2(kk) Escrow Agreement Section 1.2(ll) Exchange Act Section 4.5 Excluded Assets Section 1.2(mm) Excluded Assets Assignment Section 1.2(nn) Excluded Company Records Section 1.2(r)(v) Execution Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aFinancial Statements Section 1.2(oo) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cFinal Allocation Section 2.2(b)(iv) Company’s knowledge 9.10(bFinancing Section 4.7 FTC Section 5.5 Fundamental Representations Section 11.4(a) Company Governmental Authority Section 1.2(pp) Hard Consent Section 5.11(b)(i) Hazardous Materials Section 1.2(qq) HSR Act Section 1.2(rr) Hydrocarbons Section 1.2(ss) Imbalance Section 1.2(tt) INC Section 1.2(uu) Included Title Defect Properties Section 6.4(b)(ii) Income Taxes Section 1.2(vv) Indemnified Liabilities Section 11.2(b)(iii) Indemnified Person Section 11.3(a) Indemnifying Person Section 11.3(a) Information Statement Section 5.16 Intellectual Property Section 1.2(ww) Intended Tax Treatment Section 2.2(b)(i) Interim Breach Section 11.2(b)(ii) Interim Breach Provision Section 11.2(b)(ii) Laws Section 1.2(xx) Lease Annex Section 1.2(yy) Liens Section 1.2(zz) Loan Section 1.2(aaa) Lowest Cost Response Section 1.2(bbb) Material Adverse Effect 3.1(aSection 3.31(e) Company Option 2.4(aMaterial Contract Section 1.2(ccc) Company Preferred Stock 3.3(aNet Revenue Interest Section 1.2(ddd) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNORM Section 3.8 Organizational Documents Section 1.2(eee) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOther PSA Section 1.2(fff) Outside Date 8.1(b)(iiSection 10.1(c) Parent Party or Parties Preamble Paying Agent 2.2(aPermits Section 1.2(ggg) Performance-Based DSU 2.4(cPermitted Encumbrance Section 1.2(hhh) Permits 3.9 person 9.10(bPermitted Interest Encumbrance Section 1.2(iii) Plans 3.16(aPerson Section 1.2(jjj) Phase I Activities Section 1.2(kkk) Post-Closing Statement Section 2.4(b) Pre-Effective Date Period Section 1.2(lll) Preferential Purchase Right Section 3.11(a) Proceedings Section 3.6 Proposed Allocation Section 2.2(b)(ii) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Indemnified Parties Section 11.2(b) Purchaser Parent Preamble Purchaser Parent SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cSection 4.13 Purchaser Parent Shares Section 2.1(a) Program 3.9(kPurchaser Tax Returns Section 9.2(b) Prohibited Payment 3.9(cPurchaser’s Phase I Environmental Review Section 6.2(a) Proprietary Purchaser’s Representatives Section 6.1(a) R&W Conditional Binder Section 5.18(a) R&W Policy Section 5.18(a) Registration Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cAgreement Section 8.2(g) Release 3.18(e)(iiiSection 1.2(mmm) Representatives 5.2(aReleased Parties Section 5.12 Releasing Parties Section 5.12 Remediate, Remediation or Remedial Section 1.2(nnn) Reporting Tail Endorsement 6.8(bRequired Purchaser Filings Section 5.15(a) Restraints 8.1(b)(iRetained Employee-Related Liabilities Section 1.2(ooo) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRidgewood Section 5.1 Ridgewood MSA Section 1.2(ppp) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 Riverstone Section 1.2(b) Schedule TO 1.1(bRiverstone Portfolio Company or Riverstone Portfolio Companies Section 1.2(b) SEC 1.1(a) Scheduled Closing Date Section 8.1 Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeismic Data Section 1.2(qqq) Shares Recitals Special Meeting 1.8(a)(iSeller Preamble Seller Indemnified Parties Section 11.2(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Tax Section 1.2(rrr) Superior Proposal 5.2(bSeller Tax Returns Section 9.2(a) Surviving Corporation 1.3(aSeller’s Knowledge Section 1.2(sss) Sinking Funds Section 1.2(mm)(xiii) Specified Matters Section 3.33 Straddle Period Section 1.2(ttt) Suspended Funds Section 1.2(uuu) Tax 3.15(a) Taxable 3.15(aSection 1.2(vvv) Tax Effective Date Section 1.2(www) Tax Proceeding Section 9.4 Tax Return 3.15(aSection 1.2(xxx) Tender Completion Time 6.2 Tender Third-Party Loans Section 1.2(yyy) Title Arbitrator Exhibit D Title Benefit Section 1.2(zzz) Title Benefit Amount Section 6.5(b) Title Deductible Section 6.5(c) Title Defect Section 1.2(aaaa) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Dispute Election Section 6.4(b) Title Notice Section 1.2(bbbb) Title Threshold Section 6.5(c) Transaction Costs Section 1.2(cccc) Transaction Documents Section 5.2 Transfer Taxes Section 9.5 Treasury Regulations Section 1.2(dddd) Unadjusted Purchase Price Section 2.1(a) Well Annex Section 1.2(eeee) Willful Breach Section 1.2(ffff) Working Interest Section 1.2(gggg) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 10, 2011 is 2019 (the “Execution Date”), by and among CUBIST PHARMACEUTICALSILX Holdings III LLC, INC. a Delaware limited liability company (“Seller”), Talos Production Inc., a Delaware corporation (“Purchaser”), and solely with respect to its obligations related to the Purchaser Parent Shares (as defined herein), Talos Energy Inc., a Delaware corporation (“Purchaser Parent”). Seller, a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation Purchaser and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (Purchaser Parent are referred to collectively as the “CompanyParties” and individually as a “Party.”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b8.3(a) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cAction 3.10 Affected Employees 5.17(a) Affiliate 3.3(d8.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.2(a)(iii)(B) Assignee 9.5(aAnti-Corruption Laws 8.3(c) award 3.3(bAntitrust Laws 5.5(a) Book-Entry Share 2.1(cShares 2.3(b) business day 9.10(bBusiness Day 8.3(d) CERCLA 3.18(bCARES Act 8.3(e) Certificate of Merger 1.4 Certificate 2.1(c1.3 Certificates 2.3(b) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Closing Tax Opinion 6.3(e) COBRA 3.12(c)(vi) Code 2.6 Recitals Company Preamble Company Balance Sheet 3.6(aAcquisition Proposal 5.2(a)(xi)(A) Company Adverse Recommendation Change 5.2(a)(iii)(A) Company Board of Directors Recitals 2.2(f) Company Board Designees 5.18(a) Company Business IP 3.20(b) Company Business Trade Secrets 3.20(d) Company Bylaws 3.1(b) Company Charter 3.1(b) Company Common Stock 2.1(a) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cEquity Plans 2.2(a) Company’s knowledge 9.10(bCompany ESPP 2.2(f) Company Expenses 7.3(e) Company Intervening Event 5.2(a)(xi)(B) Company Material Adverse Effect 3.1(aContract 3.16(a) Company Option 2.4(a2.2(a) Company Plans 3.12(a) Company Preferred Stock 3.3(a3.2(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSU 2.2(b) Company Restricted Stock 2.4(bRegistered IP 3.20(a) Company Rights 3.3(aRSU 2.2(b) Company Rights Agreement 3.3(aSAR 2.2(c) Company SEC Reports 3.5 Documents 3.6(a) Company Stock Awards 3.2(b) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a3.4(a) Company Subsidiary 3.4(aStockholders Meeting 5.3(a) Company Superior Proposal 5.2(a)(xi)(C) Company Tax Counsel 5.12(a)(iv) Company Termination Fee 7.3(b) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.5.4
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: 2018 and 2020 Performance Unit Consideration 6.9(e)(i)
(a) Acquisition Proposal 5.2(a1.1(b) Adverse Recommendation Change 5.2(cAdjusted Performance Unit Award 6.9(a)(ii) Adjusted RSU 2.8(b)(i) Affiliate 3.3(d1.1(c) Agreement Preamble Alternative Acquisition Antitrust Law 1.1(d) Approval Time 5.5(b) Australia Credit Agreement 5.2(c1.1(e) Assignee 9.5(aBonus Termination Percentage 6.9(f) award 3.3(bBusiness Day 1.1(f) Book-Entry Share 2.1(cBylaws 3.1(c) business day 9.10(bCanada Credit Agreement 1.1(g) CERCLA 3.18(bCancelled Shares 2.7(a)(iii) Capitalization Date 3.7(a) Cash Consideration 2.7(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c0 Certificates 2.9(d) Charter 1.1(h) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 Code 2.6 1.1(i) Company Preamble Company Balance Sheet 3.6(a2020 Bonus Pool 6.9(f) Company Board of Directors Recitals 1.1(j) Company Board Recommendation 3.3(a) Company Board Recommendation Change 5.5(a)(iii) Company Common Stock 1.1(k) Company Credit Agreement 1.1(l) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cDirector RSU 2.8(b)(ii) Company’s knowledge 9.10(bCompany Employee RSU 2.8(b)(i) Company ESPP 1.1(m) Company Indebtedness 1.1(n) Company Indenture 1.1(o) Company Intellectual Property 1.1(p) Company Material Adverse Effect 3.1(a1.1(q) Company Option 2.4(aOptions 1.1(r) Company Performance Unit Award 1.1(t) Company Preferred Stock 3.3(a1.1(u) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs 1.1(s) Company Restricted Stock 2.4(bRegistered Intellectual Property 3.15(a) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSUs 1.1(v) Company SEC Reports 3.5 3.9 Company Stockholder Approval 6.1 Securities 3.7(c) Company Stock Plans 2.4(a1.1(w) Company Subsidiary 3.4(aStockholder Meeting 6.4(a) Company Stockholders 1.1(x) Company Termination Fee 1.1(y) Confidentiality Agreement 1.2(c9.4 Continuation Period 6.9(c) Continuing Employee 6.11(bEmployees 1.1(z) CPR Recitals CPR Agreement Recitals Current Contract 1.1(aa) Converted Shares 2.7(a)(iii) Copyrights 1.1(rr) COVID-19 1.1(bb) COVID-19 Measures 1.1(cc) D&O Insurance 6.8(b) Delisting Period 6.3 Data Privacy Laws 1.1(dd) DGCL Recitals Director RSU Consideration 2.8(b)(ii) Dissenting Company Shares 2.3(a2.7(d)(i) DSU 2.4(cDividend Consideration 2.7(a)(ii) DOJ 1.1(ee) DTC 2.9(e) Effective Time 1.4 0 Effects 1.1(q) Electronic Delivery 9.13 Employee Release 6.11(dPlan 1.1(ff) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Enforceability Exceptions 3.2
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) : Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dNotice Period 5.3(c)(ii)(2) Agreement Preamble Alternate Debt Financing 6.5(d) Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBlackstone 6.2(b) award 3.3(bCapex Budget 5.2(l) Book-Entry Share 2.1(cCapitalization Date 3.7(a) business day 9.10(bCash Replacement Company Option Amounts 2.8(a)(ii) CERCLA 3.18(bCash Replacement Company RSU Amounts 2.8(b)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(b) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIT Assets 3.21(a) Company Related Parties 8.3(e) Company SEC Documents Article III Company Securities 3.7(c) Company Stockholder Meeting 6.4(a) Copyrights 1.1(xx) D&O Insurance 6.10(c) Debt Commitment Letter 4.11(a) Debt Financing 4.11(a) DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Enforcement Expenses 8.3(f) Equity Award Holders 2.8(c) Equity Commitment Letter 4.11(a) Equity Financing 4.11(a) Fee Letter 4.11(a) Financing 4.11(a) Financing Letters 4.11(a) Financing Sources Protection Provisions 8.4 Foreign Employee Plans 3.18(h) Guarantees Recitals Guarantors Recitals Indemnified Persons 6.10(a) Initial Termination Date 8.1(c) Intervening Event Notice Period 5.3(c)(i)(1) Last Condition 2.3 Lease 3.14(b) Leased Real Property 3.14(b) Marks 1.1(xx) Maximum Annual Premium 6.10(c) Merger Recitals Merger Sub Preamble Multiemployer Plan 3.18(b) New Debt Commitment Letters 6.5(d) New Plan 6.11(d) Old Plans 6.11(d) Other Indemnified Persons 6.10(e) Other Required Company Filing 6.3(b) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Disclosure Letter Article IV Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Related Parties 8.3(e) Parent Termination Fee 8.3(c) Party Preamble Paying Patents 1.1(xx) Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(bPayoff Letters 6.6(c)(i) Plans 3.16(aPer Share Price 2.7(a)(ii) Post-Closing SEC Reports 6.3 Principal Stockholders Preferred Equity Financing Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPrivacy Requirements 3.21(b) Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Requisite Stockholder Approval 3.4
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized In addition to the terms defined in Section 1.1, the following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) : Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dNotice Period 5.3(d)(ii)(1) Agreement Preamble Alternate Debt Financing 6.5(d) Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aCapitalization Date 3.7(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCash Replacement Company RSU Amount 2.8(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.11 Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(c)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bRelated Parties 8.3(e)(ii) Company SEC Documents Article III Company Securities 3.7(c) Company Termination Fee 8.3(b) D&O Insurance 6.10(c) Debt Commitment Letters 4.12(a) Debt Financing 4.12(a) DGCL Recitals Dissenting Company Shares 2.7(c) DPA 4.5 DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.15 Enforceability Exceptions 3.2 Enforcement Expenses 8.3(f) Equity Commitment Letter 4.12(a) Equity Financing 4.12(a) Fee Letter 4.12(a) Financing 4.12(a) Financing Letters 4.12(a) Indemnified Persons 6.10(a) Interim Period 5.1 Intervening Event Notice Period 5.3(d)(i)(1) Lease 3.14 Leased Real Property 3.14 Limited Guarantee Recitals Limited Guarantor Recitals Maximum Annual Premium 6.10(c) Merger Recitals Merger Sub Preamble New Debt Commitment Letters 6.5(d) New Plan 6.11(b) Old Plans 6.11(b) Other Required Company Filing 6.3(b) Other Indemnified Persons 6.10(e) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Related Parties 8.3(e)(i) Parent Termination Fee 8.3(c) Party Preamble Paying Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(bPer Share Price 2.7(a)(ii) Plans 3.16(a) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aTax Contest 6.16(b) Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(bReplacement Company MSU Award 2.8(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bReplacement Company PSU Award 2.8(c) Schedule 14D-9 1.2(b13e-3 6.3(c) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Stockholder Consent 3.4 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aUncertificated Shares 2.9(c) Taxable 3.15(aUnvested Company RSU 2.8(a)(ii) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”RSU Consideration 2.8(a)(i), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) : Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dTermination Fee 8.3(b)(iv) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBIS 3.21(b) award 3.3(bBylaws 3.1 Capitalization Date 3.7(a)(i) Book-Entry Share 2.1(cChange of Recommendation Termination Fee 8.3(b)(iii) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Charter 3.1 Chosen Courts 9.10 Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Collective Bargaining Agreement 3.19(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(b) Company Breach Notice Period 8.1(e) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIntellectual Property 3.16(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(aOwned IP 3.16(b) Company Preferred Stock 3.3(a3.7(a)(i) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aProduct 3.22(a) Company SEC Reports 3.5 3.9 Company Securities 3.7(c) Company Stockholder Approval 6.1 Company Stock Plans 2.4(aMeeting 6.4(a) Company Subsidiary 3.4(aContracting Parties 9.12 DGCL 3.1 Electronic Delivery 9.14 Expense Reimbursement 8.3(b)(i) Confidentiality Agreement 1.2(cFDA 3.22(a) Continuing Employee 6.11(bForeign Benefit Plan 3.18(i) CPR Recitals CPR Fully Participating Parties 6.16(a) Healthcare Authorities 3.22(a) Lease 3.14(b) Leased Real Property 3.14(b) Loan Agreement Recitals Current D&O Insurance 6.8(bLock-Up Shares 6.15(a) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aNew Securities 6.16(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(cNonparty Affiliates 9.12 OFAC 3.21(b) Offer Recitals Offer Condition 1.1(aNotice 6.16(b) Offer Documents 1.1(cOfferee 6.16(a) Offer Price Recitals Offer to Purchase 1.1(aParticipating Parties 6.16(a) on a fully diluted basis 9.10(bParties Preamble Party Preamble Permitted Transferees 6.15(b)(ii) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPreemptive Percentage 6.16(a) Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(bPurchaser Preamble Purchaser Breach Notice Period 8.1(g) Regulation M-A 1.1(cRecall 3.22(b) Release 3.18(e)(iiiRegistration Rights Agreement Recitals Representatives 5.3(a) Representatives 5.2(aRequisite Stockholder Approval 3.4(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dSeries B-2 Conversion 6.2(a) Termination Fee 8.2(bDate 8.1(c) Time-Vested DSU 2.4(cTrade Laws 3.21(b) Top-Up Option 1.10(aTransfer 6.15(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.VGO Drawdown Preamble VGO Illiquid Investments Preamble Viking Transaction Recitals
Appears in 1 contract
Samples: Series B 2 Convertible Preferred Stock Purchase Agreement (Fluidigm Corp)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: “Agreement” Preamble “Alternate Debt Financing” 6.5(d) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble “Alternative Acquisition Agreement 5.2(cAgreement” 5.3(a) Assignee 9.5(a“Capitalization Date” 3.8(a) award 3.3(b“Carveout Transaction” 6.19(a) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) “Certificate of Merger 1.4 Certificate 2.1(cMerger” 2.2 “Certificates” 2.9(c) “Chosen Courts” 9.10(a) “Closing” 2.3 “Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Date” 2.3 “Collective Bargaining Agreement” 3.21(a) “Committed Bidder” 5.3(g) “Company” Preamble Company Balance Sheet 3.6(a) “Company Board of Directors Recitals Recommendation” 3.3(a) “Company Board Recommendation Change” 5.3(c)(i) “Company Breach Notice Period” 8.1(e) “Company Disclosure Letter SECTION 3 Letter” Article III “Company Joint Venture 3.4(cRelated Parties” 8.3(f)(ii) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 “Company Restricted Share 2.4(bConsideration” 2.8(a) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) “Company SEC Reports 3.5 Reports” 3.10 “Company Securities” 3.8(c) “Company Stockholder Approval 6.1 Meeting” 6.4(a) “Company Stock Plans 2.4(aTermination Fee” 8.3(b)(i) Company Subsidiary 3.4(a“Conditional Commitment” 5.3(g) “Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan Agreement” 9.4 “Continuation Period” 6.11(c) Program 3.9(k“D&O Insurance” 6.10(c) Prohibited Payment 3.9(c“Debt Commitment Letters” 4.11(a) Proprietary Rights 3.12(a“Debt Financing” 4.11(a) Proxy Statement 1.8(a)(ii“DGCL” Recitals “Dissenting Company Shares” 2.7(c)(i) Real Property 3.12(b“DTC” 2.9(d) Regulation M-A 1.1(c“Effective Time” 2.2 “Electronic Delivery” 9.14 “Employee Plans” 3.20(a) Release 3.18(e)(iii“Equity Commitment Letter” Recitals “Equity Financing” Recitals “Equity Investors” Recitals “ERISA Affiliate” 3.20(a) Representatives 5.2(a“Fee Letter” 4.11(a) Reporting Tail Endorsement 6.8(b“Financial Advisor” 3.3(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Financing” 4.11(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Del Frisco's Restaurant Group, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) 8-K Filing Section 3.5 Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cSection 3.10(h)(i) Affiliate 3.3(dSection 2.1(i) Agreement Preamble Alternative Acquisition Agreement 5.2(cAuthorized Shares Proposal Section 3.8(a) Assignee 9.5(aBalance Sheet Section 2.1(k)(iii) award 3.3(bBison Designees Section 3.12 (a) Book-Entry Share 2.1(cBoard of Directors Section 1.3(c)(v) business day 9.10(bBribery Act Section 2.1(n)(i) CERCLA 3.18(bBylaws Section 1.3(c)(v) Certificate of Merger 1.4 Certificate 2.1(cIncorporation Section 1.3(c)(v) CFIUS Section 2.1(kk) CFIUS Approval Section 2.1(kk) Class A Common Stock Preamble Class B Common Stock Section 2.1(c)(i) Closing 1.5 Closing Amount Recitals Section 1.3(a) Closing Date 1.5 Section 1.3(a) Code 2.6 Section 2.1(x)(iii) Company Preamble Company Balance Sheet 3.6(aIntellectual Property Section 2.1(v)(ii) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIP Agreements Section 2.1(v)(v) Company Plan Section 2.1(cc)(i) Company Recommendation Change Section 3.10(d) Company Software Section 2.1(v)(ix) Company Stock Plans Section 2.1(c)(i) Contingent Obligation Section 2.1(q) Contracts Section 2.1(hh)(x)(i) Control Section 4.11 Controlling Section 4.11 Controlled Section 4.11 Convertible Notes Section 1.4 (vi) Definitive Transaction Agreement Section 3.10(h)(ii) Elimination Proposal Section 3.8(a) Eligible Market Section 3.4 Employment Practices Section 2.1(dd)(i) Encumbrance Section 2.1(b) Environmental Laws Section 2.1(w) ERISA Section 2.1(cc)(i) ERISA Affiliate Section 2.1(cc)(i) Escrow Agent Section 1.5 Escrow Agreement Section 1.5 Escrow Amount Section 1.5 Exchange Act Section 2.1(c)(i) Exchange Agreements Section 1.5 Exon-Fxxxxx Section 2.1(kk) FCPA Section 2.1(n)(i) GAAP Section 2.1(k)(ii) Government Official Section 2.1(n)(i) Governmental Authority Section 2.1(n)(i) Hazardous Materials Section 2.1(w) Indebtedness Section 2.1(q) Indemnified Party Section 4.6 Indemnifying Party Section 4.6 Information Privacy and Security Laws Section 2.1(ee) Intellectual Property Section 2.1(v) Intervening Event Section 3.10(h)(iii) Issuer Covered Person(s) Section 2.1(gg) IT Systems Section 2.1(ff) Losses Section 4.6 Material Adverse Effect 3.1(aSection 2.1(j) Company Option 2.4(aMaterial Contract Section 2.1(hh)(y) Company Preferred Stock 3.3(aMoney Laundering Laws Section 2.1(n)(ii) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNasdaq Approval Proposal Section 3.8(a) Company Restricted Stock 2.4(bNon-Solicitation Period Section 3.10(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Other Anticorruption Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bSection 2.1(n)(i) Outside Date 8.1(b)(iiSection 4.2(b)(iii) Parent Outstanding Options Section 2.1(c)(i) Outstanding Warrants Section 2.1(c)(i) Owned Intellectual Property Section 2.1 (v)(ii) Party Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Parties Preamble
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location 2005 Stock Option Plan 8.3(a) 2006 Warrant Agreement shall have the defined meanings that appear in the provisions of the 8.3(b) 2011 Warrant Agreement listed below. Acceptance Time 5.2(b4.8(e) Abax Commitment Letter 4.8(b) Abax Debt Financing 4.8(b) Abax Equity Financing 4.8(b) Abax Financing 4.8(b) Abax Funds 4.8(b) Acquisition Proposal 5.2(a8.3(c) Action 3.9 Adverse Recommendation Change 5.2(c5.4(c) Affiliate 3.3(d8.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(bArticles of Merger 1.3 Bank Lender 4.8(b) Book-Entry Share 2.1(cShares 2.3(b) business day 9.10(bBusiness Day 8.3(e) CERCLA 3.18(bCDB Debt Financing 4.8(b) Certificate of Merger 1.4 Certificate 2.1(cCertificates 2.3(b) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 2.4 Company Preamble Company Balance Sheet 3.6(aBoard Recitals Company Bylaws 3.1(b) Company Board of Directors Recitals Charter 3.1(b) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bRegistered IP 3.20(a) Company SEC Documents 3.5(a) Company Stock Option 2.2(a) Company Stock Plans 2.2(a) Company Stockholder Approval 3.3(a) Company Stockholders’ Meeting 5.5(b) Company Termination Fee 7.3(b) Company Warrant 2.2(b) Confidentiality Agreement 5.6(b) Contract 3.4(a) Contribution Agreement 4.8(b) control 8.3(f) Costs 5.10(a) Definition Location Debt Financing 4.8(b) DTC 2.3(e) DTC Payment 2.3(e) Effective Time 1.3 Environmental Laws 8.3(g) Environmental Permits 8.3(h) Evaluation Date 3.5(c) Exchange Act 3.4(b) FCPA 3.11 Financing Documents 4.8(b) GAAP 3.5(b) Governmental Entity 3.4(b) Guarantee 4.14 Holdco 4.8(b) Indemnified Parties 5.10(a) Intellectual Property 3.20(c) knowledge 8.3(i) Law 3.4(a) Liens 3.2(c) Majority of the Minority Approval 3.3(a) Majority Outstanding Approval 3.3(a) Material Adverse Effect 3.1(a8.3(j) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Material Contract 3.17 Materials of Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Concern 8.3(k), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAnnual Bonus 6.9(d) award 3.3(bAnti-Money Laundering Laws 3.25 Capex Budget 5.2(k) Book-Entry Share 2.1(cCapitalization Date 3.7(a) business day 9.10(bCash Replacement Company Option Amounts 2.8(a)(ii) CERCLA 3.18(bCash Replacement Company RSU Amounts 2.8(b)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10 Class A Common Stock 2.7(a)(ii) Class B Common Stock 2.7(a)(ii) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.9(d) Company Related Parties 8.3(e)(i) Company SEC Documents Article III Company Securities 3.7(d) Company Stockholder Meeting 6.4(a) Continuation Period 6.9(b) Copyrights 1.1(vv) D&O Insurance 6.8(c) Data Protection Requirements 3.21 DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Enforcement Expenses 8.3(d) Equity Award Holders 2.8(c) Excluded Benefits 6.9(b) Export/Import Laws 3.26 Final Exercise Date 2.8(d) Foreign Employee Plan 3.18(g) Xxxxxxx Xxxxx 3.3(b) Indemnified Person 6.8(a) Insurance Policies 3.23 IP Contracts 3.16(d) Lease 3.14 Leased Real Property 3.14 Marks 1.1(vv) Maximum Annual Premium 6.8(c) Merger Recitals Merger Sub Preamble Multiemployer Plan 3.18(b) New Plan 6.9(c) Notice Period 5.3(c)(ii)(A) Old Plans 6.9(c) Other Required Company Filing 6.3(b) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Disclosure Letter Article IV Parent Material Adverse Effect 3.1(a7.3(a) Company Option 2.4(aParty Preamble Patents 1.1(vv) Company Preferred Stock 3.3(aPayment Agent 2.9(a) Company Quarterly Balance Sheet 3.7 Company Restricted Payment Fund 2.9(b) Per Share 2.4(bPrice 2.7(a)(ii) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Personal Information 3.21 Privacy Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a3.21(a) Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Requisite Stockholder Approval 3.4 Sanctioned Persons 3.25 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aUncertificated Shares 2.9(c) Taxable 3.15(aUnvested Company Option 2.8(a)(ii) Tax Return 3.15(aUnvested Company RSU 2.8(b)(ii) Tender Completion Time 6.2 Tender and Vested Equity Award Consideration 2.8(b)(i) Vested Option Consideration 2.8(a)(i) Vested RSU Consideration 2.8(b)(i) Voting Agreements Agreement Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery WARN Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”5.2(r), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Poshmark, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the Agreement listed Section or place indicated below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(cAffiliate Section 1.3(a) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(cAuthorizations Section 2.17 Benefit Plans Section 2.21(a) business day 9.10(bSection 8.12(e) CERCLA 3.18(bBuyer Preamble Buyer Indemnified Parties Section 6.2 Buyer’s Plans Section 4.4 Capital Stock Section 1.3(a) Certificate of Merger 1.4 Certificate 2.1(cSection 1.1(b) Charter Section 1.3(a) Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Section 1.2 Code 2.6 Section 2.21(a) Company Preamble Company Balance Sheet 3.6(aCharter Documents Section 2.1 Company Intellectual Property Section 2.13(f) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cPlans Section 4.4 Contest Section 4.1(e) Company’s knowledge 9.10(bCut-Off Date Section 6.1 Designated Firm Section 8.14 DGCL Section 1.1(a) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dispute Section 8.14 Dissenting Shares 2.3(a) DSU 2.4(cSection 1.1(f) Effective Time 1.4 Employee Release 6.11(dSection 1.1(b) Environment Section 2.22(b) Environmental Claim Section 2.22(b) Environmental Laws 3.18(e)(iSection 2.22(b) Equity Rollover Value Section 1.3(a) ERISA 3.16(aSection 2.21(a) ERISA Affiliate 3.16(bEscrow Agent Section 1.3(a) Escrow Agreement Section 1.3(a) Escrow Fund Section 1.3(a) Exchange Act 1.1(aAgent Section 1.3(a) Exchange Fund 2.2(aSection 1.3(a) Expiration Date 1.1(a) FCPA 3.9(c) Fundamental Reps Section 6.1 FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iSection 2.14 GAAP Section 1.3(a) Governmental Entity 9.10(bAuthority Section 1.3(a) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aSubstances Section 2.22(b) Indemnified Parties 6.8(aPersons Section 4.2(a) Independent Directors 6.9(aIntellectual Property Section 2.13(f) IRS 3.16(aIP Licenses Section 2.13(c) Laws 3.9(bLease Section 2.11(b) Layoff Laws 3.17(bLeased Real Property Section 2.11(b) Maximum Premium 6.8(bLegal Requirements Section 2.16 Lien Section 1.3(a) Losses Section 6.5 Made Available Section 8.12(n) MAE Section 1.3(a) Material Contracts Section 2.10 Material Customers Section 2.15 Merger Introduction Merger Consideration Section 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(cSub Preamble OFAC Section 2.29 Option Amount Section 1.3(a) Minimum Condition Annex I Notice Options Section 1.3(a) Option Rollover Value Owned Real Property Section 1.3(a) Section 2.11(a) Parent Parent Common Stock Parent Option Agreements Parent Options Parent Reports Payment Spreadsheet Section 1.3(a) Section 1.3(a) Section 1.6(g) Section 1.3(a) Section 3.9 Section 1.6(b) Permitted Liens Section 2.12(b) Person Section 1.3(a) Pre-Closing Tax Periods Section 4.1(b) Prior Service Section 4.4 Pro Rata Share Section 6.2(vi) Proceeding Section 4.2(a) Protected Seller Communications Section 8.14 Reference Date Section 2.13(d) Remedies Exceptions Section 2.6 Representative Section 8.13(a) Representative Fund Section 1.3(a) Response Period 5.2(dSection 6.4(a) OECD Convention 3.9(cRollover Sellers Section 1.3(a) Offer Recitals Offer Condition Rollover Shares Section 1.3(a) Sale Bonuses Section 1.3(a) SEC Section 3.9 Securities Section 1.3(a) Seller Indemnified Parties Section 6.3 Seller(s) Section 1.3(a) Sellers’ Expenses Section 1.3(a) Share Rollover Value Section 1.3(a) Stockholder Approval Section 2.4 Straddle Period Section 4.1(c) Subsidiary(ies) Section 2.2 Substituted Options Section 1.3(a) Substituted Shares Section 1.3(a) Summit Partners Preamble Surviving Corporation Section 1.1(a) Offer Documents 1.1(cTax Benefit Section 6.5 Tax Returns Section 2.18(e) Offer Price Recitals Offer to Purchase 1.1(aTax(es) on a fully diluted basis 9.10(bSection 2.18(e) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (Transactions Introduction [ The remainder of this “Agreement”) dated as of October 24, 2011 page is among CUBIST PHARMACEUTICALS, INCintentionally left blank. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.]
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of certain terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection numbers where such definitions are contained: TERM SECTION: 401(k) Acquisition Proposal 5.2(aPlan Accounting Arbitrator 6.18(g) Adverse Recommendation Change 5.2(c3.2(c) Affiliate 3.3(dAcquired Assets 2.1 Actual Accruals Amount 3.6(b) Actual Book Value Amount 3.2(c) Actual Seller-Owed Commissions 3.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(cTransaction 7.6 Arbitrator 12.9(c) Assignee 9.5(aAssumed Contracts 2.1(b) award 3.3(bAssumed Liabilities 2.3 Assumed Pre-Closing Benefit Plan Liabilities 2.3 Basket Amount 11.2(b)(i) Book-Entry Share 2.1(cBloxom Preamble Book Value Statement 3.2(b) business day 9.10(bBusiness Recital A Buyer Preamble Buyer Financial Statements 5.5(a) CERCLA 3.18(bBuyer Indemnified Persons 11.2(a)
(a) Certificate of Merger 1.4 Certificate 2.1(cBuyer Interim Balance Sheet Date 5.5(a) Cap 11.2(b)(ii) Closing 1.5 Closing Amount Recitals 4.1 Closing Date 1.5 Code 2.6 Company Preamble Company 4.1 Consent Delay 10.1(b) Competing Business 6.17; 8.3(a) Covered Claims 12.9(e) Dollar 1 Matters 11.2(a)(vii) Estimated Accruals Amount 3.6(a) Estimated Book Value Amount 3.2(a) Estimated Seller-Owed Commissions 3.3(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Extension Period 10.1(b) FCRA 8.8(d) Financial Statements 6.5(a) Global Settlement Funds 9.2(f) Indemnified Person 11.4(a) Indemnifying Person 11.4(a) Initial Termination Date 10.1(b) Interim Balance Sheet 3.6(a6.5(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Interim Balance Sheet 3.7 Company Date 6.5(a) JAMS 12.9(a) Xxxxxxx Preamble Leased Property 6.20(a)(i) Licensing Approval Delay 10.1(b) TERM SECTION: Neutral Accounting Firm 3.2(c) Non-Signatory Action 12.9(e) Nonassignable Assets 8.9 Party (ies) Preamble Property Taxes 8.4(b) Purchase Price 3.1 PTO 8.5(b) Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(bGeographic Area 8.3(a) Schedule 14D-9 1.2(bSupplement 7.7 Seller Preamble Seller IP License 6.15(d) Schedule TO 1.1(bServicing Condition Notice 9.2(g)(ii) SEC 1.1(aStockholders Preamble Stockholder Representative 12.15 Specified Representations 11.1(a) Securities Act 3.11(cStraddle Period 8.4(b) Severance 6.11(dSurvival Period 11.1(a) Shares Recitals Special Meeting 1.8(a)(iTransferred Personal Property 2.1(d) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Wind Down 8.7(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAnti-Money Laundering Laws 3.27 Capex Budget 5.2(k) award 3.3(bCapitalization Date 3.7(a) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCash Replacement Company RSU Amounts 2.8(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.10(c) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(e)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bPlans 6.11(c) Company Related Parties 8.3(f) Company SEC Documents Article III Company Securities 3.7(d) Company Stockholder Meeting 6.5 Continuation Period 6.11(c) D&O Insurance 6.10(c) DGCL Recital Dissenting Company Shares 2.7(c) DTC 2.10(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Enforcement Expenses 8.3(e) Equity Award Holders 2.8(b) FCPA 3.25(a) Foreign Employee Plan 3.18(h) Indemnified Person 6.10(a) Indemnified Persons 6.10(a) Information Security Reviews 3.21(c) Lease 3.14(a) Leased Real Property 3.14(a) Licenses In 3.16(a) Licenses Out 3.16(a) Maximum Annual Premium 6.10(c) Merger Recital Merger Sub Preamble New Plan 6.11(d) Notice Period 5.3(d)(ii)(3) Official 3.25(a) Old Plans 6.11(d) Other Indemnified Persons 6.10(e) Other Required Company Filing 6.4(b) Owned Company Shares 2.7(a)(iii) Parent Preamble Parent Material Adverse Effect 3.1(a7.3(a) Company Option 2.4(aParty Preamble Payment Agent 2.10(a) Company Preferred Stock 3.3(aPayment Fund 2.10(b) Company Quarterly Balance Sheet 3.7 Company Restricted Per Share 2.4(bPrice 2.7(a)(ii) Company Restricted Stock 2.4(bPOCA 3.25(a) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPrivacy Requirements 3.21(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii6.4(a) Representatives 5.2(a5.3(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Requisite Stockholder Approval 3.4 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aThird Party IP 3.16(b)(iii) Taxable 3.15(aTrade Approvals 3.26(a) Tax Return 3.15(aTrade Laws 3.26(a) Tender Completion Time 6.2 Tender and UKBA 3.25(a) Uncertificated Shares 2.10(c) Unvested Company RSU 2.8(a)(ii) Vested RSU Consideration 2.8(a)(i) Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Recital Warrant Consideration 2.9(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Kaleyra, Inc.)
INDEX OF DEFINED TERMS. Capitalized The following defined terms have the meanings ascribed to such terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed Sections set forth below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d: Acquired Entities Recitals Acquired Interests Recitals Actual Cash 2.4 Actual Company Expenses 2.4 Actual Indebtedness 2.4 Actual Net Working Capital 2.4 Agreed Claims 7.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cAllocation 2.8 Balance Sheet Date 3.13 Closing 2.6 Closing Balance Sheet 2.3(a) Closing 1.5 Date 2.6 Closing Amount Payment Certificate 2.2(b) Company Recitals Continuing Employees 6.3 Dispute Notice 2.3(b) DOL 3.17(b) Enforceability Exceptions 4.1 ERISA Affiliate 3.17(a) Estimated Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a2.2(c) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cEstimated Net Working Capital Deficiency 2.2(d) Company’s knowledge 9.10(bEstimated Net Working Capital Excess 2.2(d) Company Final Disputed Items 2.3(c) Financial Statements 3.13 FLSA 3.23(a) Indemnified Party 7.3(a) Indemnifying Party 7.3(a) IP Licenses 3.10(a) Purchaser Preamble Leased Premises 3.20(b) Leases 3.20(b) Manifest Error 2.3(c) Material Adverse Effect 3.1(aContracts 3.11(a) Company Option 2.4(aMaterial Customer 3.28 Material Vendor 3.29 Non-Recourse Party 8.3 Notices 8.7 Objection Notice 7.3(b) Company Preferred Stock 3.3(aPre-Closing Period Tax Return 6.2(b)(ii) Company Quarterly Purchase Price 2.2(a) Purchaser Preamble Purchaser Balance Sheet 3.7 Company Restricted Share 2.4(bDate 5.7 Purchaser Closing Certificate 2.3(a) Company Restricted Stock 2.4(bPurchaser Financial Statements 5.7 Purchaser Indemnified Parties 7.2(a) Company Rights 3.3(aPurchaser Preamble Relevant Courts 8.12 Resolution Period 2.3(b) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a5.7 Sellers Preamble Straddle Periods 6.2(b)(ii) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Survival Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a7.1(a) Tax 3.15(a) Taxable 3.15(aContest 6.2(e) Tax Return 3.15(aIndemnification Obligations 6.2(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dThird-Party Claim 7.3(d) Termination Fee 8.2(bThird-Party Claim Notice 7.3(d) Time-Vested DSU 2.4(cThreshold 7.4(a) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Transfer Taxes 6.2(f), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Equity Purchase Agreement (Innovex International, Inc.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions Each of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) following terms is defined on the page set forth below opposite such term: Term: Section: Agreement Preamble Alternative Acquisition Agreement 5.2(cAllocation Principle 3.2(b)(i) Assignee 9.5(aA/R and WIP Schedule 3.2(b)(i) award 3.3(bBalance Sheet Date 4.9 Business Recitals Buyer Preamble Buyer Indemnified Parties 10.2 Claim Notice 10.5(a) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClaim Response 10.5(c) Closing 1.5 2.2 Closing Amount Recitals Cash Payment 3.1(a) Closing Date 1.5 Code 2.6 2.2 Closing Payment 3.1(b) Closing Shares 3.1(b) Company Preamble Company Balance Sheet 3.6(aIntellectual Property 4.21(c) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aStockholders Preamble Confidential Information 7.5(a) Confidentiality Agreement 1.2(c11.1 Contingent Cash 3.3(c)(i) Continuing Employee 6.11(bContingent Payment 3.3(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContingent Payment Determination Date 3.3(b) Delisting Period 6.3 DGCL Recitals Dissenting Contingent Shares 2.3(a3.3(c)(iii) DSU 2.4(cContingent Share Value 3.3(c)(iii) Covered Persons 8.1(a) Deductible Amount 10.4(a) Delaware Courts 10.10(a) E&O Policy 8.1(b) Effective Time 1.4 Employee Release 6.11(d2.2 Employment Agreements 2.3(a)(ix) Environmental Laws 3.18(e)(iEquipment 4.11 Financial Statements 4.9 Fundamental Representations 10.1(a) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aIndemnification Claim 10.5(a) Indemnified Party 10.5(a) Indemnifying Party 10.5(a) Leased Real Property 4.14 Leases 4.14 Licenses and Permits 4.24 Lock-Up Agreement 3.4(b) Material Contracts 4.6(a) Owned Intellectual Property 4.21(a) Owned Real Property 4.13 Party or Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cTax Period 7.1(a) Program 3.9(kPromissory Note 3.1(c) Prohibited Payment 3.9(cPurchase Price 3.1 Response Period 10.5(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(aRule 144 5.8(f) Securities Act 3.11(c3.4(c) Severance 6.11(dSeller Indemnified Parties 10.3 Share Value 3.1(b) Shares Recitals Special Meeting 1.8(a)(iStay Bonus Agreements 2.3(a)(x) Sub Stockholder Representative Preamble Sub Common Stock 2.1 Successor Plan 6.11(cStraddle Period 7.1(b) Superior Proposal 5.2(bStraddle Period Returns 7.1(b) Surviving Corporation 1.3(aTarget Cash 3.2(a) Target Gross Revenues 3.3(a)(i) Target Operating Profit 3.3(a)(i) Tax 3.15(aContest 7.1(d) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Third Party Claim 10.5(e), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: 401(k) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dPlan 1.1(ddd)(xiv) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAlternate Debt Financing 6.5(e) award 3.3(bAnnual Bonus 6.11(c) Book-Entry Share 2.1(cCapex Budget 5.2(k) business day 9.10(b) CERCLA 3.18(bCapitalization Date 3.7(a) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10 Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Commitment Letters 4.12(a) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.11(c) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRelated Parties 8.3(g)(iii) Company SEC Reports 3.5 Documents Article III Company Securities 3.7(d) Company Software 3.16(e) Company Stockholder Approval 6.1 Company Stock Plans 2.4(aMeeting 6.4(a) Company Subsidiary 3.4(aContinuation Period 6.11(a) Confidentiality Agreement 1.2(cCopyrights 1.1(yy) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current Covenant Exceptions 5.1 D&O Insurance 6.8(b6.10(c) Delisting Period 6.3 Data Privacy Requirements 3.21 Debt Commitment Letter 4.12(a) Debt Financing 4.12(a) DGCL Recitals Dissenting Company Shares 2.3(a2.7(c) DSU 2.4(cDTC 2.9(d) Effective Time 1.4 Employee Release 6.11(d2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Equity Award Consideration 2.8(c) Environmental Laws 3.18(e)(iEquity Award Holders 2.8(d) ERISA 3.16(aEquity Commitment Letter 4.12(a) ERISA Affiliate 3.16(bEquity Financing 4.12(a) Exchange Act 1.1(aFinal Exercise Date 2.8(e) Exchange Fund 2.2(aFinancing 4.12(a) Expiration Date 1.1(aForeign Plans 3.18(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aGuarantee Recitals Guarantor Recitals Houlihan Lokey 3.3(b) Indemnified Parties 6.8(aPersons 6.10(b) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(bLease 3.14 Leased Real Property 3.14 Marks 1.1(yy) Maximum Annual Premium 6.8(b6.10(c) Merger 1.3(aRecitals Merger Sub Preamble Multiemployer Plan 3.18(b) Merger Agreement Annex I Merger Consideration 2.1(cNew Plan 6.11(b) Minimum Condition Annex I Notice Period 5.2(d5.3(c)(i)(2) OECD Convention 3.9(cOld Plans 6.11(b) Offer Recitals Offer Condition 1.1(aOption Consideration 2.8(a) Offer Documents 1.1(cOther Applicable Antitrust Laws 6.2 Other Indemnified Persons 6.10(e) Offer Price Recitals Offer to Purchase 1.1(aOther Required Company Filing 6.3(b) on a fully diluted basis 9.10(bOwned Company Shares 2.7(a)(iii) Outside Date 8.1(b)(ii) Owned Real Property 3.14 Parent Preamble Paying Parent Termination Fee 8.3(c) Party Preamble Patents 1.1(yy) Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPer Share Price 2.7(a)(ii) Proxy Statement 1.8(a)(ii6.3(a) PSU Consideration 2.8(c) Real Property 3.12(b3.14 Requisite Stockholder Approval 3.4 Required Amount 4.12(c) Regulation M-A 1.1(cRSU Consideration 2.8(b) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(bSoftware 1.1(yy) Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aTransfer Taxes 8.3(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Uncertificated Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”2.9(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bAccounting Arbitrator Section 2.2(b)(iii) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Membership Interests Recitals Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(b) Affiliate Contract Section 1.2(ccc)(xv) Affiliate Transactions Section 5.10 Agreed Rate Section 1.2(c) Agreement Preamble Alternative Acquisition Allocated Value Section 2.2(a) Allocation Objection Notice Section 2.2(b)(ii) Antitrust Laws Section 1.2(d) Asset Taxes Section 1.2(e) Assignment of Interests Section 8.2(a) Benefit Plan Section 1.2(f) BOEM Section 1.2(g) BSEE Section 1.2(h) Burdens Section 1.2(i) Business Day Section 1.2(j) Cash Purchase Price Section 2.1(a) Casualty Loss Section 5.13 Claim Section 11.3(b) Claim Notice Section 11.3(b) Closing Section 8.1 Closing Cash Payment Section 2.4(a) Closing Date Section 8.1 Closing Settlement Statement Section 2.4(a) Code Section 1.2(k) Company or Companies Section 1.2(l) Company Assets Section 1.2(m) Company Business or Company Businesses Section 1.2(n) Company Contract Section 1.2(o) Company Derivatives Section 1.2(p) Company Leases Section 1.2(m)(i) Company Operating Expenses Section 1.2(q) Company Personal Property Section 1.2(m)(vii) Company Properties Section 1.2(m)(iii) Company Records Section 1.2(r) Company Rights-of-Way Section 1.2(m)(vi) Company Units Section 1.2(m)(iii) Company Xxxxx Section 1.2(m)(ii) Confidentiality Agreement 5.2(cSection 1.2(s) Assignee 9.5(aConsent Section 3.11(b) award 3.3(bConsolidated Group Section 1.2(t) BookControlled Group Liabilities Section 1.2(u) Credit Agreement Section 1.2(v) Cure Period Section 1.2(w) Customary Post-Entry Share Closing Consents Section 1.2(x) Cut-Off Date Section 1.4(c) Damages Section 11.2(d) Decommission or Decommissioning Section 1.2(y) Defect Arbitrator Exhibit D Defect Escrow Account Section 1.2(z) Defensible Title Section 1.2(aa) Deposit Section 2.1(c) business day 9.10(bDerivatives Section 5.7 Determination Date Section 2.4(b)(ii) CERCLA 3.18(bDispute Auditor Section 2.4(b)(ii) Certificate of Merger 1.4 Certificate 2.1(cDisputed Amount Section 6.7 Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 DOJ Section 5.5 Effective Time Section 1.2(bb) Closing 1.5 Closing Environmental Arbitrator Exhibit D Environmental Defect Section 1.2(cc) Environmental Defect Amount Recitals Closing Section 1.2(dd) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Deductible Section 6.6(d) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 1.2(ee) Environmental Liabilities Section 1.2(ff) Environmental Notice Section 1.2(gg) Environmental Threshold Section 6.5(c) ERISA Section 1.2(hh) ERISA Affiliate Section 1.2(ii) Escrow Account Section 1.2(jj) Escrow Agent Section 1.2(kk) Escrow Agreement Section 1.2(ll) Exchange Act Section 4.5 Excluded Assets Section 1.2(mm) Excluded Assets Assignment Section 1.2(nn) Excluded Company Records Section 1.2(r)(v) Execution Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aFinancial Statements Section 1.2(oo) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cFinal Allocation Section 2.2(b)(iv) Company’s knowledge 9.10(bFinancing Section 4.7 FTC Section 5.5 Fundamental Representations Section 11.4(a) Company Governmental Authority Section 1.2(pp) Hard Consent Section 5.11(b)(i) Hazardous Materials Section 1.2(qq) HSR Act Section 1.2(rr) Hydrocarbons Section 1.2(ss) Imbalance Section 1.2(tt) INC Section 1.2(uu) Included Title Defect Properties Section 6.4(b)(ii) Income Taxes Section 1.2(vv) Indemnified Liabilities Section 11.2(b)(iii) Indemnified Person Section 11.3(a) Indemnifying Person Section 11.3(a) Information Statement Section 5.16 Intellectual Property Section 1.2(ww) Intended Tax Treatment Section 2.2(b)(i) Interim Breach Section 11.2(b)(ii) Interim Breach Provision Section 11.2(b)(ii) Laws Section 1.2(xx) Lease Annex Section 1.2(yy) Liens Section 1.2(zz) Loan Section 1.2(aaa) Lowest Cost Response Section 1.2(bbb) Material Adverse Effect 3.1(aSection 3.31(e) Company Option 2.4(aMaterial Contract Section 1.2(ccc) Company Preferred Stock 3.3(aNet Revenue Interest Section 1.2(ddd) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNORM Section 3.8 Organizational Documents Section 1.2(eee) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOther PSA Section 1.2(fff) Outside Date 8.1(b)(iiSection 10.1(c) Parent Party or Parties Preamble Paying Agent 2.2(aPermits Section 1.2(ggg) Performance-Based DSU 2.4(cPermitted Encumbrance Section 1.2(hhh) Permits 3.9 person 9.10(bPermitted Interest Encumbrance Section 1.2(iii) Plans 3.16(aPerson Section 1.2(jjj) Phase I Activities Section 1.2(kkk) Post-Closing Statement Section 2.4(b) Pre-Effective Date Period Section 1.2(lll) Preferential Purchase Right Section 3.11(a) Proceedings Section 3.6 Proposed Allocation Section 2.2(b)(ii) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Indemnified Parties Section 11.2(b) Purchaser Parent Preamble Purchaser Parent SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cSection 4.13 Purchaser Parent Shares Section 2.1(a) Program 3.9(kPurchaser Tax Returns Section 9.2(b) Prohibited Payment 3.9(cPurchaser’s Phase I Environmental Review Section 6.2(a) Proprietary Purchaser’s Representatives Section 6.1(a) R&W Conditional Binder Section 5.18(a) R&W Policy Section 5.18(a) Registration Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cAgreement Section 8.2(g) Release 3.18(e)(iiiSection 1.2(mmm) Representatives 5.2(aReleased Parties Section 5.12 Releasing Parties Section 5.12 Remediate, Remediation or Remedial Section 1.2(nnn) Reporting Tail Endorsement 6.8(bRequired Purchaser Filings Section 5.15(a) Restraints 8.1(b)(iRetained Employee-Related Liabilities Section 1.2(ooo) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRidgewood Section 5.1 Ridgewood MSA Section 1.2(ppp) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 Riverstone Section 1.2(b) Schedule TO 1.1(bRiverstone Portfolio Company or Riverstone Portfolio Companies Section 1.2(b) SEC 1.1(a) Scheduled Closing Date Section 8.1 Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeismic Data Section 1.2(qqq) Shares Recitals Special Meeting 1.8(a)(iSeller Preamble Seller Indemnified Parties Section 11.2(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Tax Section 1.2(rrr) Superior Proposal 5.2(bSeller Tax Returns Section 9.2(a) Surviving Corporation 1.3(aSeller’s Knowledge Section 1.2(sss) Sinking Funds Section 1.2(mm)(xiii) Specified Matters Section 3.33 Straddle Period Section 1.2(ttt) Suspended Funds Section 1.2(uuu) Tax 3.15(a) Taxable 3.15(aSection 1.2(vvv) Tax Effective Date Section 1.2(www) Tax Proceeding Section 9.4 Tax Return 3.15(aSection 1.2(xxx) Tender Completion Time 6.2 Tender Third-Party Loans Section 1.2(yyy) Title Arbitrator Exhibit D Title Benefit Section 1.2(zzz) Title Benefit Amount Section 6.5(b) Title Deductible Section 6.5(c) Title Defect Section 1.2(aaaa) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Dispute Election Section 6.4(b) Title Notice Section 1.2(bbbb) Title Threshold Section 6.5(c) Transaction Costs Section 1.2(cccc) Transaction Documents Section 5.2 Transfer Taxes Section 9.5 Treasury Regulations Section 1.2(dddd) Unadjusted Purchase Price Section 2.1(a) Well Annex Section 1.2(eeee) Willful Breach Section 1.2(ffff) Working Interest Section 1.2(gggg) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 10, 2011 is 2019 (the “Execution Date”), by and among CUBIST PHARMACEUTICALSILX Holdings II, INC. LLC, a Delaware limited liability company (“Seller”), Talos Production Inc., a Delaware corporation (“Purchaser”), and solely with respect to its obligations related to the Purchaser Parent Shares (as defined herein), Talos Energy Inc., a Delaware corporation (“Purchaser Parent”). Seller, a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation Purchaser and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (Purchaser Parent are referred to collectively as the “CompanyParties” and individually as a “Party.”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location 2023 Equity Incentive Plan 1.1(a) 2023 Equity Incentive Plan Proposal 7.15(a) 2023 ESPP 1.1(b) 2023 ESPP Proposal 7.15(b) 2023 Plans 1.1(c) Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b1.1(d) Accounting Firm 3.7(e) Acquisition Inquiry 1.1(e) Acquisition Proposal 5.2(a1.1(f) Adverse Recommendation Change 5.2(cAcquisition Transaction 1.1(g) Action 4.9 Adjusted Warrant 3.3(c) Affiliate 3.3(d1.1(h) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(bAllocation Certificate 7.13 Amended Charter Proposals Recitals Anticipated Closing Date 3.7(a) Book-Entry Share 2.1(cShares 3.4(b) business day 9.10(bBusiness Day 1.1(i) CERCLA 3.18(bCash Determination Date 3.7(a) Cash Dividend Recitals Certificate of Merger 1.4 Certificate 2.1(c2.4 Certificates 3.4(b) Closing 1.5 Closing Amount Charter Amendment Proposal Recitals Closing 2.3 Closing Date 1.5 2.3 COBRA 4.12(c)(iv) Code 2.6 Recitals Company Preamble Company Balance Sheet 3.6(aAudited Financial Statements Section 7.1(g) Company Board of Directors Recitals Company Board Adverse Recommendation Change 7.2(c) Company Board Recommendation 7.2(c) Company Budget 6.2(b)(vi) Company Bylaws 4.1(b) Company Capital Stock 1.1(j) Company Charter 4.1(b) Company Common Stock 1.1(k) Company Disclosure Letter SECTION 3 Article IV Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEquity Plan 1.1(l) Company Material Adverse Effect 3.1(aFinancial Statements 4.6(a) Company Option 2.4(aFundamental Representations 1.1(m) Company Interim Financial Statements 4.6(a) Company Intervening Event 7.2(d) Company Notice Period 7.2(d) Company Options 1.1(n) Company Outstanding Shares 3.1(a)(i)(A) Company Owned IP 1.1(o) Company Plans 4.12(a) Company Preferred Stock 3.3(a1.1(p) Company Quarterly Balance Sheet 3.7 Privacy Laws 4.19(e) Company Restricted Share 2.4(bProducts 4.11(c) Company Restricted Shares 3.2 Company Series B Preferred Stock 2.4(b1.1(q) Company Rights 3.3(aStock Awards 4.2(b) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Recitals Company Stock Plans 2.4(aSupport Agreements Recitals Company Triggering Event 1.1(r) Company Subsidiary 3.4(aUnaudited Interim Financial Statements Section 7.1(g) Company Valuation 3.1(a)(i)(B) Company Value Per Share 3.1(a)(i)(C) Company Warrant 1.1(s) Concurrent PIPE Investment Recitals Concurrent PIPE Investment Amount Recitals Concurrent PIPE Investors Recitals Confidentiality Agreement 1.2(c1.1(t) Continuing Employee 6.11(bContract 4.5(a) CPR Recitals CPR Agreement Recitals Current control 1.1(u) Controlled Group 4.12(b) D&O Insurance 6.8(bIndemnified Parties 7.5(a) Delisting Period 6.3 Delaware Secretary of State 2.4 Delivery Date 3.7(a) DGCL Recitals Dispute Notice 3.7(b) Dissenting Shares 2.3(a) DSU 2.4(c3.6 Dividend Record Date 7.14(a) Effective Time 1.4 Employee Release 6.11(d2.4 End Date 9.1(b) Environmental Laws 3.18(e)(iLaw 4.14(b) Equity Plan Proposals 7.15(a) ERISA 3.16(a) ERISA Affiliate 3.16(b4.12(a) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”4.5(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following terms have the meanings assigned to such terms in the Sections of this Agreement shall have the defined meanings that appear in the provisions of the set forth below opposite such term: Acquisition Agreement listed below. Acceptance Time 5.2(b5.3(c) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(dAdjusted Initial Closing Shares 2.11(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cBankruptcy and Equitable Exceptions 3.4(b) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Business Day 1.2 Certificate of Merger 1.4 Certificate 2.1(c) 1.3 Closing 1.5 1.2 Closing Amount Recitals Average 2.6 Closing Date 1.5 Code 2.6 1.2 COBRA Coverage 4.14(d), 3.14(d) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.5(a) Company Board Bylaws 3.1 Company Certificate 2.1(d) Company Certificate of Directors Recitals Incorporation 3.1 Company Certificates 2.1(d) Company Common Stock 2.1 Company Disclosure Letter SECTION Schedule 3 Company Joint Venture 3.4(cEmployee Plans 3.14(a) Company’s knowledge 9.10(bCompany ERISA Affiliate 3.14(a) Company Financial Statements 3.6(b) Company Insurance Policies 3.18(a) Company Intellectual Property Rights 3.21(a) Company Material Adverse Effect 3.1(a) 3 Company Option 2.4(aMaterial Contracts 3.9(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bSEC Reports 3.6(a) Company Restricted Stock 2.4(bStipulated Expenses 8.3(d) Company Rights 3.3(aStock Options 2.4(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary Stockholder Approval 3.4(a) Company Third Party Intellectual Property Rights 3.21(g) Company Warrants 2.2 Company’s Most Recent SEC Balance Sheet 2.10(e)(i) Competing Proposal 5.3(a) Confidentiality Agreement 1.2(c6.4(b) Continuing Employee 6.11(bContingent Term 2.11(b)(iii) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContingent Value Shares 2.1(b) Delisting Period 6.3 Designees 6.6 DGCL Recitals Diligence and Reporting Obligations 3.9(c) Dispute Net Cash Determination Date 2.10(d) Dispute Notice 2.10(b) Dissenting Shares 2.3(a) DSU 2.4(c2.1(e) Effective Time 1.4 Employee Release 6.11(d1.3 Emergent 2.11(c) Emergent Event 2.11(c) Emergent Milestone Shares 2.11(c) Emergent Purchase Agreement 2.11(c) environment 3.20(l) Environmental Laws 3.18(e)(iLaw 3.20(l) ERISA 3.16(a3.14(a) ERISA Affiliate 3.16(bEscrowed Shares 2.12 ESPP 2.4(f) Estimated Net Cash 2.10(a) Exchange Act 1.1(a3.3(d) Exchange Fund 2.2(aExcluded Shares 2.3 Financial Statements 3.6(b) Expiration First Anticipated Closing Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i2.10(a) Governmental Entity 9.10(bAuthority 3.4(d) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aXxxxxxxx Xxxxx 4.24 IND 4.11(b), 3.11(b) Indemnified Parties 6.8(a6.9(b) Independent Directors 6.9(aInitial Closing Shares 2.1(a) Interim Period 5.1(a) IRS 3.16(a3.14(a) Laws 3.9(bLapse Date 2.10(b) Layoff Laws Law 2.1(e) Lease Documents 3.17(e) Leased Facilities 3.17(b) Maximum Premium 6.8(bLeases 3.17(b) Liens 3.2(c) Lock-Up Agreements Recitals Material Permit 3.11(a) Materials of Environmental Concern 3.20(l) Merger 1.3(aRecitals Merger Consideration 2.1(d) Merger Agreement Annex I Sub Preamble Merger Consideration 2.1(cSub Common Stock 2.5 Most Recent Balance Sheet 3.7 Most Recent Balance Sheet Date 3.7 Net Cash 2.10(e)(i) Minimum Condition Annex I Notice Net Cash Statement 2.10(a) New Parent Proposal 5.3(c) NGM 2.6 Non-Dispute Net Cash Determination Date 2.10(c) Option Exercise Period 5.2(d2.4(b) OECD Convention 3.9(cOrder 5.3(b) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOther Filings 6.1(b) Parent Preamble Paying Agent 2.2(aParent Board Recommendation 4.5(a) Performance-Based DSU 2.4(cParent Common Stock 2.1(a) Permits 3.9 person 9.10(bParent Disclosure Schedule 4.0 Parent Employee Plans Affiliate 4.14(a) Parent ERISA Affiliate 4.14(a) Parent ESPP Shares 4.3(b) Parent Financial Statements 4.6(b) Parent Insurance Policies 4.18(a) Parent Intellectual Property Rights 4.21(a) Parent Lease Documents 4.17(e) Parent Leased Facilities 4.17(b) Parent Leases 4.17(b) Parent Material Adverse Effect 4.0 Parent Material Contracts 4.9(a) Parent Material Permit 4.11(a) Parent Option Shares 4.3(b) Parent Preferred Stock 4.3(a) Parent Share Amount 2.1(c) Parent SEC Reports 4.6(a) Parent Stipulated Expenses 8.3(d) Parent Stock Plans 4.3(b) Parent Stockholder Approval 4.4(a) Parent Third Party Intellectual Property Rights 4.21(g) Parent Warrant Shares 4.3(b) Parent Warrants 4.3(b) Parent’s Most Recent Balance Sheet 4.7 Parent’s Most Recent Balance Sheet Date 4.7 Proxy Statement 3.16(b) Registered Company Intellectual Property Rights 3.21(c) Registered Parent Intellectual Property Rights 4.21(c) Registration Statement 3.16(a) PostRegulation S-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cK 3.9(a) Release 3.18(e)(iii3.20(l) Representatives 5.2(areporting tail coverage 6.9(a) Reporting Tail Endorsement 6.8(bRepresentative 5.3(a) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bReturns 3.19(b) SEC 1.1(a3.2(d) Securities Act 3.11(c3.2(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cMeetings 3.16(b) Superior Competing Proposal 5.2(b5.3(b) Surviving Corporation 1.3(a1.1 Tax 3.19(a) Tax 3.15(aTermination Fee 8.3(b) Taxable 3.15(aThird Party 5.3(a) Tax Return 3.15(aTransaction Document 5.3(c) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS This AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated ), is made and entered into as of October 2414, 2011 is 2009 by and among CUBIST PHARMACEUTICALSOXiGENE, INC. Inc., a Delaware corporation (“Parent”), OXiGENE Merger Sub, Inc., a Delaware corporation, FRD ACQUISITION CORPORATION corporation and wholly owned Subsidiary of Parent (“Merger Sub”), VaxGen, Inc., a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”) and Xxxxx Xxxxx, as representative of the Company’s stockholders (the “Stockholder Representative”). Parent, Merger Sub and the Company are sometimes referred to herein each individually as a Delaware corporation“Party” and, collectively, as the “Parties.”
Appears in 1 contract
Samples: Merger Agreement (Oxigene Inc)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection number where such definition is contained: TERM: SECTION: Actuarial Arbitrator Section 2.2(b) Acquisition Proposal 5.2(aFinancing Section 6.7 Agreement Preface Audited Financial Statements Section 4.5(a) Adverse Recommendation Change 5.2(cBusiness Agreements Section 4.14 Business Employees Section 7.1(a) Affiliate 3.3(dBuyer Preface Buyer’s Breach Notice Section 11.1(a)(iv) Agreement Preamble Alternative Acquisition Agreement 5.2(cClaim Notice Section 10.4(a) Assignee 9.5(aClass A Common Stock Section 4.4(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClass B Common Stock Section 4.4(a) Closing 1.5 Closing Amount Recitals Section 1.2(a) Closing Date 1.5 Code 2.6 Section 1.2(a) Closing Retirement Underfunding Section 2.1 Closing Retirement Underfunding Statement Section 2.1 Company Preamble Preface Company Balance Sheet 3.6(aAgent Section 7.2(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aIntellectual Property Section 4.11(b) Confidentiality Agreement Section 6.4(a) Controlling Party Section 10.5(b) Escrow Agreement Section 1.2(c) Continuing Employee 6.11(bEscrow Amount Section 1.2(c) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bExpense Amount Section 1.2(e) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aExpense Statement Section 1.2(e) DSU 2.4(cFinancial Statements Section 4.5(a) Effective Time 1.4 Employee Release 6.11(dFirearms Regulations Section 4.12 Indemnified Party Section 10.4(a) Environmental Laws 3.18(e)(iIndemnitor Section 10.4(a) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(aInformation Section 6.4(b) IRS 3.16(aSection 4.8(k) Laws 3.9(bLeases Section 4.10(b) Layoff Laws 3.17(bLeased Real Property Section 4.10(b) Maximum Premium 6.8(bMost Recent Audited Balance Sheet Date Section 4.5(a) Merger 1.3(aMost Recent Financial Statements Section 4.5(a) Merger New Haven Property Section 4.16(e) Non-Competition Agreement Annex I Merger Consideration 2.1(cSection 8.10 TERM: SECTION: North Haven AOCs Section 7.6 North Haven Property Section 4.16(e) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostParties Preface Pre-Closing SEC Reports 6.3 Principal Stockholders Recitals Straddle Period Section 7.3(c) Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiPeriod Returns Section 7.3(b) Representatives 5.2(aSection 6.4(b) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Required Consents Section 8.3 Securities Act 3.11(cSection 5.8 Seller(s) Severance 6.11(dPreface Share(s) Shares Recitals Special Meeting 1.8(a)(iShareholders’ Representative Section 12.1(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cThe Xxxxxx Company Section 7.4 Threshold Amount Section 10.1(a)(i) Superior Proposal 5.2(bTMC Lease Section 4.10(a)(ii) Surviving Corporation 1.3(aTrademark Coexistence Agreement Section 8.5 Transfer Act Section 4.16(h) Tax 3.15(aVintage Firearms Section 6.13 Waiver and Termination Agreement Section 4.30 Xxxxxxx Section 4.3(c) Taxable 3.15(aXxxxxxx Credit Agreement Section 4.3(c) Tax Return 3.15(a) Tender Completion Time 6.2 Tender Xxxxxx and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Xxxx Section 1.2(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Definition Location Acceptable Confidentiality Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b8.3(a) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cAction 3.10 Affected Employees 5.17(a) Affiliate 3.3(d8.3(b) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.2(a)(iii)(B) Assignee 9.5(aAnti-Corruption Laws 8.3(c) award 3.3(bAntitrust Laws 5.5(a) Book-Entry Share 2.1(cShares 2.3(b) business day 9.10(bBusiness Day 8.3(d) CERCLA 3.18(bCARES Act 8.3(e) Certificate of Merger 1.4 Certificate 2.1(c1.3 Certificates 2.3(b) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Closing Tax Opinion 6.3(e) COBRA 3.12(c)(vi) Code 2.6 Recitals Company Preamble Company Balance Sheet 3.6(aAcquisition Proposal 5.2(a)(xi)(A) Company Adverse Recommendation Change 5.2(a)(iii)(A) Company Board of Directors Recitals 2.2(f) Company Board Designees 5.18(a) Company Business IP 3.20(b) Company Business Trade Secrets 3.20(d) Company Bylaws 3.1(b) Company Charter 3.1(b) Company Common Stock 2.1(a) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cEquity Plans 2.2(a) Company’s knowledge 9.10(bCompany ESPP 2.2(f) Company Expenses 7.3(e) Company Intervening Event 5.2(a)(xi)(B) Company Material Adverse Effect 3.1(aContract 3.16(a) Company Option 2.4(a2.2(a) Company Plans 3.12(a) Company Preferred Stock 3.3(a3.2(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSU 2.2(b) Company Restricted Stock 2.4(bRegistered IP 3.20(a) Company Rights 3.3(aRSU 2.2(b) Company Rights Agreement 3.3(aSAR 2.2(c) Company SEC Reports 3.5 Documents 3.6(a) Definition Location Company Stock Awards 3.2(b) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a3.4(a) Company Subsidiary 3.4(aStockholders Meeting 5.3(a) Company Superior Proposal 5.2(a)(xi)(C) Company Tax Counsel 5.12(a)(iv) Company Termination Fee 7.3(b) Confidentiality Agreement 1.2(c5.4 Contract 8.3(f) Continuing Employee 6.11(bcontrol 8.3(g) CPR Recitals CPR Agreement Recitals controlled 8.3(g) controlled by 8.3(g) Copyrights 8.3(n) COVID-19 8.3(h) COVID-19 Measures 8.3(i) Credit Facility Terminations 5.13 Current D&O Insurance 6.8(bESPP Offering Period 2.2(f) Delisting Period 6.3 Delaware Secretary of State 1.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(cDomain Names 8.3(n) Effective Time 1.4 Employee Release 6.11(d1.3 Environmental Law 3.14(c) Environmental Laws 3.18(e)(iPermits 3.14(d) ERISA 3.16(a) ERISA Affiliate 3.16(b3.12(a) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”3.5(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection number where such definition is contained: Actuarial Arbitrator Section 2.2(b) Acquisition Proposal 5.2(aFinancing Section 6.7 Agreement Preface Audited Financial Statements Section 4.5(a) Adverse Recommendation Change 5.2(cBusiness Agreements Section 4.14 Business Employees Section 7.1(a) Affiliate 3.3(dBuyer Preface Buyer’s Breach Notice Section 11.1(a)(iv) Agreement Preamble Alternative Acquisition Agreement 5.2(cClaim Notice Section 10.4(a) Assignee 9.5(aClass A Common Stock Section 4.4(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClass B Common Stock Section 4.4(a) Closing 1.5 Closing Amount Recitals Section 1.2(a) Closing Date 1.5 Code 2.6 Section 1.2(a) Closing Retirement Underfunding Section 2.1 Closing Retirement Underfunding Statement Section 2.1 Company Preamble Preface Company Balance Sheet 3.6(aAgent Section 7.2(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aIntellectual Property Section 4.11(b) Confidentiality Agreement Section 6.4(a) Controlling Party Section 10.5(b) Escrow Agreement Section 1.2(c) Continuing Employee 6.11(bEscrow Amount Section 1.2(c) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bExpense Amount Section 1.2(e) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aExpense Statement Section 1.2(e) DSU 2.4(cFinancial Statements Section 4.5(a) Effective Time 1.4 Employee Release 6.11(dFirearms Regulations Section 4.12 Indemnified Party Section 10.4(a) Environmental Laws 3.18(e)(iIndemnitor Section 10.4(a) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(aInformation Section 6.4(b) IRS 3.16(aSection 4.8(k) Laws 3.9(bLeases Section 4.10(b) Layoff Laws 3.17(bLeased Real Property Section 4.10(b) Maximum Premium 6.8(bMost Recent Audited Balance Sheet Date Section 4.5(a) Merger 1.3(aMost Recent Financial Statements Section 4.5(a) Merger New Haven Property Section 4.16(e) Non-Competition Agreement Annex I Merger Consideration 2.1(cSection 8.10 North Haven AOCs Section 7.6 North Haven Property Section 4.16(e) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) PostParties Preface Pre-Closing SEC Reports 6.3 Principal Stockholders Recitals Straddle Period Section 7.3(c) Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiPeriod Returns Section 7.3(b) Representatives 5.2(aSection 6.4(b) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Required Consents Section 8.3 Securities Act 3.11(cSection 5.8 Seller(s) Severance 6.11(dPreface Share(s) Shares Recitals Special Meeting 1.8(a)(iShareholders’ Representative Section 12.1(a) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cThe Xxxxxx Company Section 7.4 Threshold Amount Section 10.1(a)(i) Superior Proposal 5.2(bTMC Lease Section 4.10(a)(ii) Surviving Corporation 1.3(aTrademark Coexistence Agreement Section 8.5 Transfer Act Section 4.16(h) Tax 3.15(aVintage Firearms Section 6.13 Waiver and Termination Agreement Section 4.30 Xxxxxxx Section 4.3(c) Taxable 3.15(aXxxxxxx Credit Agreement Section 4.3(c) Tax Return 3.15(a) Tender Completion Time 6.2 Tender Xxxxxx and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Xxxx Section 1.2(a), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b: 2018 and 2020 Performance Unit Consideration 6.9(e)(i)
(a) Acquisition Proposal 5.2(a1.1(b) Adverse Recommendation Change 5.2(cAdjusted Performance Unit Award 6.9(a)(ii) Adjusted RSU 2.8(b)(i) Affiliate 3.3(d1.1(c) Agreement Preamble Alternative Acquisition Antitrust Law 1.1(d) Approval Time 5.5(b) Australia Credit Agreement 5.2(c1.1(e) Assignee 9.5(aBonus Termination Percentage 6.9(f) award 3.3(bBusiness Day 1.1(f) Book-Entry Share 2.1(cBylaws 3.1(c) business day 9.10(bCanada Credit Agreement 1.1(g) CERCLA 3.18(bCancelled Shares 2.7(a)(iii) Capitalization Date 3.7(a) Cash Consideration 2.7(a)(ii) Certificate of Merger 1.4 Certificate 2.1(c0 Certificates 2.9(d) Charter 1.1(h) Chosen Courts 9.10(a) Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 2.3 Code 2.6 1.1(i) Company Preamble Company Balance Sheet 3.6(a2020 Bonus Pool 6.9(f) Company Board of Directors Recitals 1.1(j) Company Board Recommendation 3.3(a) Company Board Recommendation Change 5.5(a)(iii) Company Common Stock 1.1(k) Company Credit Agreement 1.1(l) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cDirector RSU 2.8(b)(ii) Company’s knowledge 9.10(bCompany Employee RSU 2.8(b)(i) Company ESPP 1.1(m) Company Indebtedness 1.1(n) Company Indenture 1.1(o) Company Intellectual Property 1.1(p) Company Material Adverse Effect 3.1(a1.1(q) Company Option 2.4(aOptions 1.1(r) Company Performance Unit Award 1.1(t) Company Preferred Stock 3.3(a1.1(u) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bPSUs 1.1(s) Company Restricted Stock 2.4(bRegistered Intellectual Property 3.15(a) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSUs 1.1(v) Company SEC Reports 3.5 3.9 Company Stockholder Approval 6.1 Securities 3.7(c) Company Stock Plans 2.4(a1.1(w) Company Subsidiary 3.4(aStockholder Meeting 6.4(a) Company Stockholders 1.1(x) Company Termination Fee 1.1(y) Confidentiality Agreement 1.2(c9.4 Continuation Period 6.9(c) Continuing Employee 6.11(bEmployees 1.1(z) CPR Recitals CPR Agreement Recitals Current Contract 1.1(aa) Converted Shares 2.7(a)(iii) Copyrights 1.1(rr) COVID-19 1.1(bb) COVID-19 Measures 1.1(cc) D&O Insurance 6.8(b) Delisting Period 6.3 Data Privacy Laws 1.1(dd) DGCL Recitals Director RSU Consideration 2.8(b)(ii) Dissenting Company Shares 2.3(a2.7(d)(i) DSU 2.4(cDividend Consideration 2.7(a)(ii) DOJ 1.1(ee) DTC 2.9(e) Effective Time 1.4 0 Effects 1.1(q) Electronic Delivery 9.13 Employee Release 6.11(dPlan 1.1(ff) Enforceability Exceptions 3.2 Environmental Laws 3.18(e)(i1.1(gg) ERISA 3.16(a) ERISA Affiliate 3.16(b1.1(hh) Exchange Act 1.1(a1.1(ii) Exchange Agent 2.9(a) Exchange Fund 2.2(a2.9(b) Expiration Date 1.1(aExchange Ratio Reduction Number 2.9(c) FCPA 3.9(c3.24 Foreign Plan 3.17(a) FDA 3.9(dFractional Entitlements 2.7(c) Good Clinical Practices 3.9(hFractional Share Consideration 2.7(c) Good Laboratory Practices 3.9(hFTC 1.1(jj) Good Manufacturing Practices 3.9(iGAAP 1.1(kk) Governmental Entity 9.10(bAuthority 1.1(ll) Governmental Authorization 1.1(mm) Group 1.1(nn) Hazardous Materials 3.18(e)(ii1.1(oo) HSR Act 3.19 IC Plans 6.11(a1.1(pp) Incentive Compensation Plan 6.11(aIndebtedness 1.1(qq) Indemnified Parties Persons 6.8(a) Independent Directors 6.9(aIntellectual Property 1.1(rr) IRS 3.16(aIntercompany Australia Facility Agreement 1.1(ss) Laws 3.9(bIntervening Event 1.1(tt) Layoff Laws 3.17(bXxxxxxxx 1.1(uu) Knowledge of Parent 1.1(vv) Knowledge of the Company 1.1(ww) LAOD Credit Agreement 1.1(xx) Law 1.1(yy) Lease 3.14(b) Leased Real Property 3.14(b) Legal Proceeding 1.1(zz) Lien 1.1(aaa) Loan 1.1(bbb) Loan Agreement 3.20 Marks 1.1(rr) Material Contract 1.1(ccc) Maximum Premium 6.8(b) Merger 1.3(aRecitals Merger Sub Preamble Multiemployer Plan 3.17(b) Merger New Plan 6.9(d) Non-Recourse Subsidiary 1.1(eee) NYSE 1.1(fff) ODAF Credit Agreement Annex I Merger 1.1(ggg) ODART Credit Agreement 1.1(hhh) Old Plans 6.9(d) Option Consideration 2.1(c2.8(d) Minimum Condition Annex I Notice Period 5.2(dOrder 3.22(b) OECD Convention 3.9(cOrganizational Documents 1.1(jjj) Offer Recitals Offer Condition 1.1(aOther Required Filing 6.3(b) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOwned Company Shares 2.7(a)(iii) Parent Preamble Paying Agent 2.2(aParent Board 1.1(kkk) Performance-Based DSU 2.4(cParent Common Stock 1.1(lll) Parent Disclosure Letter Article IV Parent Material Adverse Effect 7.3(a) Parent Options 1.1(nnn) Parent RSUs 1.1(ooo) Parent SEC Reports 4.8 Parent Securities 4.6(c) Parent Stock Plans 1.1(ppp) Parent Trading Price 1.1(qqq) Party Preamble Patents 1.1(rr) Permits 3.9 person 9.10(b3.19(b) Plans 3.16(aPermitted Liens 1.1(rrr) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPerson 1.1(sss) Program 3.9(kPersonal Data 1.1(ttt) Prohibited Payment 3.9(cPORT Credit Agreement 1.1(uuu) Proprietary Rights 3.12(aProcessing 1.1(vvv) Products 1.1(www) Proxy Statement 1.8(a)(ii) Real Property 3.12(b6.3(a)(i) Regulation MS-A 1.1(c) K 3.11 Release 3.18(e)(iii1.1(xxx) Representatives 5.2(a5.5(a) Reporting Tail Endorsement 6.8(bRequisite Filings 6.3(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Requisite Stockholder Approval 3.4 Sanctions 3.24
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d3.3(c) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.2(a) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b9.9(b) Certificate of Merger 1.4 Certificate 2.1(c) Change 3.1(a) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter Schedule SECTION 3 Company Intellectual Property 3.12(b) Company Joint Venture 3.4(c) 3.4 Company’s knowledge 9.10(b9.9(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRSU 2.4(b) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a3.4 Company Transaction Expenses Annex I Company Warrant 2.4(d) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b6.9(c) Delisting Period 6.3 6.4 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(dEnvironmental Law 3.19(f)(i) Environmental Laws 3.18(e)(iLiability 3.19(f)(ii) Environmental Permits 3.19(f)(iii) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Fee Schedule 3.12(c) FIRPTA Certificate 6.13 Good Clinical Practices 3.9(h3.9(g) Good Laboratory Practices 3.9(h3.9(g) Good Manufacturing Practices 3.9(i3.9(h) Governmental Entity 9.10(b9.9(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.19(f)(iv) Indemnified Parties 6.8(aParty 6.9(a) Independent Directors 6.9(a6.10(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b6.9(c) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b9.9(b) Outside Date 8.1(b)(ii) Parent Preamble Patents 3.12(a) Paying Agent 2.2(a) Performance-Based DSU 2.4(cPermits 3.9(a) Permits 3.9 person 9.10(b9.9(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 6.4 Pre-Closing Period 5.1 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Purchase Agreement 1.8(b) Real Property 3.12(b3.18(a) Regulation M-A 1.1(c) Release 3.18(e)(iiiReporting Tail Endorsement 6.9(c) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aAgreement 3.3(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b1.1(c) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 6.3 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) Trade Secrets 3.12(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24July 20, 2011 is among CUBIST PHARMACEUTICALS, PFIZER INC. (“Parent”), a Delaware corporation, FRD ECLIPSE ACQUISITION CORPORATION CORP. (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION ICAGEN, INC. (the “Company”), a Delaware corporation.. WHEREAS, Parent and the Board of Directors of each of Sub and the Company has approved the acquisition of the Company by Parent on the terms and conditions set forth in this Agreement;
Appears in 1 contract
Samples: Merger Agreement (Icagen Inc)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b2019 Notes Section 5.12(b) Acquisition Proposal 5.2(a2019 Notes Indenture Section 5.12(b) Adverse Recommendation Change 5.2(c.pdf Section 8.3 Action Section 3.13 Adjusted Company 2015 Award Section 2.3(d) Affiliate 3.3(dAffiliates Section 8.16(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cFinancing Section 5.18(d) Assignee 9.5(aAlternative Commitment Letter Section 5.18(d) award 3.3(bAntitrust Laws Section 5.6(d) Antitrust Restraint Section 5.6(e) Appraisal Provisions Section 2.1(b) Board Recommendation Notice Section 5.3(f) Book-Entry Share 2.1(cShares Section 2.1(a)(iii) business day 9.10(bBusiness Combination Section 7.2(f) CERCLA 3.18(bBusiness Day Section 8.16(b)(ii) Cancelled Shares Section 2.1(a)(ii) Cash Consideration Section 2.1(a)(iii) Certificate Section 2.1(a)(iii) Certificate of Merger 1.4 Certificate 2.1(cSection 1.3 Clean Team Agreement Section 8.16(b)(iii) Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Section 1.2 Code 2.6 Section 8.16(b)(iv) Collective Bargaining Agreement Section 3.15(k) Commitment Letter Section 4.19(a) Company Preamble Company Balance Sheet 3.6(aAcquisition Agreement Section 5.3(a) Company Acquisition Proposal Section 5.3(i)(i) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Board Recommendation Section 3.22 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bChange of Recommendation Section 5.3(b) Company Material Adverse Effect 3.1(aCommon Stock Section 3.4(a) Company Covenant Individuals Section 5.1(b)(M) Company Disclosure Schedule ARTICLE III Company Employees Section 5.5(a) Company FCPA Section 3.8(b)(ii) Company Financial Advisor Section 3.21 Company Foreign Plan Section 3.15(a) Company Option 2.4(aSection 2.3(a) Company Organizational Documents Section 3.1 Company Permits Section 3.19 Company Plans Section 3.15(a) Company Preferred Stock 3.3(aSection 3.4(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Related Party Section 8.11 Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aAward Section 2.3(b) Company SEC Reports 3.5 Documents Section 3.7(a) Company Stock Awards Section 8.16(b)(vi) Company Stock Plans Section 8.16(b)(vii) Company Stock Unit Award Section 2.3(c) Company Stockholders Recitals Company Stockholder Approval 6.1 Section 3.3 Company Stock Plans 2.4(aStockholders’ Meeting Section 5.4(b) Company Subsidiary 3.4(aOrganizational Documents Section 3.2 Company Superior Proposal Section 5.3(i)(ii) Confidentiality Agreement 1.2(cSection 5.2(e) Continuing Employee 6.11(bConsent Section 5.6(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bContract Section 3.16 control Section 8.16(a) Delisting Period 6.3 controlled by Section 8.16(a) Controlled Group Liability Section 8.16(b)(viii) Copyrights Section 8.16(b)(xiv) Costs Section 7.2(a) DGCL Recitals Section 1.1 Dissenting Shares 2.3(aSection 2.1(b) DSU 2.4(cDissenting Stockholder Section 2.1(b) DOJ Section 5.6(b) Effective Time 1.4 Employee Release 6.11(dSection 1.3 End Date Section 7.1(c) Environmental Laws 3.18(e)(i) ERISA 3.16(a) Section 3.20 Environmental Permit Section 3.20 ERISA Affiliate 3.16(bSection 8.16(b)(ix) Event Section 8.16(b)(xvii) Exchange Act 1.1(aARTICLE III Exchange Agent Section 2.2(a) Exchange Agent Agreement Section 2.2(a) Exchange Fund 2.2(aSection 2.2(b) Expiration Date 1.1(aExcluded Company Event Section 6.3(a) FCPA 3.9(cExcluded Employees Section 5.5(a) FDA 3.9(dExcluded Parent Event Section 6.2(a) Good Clinical Practices 3.9(hExisting Credit Agreement Section 8.16(b)(x) Good Laboratory Practices 3.9(hFinancing Section 4.19(a) Good Manufacturing Practices 3.9(iFinancing Conditions Section 4.19(b) Financing Sources Section 8.16(b)(x) Fractional Share Cash Amount Section 2.1(d) FTC Section 5.6(b) GAAP Section 3.7(a) Governmental Entity 9.10(bAuthority Section 8.16(b)(xii) Hazardous Materials 3.18(e)(ii) Section 3.20 HSR Act 3.19 IC Plans 6.11(aSection 3.5(d) Incentive Compensation Plan 6.11(aIndebtedness Section 8.16(b)(xiii) Indemnified Parties 6.8(aInitial End Date Section 7.1(c) Independent Directors 6.9(aIntellectual Property Section 8.16(b)(xiv) IRS 3.16(aIT Assets Section 8.16(b)(xv) knowledge Section 8.16(a) Law Section 3.5(c) Laws 3.9(bSection 3.5(c) Layoff Laws 3.17(bLetter of Transmittal Section 2.2(c) Maximum Premium 6.8(bLiability Section 8.16(b)(xvi) Lien Section 3.5(b) Marks Section 8.16(b)(xiv) Material Adverse Effect Section 8.16(b)(xvii) Material Company Contract Section 3.16 Measurement Date Section 3.4(a) Merger 1.3(aRecitals Merger Consideration Section 2.1(a)(iii) Merger Agreement Annex I Merger Consideration 2.1(cSub Preamble Multiemployer Plan Section 3.15(a) Minimum Condition Annex I Notice Period 5.2(dMultiple Employer Plan Section 3.15(f) OECD Convention 3.9(cNasdaq Section 8.16(b)(xviii) Offer Recitals Offer Condition 1.1(aNet Option Shares Section 8.16(b)(xix) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOrder Section 5.6(d) Parent Preamble Paying Agent 2.2(aParent Board Recitals Parent Common Stock Section 4.4(a) Parent Disclosure Schedule ARTICLE IV Parent FCPA Section 4.8(b)(ii) Parent Measurement Date Section 4.4(a) Parent Organizational Documents Section 4.1 Parent Preferred Stock Section 4.4(a) Parent SEC Documents Section 4.7(a) Parent Stock Plans Section 8.16(b)(xx) Parent Trading Price Section 8.16(b)(xxi) Patents Section 8.16(b)(xiv) Payoff Amount Section 5.12(a) Payoff Letter Section 5.12(a) PBGC Section 3.15(e) Performance-Based DSU 2.4(c2015 Award Section 2.3(d) Permits 3.9 Permitted Lien Section 8.16(b)(xxii) person 9.10(bSection 8.16(a) Plans 3.16(aPersonal Information Section 8.16(b)(xxiii) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPlans Section 5.5(b) Program 3.9(kPrivacy Laws Section 8.16(b)(xxiv) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aCommitment Letter Amendments Section 5.18(b) Proxy Statement 1.8(a)(iiSection 3.12 Qualified Company Plans Section 3.15(b) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiRegistration Statement Section 3.12 Regulatory Fee Section 7.2(e) Representatives 5.2(aSection 5.3(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bRevolving Credit Facility Section 8.16(b)(xxv) SEC 1.1(aSection 3.7(a) Securities Act 3.11(cSection 3.7(a) Severance 6.11(dSensitive Data Section 8.16(b)(xxvi) Shares Recitals Special Meeting 1.8(a)(iSRO Section 8.16(b)(xxvii) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cConsideration Section 2.1(a)(iii) Stock Consideration Cash Value Amount Section 8.16(b)(xxviii) Subsidiaries Section 8.16(a) Superior Proposal 5.2(bNotice Section 5.3(e) Surviving Corporation 1.3(aCompany Section 1.1 Tax Returns Section 3.9(e)(i) Tax 3.15(aTaxes Section 3.9(e)(ii) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTaxing Authority Section 8.16(b)(xxix) Termination Fee 8.2(bSection 7.2(b) Time-Trade Secrets Section 8.16(b)(xiv) Vested DSU 2.4(cStock Unit Award Section 2.3(c) Top-Up Option 1.10(aUnderlying Shares Section 8.16(b)(xxx) Top-Up Shares 1.10(aunder common control with Section 8.16(a) UK Bribery Act 3.9(cU.S. Company Employees Section 5.5(b) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”Vested Stock Unit Award Section 2.3(c) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Withdrawal Liability Section 8.16(b)(xxxi), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (Office Depot Inc)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection number where such definition is contained: 1993 Plan 3.3 (b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c1997 Plan 3.3 (b) Affiliate 3.3(d9.3 (a) Affiliate Agreement Preamble Alternative Acquisition 6.12 Agreement 5.2(cFirst Paragraph Benefit Plans 3.12 (a) Assignee 9.5(aBenefit Plan Termination Date 5.3 (b) award 3.3(bBusiness Day 9.3 (b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCertificates 2.2 (b) Certificate of Merger 1.4 Certificate 2.1(c) 1.3 Certifications 3.5 Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 Code 2.6 Company Preamble Company Balance Sheet 3.6(a2.2 (f) Company First Paragraph Company Board of Directors Recitals Approval 3.4 (c) Company Common Stock 2.1 (a) Company Disclosure Letter SECTION Schedule Article 3 Company Joint Venture 3.4(cFinancial Statements 3.5 (b) Company’s knowledge 9.10(bCompany Intellectual Property 3.15 (a) Company Listed Contracts 3.9 (a) Company Material Adverse Effect 3.1(aBreach 8.1 (c) Company-owned Intellectual Property 3.15 (i)(iv) Company Option 2.4(a) Permits 3.8 Company Preferred Stock 3.3(a3.3 (a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bProducts 3.15 (i)(vi) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRegistered Intellectual Property 3.15 (a) Company SEC Reports Documents 3.5 (a) Company SEC Financial Statements 3.5 (a) Company Source Code 3.15 (i)(vii) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a3.4 (b) Company Subsidiary 3.4(aStockholders’ Meeting 6.2 (a) Company Triggering Event 8.1 (d) Company Warrant 2.1 (e) Confidentiality Agreement 1.2(c6.3 Contract 9.3 (c) Continuing Employee 6.11(bControlled Group Member 3.10 (a)(ii) CPR Recitals CPR Agreement Recitals Current Copyrights 3.15 (i)(i) D&O Insurance 6.8(bPolicy 6.8 (b) Delisting Period 6.3 Debt Obligations 3.9 (a)(vii) Delaware Secretary of State 1.3 Dissenting Shares 2.2 (f) Dissenting Stockholders 2.2 (f) DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d1.3 Employment Agreement 5.3 (b) End Date 8.1 (b)(i) Environmental Claims 3.17 (d)(i) Table of Contents Environmental Laws 3.18(e)(i3.17 (d)(ii) Environmental Permits 3.17 (d)(iii) Equity Benefit Plans 3.10 (a)(i) ERISA 3.16(a3.10 (a)(ii) ERISA Affiliate 3.16(bBenefit Plans 3.10 (a)(ii) Exchange Act 1.1(a3.3 (d) Exchange Fund 2.2(aAgent 2.2 (a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) GAAP 3.5 Governmental Entity 9.10(b3.4 (e) Hazardous Materials 3.18(e)(ii3.17 (d)(iv) HSR Act 3.19 IC Plans 6.11(a3.4 (e) Incentive Compensation Plan 6.11(aIntellectual Property 3.15 (i)(i) Indemnified Parties 6.8(aJDA Recitals JDA Agreement Recitals Knowledge 9.3 (d) Independent Directors 6.9(aLegal Requirements 9.3 (e) IRS 3.16(aLegal Restraints 7.1 (f) Laws 3.9(bLicensed Intellectual Property 3.15 (a) Layoff Laws 3.17(b) Maximum Premium 6.8(bLiens 3.2 Material Adverse Effect 9.3 (f) Merger 1.3(aRecitals Merger Consideration 2.1 (c) Merger Agreement Annex I Merger Consideration 2.1(cSub First Paragraph Non-ERISA Benefit Plans 3.10 (a)(iii) Minimum Condition Annex I Notice Period 5.2(dOption 3.3 (b) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiOrdinary Course of Business 9.3 (g) Parent Preamble Paying Agent 2.2(aFirst Paragraph Party(ies) Performance-Based DSU 2.4(c9.3 (h) Permits 3.9 person 9.10(bPatent Applications 3.15 (i)(ii) Plans 3.16(aPatents 3.15 (i)(i) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(aPerson 9.3 (i) Proxy Statement 1.8(a)(ii6.1 (a) Real Property 3.12(b) Regulation M-A 1.1(cPublic Software 3.15 (h) Release 3.18(e)(iii3.17 (d)(v) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(iRegistration Statement 6.1 (a) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a3.3 (g) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(bRights Agreement 3.3 (a) SEC 1.1(a3.4 (e) Securities Act 3.11(c4.5 (a) Severance 6.11(dShare Right Award 2.1 (d)(iv) Shares Recitals Special Meeting 1.8(a)(iShrinkwrap Software 3.15 (i)(v) Sub Preamble Sub Common Software 3.15 (i)(i) Stock 2.1 Successor Plan 6.11(cPlans 3.3 (b) Subsidiary(ies) 9.3 (j) Superior Proposal 5.2(b5.2 (a) Surviving Corporation 1.3(a1.1 Takeover Proposal 5.2 (a) Tax 3.15(aTaxes 3.13 Trade Secrets 3.15 (i)(i) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTrademarks 3.15 (i)(i) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER 6.6 (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
Samples: Merger Agreement (QRS Corp)
INDEX OF DEFINED TERMS. Capitalized Solely for convenience purposes, the following is a list of certain terms that are defined in this Agreement shall have and the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(bSection numbers where such definitions are contained: TERM: SECTION: Accounting Arbitrator 3.2(c) Acquisition Proposal 5.2(aAcquired Assets 2.1 Acquired Seller Pipeline Bonus Amount 3.7(a)(i) Adverse Recommendation Change 5.2(cActual Book Value Amount 3.2(c) Affiliate 3.3(dActual Excluded Seller Pipeline Loan Commissions 3.4(a)(ii) Agreement Actual Seller-Owed Commissions 3.4(b)(ii) After Tax 3.7(a)(ii) Alternative Transaction 7.6 Annual Earnout Amount 3.7(a)(iii) Arbitrator 12.9(c) Assumed Contracts 2.1(b) Assumed Liabilities 2.3 Basket Amount 11.2(b)(i) Book Value Statement 3.2(b) Business Recital A Buyer Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cBuyer Indemnified Persons 11.2(a) Closing 1.5 Closing Amount Recitals 4.1 Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a4.1 Competing Business 8.3(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cCovered Claims 12.9 Division 3.7(a)(iv) Company’s knowledge 9.10(bDivision Earnings 3.7(a)(v) Company Material Adverse Effect 3.1(aDivision MSR 3.7(a)(vi) Company Option 2.4(aDivision MSR Payment 3.7(a)(vii)(G) Company Preferred Stock 3.3(aDivision Net Income 3.7(a)(vii) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bDollar 1 Matters 11.2(a)(v) Company Restricted Stock 2.4(bEarnout Amounts 3.7(a)(viii) Company Rights 3.3(aEarnout Cap 3.7(a)(ix) Company Rights Agreement 3.3(aEarnout Floor 3.7(a)(x) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aEarnout Statement 3.7(b)(i) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(cEarnout Year 3.7(a)(x) Effective Time 1.4 Employee Release 6.11(d4.1 Estimated Book Value Amount 3.2(a) Environmental Laws 3.18(e)(iEstimated Excluded Seller Pipeline Loan Commissions 3.4(a)(i) ERISA 3.16(aEstimated Seller-Owed Commissions 3.4(b)(i) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund Excluded Assets 2.2 Excluded Liabilities 2.4 Excluded Seller Pipeline Loans 2.2(a) Expiration Date 1.1(aFCRA 8.8(c) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(aSeller Financial Statements 6.5(a) Indemnified Parties 6.8(aPerson 11.4(a) Independent Directors 6.9(aIndemnifying Person 11.4(a) IRS 3.16(aInitial Cap 11.2(b)(ii) Laws 3.9(bInterim Balance Sheet Date 6.5(a) Layoff Laws 3.17(bJAMS 12.9(a) Maximum Premium 6.8(bLeased Property 6.21(b)(i) Merger 1.3(aLiquidity Event 3.7(a)(xii) Merger Agreement Annex I Merger Consideration 2.1(cLiquidity Event Earnout Amount 3.7(a)(xiii) Minimum Condition Annex I Notice Loan Loss 11.2(b)(ii)(B) Measuring Period 5.2(d3.7(a)(xiv) OECD Convention 3.9(cNeutral Accounting Firm 3.2(c) Offer Recitals Offer Condition 1.1(aNon-Signatory Action 12.9(e) Offer Documents 1.1(cNonassignable Assets 8.9 Party(ies) Offer Preamble Property Taxes 8.4(b) Purchase Price Recitals Offer to Purchase 1.1(a3.1 Registration Statement 8.6(a) on a fully diluted basis 9.10(bRestricted Geographic Area 8.3(a) Outside Date 8.1(b)(iiSecond Cap 11.2(b)(ii)(A) Parent Seller Preamble Paying Agent 2.2(aSeller Interim Balance Sheet 6.5(a) Performance-Based DSU 2.4(cSeller IP License 6.16(d) Permits 3.9 person 9.10(bSeller Party Representative 12.16(a) Plans 3.16(aShareholders Preamble Seller Specified Representations 11.1(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cStraddle Period 8.4(b) Program 3.9(kSurvival Period 11.1(a) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Trust Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Wind Down 8.7(b), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Term Section Affiliate 3.3(d8.1(a) Agreement Preamble Alternative Acquisition Agreement 5.2(cAvailable Financing 5.17(d) Assignee 9.5(a) award 3.3(b) Bankruptcy and Equity Exception 3.4 Book-Entry Share Shares 2.1(c) business day 9.10(b) CERCLA 3.18(bBusiness Day 8.1(b) Certificate of Merger 1.4 Certificate 1.3 Certificates 2.1(c) Closing 1.5 1.2 Closing Amount Recitals Closing Date 1.5 Date. 1.2 COBRA 3.22(g) Code 2.6 2.2(e) Collective Bargaining Agreement 3.20(c) Company Preamble Company Balance Sheet 3.6(aAssets 3.9(a) Company Benefit Plans 3.22(a) Company Board of Directors Recommendation 3.3 Company Common Stock Recitals Company Contracts 3.9(b) Company Disclosure Letter SECTION 3 III Company Joint Venture 3.4(cEquity Plans 3.11(a) Company’s knowledge 9.10(bCompany Financial Advisor 3.34 Company Intellectual Property 3.27(a) Company Material Adverse Effect 3.1(a8.1(c) Company Option 2.4(aOrganizational Documents 3.5 Company Parties 7.6(e)(i) Company Permits 3.30(a) Company Preferred Stock 3.3(a3.10(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aProxy Statement 3.8(b) Company SEC Reports 3.5 Company Stockholder Approval 6.1 3.13 Company Stock Plans 2.4(aOption 2.3(a) Company Subsidiary 3.4(aStockholders Meeting 3.8(b) Confidentiality Agreement 1.2(c5.2(b) Continuing Employee 6.11(b5.7(d) CPR Recitals CPR Agreement Recitals Contracts 8.1(d) Current D&O Insurance 6.8(bEmployee 5.7(b) Delisting Period 6.3 Debt Commitment Letter 4.7(a) Debt Financing 4.7(a) DGCL Recitals 1.1 Dissenting Shares 2.3(a2.4(a) DSU 2.4(cDOL 3.22(b) Effective Time 1.4 1.3 Employee Release 6.11(dBenefit Plan 8.1(e) Environmental Costs 3.26(b)(ii) Environmental Laws 3.18(e)(i3.26(a)(ii) Environmental Matters 3.26(a)(i) Equity Financing 4.7(a) ERISA 3.16(a8.1(f) ERISA Affiliate 3.16(b8.1(g) Exchange Act 1.1(a3.8(b) Exchange Fund 2.2(aExcluded Party 5.3(d) Expiration Excluded Plans 5.7(b) Excluded Shares 2.1(b) Excluded Subsidiary 8.1(h) Expenses 5.13 Experienced Counsel 5.3(f)(i) Experienced Financial Advisor 5.3(f)(i) Financing 4.7(a) Financing Agreements 8.1(i) Financing Sources 5.17(d)(ii) GAAP 3.16(a)(ii) Go-Shop End Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i5.3(a) Governmental Entity 9.10(b3.8 Greenbriar Confidentiality Agreement 5.2(b) Greenbriar Funds 8.1(j) Hazardous Materials 3.18(e)(iiSubstances 8.1(k) HSR Act 3.19 IC Plans 6.11(a3.8(d) Incentive Compensation Plan 6.11(aIn-The-Money Option 2.3(a) Indebtedness 8.1(l) Indemnified Parties 6.8(a5.8(a) Independent Directors 6.9(aIntellectual Property 8.1(m) IP Licenses 3.27(c) IRS 3.16(a3.22(b) Knowledge 8.1(n) Laws 3.9(b8.1(o) Layoff Laws 3.17(bLegal Actions 3.19 Liabilities 3.17 Licensed Intellectual Property 3.27(a) Liens 8.1(p) Maximum Premium 6.8(b5.8(c) Merger 1.3(a) Merger Agreement Annex I Recitals Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(dMerger Sub Preamble Nasdaq 3.8(c) OECD Convention 3.9(cNew Debt Commitment Letter 5.17(c) Offer Recitals Offer Condition 1.1(aOffering Documents 5.17(d)(i) Offer Documents 1.1(cOption Merger Consideration 2.3(a) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bOrders 8.1(q) Outside Termination Date 8.1(b)(ii7.2(a) Owned Intellectual Property 3.27(a) Parent Preamble Parent Assets 4.5(a) Parent Benefit Plan 5.7(d) Parent Contracts 4.5(b) Parent Disclosure Letter IV Parent Material Adverse Effect 8.1(r) Parent Parties 7.6(e)(ii) Paying Agent 2.2(a) Performance-Based DSU 2.4(cPayment Fund 2.2(b) PBGC 3.22(b) Permits 3.9 person 9.10(b3.30(a) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Person 8.1(s), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b75% Uncured Provision Section 6.6(c) Acquisition Proposal 5.2(aAccounting Principles Section 1.2(a) Adverse Recommendation Change 5.2(cAcquired Interests Recitals Adjustment Notice Section 2.4(b) Affiliate 3.3(dSection 1.2(b) Agreed Rate Section 1.2(c) Agreement Preamble Alternative Acquisition Agreement 5.2(cAllocated Value Section 1.2(d) Assignee 9.5(aAssignment of Acquired Interests Section 8.2(a) award 3.3(bBusiness Contractors Section 1.2(e) Book-Entry Share 2.1(cBusiness Day Section 1.2(f) business day 9.10(bBusiness Employees Section 1.2(g) CERCLA 3.18(bCapital Expenditure Plans Section 5.2 Cash Purchase Price Section 2.1(a) Certificate of Merger 1.4 Certificate 2.1(cClaim Section 11.2(b) Claim Notice Section 11.2(b) Closing 1.5 Section 8.1 Closing Amount Recitals Cash Payment Section 2.4(a) Closing Date 1.5 Section 8.1 Closing Settlement Statement Section 2.4(a) Code 2.6 Section 1.2(h) Company Preamble Company Balance Sheet 3.6(aContract Section 1.2(i) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEarned Leases Section 1.2(j) Company Equipment Section 1.2(k) Company Final Partnership Income Tax Return Section 1.2(l) Company Parties Section 1.2(m) Company Properties Section 1.2(n) Company Records Section 1.2(o) Company Unearned Leases Section 1.2(p) Company Xxxxx Section 1.2(q) Confidentiality Agreement Section 6.1(c) Consolidated Group Section 1.2(r) Controlled Group Liabilities Section 1.2(s) Credit Agreement Section 1.2(t) Cure Election Section 6.4(b) Cure Period Section 1.2(u) Customary Post-Closing Consents Section 1.2(v) D&O Indemnified Parties Section 5.14(b) Damages Section 11.1(d) Debt Payoff Amount Section 1.2(w) Debt Payoff Letters Section 1.2(x) Defect Deductible Section 6.4(g) Defect Response Date Section 6.4(b) Derivatives Section 5.8 Determination Date Section 2.4(b)(ii) Disclosing Party Section 5.20 Dispute Auditor Section 2.4(b)(ii) Dispute Election Section 6.4(b) Disputed Environmental Amount Section 6.6(c) Disputed Environmental Matter Section 6.7 Disputed Matter Section 6.7 Disputed Title Matter Section 6.7 Disputed Title Amounts Section 1.2(y) Due Date Section 9.2(e) E&P Business Section 1.2(z) EF Holdings Preamble Effective Time Section 1.2(aa) Effective Time Net Working Capital Section 1.2(bb) Employed Properties Section 3.16 Employee Plans Section 1.2(cc) EnCap Affiliate Section 1.2(dd) End Date Section 10.1 ENLC Section 7.1(d) EnLink Purchaser Section 7.1(d) ENLK Section 7.1(d) Environmental Defect Section 1.2(ee) Environmental Defect Amount Section 1.2(ff) Environmental Defect Deadline Section 6.6(a) Environmental Defect Property Section 6.6(b) Environmental Dispute Election Section 6.6(c) Environmental Laws Section 3.8 Environmental Liabilities Section 1.2(gg) Environmental Notice Section 1.2(hh) Environmental Threshold Section 6.6(d) Equity Interests Section 3.3(d) ERISA Section 1.2(ii) ERISA Affiliate Section 1.2(jj) Escrow Account Section 1.2(kk) Escrow Agent Section 1.2(ll) Escrow Agreement Section 8.2(g) Escrow Amount Section 1.2(mm) Exchange Section 9.10 Exchange Act Section 4.13 Excluded Assets Section 1.3 Excluded Company Records Section 1.2(o)(iv) Execution Date Preamble Existing Business Section 3.16 Farmout Agreements Section 1.2(nn) FE-STACK Section 7.1(d) Xxxxx Energy Section 1.2(oo) Xxxxx Energy Final Partnership Income Tax Return Section 1.2(pp) Xxxxx Energy GP Section 1.2(qq) Final Section 2.2(b) Schedule Section 2.2(c) Financial Statements Section 1.2(rr) Financing Section 4.7 FS Investments Preamble Fundamental Representations Section 11.3(a) Governmental Authority Section 1.2(ss) Governmental Authorizations Section 1.2(tt) Hazardous Materials Section 1.2(uu) Hydrocarbons Section 1.2(vv) Imbalance Section 1.2(ww) Income Taxes Section 1.2(xx) Indemnified Person Section 11.2(a) Indemnifying Person Section 11.2(a) Intellectual Property Section 1.2(yy) Invasive Activities Section 6.2(a) Laws Section 1.2(zz) Lease Burdens Section 1.2(aaa) Leases Section 1.2(bbb) Liabilities Section 3.18 Liens Section 1.2(ccc) Listed Interests Section 1.2(ddd) Loan Section 1.2(eee) Lowest Cost Response Section 1.2(fff) Material Adverse Effect 3.1(aSection 3.30(e) Company Option 2.4(aMaterial Contract Section 1.2(ggg) Company Preferred Stock 3.3(aMultiemployer Plan Section 1.2(hhh) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bNet Mineral Acres Section 1.2(iii) Company Restricted Stock 2.4(bNet Revenue Interest Section 1.2(jjj) Company Rights 3.3(aNew Bonds and LCs Section 5.11 New Interests Section 5.15(a) Company Rights Agreement 3.3(aNon-Compete Parties Section 1.2(kkk) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(aNon-Target Depths Section 5.22(c) Company Subsidiary 3.4(aOperator Section 5.15(c) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Organizational Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(iiSection 1.2(lll) Parent Preamble Paying Agent 2.2(aParty; Parties Preamble Payout Balance(s) Performance-Based DSU 2.4(cSection 3.19 Permitted Encumbrance Section 1.2(mmm) Permits 3.9 person 9.10(bPerson Section 1.2(nnn) Plans 3.16(aPhase I Activities Section 1.2(ooo) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Period Section 1.2(ppp) Pre-Closing Period Section 1.2(qqq) Prior Plan 6.11(cAssignment Section 1.2(rrr) Program 3.9(kPost-Closing Statement Section 2.4(b) Prohibited Payment 3.9(cPreliminary Section 2.2(b) Proprietary Schedule Section 2.2(b) Proposal Section 5.2(q) Purchase Price Section 2.1(a) Purchaser Preamble Purchaser Material Adverse Effect Section 4.4 Purchaser Parent Preamble Purchaser’s Environmental Review Section 6.2(a) Purchaser’s Phase 1 Environmental Review Section 6.2(a) Purchaser’s Representatives Section 6.1(a) Receiving Party Section 5.20 Registration Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(cAgreement Section 8.2(j) Release 3.18(e)(iiiSection 1.2(sss) Representatives 5.2(aRemediate, Remediation, Remedial Section 1.2(ttt) Reporting Tail Endorsement 6.8(bReplacement Acreage Section 6.4(f) Restraints 8.1(b)(iReplacement Interests Section 6.4(f) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(aRetained Employee Liabilities Section 1.2(uuu) Xxxxxxxx-Xxxxx Act 3.6(bRetained Liabilities Section 11.1(b)(iii) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(aRevised Assignment Section 1.2(vvv) Securities Act 3.11(cSection 3.1(e) Severance 6.11(dSeller; Sellers Preamble Seller Consolidated Group Section 1.2(www) Shares Recitals Special Meeting 1.8(a)(iSeller Consolidated Return Section 1.2(xxx) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(cSeller Taxes Section 9.1(a) Superior Proposal 5.2(bSooner Entities Section 1.2(yyy) Surviving Corporation 1.3(aSooner Trend Minerals Section 1.2(zzz) Straddle Period Section 1.2(aaaa) Supplemental Disclosure Section 5.20 Survival Period Section 6.8 Suspended Funds Section 1.2(bbbb) Tall Oak Section 7.1(d) Target Depth(s) Section 1.2(cccc) Tax 3.15(aSection 1.2(dddd) Taxable 3.15(aTax Affidavit Section 7.2(e) Tax Audit Section 9.5(a) Tax Indemnified Person Section 9.5(a) Tax Return 3.15(aSection 9.2(b) Tender Completion Time 6.2 Tender Tax Return Preparer Section 9.2(e) Tax Sharing Agreement Section 9.3 TD Purchase Price Adjustment Amount Section 6.4(c) Terminating Agreements Section 5.12 Termination Period Section 5.20 Third-Party Loans Section 1.2(eeee) Title Benefit Section 1.2(ffff) Title Benefit Amount Section 6.5(b) Title Defect Section 1.2(gggg) Title Defect Amount Section 6.5(a) Title Defect Deadline Section 6.4(a) Title Defect Property Section 6.4(b) Title Notice Section 1.2(hhhh) Title Threshold Section 6.4(g) XXX-STACK Section 5.3(e) XXX-STACK Purchase Agreement Section 7.1(d) XXX-STACK Seller Section 7.1(d) TOMPC Section 7.1(d) TOMPC Purchase Agreement Section 7.1(d) Transfer Taxes Section 12.3 Transaction Costs Section 1.2(jjjj) Ultimate Parent Preamble Ultimate Parent SEC Reports Section 4.13 Ultimate Parent Shares Section 2.1(a) Unadjusted Purchase Price Section 2.1(a) Weighted NRI Section 5.22(c) Well Data Sharing Agreement Section 1.2(kkkk) Wholly-Owned Subsidiary Section 1.2(llll) Working Interest Section 1.2(mmmm) This Purchase and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER Sale Agreement (this “Agreement”) ), is dated as of October 24December 6, 2011 is among CUBIST PHARMACEUTICALS, INC. 2015 (the “ParentExecution Date”), a Delaware corporationby and among (i) Xxxxx Energy Holdings, FRD ACQUISITION CORPORATION (“Sub”)LLC, a newly-formed limited liability company organized under the Laws of the State of Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), (ii) EnCap Fex Holdings, LLC, a limited liability company organized under the Laws of the State of Delaware corporation(“EF Holdings”), (iii) Xxxxx Xxxxx Investments, LLC, a limited liability company organized under the Laws of the State of Delaware (“FS Investments” and, together with EF Holdings, “Sellers” and each a “Seller”), (iv) DEPCO Delaware, L.L.C., a limited liability company organized under the Laws of the State of Delaware (“Purchaser”) and a wholly-owned subsidiary of Devon Energy Production Company, L.P., a limited partnership organized under the Laws of the State of Oklahoma (“Purchaser Parent”), (v) Purchaser Parent, and, (vi) solely with respect to its obligations related to the Ultimate Parent Shares (as defined herein), Devon Energy Corporation, a corporation organized under the Laws of the State of Delaware (“Ultimate Parent” and, individually or together, as the context requires, with Purchaser Parent, “Parent”). The Company, Sellers, Purchaser and Parent are referred to collectively as the “Parties” and individually as a “Party.”
Appears in 1 contract
Samples: Purchase and Sale Agreement (EnCap Energy Capital Fund X, L.P.)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(cActive Employees Section 5.8(a) Affiliate 3.3(dSection 8.1(a) Agreement Preamble Alternative Acquisition Merger Section 2.9 Alternative Merger Effective Time Section 2.9 Alternative Merger Sub I Section 2.9 Articles of Merger Section 1.3 Asset Purchase Agreement 5.2(cSection 8.1(b) Assignee 9.5(aAsset Sale Section 8.1(c) award 3.3(bBusiness Day Section 8.1(d) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(bCapitalization Date Section 3.10(a) Certificate of Merger 1.4 Certificate 2.1(cSection 2.1(a) Class B OP Units Section 2.2(a) Class C OP Units Section 2.2(a) Class D OP Units Section 3.10(a) Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Section 1.2 Club Documents Section 3.24(f) COBRA Section 3.18(g) Code 2.6 Section 2.3(f) Commitment Letter Section 4.7 Common OP Units Section 2.2(a) Common Stock Section 3.10(a) Company Preamble Company Balance Sheet 3.6(aAssets Section 3.9(b) Company Awards Section 2.4(b) Company Benefit Plans Section 3.18(a) Company Board of Directors Recitals Recommendation Section 3.3(a) Company Contracts Section 3.9(c) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(cEmployee Section 3.18(a) Company’s knowledge 9.10(b) Company Financial Advisor Section 3.29 Company Material Adverse Effect 3.1(aSection 8.1(d) Company Option Section 2.4(a) Company Preferred Stock 3.3(aOrganizational Documents Section 3.5 Company Permits Section 3.26(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bProxy Statement Section 3.8(b) Company Restricted Stock 2.4(bAward Plans Section 3.10(c) Company Rights 3.3(aStockholders Meeting Section 3.8(b) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aTermination Fee Section 7.6(b) Confidentiality Agreement 1.2(cSection 5.3(b) Continuing Employee 6.11(bContinuation Period Section 5.8(a) CPR Recitals CPR Contracts Section 8.1(f) Credit Agreement Recitals Current D&O Insurance 6.8(bSection 8.1(g) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(aDamages Amount Section 8.13(b) DSU 2.4(cDamages Opinion Section 8.13(b) Effective Time 1.4 Employee Release 6.11(dDamages Ruling Section 8.13(b) Environmental Laws 3.18(e)(iDebt Financing Section 4.7 Debt Offers Section 2.10(a) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Department Section 1.3
Appears in 1 contract
Samples: Merger Agreement (Meristar Hospitality Operating Partnership Lp)
INDEX OF DEFINED TERMS. Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(aDefinition Location 409A Authorities 3.12(e) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d5.2(b)(i) Agreement Preamble Agreement of Merger 1.3 AJCA 3.12(e) Alternative Acquisition Agreement 5.2(c5.2(b)(ii) Assignee 9.5(aAnti-Corruption Laws 3.24(a) award 3.3(bAssumed Restricted Stock Award 2.2(c) Assumed Stock Option 2.2(a) Book-Entry Share 2.1(cShares 2.3(b) business day 9.10(b) CERCLA 3.18(b) Certificate California Secretary of Merger 1.4 Certificate 2.1(cState 1.3 CCC Recitals Certificates 2.3(b) Closing 1.5 Closing Amount Recitals 1.2 Closing Date 1.5 1.2 COBRA 3.12(c)(viii) Code 2.6 2.4 Company Preamble Company Balance Sheet 3.6(aArticles 3.1(b) Company Board of Directors Recitals Company Bylaws 3.1(b) Company Data Protection Policies 3.20(b) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bEmployee Plans 5.14(a) Company Material Adverse Effect 3.1(aPlan 3.12(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bRegistered IP 3.19(f) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aAward 2.2(c) Company SEC Reports 3.5 Documents 3.6(a) Company Stockholder Shareholder Approval 6.1 Recitals Company Source Code 3.19(j) Company Stock Awards 3.2(b) Company Stock Option 2.2(a) Company Stock Plans 2.4(a2.2(a) Company Subsidiary 3.4(aComparable Plans 5.14(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals 5.4 Dissenting Shares 2.3(a2.5 E.O. 11246 3.16(e) DSU 2.4(cE.O. 13706 3.16(e) Effective Time 1.4 Employee Release 6.11(d) 1.3 Environmental Laws 3.18(e)(iPermits 3.14(a) ERISA 3.16(a) ERISA Affiliate 3.16(b3.12(a) Exchange Act 1.1(a3.5(b) Exchange Fund 2.2(a) Expiration Date 1.1(aDefinition Location Excluded Shares 2.1(b) FCPA 3.9(c3.24(a) FDA 3.9(dGAAP 3.6(b) Good Clinical Practices 3.9(hGovernment Contract 3.16(a)(v) Good Laboratory Practices 3.9(hGovernment Officials 3.24(a) Good Manufacturing Practices 3.9(iIRS 3.12(a) Governmental Entity 9.10(bLeased Real Property 3.18(b) Hazardous Materials 3.18(e)(iiLeases 3.18(b) HSR Act 3.19 IC Plans 6.11(aMaterial Contract 3.16(a) Incentive Measurement Date 3.2(a) Merger Recitals Merger Consideration 2.1(a) Merger Sub Preamble Nonqualified Deferred Compensation Plan 6.11(a3.12(e) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(bNon-U.S. Benefit Plan 3.12(c)(ix) Outside Date 8.1(b)(ii7.1(b)(i) Parent Preamble Parent Disclosure Letter Article IV Parent Expenses 7.3(c) Participant 3.12(f) Paying Agent 2.2(a2.3(a) Performance-Based DSU 2.4(cPayment Fund 2.3(a) Permits 3.9 person 9.10(bPBGC 3.12(c)(iv) Plans 3.16(aPension Plan 3.12(b) PostPre-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(cPeriod 5.1 Preliminary Notice 5.3(d) Program 3.9(kPrivacy Laws 3.20(a) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) XxxxxxxxRelated Party 3.23 Sxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b3.6(a) SEC 1.1(a3.6(a) Section 503 3.16(e) Securities Act 3.11(c3.6(a) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Shareholder Written Consent Recitals
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms As used in this Agreement Agreement, the following terms shall have the defined meanings that appear assigned to them in the provisions of the respective locations set forth below: 2013 Balance Sheet Section 5.5 338(g) Election Section 9.10(c) Accounting Firm Section 2.3(c) Accrued Vacation Days Section 8.9 Actuary Section 2.4(c) Allocation Section 2.5(a) Alternate Financing Section 7.7(c) Anti-Corruption Laws Section 5.20(a) Applicable Tax Contest Section 9.9(a) Assumed Employee Liabilities Annex B-1 Assumption Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share Section 2.1(c) business day 9.10(bAutomatic Transferred Employee Section 8.2(b) CERCLA 3.18(bBasket Section 10.4(a) Certificate of Merger 1.4 Certificate 2.1(cBonus Payment Schedule Section 8.10(b) Business IP Section 5.10(b) Business IP License Section 5.10(h) Business IT Systems Section 7.11(b) Business Real Property Section 5.8(b) Business Transfer Documents Section 2.1(f) Buyer Preamble Buyer Damages Section 11.2(a) Buyer Fee Section 11.2(b) Buyer Indemnitees Section 10.2 Buyer-Signed Tax Returns Section 9.8(a) Buyer’s 401(k) Plan Section 8.11 Cap Section 10.4(a) Cash Equivalents Cap Section 1.1 Claim Section 10.5 Closing Account Principles Section 2.3(a) Closing 1.5 Date Section 3.1(a) Closing Amount Recitals Net Indebtedness Section 2.3(a) Closing Net Funded Level Section 2.4(a) Closing Net Working Capital Section 2.3(a) Commitment Letters Section 6.8(a) Competitive Activity Section 7.6(a) Continuing Credit Support Obligations Section 7.10(c) Copyright Assignment Agreement Section 2.1(a) Copyrights Section 5.10(i) Debt Commitment Letter Section 6.8(a) Debt Financing Section 6.8(a) Debt Financing Sources Section 12.17 Deferred Business Section 3.1(b) Deferred Jurisdiction Section 3.1(b) Deferred Jurisdiction Employee Section 3.1(b) Deferred Transfer Section 3.1(b) Definitive Agreements Section 7.7(a) Disclosure Letter Section 1.3(c) Domain Name Assignment Agreement Section 2.1(a) Domain Names Section 5.10(i) Employee Representative Bodies Section 8.13 Environmental Loss Section 10.7(b) Environmental Permit Section 7.3(b) Equity Commitment Letter Section 6.8(a) Equity Financing Section 6.8(a) Equity Interest Certificates Section 2.1(a) Estimated Net Working Capital Section 2.2(b) Estimated Net Funded Level Section 2.2(b) Estimated Net Indebtedness Section 2.2(b) Estimated Statement Section 2.2(b) EU Section 8.2(b) European Employee Section 8.2(b) European Separation Pay Section 8.6(b) Excluded Assets Annex A-2 Excluded Benefits Section 8.4 Excluded Tax Liabilities Annex B-2 Fee Letter Section 6.8(b) Financial Statements Section 5.5(a) Financing Section 6.8(a) FIRPTA Affidavits Section 9.5 General Assignment Agreement Section 2.1(a) Governmental Competition Authority Section 7.4(a) Indemnified Party Section 10.5 Indemnifying Party Section 10.5 Indemnified Tax Party Section 9.1(d) Indemnifying Tax Party Section 9.1(d) Interim Period Section 3.1(b) IP Rights Section 5.10(i) Jointly Owned IP Section 5.10(c) Leased Real Property Section 5.8(b) Legacy Liabilities Annex B-2 Lenders Section 6.8(a) Like-Kind Assets Section 9.11(a) Local Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(aSection 3.1(b) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(cMajor Customers Section 5.22 Major Suppliers Section 5.22 Material Contracts Section 5.9(a) Company’s knowledge 9.10(b) Company Material Adverse Effect Month End Waiver Notice Section 3.1(a) Company Option New Contract Section 7.11(d) Net Funded Level Price Adjustment Due Date Section 2.4(g) Net Funded Level Statement Section 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”Net Working Capital Target Section 2.2(c), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized Each of the terms in this Agreement set forth below shall have the defined meanings that appear meaning ascribed thereto in the provisions of the Agreement listed below. Acceptance Time 5.2(bfollowing sections: Applicable Rate 2.2(c) Acquisition Proposal 5.2(aAudited Financial Statements 4.6(a) Adverse Recommendation Change 5.2(cBankruptcy Code 5.6 Basket 8.4(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cClaim Notice 8.5(a) Closing 1.5 Notice 2.2(d) Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aPayment 2.2(b) Confidentiality Agreement 1.2(c6.3 Covered Loss 8.4(b) Continuing Employee 6.11(bCut-off Date 8.5(a) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bDeferred Payment 2.2(c) Delisting Delaware Courts 10.10 Dispute Notice 2.3(b) DP Setoff Amount 8.6(a) Earnout Due Date 2.3(f) Earnout Payment 2.3(g)(i) Earnout Period 6.3 DGCL Recitals Dissenting Shares 2.3(a2.3(g)(ii) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d[********] 2.3(g)(iii) Environmental Authorizations 4.13 Employee 6.5(d) Employee LLC Preamble Employee Plan 4.14(a) Employment and Labor Laws 3.18(e)(i4.15(b) ERISA 3.16(aEO Setoff Amount 8.6(a) ERISA Affiliate 3.16(b4.14(a) Exchange Act 1.1(aExisting Insurance 6.7(b) Exchange Fund Existing Purchaser Assets 6.4(b) Farming and Residential Leases 4.10(b) Final Earnout Payment Statement 2.3(e) Indemnity Cap 8.4(d) Initial Tax Allocation Statement 2.4 Interested Party 4.17 Interim Balance Sheet 4.6(b) Interim Financial Statements 4.6(b) Leased Real Property 4.10(a) Leases 4.10(a) Litigation Period 8.9(a) Loss 8.2(a) Merger Recitals Merger Agreement Recitals Operationally Autonomous 2.3(i) Owned Real Property 4.10(b) Ownership Percentage 2.2(f) PCB 4.13(e) Pending Matters 8.9(a) PinnOak Preamble PinnOak Welfare Plans 6.5(a) Pre-Closing Period 6.6(b) Pre-Closing Straddle Period 6.6(c) Preliminary Earnout Payment Statement 2.3(a) Purchase Price 2.2(a) Expiration Date 1.1(aPurchaser Preamble Purchaser Indemnified Party 8.2(a) FCPA 3.9(cPurchaser Indemnifying Party 8.3(a) FDA 3.9(dPurchaser Welfare Plans 6.5(a) Good Clinical Practices 3.9(hQGPII Preamble QPII Preamble QPII-AIV Recitals Questor 2.3(i) Good Laboratory Practices 3.9(hQuestor Members Preamble Regent Preamble Regulatory Law 6.4(c) Good Manufacturing Practices 3.9(iSBSII Preamble SBSII3(c)1 Preamble Selling Unit Holder Indemnified Party 8.3(a) Governmental Entity 9.10(bSelling Unit Holder Indemnifying Party 8.4(a) Hazardous Materials 3.18(e)(iiSelling Unit Holders Preamble Sellers Representative 10.12(a) HSR Act 3.19 IC Plans 6.11(aSetoff Amount 8.6(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Straddle Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a6.6(b) Tax 3.15(aAllocation Statement 2.4 Terminating Sellers Breach 9.1(c) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dTerminating Purchaser Breach 9.1(b) Termination Fee 8.2(b9.4 Third Party Claim 8.5(a) Time-Vested DSU 2.4(c[********] 2.3(g)(iv) Top-Up Option 1.10(aTransaction Expense Amount 2.2(d) Top-Up Shares 1.10(aTransfer Taxes 6.6(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Units Recitals
Appears in 1 contract
INDEX OF DEFINED TERMS. Capitalized terms The following terms, as used in this Agreement shall Agreement, have the defined meanings that appear given to them in the provisions of the Agreement listed section or place indicated below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c: AAA Section 1.7(c) Affiliate 3.3(dSection 1.3(a) Agreed Amount Section 1.3(a) Agreement Arbitral Tribunal Preamble Alternative Acquisition Agreement 5.2(cSection 9.4 Articles Section 1.6(a) Assignee 9.5(aAnti-Bribery Laws Section 2.16(c) award 3.3(bAntitrust Laws Section 1.3(a) Book-Entry Share 2.1(cAuthorizations Award Section 2.17 Section 1.6(f) business day 9.10(bBenefit Plans Section 2.21(a) CERCLA 3.18(bBuyer Buyer Common Stock Preamble Section 1.6(f) Certificate Buyer Indemnified Parties Section 7.2 Buyer’s Plans Capitalization Letter Cause Section 5.12 Section 2.7 Section 1.3(a) Change of Merger 1.4 Certificate 2.1(cControl Obligation Section 1.3(a) Claimed Amount Section 1.3(a) Claims Section 5.14 Closing 1.5 Closing Amount Recitals Section 1.2 Closing Date 1.5 Section 1.2 Closing Indebtedness Section 1.3(a) Code 2.6 Company Company Employee Section 2.21(e) Preamble Company Balance Sheet 3.6(aSection 1.3(a) Company Board of Directors Recitals Intellectual Property Section 1.3(a) Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(bLicensed Intellectual Property Section 1.3(a) Company Material Adverse Effect 3.1(aSection 1.3(a) Company Option 2.4(aOwned Intellectual Property Section 1.3(a) Company Preferred Stock 3.3(aPlans Section 5.12 Company Registrations Section 1.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(bSecurity(ies) Section 1.3(a) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aSource Code Section 1.3(a) Confidentiality Agreement 1.2(cSection 5.1(b) Continuing Contest Section 5.8(c) ActiveUS 136966801v.1 Controlling Party Section 7.5(b) Customer Offerings Section 1.3(a) Cut-Off Date Designated Firm Disability Disclosed Tax Matters Dispute Section 7.1 Section 9.13 Section 9.13 Section 5.8(a)(v) Section 1.3(a) Disputed Items Section 1.7(b) Disputed Items Notice Section 1.7(b) Documentation Section 1.3(a) DOL Section 2.20(h) EAD Section 2.20(h) Employee 6.11(bShareholders Entity Employee Shareholder Introduction Section 1.6(f) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(bEnvironment Section 2.22(a)(i) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(dEnvironmental Claim Section 2.22(a)(ii) Environmental Laws 3.18(e)(iSection 2.22(a)(iii) ERISA 3.16(aEscrow Agent Section 1.4(b) ERISA Affiliate 3.16(bEscrow Agreement Section 6.1(f) Exchange Act 1.1(aEscrow Fund Section 1.4(b) Exchange Fund 2.2(aEstimated Purchase Price Section 1.3(a) Expiration Date 1.1(aEstimated Purchase Price Certificate Section 1.3(b) FCPA 3.9(cExcluded Matters Section 4.7 Exploit Section 1.3(a) FDA 3.9(dFinal Purchase Price Section 1.3(a) Financial Statements Section 2.8(a) Fundamental Representations Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(iReason Section 7.1 Section 1.3(a) Governmental Entity 9.10(bAuthority Section 1.3(a) Grant Date Grossed Up Amount Section 2.7 Section 1.6(f) Hazardous Materials 3.18(e)(iiSubstances Holdback Letter Section 2.22(a)(iv) Section 1.6(f) HSR Act 3.19 IC Plans 6.11(aICC Rules Section 1.3(a) Incentive Compensation Plan 6.11(aSection 9.4 IFRS Section 1.3(a) Indemnified Parties 6.8(aParty Section 7.5(a) Indemnified Persons Section 5.10(a) Indemnifying Party Section 7.5(a) Independent Directors 6.9(aAccounting Firm Individual Employee Shareholder Section 1.7(c) IRS 3.16(aSection 1.6(f) Laws 3.9(bInformation Practices Section 2.16(d) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger Information Statement Section 5.13 Intellectual Property Section 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.ActiveUS 136966801v.1
Appears in 1 contract
Samples: Securities Purchase Agreement (Progress Software Corp /Ma)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) : Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aBIS 3.21(b) award 3.3(bBylaws 3.1 Capitalization Date 3.7(a) Book-Entry Share 2.1(cCFIUS 4.5 Charter 3.1 Charter Agreements 7.2(k) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(cChosen Courts 10.10(a) Closing 1.5 Closing Amount Recitals 2.2 Closing Date 1.5 Code 2.6 2.2 Collective Bargaining Agreement 3.19(a) Comcast Agreement(s) 7.2(l) Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(c) Company Breach Notice Period 9.1(e) Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Article III Company Preferred Stock 3.3(a3.7(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(aRelated Parties 9.3(e)(i) Company SEC Reports 3.5 3.9 Company Securities 3.7(c) Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(aMeeting 6.4(a) Confidentiality Agreement 1.2(c10.4 Contracting Party 10.12 Copyrights 1.1(tt) Continuing Employee 6.11(bData 1.1(tt) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a3.1 Electronic Delivery 10.14 Expense Reimbursement 9.3(b)(iii) Indemnified Parties 6.8(aParty 8.4(d) Independent Directors 6.9(aIndemnity Cap 8.4(a) IRS 3.16(aIndemnifying Party 8.4(d) Laws 3.9(bLease 3.14(b) Layoff Laws 3.17(bLeased Real Property 3.14(b) Maximum Premium 6.8(bLosses 8.2 Marks 1.1(tt) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Nonparty Affiliate 10.12 Notice Period 5.2(d5.3(d)(ii)(3) OECD Convention 3.9(cOFAC 3.21(a) Offer Recitals Offer Condition 1.1(aOwned Real Property 3.14(a) Offer Documents 1.1(cParty Preamble Patents 1.1(tt) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Payoff Letters 6.6 Proxy Statement 1.8(a)(ii6.3(a) Purchaser Preamble Purchaser Breach Notice Period 9.1(g) Purchaser Related Parties 9.3(e)(ii) Real Property 3.12(b3.14(b) Regulation M-A 1.1(c) Release 3.18(e)(iiiRecovery Costs 9.3(d) Representatives 5.2(a5.3(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(dRequisite Stockholder Approvals 3.4 Stockholders Agreement 7.2(j) Termination Fee 8.2(bDate 9.1(c) TimeThird-Vested DSU 2.4(cParty Claim 8.5 Trade Laws 3.21(a) Top-Up Option 1.10(aTrade Secrets 1.1(tt) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Transaction Recitals
Appears in 1 contract
Samples: Series B Convertible Preferred Stock Purchase Agreement (Comscore, Inc.)
INDEX OF DEFINED TERMS. Capitalized The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement shall have the defined meanings that appear in the provisions set forth opposite each of the Agreement listed capitalized terms below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d: 102 Trustee Amounts 2.8(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c5.3(a) Assignee 9.5(aAnnual Bonus 6.11(e) award 3.3(bAnti-Money Laundering Laws 3.25 Capex Budget 5.2(k) Book-Entry Share 2.1(cCapitalization Date 3.7(a) business day 9.10(bCash Replacement Company PSU Amounts 2.8(c)(ii) CERCLA 3.18(bCash Replacement Company RSU Amounts 2.8(b)(ii) Certificate of Merger 1.4 Certificate 2.1(c2.2 Certificates 2.9(c) Chosen Courts 9.10 Closing 1.5 Closing Amount Recitals 2.3 Closing Date 1.5 Code 2.6 2.3 Company Preamble Company Balance Sheet 3.6(aBoard Recommendation 3.3(a) Company Board of Directors Recitals Recommendation Change 5.3(d)(i) Company Disclosure Letter SECTION 3 Article III Company Joint Venture 3.4(c) Company’s knowledge 9.10(bIncentive Plan 6.11(e) Company Related Parties 8.3(f)(ii) Company SEC Documents Article III Company Securities 3.7(d) Company Stockholder Meeting 6.4(a) Continuation Period 6.11(c) Copyrights 1.1(xx) D&O Insurance 6.10(c) Data Protection Requirements 3.21 Debt Financing 6.6(a) DGCL Recitals Dissenting Company Shares 2.7(c) DTC 2.9(d) Effective Time 2.2 Electronic Delivery 9.14 Enforceability Exceptions 3.2 Enforcement Expenses 8.3(e) Equity Award Holders 2.8(d) Equity Commitment Letter 4.12(a) Equity Financing 4.12(a) Expense Amount 8.3(c) Export/Import Laws 3.26 FCPA 3.24 Final Exercise Date 2.8(e) Foreign Employee Plan 3.18(g) Foreign Regulatory Consents 6.2(a) Guarantee Recitals Guarantor Recitals Indemnified Person 6.10(a) Interim Options Tax Ruling 6.20 IP Contracts 3.16(d) Israeli Subsidiaries 3.19(b) Lease 3.14 Leased Real Property 3.14 Marks 1.1(xx) Maximum Annual Premium 6.10(c) Merger Recitals Merger Sub Preamble Multiemployer Plan 3.18(b) New Plan 6.11(d) Notice Period 5.3(c)(ii)(A) Old Plans 6.11(d) Option Consideration 2.8(a) Options Tax Ruling 6.20 Other Indemnified Persons 6.10(e) Other Required Company Filing 6.3(b) Owned Company Shares 2.7(a)(iii) Owned Real Property 3.14 Parent Preamble Parent Liability Limitation 8.3(f)(i) Parent Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii7.3(a) Parent Related Parties 8.3(f)(i) Party Preamble Paying Patents 1.1(xx) Payment Agent 2.2(a2.9(a) Performance-Based DSU 2.4(cPayment Fund 2.9(b) Permits 3.9 person 9.10(bPayoff Letters 6.6(c)(i) Plans 3.16(aPer Share Price 2.7(a)(ii) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Personal Information 3.21 Proxy Statement 1.8(a)(ii6.3(a) Real Property 3.12(b3.14 Representatives 6.6(e) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) Xxxxxxxx-Xxxxx Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Requisite Stockholder Approval 3.4 Sanctioned Persons 3.25 Surviving Corporation 1.3(a2.1 Termination Date 8.1(c) Tax 3.15(aUncertificated Shares 2.9(c) Taxable 3.15(aUnvested Company PSU 2.8(c)(ii) Tax Return 3.15(aUnvested Company RSU 2.8(b)(ii) Tender Completion Time 6.2 Tender and Vested Equity Award Consideration 2.8(c)(i) Vested PSU Consideration 2.8(c)(i) Vested RSU Consideration 2.8(b)(i) Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.Agreement Recitals
Appears in 1 contract
